

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 November 2011 (10.11.2011)

PCT

(10) International Publication Number
WO 2011/138392 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) *C07K 16/46* (2006.01)
A61K 39/395 (2006.01) *C12N 15/113* (2010.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/EP2011/057202

(22) International Filing Date:

5 May 2011 (05.05.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/331,985 6 May 2010 (06.05.2010) US

(71) Applicant (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CONG, Feng** [CN/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **ETTENBERG, Seth** [US/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **HARTLEPP, Felix** [DE/DE]; Morphosys AG, Lena-Christ-Strasse 48, 82152 Planegg (DE). **KLAGGE, Ingo** [DE/DE]; Morphosys AG, Lena-Christ-Strasse 48, 82152 Planegg (DE).

(74) Agent: **VON SPRECHER, Georg**; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))



WO 2011/138392 A1

(54) Title: COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC LOW DENSITY LIPOPROTEIN -RELATED PROTEIN 6 (LRP6) ANTIBODIES

(57) Abstract: The present disclosure relates to antibodies targeting LRP6 and compositions and methods of use thereof.

COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC LOW DENSITY LIPOPROTEIN –RELATED PROTEIN 6 (LRP6) ANTIBODIES

Related Applications

This application claims priority to US Provisional Application Serial No. 61/331,985 filed May 6, 2010, the contents of which are incorporated herein by reference in its entirety.

Field of the Invention

The present invention relates to antibodies that specifically bind to LRP6. The invention more specifically relates to specific antibodies that are LRP6 antagonists.

Background of the Invention

The Wnt/ β -catenin pathway regulates diverse biological processes during development and tissue homeostasis through modulating the protein stability of β -catenin (Clevers *et al.*, (2006) *Cell* 127:469-480; and Logan *et al.*, (2004) *Annu. Rev Cell Dev. Biol* 20:781-810). In the absence of Wnt signaling, cytoplasmic β -catenin is associated with the β -catenin destruction complex that contains multiple proteins including adenomatous polyposis coli (APC), Axin, and glycogen synthase kinase 3 (GSK3). In this complex, β -catenin is constitutively phosphorylated by GSK3 and degraded by the proteasome pathway. The Wnt signal is transduced across the plasma membrane through two distinct receptors, the serpentine receptor Frizzled, and the single-transmembrane protein LRP5 or LRP6. The Wnt proteins promote the assembly of the Frizzled-LRP5/6 signaling complex, and induce phosphorylation of the cytoplasmic PPPSPxS motifs of LRP5/6 by GSK3 and Casein Kinase I. Phosphorylated LRP5/6 bind to Axin and inactivate the β -catenin degradation complex. Stabilized β -catenin enters the nucleus, binds to the TCF family transcription factors, and turns on transcription.

The large extracellular domain of LRP5/6 contains four YWTD-type β -propeller regions that are each followed by an EGF-like domain, and the LDLR domain. Each propeller region contains six YWTD motifs that form a six-bladed β -propeller structure.

Biochemical studies suggest that Wnt proteins physically interact with both Frizzled and LRP6 and induce formation of Frizzled-LRP6 signaling complex (Semenov *et al.*, (2001) *Curr. Biol* 11, 951-961; and Tamai *et al.*, (2000) *Nature* 407, 530-535). Besides Wnt proteins, the large extracellular domain of LRP5/6 binds to multiple secreted Wnt

modulators, including Wnt antagonist DKK1 and Sclerostin (SOST), and Wnt agonist R-Spondins.

Deregulation of the Wnt signaling pathway has been linked to many human diseases. The Wnt/LRP5/6 signaling pathway plays important roles in tissue homeostasis and regeneration. Wnt signaling promotes bone formation by increasing the growth and differentiation of osteoblasts (Baron *et al.*, (2006) *Curr. Top. Dev. Biol* 76:103-127). Gain-of-function mutations of LRP5 (Boyden *et al.*, (2002) *N. Engl. J Med* 346:1513-1521; Little *et al.*, (2002) *Am. J Hum. Genet.* 70:11-19; Van Wesenbeeck *et al.*, (2003) *Am. J Hum. Genet.* 72: 763-71) and loss-of-function mutations of Wnt antagonist SOST (Balemans *et al.*, (2001) *Hum. Mol Genet.* 10:537-543; Brunkow *et al.*, (2001) *Am. J Hum. Genet.* 68:577-589) both lead to high bone mass diseases. Wnt signaling is also critical for the homeostasis of intestinal epithelium by maintaining the proliferative status of stem cells in the intestinal crypt (Pinto *et al.*, (2005) *Biol Cell* 97:185-196). Wnt signaling is also critical for kidney repair and regeneration (Lin SL *PNAS* 107:4194, 2010). In addition, mutations in pathway components such as APC and β -catenin have been associated with human cancers. Recent studies suggest that overexpression of Wnt proteins and/or silencing of Wnt antagonists such as DKK1, WISP and sFRPs promote cancer development and progression (Akiri *et al.*, (2009) *Oncogene* 28:2163-2172; Bafico *et al.*, (2004) *Cancer Cell* 6:497-506; Suzuki *et al.*, (2004) *Nat Genet.* 36:417-422; Taniguchi *et al.*, (2005) *Oncogene.* 24:7946-7952; Veeck *et al.*, (2006) *Oncogene.* 25:3479-3488; Zeng *et al.*, (2007) *Hum. Pathol.* 38:120-133). In addition, Wnt signaling has been implicated for the maintenance of cancer stem cells (Jamieson *et al.*, (2004) *Cancer Cell* 6:531-533 and Zhao *et al.*, (2007) *Cancer Cell* 12:528-541).

Accordingly, a need exists for agents that antagonize Wnt signaling at the extracellular level as therapy for diseases associated with aberrant canonical Wnt signaling.

Summary of the Invention

The invention provides LRP6 antibodies (e.g., monovalent, bivalent) and methods of making LRP6 antibodies that inhibit or enhance the canonical Wnt signaling pathway.

The LRP6 antibodies of the invention bind to distinct LRP6 β -propeller regions.

Propeller 1 antibodies bind to the β -propeller 1 domain and block Propeller1-dependent Wnts such as Wnt1, Wnt2, Wnt6, Wnt7A, Wnt7B, Wnt9, Wnt10A, Wnt10B. Propeller 3 antibodies bind to the β -propeller 3 domain and block Propeller3-dependent Wnts such as

Wnt3a and Wnt3. The invention is based on the surprising discovery that LRP6 antibodies differentiate Propeller 1 and Propeller 3 ligands into two separate classes and bind to distinct epitopes of the LRP6 target. Another surprising discovery is that conversion of fragments of the LRP6 antibodies (e.g., Fabs) to full length IgG antibody results in an antibody that potentiates (enhances) a Wnt signal in the presence of another protein such as a Wnt 1 or Wnt 3 ligand. In addition to Wnt ligands LRP6 Propeller 1 antibodies are expected to inhibit the interaction with other Propeller 1 binding ligands (e.g. Sclerostin, Dkk1). Similarly, Propeller 3 antibodies are expected to inhibit the interaction with other propeller 3 binding ligands (e.g. Dkk1). Furthermore, propeller 1 and 3 binding antibodies may be expected to affect the activity of other Wnt signaling modulators e.g. R-spondins.

Accordingly, in one aspect the invention pertains to an isolated bivalent antibody or a bivalent fragment thereof to a low density lipoprotein-related protein 6 (LRP6) that potentiates a Wnt signal by clustering one or more LRP6 receptors in the presence of an unblocked LRP6 binding protein. In one embodiment, the antibody clusters one or more LRP6 receptors by binding to a Propeller region selected from the group consisting of Propeller 1 and Propeller 3. In one embodiment, the LRP6 binding protein is a Wnt binding protein selected from the group consisting of Wnt 1, Wnt 3, and Wnt 3a.

In another aspect, the invention pertains to an isolated bivalent antibody or a bivalent fragment thereof to a low density lipoprotein-related protein 6 (LRP6) that avoids potentiation of a Wnt signal by clustering one or more LRP6 receptors in the presence of an unblocked LRP6 binding protein.

In another aspect, the invention pertains to an isolated monovalent antibody or monovalent fragment thereof to a low density lipoprotein-related protein 6 (LRP6) that avoids potentiation of a Wnt signal by clustering one or more LRP6 receptors in the presence of an unblocked LRP6 binding protein.

In one aspect the invention pertains to an isolated antibody or fragment thereof to a low density lipoprotein-related protein 6 (LRP6) protein, having a dissociation (K_D) of at least $1 \times 10^7 M^{-1}$, $10^8 M^{-1}$, $10^9 M^{-1}$, $10^{10} M^{-1}$, or $10^{11} M^{-1}$, $10^{12} M^{-1}$, $10^{13} M^{-1}$, wherein the antibody or fragment thereof is monovalent or bivalent. In one embodiment, the antibody or fragment thereof inhibits a canonical Wnt pathway as measured by in vitro binding to

human LRP6 in a Solution Equilibrium Titration assay with a K_D of 0.001nM-1 μ M, wherein the antibody or fragment thereof is monovalent or bivalent.

In another aspect, the invention pertains to an isolated antibody or fragment thereof to a low density lipoprotein-related protein 6 (LRP6) protein that inhibits a canonical Wnt pathway as measured by in vitro binding to human LRP6 in a Solution Equilibrium Titration (SET) assay with a EC_{50} of less than or equal to 300 μ M (0.3pM), wherein the antibody or fragment thereof is monovalent or bivalent.

In another aspect, the invention pertains to an isolated bivalent antibody or a bivalent fragment thereof, to a low density lipoprotein-related protein 6 (LRP6) that potentiates a Wnt signal by clustering one or more LRP6 receptors in the presence of an unblocked LRP6 binding protein. The antibody clusters one or more LRP6 receptors by binding to a Propeller region of the LRP6 molecule selected from the group consisting of Propeller 1 and Propeller 3. In one embodiment, the LRP6 binding protein is a Wnt binding protein selected from the group consisting of Wnt 1, Wnt 3, and Wnt 3a.

In another aspect, the invention pertains to an antibody or fragment thereof to LRP6 protein, that cross competes with an antibody described in Table 1, wherein the antibody or fragment thereof is monovalent or bivalent; an antibody or fragment thereof that interacts with (e.g., by binding, steric hinderance, stabilizing/destabilizing, spatial distribution) the same epitope as an antibody described in Table 1. In one embodiment, the antibody or fragment thereof is a monoclonal antibody. In another embodiment, the antibody or fragment thereof is a human or humanized antibody. In another embodiment, the antibody or fragment thereof is a chimeric antibody. In one embodiment, the antibody or fragment thereof comprises a human heavy chain constant region and a human light chain constant region. In one embodiment, the antibody or fragment thereof is a single chain antibody. In another embodiment, the antibody or fragment thereof is a Fab fragment. In yet another embodiment, the antibody or fragment thereof is a scFv. In one embodiment, the antibody or fragment thereof binds to both human LRP6 and cynomolgus LRP6. In one embodiment, the antibody or fragment thereof is an IgG isotype. In another embodiment, the antibody or fragment thereof comprises a framework in which amino acids have been substituted into the antibody framework from the respective human VH or VL germline sequences.

In one aspect, the invention pertains to an isolated antibody or fragment thereof to LRP6 comprising 1, 2, 3, 4, 5, or 6 CDRs of any of the antibodies in Table 1, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the LRP6 antibodies disclosed herein bind to the Propeller 1 region of LRP6. Accordingly, the invention pertains to an isolated antibody or fragment thereof to LRP6 comprising a heavy chain CDR3 selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 25, SEQ and SEQ ID NO: 43, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated antibody or fragment thereof to LRP6 comprising a heavy chain CDR1 selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 44, SEQ ID NO: 60, and SEQ ID NO: 62 and a VL selected from the group consisting of SEQ ID NO: 13, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 43, SEQ ID NO: 59, and SEQ ID NO: 61, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated antibody or fragment thereof to LRP6 which antibody comprises a VH comprising SEQ ID NO: 14 and a VL comprising SEQ ID NO: 13, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated antibody or fragment thereof to LRP6 which antibody comprises a VH comprising SEQ ID NO: 34 and a VL comprising SEQ ID NO: 33, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated antibody or fragment thereof to LRP6 which antibody comprises a VH comprising SEQ ID NO: 36 and a VL comprising SEQ ID NO: 35, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated antibody or fragment thereof to LRP6 which antibody comprises a VH comprising SEQ ID NO: 44 and a VL comprising SEQ ID NO: 43, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated antibody or fragment thereof to LRP6 which antibody comprises a VH comprising SEQ ID NO: 36 and a VL comprising SEQ ID NO: 35, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated antibody or fragment thereof to LRP6 which antibody comprises a VH comprising SEQ ID NO: 60 and a VL comprising SEQ ID NO: 59, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated antibody or fragment thereof to LRP6 which antibody comprises a VH comprising SEQ ID NO: 61 and a VL comprising SEQ ID NO: 62, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated antibody or fragment thereof, comprising at least one heavy chain CDR sequence that is identical to SEQ ID NO: 1, 2, 3, 21, 22, 23, 47, 48, and 49, wherein the antibody binds to human LRP6 protein, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated antibody or fragment thereof, comprising at least one light chain CDR sequence that is identical to SEQ ID NO: 4, 5, 6, 24, 25, 26, 50, 51 and 52, wherein the antibody binds to human LRP6 protein, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated antibody or fragment thereof, comprising at least one heavy chain CDR sequence having at least 95% sequence identity to SEQ ID NO: 1, 2, 3, 21, 22, 23, 47, 48, and 49, wherein the antibody binds to human LRP6 protein, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated antibody or fragment thereof, comprising at least one light chain CDR sequence having at least 95% sequence identity to SEQ ID NO: 4, 5, 6, 24, 25, 26, 50, 51 and 52, wherein the antibody binds to human LRP6 protein, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated antibody or fragment thereof, comprising a heavy chain variable region CDR1 of SEQ ID NO: 1; a heavy chain variable region CDR2 of SEQ ID NO: 2; a heavy chain variable region CDR3 of SEQ ID NO: 3; a light chain variable region CDR1 of SEQ ID NO: 4; a light chain variable region CDR2 of SEQ ID NO: 5; and a light chain variable region CDR3 of SEQ ID NO: 6, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated antibody or fragment thereof, comprising a heavy chain variable CDR1 of SEQ ID NO: 21; a heavy chain variable

region CDR2 of SEQ ID NO: 22; a heavy chain variable region CDR3 of SEQ ID NO: 23; a light chain variable region CDR1 of SEQ ID NO: 24; a light chain variable region CDR2 of SEQ ID NO: 25; and a light chain variable region CDR3 of SEQ ID NO: 26, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated antibody or fragment thereof, comprising a heavy chain variable region CDR1 of SEQ ID NO: 47; a heavy chain variable region CDR2 of SEQ ID NO: 48; a heavy chain variable region CDR3 of SEQ ID NO: 49; a light chain variable region CDR1 of SEQ ID NO: 50; a light chain variable region CDR2 of SEQ ID NO: 51; and a light chain variable region CDR3 of SEQ ID NO: 52, wherein the antibody or fragment thereof is monovalent or bivalent.

In one embodiment, a fragment of the antibody that binds with LRP6 is selected from the group consisting of Fab, F(ab₂)', F(ab)₂', scFv, VHH, VH, VL, dAbs, wherein the fragment is monovalent or bivalent.

In one aspect, the invention pertains to a pharmaceutical composition comprising an antibody or fragment thereof and a pharmaceutically acceptable carrier, wherein the antibody or fragment thereof is monovalent or bivalent. In one aspect, the invention pertains a nucleic acid comprising a nucleotide sequence encoding a polypeptide comprising a heavy chain variable region identity to SEQ ID NO: 14, 34, 36, 44, 60, and 62; a nucleic acid comprising a nucleotide sequence encoding a polypeptide comprising a light chain variable region identity to SEQ ID NO: 13, 33, 35, 43, 59 and 61; a nucleic acid comprising a nucleotide sequence encoding a polypeptide comprising a heavy chain variable region having at least 98% sequence identity to SEQ ID NO: 14, 34, 36, 44, 60, and 62; a nucleic acid comprising a nucleotide sequence encoding a polypeptide comprising a light chain variable region having at least 98% sequence identity to SEQ ID NO: 13, 33, 35, 43, 59 and 61.

In one aspect, the LRP6 antibodies disclosed herein bind to the Propeller 3 region of LRP6. Accordingly, the invention pertains to an isolated antibody or fragment thereof to LRP6 comprising a CDR3 selected from the group consisting of SEQ ID NO: 69, SEQ ID NO: 93, and SEQ ID NO: 115, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated antibody or fragment thereof to LRP6 comprising a heavy chain CDR1 selected from the group consisting of SEQ ID NO: 69, SEQ ID NO: 93, and SEQ ID NO: 115; a CDR2 selected from the group consisting of SEQ ID NO: 70, SEQ ID NO: 94, and SEQ ID NO: 116; and a CDR3 selected from the group consisting of SEQ ID NO: 71, SEQ ID NO: 95, and SEQ ID NO: 117, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated antibody or fragment thereof to LRP6 comprising a light chain CDR1 selected from the group consisting of SEQ ID NO: 72, SEQ ID NO: 96, and SEQ ID NO: 118; a CDR2 selected from the group consisting of SEQ ID NO: 73, SEQ ID NO: 97, and SEQ ID NO: 119; and a CDR3 selected from the group consisting of SEQ ID NO: 74, SEQ ID NO: 98, and SEQ ID NO: 120, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated antibody or fragment thereof to LRP6 which antibody comprises a VH selected from the group consisting of SEQ ID NO: 82, SEQ ID NO: 89, SEQ ID NO: 106, SEQ ID NO: 108, SEQ ID NO: 128, SEQ ID NO: 130, and SEQ ID NO: 138; and a VL selected from the group consisting of SEQ ID NO: 81, SEQ ID NO: 90, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 127, SEQ ID NO: 129, and SEQ ID NO: 137, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated antibody or fragment thereof to LRP6 which antibody comprises a SEQ ID NO: 82 and a VL comprising SEQ ID NO: 81, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated antibody or fragment thereof to LRP6 which antibody comprises a VH comprising SEQ ID NO: 90 and a VL comprising SEQ ID NO: 89, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated antibody or fragment thereof to LRP6 which antibody comprises a VH comprising SEQ ID NO: 106 and a VL comprising SEQ ID NO: 105, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated antibody or fragment thereof to LRP6 which antibody comprises a VH comprising SEQ ID NO: 108 and a VL comprising SEQ ID NO: 107, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated antibody or fragment thereof to LRP6 which antibody comprises a VH comprising SEQ ID NO: 128 and a VL comprising SEQ ID NO: 127, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated antibody or fragment thereof to LRP6 which antibody comprises a VH comprising SEQ ID NO: 128 and a VL comprising SEQ ID NO: 127, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated antibody or fragment thereof to LRP6 which antibody comprises a VH comprising SEQ ID NO: 130 and a VL comprising SEQ ID NO: 129, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated antibody or fragment thereof to LRP6 which antibody comprises a VH comprising SEQ ID NO: 138 and a VL comprising SEQ ID NO: 137, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated antibody or fragment thereof, comprising at least one heavy chain CDR sequence that is identical to SEQ ID NO: 69, 70, 71, 93, 94, 95, 115, 116, and 117, wherein said antibody binds to human LRP6 protein, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated monoclonal antibody or fragment thereof, comprising at least one light chain CDR sequence that is identical to SEQ ID NO: 72, 73, 74, 96, 97, 98, 118, 119, and 120, wherein said antibody binds to human LRP6 protein, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated monoclonal antibody or fragment thereof, comprising at least one heavy chain CDR sequence having at least 95% sequence identity to SEQ ID NO: 70, 71, 93, 94, 95, 115, 116, and 117, wherein said antibody binds to human LRP6 protein, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to an isolated monoclonal antibody or fragment thereof, comprising at least one light chain CDR sequence having at least 95% sequence identity to SEQ ID NO: 72, 73, 74, 96, 97, 98, 118, 119, and 120, wherein said antibody binds to human LRP6 protein, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains an isolated monoclonal antibody, or fragment thereof, comprising a heavy chain variable region CDR1 of SEQ ID NO: 69; a heavy chain variable region CDR2 of SEQ ID NO: 70; a heavy chain variable region CDR3 of SEQ ID NO: 71; a light chain variable region CDR1 of SEQ ID NO: 72; a light chain variable region CDR2 of SEQ ID NO: 73; and a light chain variable region CDR3 of SEQ ID NO: 74, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains an isolated monoclonal antibody, or fragment thereof, comprising a heavy chain variable region CDR1 of SEQ ID NO: 93; a heavy chain variable region CDR2 of SEQ ID NO: 94; a heavy chain variable region CDR3 of SEQ ID NO: 95; a light chain variable region CDR1 of SEQ ID NO: 96; a light chain variable region CDR2 of SEQ ID NO: 97; and a light chain variable region CDR3 of SEQ ID NO: 98, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains an isolated monoclonal antibody or fragment thereof, comprising a heavy chain variable region CDR1 of SEQ ID NO: 115; a heavy chain variable region CDR2 of SEQ ID NO: 116; a heavy chain variable region CDR3 of SEQ ID NO: 117; a light chain variable region CDR1 of SEQ ID NO: 118; a light chain variable region CDR2 of SEQ ID NO: 119; and a light chain variable region CDR3 of SEQ ID NO: 120, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to combination of a monoclonal antibody that binds to the β -propeller 1 domain of LRP6 and monoclonal antibody that binds to the β -propeller 3 domain of LRP6, wherein the antibody or fragment thereof is monovalent.

In one aspect, the invention pertains to combination of a monoclonal antibody that binds to the β -propeller 1 domain of LRP6 and monoclonal antibody that binds to the β -propeller 3 domain of LRP6, wherein the antibody or fragment thereof is bivalent.

In one embodiment, a fragment of the antibody that binds with LRP6 is selected from the group consisting of Fab, F(ab₂)', F(ab)₂', scFv, VHH, VH, VL, dAbs, wherein the fragment is monovalent or bivalent.

In one aspect, the invention pertains to a pharmaceutical composition comprising a an antibody or fragment thereof and a pharmaceutically acceptable carrier, wherein the antibody or fragment thereof is monovalent or bivalent. In one aspect, the invention pertains to a nucleic acid comprising a nucleotide sequence encoding a polypeptide

comprising a heavy chain variable region selected from the group consisting of SEQ ID NO: 82, 89, 106, 108, 128, 130, and 138. In one aspect, the invention pertains to a nucleic acid comprising a nucleotide sequence encoding a polypeptide comprising a light chain variable region selected from the group consisting of SEQ ID NO: 81, 90, 105, 107, 127, 129, and 137. In one aspect, the invention pertains to a nucleic acid comprising a nucleotide sequence encoding a polypeptide comprising a heavy chain variable region having at least 98% sequence identity to SEQ ID NO: 82, 89, 106, 108, 128, 130, and 138. In one aspect, the invention pertains to a nucleic acid comprising a nucleotide sequence encoding a polypeptide comprising a light chain variable region having at least 98% sequence identity to SEQ ID NO: 81, 90, 105, 107, 127, 129, and 137.

In one aspect, the invention pertains to a vector comprising the nucleic acids; and isolated host cells comprising (1) a recombinant DNA segment encoding a heavy chain of the antibody and (2) a second recombinant DNA segment encoding a light chain of the antibody. The DNA segments are operably linked to a promoter, and are capable of being expressed in said host cell. The antibody is a human monoclonal antibody; and the host cell is a non-human mammalian cell line.

In one aspect, the invention pertains to a method of treating a cancer comprising selecting a subject having an LRP6 expressing cancer, administering to the subject an effective amount of a composition comprising an LRP6 antibody (e.g., a monovalent or bivalent, or fragments thereof). In one aspect, the invention pertains to a method of treating a disease mediated by a canonical Wnt signaling pathway using an antibody or fragments thereof to LRP6, wherein the antibody or fragment thereof is monovalent or bivalent. In one aspect, the invention pertains to a method of treating a cancer mediated by a canonical Wnt signaling pathway comprising selecting a subject having an LRP6 expressing cancer and administering an effective amount of a composition comprising an antibody or fragments thereof, wherein said antibody or fragment thereof is monovalent or bivalent, and wherein said cancer is selected from the group consisting of breast cancer, lung cancer, multiple myeloma, ovarian cancer, liver cancer, bladder cancer, gastric cancer, prostate cancer, acute myeloid leukemia, chronic myeloid leukemia, osteosarcoma, squamous cell carcinoma, and melanoma. In one embodiment, the cancer is breast cancer. In one embodiment, the subject is human.

In one aspect, the invention pertains to a method of treating a cancer comprising selecting a subject having an LRP6 expressing cancer, administering to said subject an effective amount of a composition comprising an antibody or antibody fragment thereof that binds to a propeller 1 region of LRP6 in combination with an antibody or antibody fragment thereof that binds to a propeller 3 region of LRP6, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to a method of treating a cancer comprising selecting a subject having an LRP6 expressing cancer, administering to said subject an effective amount of a composition comprising an antibody or antibody fragment thereof that binds to LRP6 and inhibits Wnt1 signalling by LRP6 in combination with an antibody or fragment thereof that binds to LRP6 and inhibits Wnt3 signalling by LRP6, wherein the antibody or fragment thereof is monovalent or bivalent.

In one aspect, the invention pertains to process for production of an antibody or fragments thereof of comprising culturing a host cell and isolating the antibody or fragment thereof, wherein the antibody or fragment thereof is monovalent or bivalent.

In another aspect, the invention pertains to use of an antibody or fragments thereof in the manufacture of a medicament for the treatment of a cancer mediated by a canonical Wnt signaling pathway selected from the group consisting of breast cancer, lung cancer, multiple myeloma, ovarian cancer, liver cancer, bladder cancer, gastric cancer, prostate cancer, acute myeloid leukemia, chronic myeloid leukemia, osteosarcoma, squamous cell carcinoma, and melanoma, wherein the antibody or fragment thereof is monovalent or bivalent.

In one embodiment, the invention pertains to an antibody having VH of SEQ ID NO: 14 and VL of SEQ ID NO: 13 for use in treating a cancer mediated by a canonical Wnt signaling pathway, wherein the antibody is monovalent or bivalent. In another embodiment, the invention pertains to an antibody having VH of SEQ ID NO: 34 and VL of SEQ ID NO: 36 for use in treating a cancer mediated by a canonical Wnt signaling pathway, wherein the antibody thereof is monovalent or bivalent. In another embodiment, the invention pertains to an antibody having VH of SEQ ID NO: 36 and VL of SEQ ID NO: 35 for use in treating a cancer mediated by a canonical Wnt signaling pathway, wherein the antibody is monovalent or bivalent. In another embodiment, the invention pertains to an antibody having VH of SEQ ID NO: 44 and VL of SEQ ID NO:

43 for use in treating a cancer mediated by a canonical Wnt signaling pathway, wherein the antibody is monovalent or bivalent. In another embodiment, the invention pertains to an antibody having VH of SEQ ID NO: 60 and VL of SEQ ID NO: 59 for use in treating a cancer mediated by a canonical Wnt signaling pathway, wherein the antibody is monovalent or bivalent. In another embodiment, the invention pertains to an antibody having SEQ ID NO: 62 and VL of SEQ ID NO: 61 for use in treating a cancer mediated by a canonical Wnt signaling pathway, wherein the antibody is monovalent or bivalent. In another embodiment, the invention pertains to an antibody having VH of SEQ ID NO: 82 and VL of SEQ ID NO: 81 for use in treating a cancer mediated by a canonical Wnt signaling pathway, wherein the antibody is monovalent or bivalent. In another embodiment, the invention pertains to an antibody having VH of SEQ ID NO: 90 and VL of SEQ ID NO: 89 for use in treating a cancer mediated by a canonical Wnt signaling pathway, wherein the antibody is monovalent or bivalent. In another embodiment, the invention pertains to an antibody having VH of SEQ ID NO: 106 and VL of SEQ ID NO: 105 for use in treating a cancer mediated by a canonical Wnt signaling pathway, wherein the antibody is monovalent or bivalent. In another embodiment, the invention pertains to an antibody having VH of SEQ ID NO: 108 and VL of SEQ ID NO: 107 for use in treating a cancer mediated by a canonical Wnt signaling pathway, wherein the antibody is monovalent or bivalent. In another embodiment, the invention pertains to an antibody having VH of SEQ ID NO: 128 and VL of SEQ ID NO: 127 for use in treating a cancer mediated by a canonical Wnt signaling pathway, wherein the antibody is monovalent or bivalent. In another embodiment, the invention pertains to an antibody having VH of SEQ ID NO: 130 and VL of SEQ ID NO: 129 for use in treating a cancer mediated by a canonical Wnt signaling pathway, wherein the antibody is monovalent or bivalent. In another embodiment, the invention pertains to an antibody having VH of SEQ ID NO: 138 and VL of SEQ ID NO: 137 for use in treating a cancer mediated by a canonical Wnt signaling pathway, wherein the antibody is monovalent or bivalent.

In one embodiment, the invention pertains to an antibody having VH of SEQ ID NO: 14 and VL of SEQ ID NO: 13 for use as a drug, wherein the antibody is monovalent or bivalent. In another embodiment, the invention pertains to an antibody having VH of SEQ ID NO: 34 and VL of SEQ ID NO: 33 for use as a drug, wherein the antibody is monovalent or bivalent. In another embodiment, the invention pertains to an antibody having VH of SEQ ID NO: 36 and VL of SEQ ID NO: 35 for use as a drug, wherein the

antibody is monovalent or bivalent. In another embodiment, the invention pertains to an antibody having VH of SEQ ID NO: 44 and VL of SEQ ID NO: 43 for use as a drug, wherein the antibody is monovalent or bivalent. In another embodiment, the invention pertains to an antibody having VH of SEQ ID NO: 62 and VL of SEQ ID NO: 61 for use as a drug, wherein the antibody is monovalent or bivalent. In another embodiment, the invention pertains to an antibody having VH of SEQ ID NO: 82 and VL of SEQ ID NO: 81 for use as a drug, wherein the antibody is monovalent or bivalent. In another embodiment, the invention pertains to an antibody having VH of SEQ ID NO: 90 and VL of SEQ ID NO: 89 for use as a drug, wherein the antibody is monovalent or bivalent. In another embodiment, the invention pertains to an antibody having VH of SEQ ID NO: 106 and VL of SEQ ID NO: 105 for use as a drug, wherein the antibody is monovalent or bivalent. In another embodiment, the invention pertains to an antibody having VH of SEQ ID NO: 108 and VL of SEQ ID NO: 107 for use as a drug, wherein the antibody is monovalent or bivalent. In another embodiment, the invention pertains to an antibody having VH of SEQ ID NO: 128 and VL of SEQ ID NO: 127 for use as a drug, wherein the antibody is monovalent or bivalent. In another embodiment, the invention pertains to an antibody having VH of SEQ ID NO: 130 and VL of SEQ ID NO: 129 for use as a drug, wherein the antibody is monovalent or bivalent. In another embodiment, the invention pertains to an antibody having VH of SEQ ID NO: 138 and VL of SEQ ID NO: 137 for use as a drug, wherein the antibody is monovalent or bivalent.

In one aspect, the invention pertains to an antibody or fragment thereof of the invention for use as a medicament. In one aspect, the invention pertains to an antibody or fragment thereof of the invention for use as a medicament for treatment of an LRP6 expressing cancer. In one aspect, the invention pertains to an antibody or fragment thereof of the invention for use as a medicament for treatment of an LRP6 expressing cancer, wherein the cancer is selected from the group consisting of breast cancer, lung cancer, multiple myeloma, ovarian cancer, liver cancer, bladder cancer, gastric cancer, prostate cancer, acute myeloid leukemia, chronic myeloid leukemia, osteosarcoma, squamous cell carcinoma, and melanoma.

Brief Description of Figures

Figure 1 is a graph showing FACS EC₅₀ determination of selected Fabs on PA1 cells, U266 cells and Daudi cells and the corresponding mRNA expression data (A) and knockdown of LRP6 by shRNA and the corresponding mRNA expression data B;

Figure 2A-L are graphs showing anti-LRP6 Fab fragments activity in HEK293T/17 STF cells (gene reporter assay) expressing Wnt1 or Wnt3A ligands. The data shows that anti-LRP6 Fabs selectively block Wnt1 or Wnt3 signaling;

Figure 3 shows the cross-reactivity values of anti-LRP6 β -propeller 1 and β -propeller 3 antibodies for human, mouse and cynomolgus monkey;

Figure 4 is a graph showing transient expression of various WNT ligands in HEK293T/17 STF cells (gene reporter assay) and treatment with anti-LRP6 antibodies, showing activity inhibition of particular WNTs based on antibody binding/blocking to specific β -propeller regions of LRP6;

Figure 5 is a bar chart showing that Fab conversion to IgG results in potentiation of signal from the non-blocked Wnt ligand;

Figure 6 is a western blot showing selective target inhibition of LRP6 in cellular systems;

Figure 7 is a graph showing a single i.v. dose of an LRP6 antibody that binds to β -propeller 1 region at 5mg/kg in a rodent;

Figure 8A is a table that shows genes in MMTV-Wnt1 tumors that were upregulated >2-fold relative to t=0 control with an adjusted P-value of <0.01 and Figure 8B is a table that shows genes that were downregulated >2-fold relative to t=0 control with an adjusted P-value of <0.01 8 h after administration of a single dose of MOR08168 (5 mg/kg) to MMTV-Wnt1 tumors bearing mice;

Figure 9A is a graph showing Propeller 1, but not Propeller 3 mAb, causes in vivo tumor regression in MMTV-Wnt1 model. Figure 9B is a graph showing the effect of different doses of the Propeller 1 mAb on the growth of the MMTV-Wnt1 tumor model;

Figure 10 is a graph showing Propeller 3, but not Propeller 1 mAb, causes inhibition of tumor growth in a MMTV-Wnt3 model;

Figure 11 is a graph showing Propeller 3, but not Propeller 1 mAb causes inhibition of Wnt3A-induced Super Top Flash activity in PA-1 cells *in vivo*;

Figure 12 is a figure showing solvent protected regions of LRP6 PD3-4 by MOR06475 by HDx MS (A) and that mutations of specific residues result in loss of binding of scFv MOR06475 (B);

Figure 13 is a schematic showing the β -propeller regions of LRP6;

Figure 14 is a photograph of an SDS-PAGE gel showing that all scFv molecules successfully expressed and purified from *E. coli*;

Figure 15 A-D are schematic example of multivalent antibodies. (15A) scFv scFv attached to the C-terminus of full IgG (15B) scFv scFv attached to the N-terminus of Fc (15C) scFv scFv attached to the C-terminus of Fc (15D) scFv scFv attached to the N and C terminus of Fc;

Figure 16 is a photograph of an SDS-PAGE gel showing purified biparatopic anti-LRP6 IgG scFv under non-reduced (lane 1) and reduced (lane 2) conditions;

Figure 17 shows activity in STF assay of a biparatopic antibody and respective component parts separately;

Figure 18 shows activity in STF assay of linker length comparisons in scFv molecules;

Figure 19 is a table showing the binding activity a biparatopic antibody;

Figure 20 shows the activity of a biparatopic antibody and a Prop3 antibody but not a Prop1 antibody in a PA-1/Wnt3a L-cell co-culture model;

Figure 21 is a graph showing a comparison between single i.v. doses of a Prop1 LRP6 antibody and a Prop1/3 biparatopic antibody at 5mg/kg in a rodent;

Figure 22 is a graph showing both Propeller 1 and biparatopic propeller 1/3 antibodies cause *in vivo* tumor regression in MMTV-Wnt1 model;

Figure 23 is a graph showing dose-response relationship of a Prop1/3 binding biparatopic antibody in MMTV-Wnt1 model;

Figure 24 shows that differentiation of murine MMTV-Wnt1 mammary tumors is induced by antagonistic LRP6 antibodies. A-B) Fragments of MMTV-Wnt1 tumors were

implanted subcutaneously into nude mice. Tumor-bearing mice were treated with either a single dose of PBS (control) or 5mg/kg MOR08168IgG1LALA 6475 scfv. A) Representative images of Oil Red O staining for lipid. B) Quantification of Oil Red O staining. Graph represents mean \pm SEM values. n=4 in the 72 hour group, n=3 in 24 hour group, n=2 in the 5 Day group, and n=1 for PBS (control);

Figure 25 is a graph showing activity of Prop1/3 binding biparatopic antibody in the E-Cadherin negative MDA-MB231 xenograft model;

Figure 26 shows the affinity and binding kinetics of MOR08168, MOR06475 and MOR08168IgG1LALA 6475 scfv to recombinant LRP6 PD1/2 and PD3/4. A) summary table of the affinities and on/off rates as determined by Biacore analysis. B) representative binding curves of the anti-LRP6 molecules for corresponding LRP6 receptor domains, PD1/2 and PD3/4. C) sequential binding of LRP6 PD1/2 and PD3/4 to MOR08168IgG1LALA 6475 scfv;

Figure 27 shows a schematic drawing of IgG based biparatopic antibodies;

Figure 28 are photographs of SDS-PAGE gels showing the optimization of anti-LRP6 scFv expression in *E. coli*;

Figure 29 is a table showing the effect of single mutations in MOR06475 scFv on T_m;

Figure 30 is a table showing the effect of single mutations in MOR08168 scfv on T_m;

Figure 31 is a table showing the effect of double mutations in MOR08168 scFv on T_m in material expressed in both bacterial and mammalian systems;

Figure 32 is a table summarizing the binding and functional activities of the WILD TYPE and single/double mutated versions of MOR06475 and MOR08168 scFvs in ELISA, Proteon affinity and STF reporter gene assays;

Figure 33 is an illustration of selected examples of the designed mutations. In all figures, the protein backbone is rendered in ribbon diagram while selected side chains are rendered as sticks. (a): In the homology model of scFv6475, VH:I37 is close to two aromatic residues, which were VL:F98 and VH:W103. (b) In the VH:I37F mutant of scFv6475, VH:F37 and VH:W103 could form a perpendicular pi-pi stacking interaction, while VH:F37 and VL:F98 could form another perpendicular pi-pi stacking interaction.

(c) In the homology model of scFv8168, the hydrophobic residue VH:V33 is close to a polar residue VH:N100a. (d) In the VH:V33N mutant of scFv8168, the VH:N33 side chain could form a hydrogen bond with VH:N100a, suggested by homology modeling. The hydrogen bond between the two residues is illustrated by a bond. (e): In the homology model of scFv8168, the charged residue VH:K43 did not form a salt bridge with the hydrophobic residue VH:V85. (f): The two charged side chains of VH:K43 and VH:E85 could form a salt bridge due to the VH:V85E mutation on scFv8168. The distance between the two charge groups could be 2.61Å; and

Figure 34 is a table showing thermostability measurements of biparatopic antibodies.

Detailed Description of the Invention

Definitions

In order that the present invention may be more readily understood, certain terms are first defined. Additional definitions are set forth throughout the detailed description.

The phrase “immune response” as used herein refers to the action of, for example, lymphocytes, antigen presenting cells, phagocytic cells, granulocytes, and soluble macromolecules produced by the above cells or the liver (including antibodies, cytokines, and complement) that results in selective damage to, destruction of, or elimination from the human body of invading pathogens, cells or tissues infected with pathogens, cancerous cells, or, in cases of autoimmunity or pathological inflammation, normal human cells or tissues.

The phrase “signal transduction pathway” or “signaling activity” as used herein refers to a biochemical causal relationship generally initiated by a protein-protein interaction such as binding of a growth factor to a receptor, resulting in transmission of a signal from one portion of a cell to another portion of a cell. For LRP6, the transmission involves specific phosphorylation of one or more tyrosine, serine, or threonine residues on one or more proteins in the series of reactions causing signal transduction. Penultimate processes typically include nuclear events, resulting in a change in gene expression.

The phrase “Wnt signaling pathway” as used herein refers to the canonical Wnt pathway in which members of the Wnt family of secreted protein ligands bind a receptor complex

of LRP and Frizzled (FZD) allowing β -catenin to be translocated into the nucleus, interact with the LEF/TCF transcription factors and activate target gene expression. The Wnt signaling pathway can be measured using a Wnt reporter gene assay or other measure of Wnt directed signaling (e.g., LRP6 phosphorylation, β -catenin stabilization and nuclear translocation, cellular proliferation/ survival) as described herein.

The phrase "Wnt 1 signaling pathway" refers to a canonical Wnt pathway that is activated by LRP6 interacting with the Wnt1 ligand and the class of Wnt1 binding ligands, such as Wnt2, Wnt6, Wnt7a, Wnt7b, Wnt9a, Wnt10a, or Wnt10b.

The phrase "Wnt 3 signaling pathway" refers to a canonical Wnt pathway that is activated by LRP6 interacting with the Wnt3 or a Wnt3a ligand.

The term LRP6 refers to human LRP6 as defined in Accession No. NP002327.

The term "antibody" as used herein refers to whole antibodies that interact with (e.g., by binding, steric hinderance, stabilizing/destabilizing, spatial distribution) an LRP6 epitope and inhibit signal transduction. A naturally occurring "antibody" is a glycoprotein comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds. Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, CH1, CH2 and CH3. Each light chain is comprised of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region is comprised of one domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is composed of three CDRs and four FRs arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system. The term "antibody" includes for example, monoclonal antibodies, human antibodies, humanized antibodies, camelised antibodies, chimeric antibodies, single-chain Fvs (scFv), disulfide-linked Fvs (sdFv), Fab fragments, F (ab') fragments, and anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id

antibodies to antibodies of the invention), and epitope-binding fragments of any of the above. The antibodies can be of any isotype (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass.

Both the light and heavy chains are divided into regions of structural and functional homology. The terms “constant” and “variable” are used functionally. In this regard, it will be appreciated that the variable domains of both the light (VL) and heavy (VH) chain portions determine antigen recognition and specificity. Conversely, the constant domains of the light chain (CL) and the heavy chain (CH1, CH2 or CH3) confer important biological properties such as secretion, transplacental mobility, Fc receptor binding, complement binding, and the like. By convention the numbering of the constant region domains increases as they become more distal from the antigen binding site or amino-terminus of the antibody. The N-terminus is a variable region and at the C-terminus is a constant region; the CH3 and CL domains actually comprise the carboxy-terminus of the heavy and light chain, respectively.

The phrase “antibody fragment”, as used herein, refers to one or more portions of an antibody that retain the ability to specifically interact with (e.g., by binding, steric hinderance, stabilizing/destabilizing, spatial distribution) an LRP6 epitope and inhibit signal transduction. Examples of binding fragments include, but are not limited to, a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; a F(ab)₂ fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; a Fd fragment consisting of the VH and CH1 domains; a Fv fragment consisting of the VL and VH domains of a single arm of an antibody; a dAb fragment (Ward *et al.*, (1989) Nature 341:544-546), which consists of a VH domain; and an isolated complementarity determining region (CDR).

Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird *et al.*, (1988) Science 242:423-426; and Huston *et al.*, (1988) Proc. Natl. Acad. Sci. 85:5879-5883). Such single chain antibodies are also intended to be encompassed within the term “antibody fragment”. These antibody fragments are obtained using conventional

techniques known to those of skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies.

Antibody fragments can also be incorporated into single domain antibodies, maxibodies, minibodies, diabodies, triabodies, tetrabodies, v-NAR and bis-scFv (see, *e.g.*, Hollinger and Hudson, (2005) *Nature Biotechnology* 23: 1126-1136). Antibody fragments can be grafted into scaffolds based on polypeptides such as Fibronectin type III (Fn3) (see U.S. Pat. No. 6,703,199, which describes fibronectin polypeptide monobodies).

Antibody fragments can be incorporated into single chain molecules comprising a pair of tandem Fv segments (VH-CH1-VH-CH1) which, together with complementary light chain polypeptides, form a pair of antigen binding regions (Zapata *et al.*, (1995) *Protein Eng.* 8:1057-1062; and U.S. Pat. No. 5,641,870).

The term “multivalent antibody” refers to a single binding molecule with more than one valency, where “valency” is described as the number of antigen-binding moieties present per molecule of an antibody construct. As such, the single binding molecule can bind to more than one binding site on a target receptor. Examples of multivalent antibodies include, but are not limited to bivalent antibodies, trivalent antibodies, tetravalent antibodies, pentavalent antibodies, and the like, as well as bispecific antibodies and biparatopic antibodies. For example, for the LRP6 receptor, the multivalent antibody (*e.g.*, an LRP6 biparatopic antibody) has a binding moiety for the β -propeller 1 domain binding site and a binding moiety for the β -propeller 3 domain binding site of LRP6, respectively.

The term “multivalent antibody” also refers to a single binding molecule that has more than one antigen-binding moiety for two separate target receptors. For example, a antibody that binds to both an LRP6 target receptor and a second target receptor that is not LRP6 (such as ErbB, cmet, IGFR1, Smoothed, Notch receptors). In one embodiment, a multivalent antibody is a tetravalent antibody that has four receptor binding domains. A tetravalent molecule may be bispecific and bivalent for each binding site on that target receptor.

The multivalent antibody mediates a biological effect (*e.g.*, which modulates cellular activation (*e.g.*, by binding to a cell surface receptor and resulting in transmission or

inhibition of an activating or inhibitory signal), which results in death of the cell (e.g., by a cell signal induced pathway), or which modulates a disease or disorder in a subject (e.g., by mediating or promoting cell killing, or by modulating the amount of a substance which is bioavailable).

The term “monovalent antibody” as used herein, refers to an antibody that binds to a single epitope on a target receptor such as LRP6.

The term “bivalent antibody” as used herein, refers to an antibody that binds to two epitopes on at least two identical target receptors (e.g., an antibody that binds to the β -propeller 1 domain of two LRP6 receptors, or an antibody that binds to the β -propeller 3 domain of two LRP6 receptors). The bivalent antibody may also crosslink the target receptors to one another. A “bivalent antibody” also refers to an antibody that binds to two different epitopes on at least two identical target receptors.

The term “biparatopic antibody” as used herein, refers to an antibody that binds to two different epitopes on the same target receptor, e.g., an antibody that binds to the β -propeller 1 domain and the β -propeller 3 domain of a single LRP6 receptor. The term also includes an antibody which binds to both the β -propeller 1 and β -propeller 3 domains of at least two LRP6 receptor(s).

The term “bispecific antibody” as used herein, refers to an antibody that binds to two or more different epitopes on at least two different target receptors (e.g., an LRP6 receptor and a receptor that is not a LRP6 receptor).

The phrase “isolated antibody”, as used herein, refers to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds LRP6 is substantially free of antibodies that specifically bind antigens other than LRP6). Moreover, an isolated antibody may be substantially free of other cellular material and/or chemicals. An isolated antibody that specifically binds LRP6 may, however, have cross-reactivity to other antigens, such as LRP6 molecules from other species. Moreover, an isolated antibody may be substantially free of other cellular material and/or chemicals.

The phrases “monoclonal antibody” or “monoclonal antibody composition” as used herein refers to polypeptides, including antibodies, antibody fragments, bispecific antibodies, etc. that have substantially identical to amino acid sequence or are derived from the same genetic source. This term also includes preparations of antibody molecules of single molecular composition. A monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope.

The phrase “human antibody”, as used herein, includes antibodies having variable regions in which both the framework and CDR regions are derived from sequences of human origin. Furthermore, if the antibody contains a constant region, the constant region also is derived from such human sequences, e.g., human germline sequences, or mutated versions of human germline sequences or antibody containing consensus framework sequences derived from human framework sequences analysis, for example, as described in Knappik, *et al.* (2000. *J Mol Biol* 296, 57-86). The structures and locations of immunoglobulin variable domains, e.g., CDRs, may be defined using well known numbering schemes, e.g., the Kabat numbering scheme, the Chothia numbering scheme, or a combination of Kabat and Chothia (see, e.g., *Sequences of Proteins of Immunological Interest*, U.S. Department of Health and Human Services (1991), eds. Kabat *et al.*; Al Lazikani *et al.*, (1997) *J. Mol. Bio.* 273:927-948); Kabat *et al.*, (1991) *Sequences of Proteins of Immunological Interest*, 5th edit., NIH Publication no. 91-3242 U.S. Department of Health and Human Services; Chothia *et al.*, (1987) *J. Mol. Biol.* 196:901-917; Chothia *et al.*, (1989) *Nature* 342:877-883; and Al-Lazikani *et al.*, (1997) *J. Mol. Biol.* 273:927-948.

The human antibodies of the invention may include amino acid residues not encoded by human sequences (e.g., mutations introduced by random or site-specific mutagenesis *in vitro* or by somatic mutation *in vivo*, or a conservative substitution to promote stability or manufacturing). However, the term “human antibody”, as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.

The phrase “human monoclonal antibody” as used herein refers to antibodies displaying a single binding specificity which have variable regions in which both the framework and CDR regions are derived from human sequences. In one embodiment, the human

monoclonal antibodies are produced by a hybridoma which includes a B cell obtained from a transgenic nonhuman animal, e.g., a transgenic mouse, having a genome comprising a human heavy chain transgene and a light chain transgene fused to an immortalized cell.

The phrase “recombinant human antibody”, as used herein, includes all human antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies isolated from an animal (e.g., a mouse) that is transgenic or transchromosomal for human immunoglobulin genes or a hybridoma prepared therefrom, antibodies isolated from a host cell transformed to express the human antibody, e.g., from a transfectoma, antibodies isolated from a recombinant, combinatorial human antibody library, and antibodies prepared, expressed, created or isolated by any other means that involve splicing of all or a portion of a human immunoglobulin gene, sequences to other DNA sequences. Such recombinant human antibodies have variable regions in which the framework and CDR regions are derived from human germline immunoglobulin sequences. In certain embodiments, however, such recombinant human antibodies can be subjected to *in vitro* mutagenesis (or, when an animal transgenic for human Ig sequences is used, *in vivo* somatic mutagenesis) and thus the amino acid sequences of the V_H and V_L regions of the recombinant antibodies are sequences that, while derived from and related to human germline V_H and V_L sequences, may not naturally exist within the human antibody germline repertoire *in vivo*.

The term “linker” as used herein refers to a peptide linker that consists of glycine and serine residues used to link an scFv to an IgG. An exemplary Gly/Ser linker comprises the amino acid sequence (Gly-Gly-Ser)₂, i.e., (Gly₂ Ser)_n where n is a positive integer equal to or greater than 1. For example, n=1, n=2, n=3, n=4, n=5 and n=6, n=7, n=8, n=9 and n=10. In one embodiment, the linkers include, but are not limited to, (Gly₄ Ser)₄ or (Gly₄ Ser)₃. In another embodiment, the linkers Glu and Lys residues interspersed within the Gly-Ser linkers for better solubility. In another embodiment, the linkers include multiple repeats of (Gly₂Ser), (GlySer) or (Gly₃Ser). In another embodiment, the linkers include combinations and multiples of (Gly₃Ser)+(Gly₄Ser)+(GlySer). In another embodiment, Ser can be replaced with Ala e.g., (Gly₄Ala) or (Gly₃Ala). In another embodiment, the linker comprises any combination of Gly, Ser and Pro. In yet another embodiment, the

linker comprises the motif (GluAlaAlaAlaLys)_n, where n is a positive integer equal to or greater than 1.

The term “Fc region” as used herein refers to a polypeptide comprising the CH3, CH2 and at least a portion of the hinge region of a constant domain of an antibody. Optionally, an Fc region may include a CH4 domain, present in some antibody classes. An Fc region, may comprise the entire hinge region of a constant domain of an antibody. In one embodiment, the invention comprises an Fc region and a CH1 region of an antibody. In one embodiment, the invention comprises an Fc region CH3 region of an antibody. In another embodiment, the invention comprises an Fc region, a CH1 region and a Ckappa/lambda region from the constant domain of an antibody. In one embodiment, a binding molecule of the invention comprises a constant region, e.g., a heavy chain constant region. In one embodiment, such a constant region is modified compared to a wild-type constant region. That is, the polypeptides of the invention disclosed herein may comprise alterations or modifications to one or more of the three heavy chain constant domains (CH1, CH2 or CH3) and/or to the light chain constant region domain (CL). Exemplary modifications include additions, deletions or substitutions of one or more amino acids in one or more domains. Such changes may be included to optimize effector function, half-life, etc.

The term “binding site” as used herein comprises an area on a target receptor to which an antibody or antigen binding fragment selectively binds. For example, the binding sites on LRP6 include the β- propeller 1 binding domain, β- propeller 2 binding domain, β- propeller 3 binding domain, and β- propeller 4 binding domain.

The term “epitope” as used herein refers to any determinant capable of binding with high affinity to an immunoglobulin. An epitope is a region of an antigen that is bound by an antibody that specifically targets that antigen, and when the antigen is a protein, includes specific amino acids that directly contact the antibody. Most often, epitopes reside on proteins, but in some instances, may reside on other kinds of molecules, such as nucleic acids. Epitope determinants may include chemically active surface groupings of molecules such as amino acids, sugar side chains, phosphoryl or sulfonyl groups, and may have specific three dimensional structural characteristics, and/or specific charge characteristics.

Generally, antibodies specific for a particular target antigen will bind an epitope on the target antigen in a complex mixture of proteins and/or macromolecules.

Regions of a given polypeptide that include an epitope can be identified using any number of epitope mapping techniques, well known in the art. See, e.g., *Epitope Mapping Protocols in Methods in Molecular Biology*, Vol. 66 (Glenn E. Morris, Ed., 1996) Humana Press, Totowa, New Jersey. For example, linear epitopes may be determined by e.g., concurrently synthesizing large numbers of peptides on solid supports, the peptides corresponding to portions of the protein molecule, and reacting the peptides with antibodies while the peptides are still attached to the supports. Such techniques are known in the art and described in, e.g., U.S. Patent No. 4,708,871 ; Geysen *et al.*, (1984) *Proc. Natl. Acad. Sci. USA* 8:3998-4002; Geysen *et al.*, (1985) *Proc. Natl. Acad. Sci. USA* 82:78-182; Geysen *et al.*, (1986) *Mol. Immunol.* 23:709-715. Similarly, conformational epitopes are readily identified by determining spatial conformation of amino acids such as by, e.g., x-ray crystallography and two-dimensional nuclear magnetic resonance. See, e.g., *Epitope Mapping Protocols*, supra. Antigenic regions of proteins can also be identified using standard antigenicity and hydrophathy plots, such as those calculated using, e.g., the Omega version 1.0 software program available from the Oxford Molecular Group. This computer program employs the Hopp/Woods method, Hopp *et al.*, (1981) *Proc. Natl. Acad. Sci. USA* 78:3824-3828; for determining antigenicity profiles, and the Kyte-Doolittle technique, Kyte *et al.*, (1982) *J. Mol. Biol.* 157:105-132; for hydrophathy plots.

The term “specific binding” between two entities means a binding with an equilibrium constant (K_A) (k_{on}/k_{off}) of at least $10^2 M^{-1}$, at least $5 \times 10^2 M^{-1}$, at least $10^3 M^{-1}$, at least $5 \times 10^3 M^{-1}$, at least $10^4 M^{-1}$, at least $5 \times 10^4 M^{-1}$, at least $10^5 M^{-1}$, at least $5 \times 10^5 M^{-1}$, at least $10^6 M^{-1}$, at least $5 \times 10^6 M^{-1}$, at least $10^7 M^{-1}$, at least $5 \times 10^7 M^{-1}$, at least $10^8 M^{-1}$, at least $5 \times 10^8 M^{-1}$, at least $10^9 M^{-1}$, at least $5 \times 10^9 M^{-1}$, at least $10^{10} M^{-1}$, at least $5 \times 10^{10} M^{-1}$, at least $10^{11} M^{-1}$, at least $5 \times 10^{11} M^{-1}$, at least $10^{12} M^{-1}$, at least $5 \times 10^{12} M^{-1}$, at least $10^{13} M^{-1}$, at least $5 \times 10^{13} M^{-1}$, at least $10^{14} M^{-1}$, at least $5 \times 10^{14} M^{-1}$, at least $10^{15} M^{-1}$, or at least $5 \times 10^{15} M^{-1}$.

The phrase “specifically (or selectively) binds” to an antibody (e.g., a LRP6 antibody) refers to a binding reaction that is determinative of the presence of a cognate antigen (e.g., a human LRP6) in a heterogeneous population of proteins and other biologics. In addition to the equilibrium constant (K_A) noted above, an LRP6 antibody of the invention

typically also has a dissociation rate constant (K_D) (k_{off}/k_{on}) of less than $5 \times 10^{-2}M$, less than $10^{-2}M$, less than $5 \times 10^{-3}M$, less than $10^{-3}M$, less than $5 \times 10^{-4}M$, less than $10^{-4}M$, less than $5 \times 10^{-5}M$, less than $10^{-5}M$, less than $5 \times 10^{-6}M$, less than $10^{-6}M$, less than $5 \times 10^{-7}M$, less than $10^{-7}M$, less than $5 \times 10^{-8}M$, less than $10^{-8}M$, less than $5 \times 10^{-9}M$, less than $10^{-9}M$, less than $5 \times 10^{-10}M$, less than $10^{-10}M$, less than $5 \times 10^{-11}M$, less than $10^{-11}M$, less than $5 \times 10^{-12}M$, less than $10^{-12}M$, less than $5 \times 10^{-13}M$, less than $10^{-13}M$, less than $5 \times 10^{-14}M$, less than $10^{-14}M$, less than $5 \times 10^{-15}M$, or less than $10^{-15}M$ or lower, and binds to LRP6 with an affinity that is at least two-fold greater than its affinity for binding to a non-specific antigen (e.g., HSA). In one embodiment, the LRP6 antibody has dissociation constant (K_d) of less than 3000 pM, less than 2500 pM, less than 2000 pM, less than 1500 pM, less than 1000 pM, less than 750 pM, less than 500 pM, less than 250 pM, less than 200 pM, less than 150 pM, less than 100 pM, less than 75 pM, less than 10 pM, less than 1 pM as assessed using a method described herein or known to one of skill in the art (e.g., a BIAcore assay, ELISA, FACS, SET) (Biacore International AB, Uppsala, Sweden).

The term " K_{assoc} " or " K_a ", as used herein, refers to the association rate of a particular antibody-antigen interaction, whereas the term " K_{dis} " or " K_d ," as used herein, refers to the dissociation rate of a particular antibody-antigen interaction. The term " K_D ", as used herein, refers to the dissociation constant, which is obtained from the ratio of K_d to K_a (i.e. K_d/K_a) and is expressed as a molar concentration (M). K_D values for antibodies can be determined using methods well established in the art. A method for determining the K_D of an antibody is by using surface plasmon resonance, or using a biosensor system such as a Biacore[®] system.

The term "affinity" as used herein refers to the strength of interaction between antibody and antigen at single antigenic sites. Within each antigenic site, the variable region of the antibody "arm" interacts through weak non-covalent forces with antigen at numerous sites; the more interactions, the stronger the affinity.

The term "avidity" as used herein refers to an informative measure of the overall stability or strength of the antibody-antigen complex. It is controlled by three major factors: antibody epitope affinity; the valence of both the antigen and antibody; and the structural arrangement of the interacting parts. Ultimately these factors define the specificity of the antibody, that is, the likelihood that the particular antibody is binding to a precise antigen epitope.

The phrase “antagonist antibody” as used herein refers to an antibody that binds with LRP6 and inhibits the biological activity of canonical Wnt signaling, e.g., reduces, decreases and/or inhibits LRP6 induced signaling activity in a Wnt reporter gene assay, or a phospho LRP6 assay. Examples of assays are described in more details in the examples below. In some embodiments, the antibodies reduce, decrease or inhibit LRP6 induced activity as measured in a Wnt reporter gene assay at an IC_{50} of 10nM or less, 1nM or less, or 100pM or less, 10pM, 1pM, 0.5pM, 0.1pM. In some embodiments, the activities of the antibodies can be measured by binding to LRP6 using SET, ELISA, FACS, Scatchard at an IC_{50} of 10nM or less, 1nM or less, 0.5 pM, or 100pM or less. In one embodiment, the IC_{50} is less than 300 μ M (0.3pM). In another embodiment, the IC_{50} is equal to 300 μ M (0.3pM). In yet another embodiment, IgG potentiates the activity of LRP6 Wnt.

The term “Wnt 1” as used herein refers to Wnt1, Wnt2, Wnt6, Wnt7a, Wnt7b, Wnt9a, Wnt10a, or Wnt10b.

The term “Wnt 3a” as used herein refers to Wnt3a and Wnt3.

The term “potentiate” as used herein refers to a process whereby the Wnt signal is activated and enhanced upon conversion of a fragment of an antibody to a full length IgG LRP6 antibody in the presence of a Wnt ligand.

The term “no significant potentiation” or “avoids potentiation” refers to a Wnt signal that is not activated or enhanced compared with a control antibody or fragment thereof that binds to the same epitope. No significant potentiation can be at least 10% less than control antibody or fragment thereof, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100% less than then control antibody or fragment thereof.

The term “cluster” as used herein refers to any protein that gathers or groups together LRP6 receptors and potentiates Wnt signaling. Examples of such proteins include, but are not limited to, Wnt 1 ligands, Wnt 3a ligands and Wnt 3 ligands. These proteins can cause multimerization, e.g., dimerization of two endogenous LRP6 receptors. This dimerization may result in increased avidity due to increased interactions of LRP6, which in the presence of a Wnt ligand can potentiate a Wnt signal.

The phrase “isolated antibody” refers to an antibody that is substantially free of other antibodies having different antigenic specificities (*e.g.*, an isolated antibody that specifically binds LRP6 is substantially free of antibodies that specifically bind antigens other than LRP6). An isolated antibody that specifically binds LRP6 may, however, have cross-reactivity to other antigens. Moreover, an isolated antibody may be substantially free of other cellular material and/or chemicals.

The phrase “conservatively modified variant” applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are “silent variations,” which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation of the nucleic acid. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid that encodes a polypeptide is implicit in each described sequence.

For polypeptide sequences, “conservatively modified variants” include individual substitutions, deletions or additions to a polypeptide sequence which result in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention. The following eight groups contain amino acids that are conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and

8) Cysteine (C), Methionine (M) (see, *e.g.*, Creighton, Proteins (1984)). In some embodiments, the term "conservative sequence modifications" are used to refer to amino acid modifications that do not significantly affect or alter the binding characteristics of the antibody containing the amino acid sequence.

The terms "cross-block", "cross-blocked" and "cross-blocking" are used interchangeably herein to mean the ability of an antibody or other binding agent to interfere with the binding of other antibodies or binding agents to LRP6 in a standard competitive binding assay.

The ability or extent to which an antibody or other binding agent is able to interfere with the binding of another antibody or binding molecule to LRP6, and therefore whether it can be said to cross-block according to the invention, can be determined using standard competition binding assays. One suitable assay involves the use of the Biacore technology (*e.g.* by using the BIAcore 3000 instrument (Biacore, Uppsala, Sweden)), which can measure the extent of interactions using surface plasmon resonance technology. Another assay for measuring cross-blocking uses an ELISA-based approach.

The term "optimized" as used herein refers to a nucleotide sequence has been altered to encode an amino acid sequence using codons that are preferred in the production cell or organism, generally a eukaryotic cell, for example, a cell of *Pichia*, a cell of *Trichoderma*, a Chinese Hamster Ovary cell (CHO) or a human cell. The optimized nucleotide sequence is engineered to retain completely or as much as possible the amino acid sequence originally encoded by the starting nucleotide sequence, which is also known as the "parental" sequence.

Standard assays to evaluate the binding ability of the antibodies toward LRP6 of various species are known in the art, including for example, ELISAs, western blots and RIAs. Suitable assays are described in detail in the Examples. The binding kinetics (*e.g.*, binding affinity) of the antibodies also can be assessed by standard assays known in the art, such as by Biacore analysis, or FACS relative affinity (Scatchard). Assays to evaluate the effects of the antibodies on functional properties of LRP6 (*e.g.*, receptor binding assays, modulating the Wnt pathway) are described in further detail in the Examples.

Accordingly, an antibody that "inhibits" one or more of these LRP6 functional properties (*e.g.*, biochemical, immunochemical, cellular, physiological or other biological activities,

or the like) as determined according to methodologies known to the art and described herein, will be understood to relate to a statistically significant decrease in the particular activity relative to that seen in the absence of the antibody (e.g., or when a control antibody of irrelevant specificity is present). An antibody that inhibits LRP6 activity effects such a statistically significant decrease by at least 10% of the measured parameter, by at least 50%, 80% or 90%, and in certain embodiments an antibody of the invention may inhibit greater than 95%, 98% or 99% of LRP6 functional activity.

The phrases "percent identical" or "percent identity," in the context of two or more nucleic acids or polypeptide sequences, refers to two or more sequences or subsequences that are the same. Two sequences are "substantially identical" if two sequences have a specified percentage of amino acid residues or nucleotides that are the same (*i.e.*, 60% identity, optionally 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identity over a specified region, or, when not specified, over the entire sequence), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. Optionally, the identity exists over a region that is at least about 50 nucleotides (or 10 amino acids) in length, or more preferably over a region that is 100 to 500 or 1000 or more nucleotides (or 20, 50, 200 or more amino acids) in length.

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

A "comparison window", as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well known in the art. Optimal alignment of sequences for comparison

can be conducted, *e.g.*, by the local homology algorithm of Smith and Waterman (1970) *Adv. Appl. Math.* 2:482c, by the homology alignment algorithm of Needleman and Wunsch (1970) *J. Mol. Biol.* 48:443, by the search for similarity method of Pearson and Lipman, (1988) *Proc. Nat'l. Acad. Sci. USA* 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (see, *e.g.*, Brent *et al.*, (2003) *Current Protocols in Molecular Biology*).

Two examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul *et al.*, (1977) *Nuc. Acids Res.* 25:3389-3402; and Altschul *et al.*, (1990) *J. Mol. Biol.* 215:403-410, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul *et al.*, *supra*). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W , T , and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) or 10, $M=5$, $N=-4$ and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and

Henikoff, (1989) Proc. Natl. Acad. Sci. USA 89:10915) alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands.

The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, *e.g.*, Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5787). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001.

The percent identity between two amino acid sequences can also be determined using the algorithm of E. Meyers and W. Miller (Comput. Appl. Biosci. 4:11-17 (1988)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. In addition, the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (J. Mol. Biol. 48:444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at www.gcg.com), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.

Other than percentage of sequence identity noted above, another indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions, as described below. Yet another indication that two nucleic acid sequences are substantially identical is that the same primers can be used to amplify the sequence.

The phrase "nucleic acid" is used herein interchangeably with the term "polynucleotide" and refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either

single- or double-stranded form. The term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides. Examples of such analogs include, without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs).

Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (*e.g.*, degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated. Specifically, as detailed below, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzner *et al.*, (1991) *Nucleic Acid Res.* 19:5081; Ohtsuka *et al.*, (1985) *J. Biol. Chem.* 260:2605-2608; and Rossolini *et al.*, (1994) *Mol. Cell. Probes* 8:91-98).

The phrase “operably linked” refers to a functional relationship between two or more polynucleotide (*e.g.*, DNA) segments. Typically, it refers to the functional relationship of a transcriptional regulatory sequence to a transcribed sequence. For example, a promoter or enhancer sequence is operably linked to a coding sequence if it stimulates or modulates the transcription of the coding sequence in an appropriate host cell or other expression system. Generally, promoter transcriptional regulatory sequences that are operably linked to a transcribed sequence are physically contiguous to the transcribed sequence, *i.e.*, they are *cis*-acting. However, some transcriptional regulatory sequences, such as enhancers, need not be physically contiguous or located in close proximity to the coding sequences whose transcription they enhance.

The terms “polypeptide” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymer. Unless otherwise indicated, a particular polypeptide sequence also implicitly encompasses conservatively modified variants thereof.

The term “subject” includes human and non-human animals. Non-human animals include all vertebrates, *e.g.*, mammals and non-mammals, such as non-human primates, sheep, dog, cow, chickens, amphibians, and reptiles. Except when noted, the terms “patient” or “subject” are used herein interchangeably.

The term “anti-cancer agent” means any agent that can be used to treat a cell proliferative disorder such as cancer, including cytotoxic agents, chemotherapeutic agents, radiotherapy and radiotherapeutic agents, targeted anti-cancer agents, and immunotherapeutic agents.

“Tumor” refers to neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.

The term “anti-tumor activity” means a reduction in the rate of tumor cell proliferation, viability, or metastatic activity. A possible way of showing anti-tumor activity is show a decline in growth rate of abnormal cells that arises during therapy or tumor size stability or reduction. Such activity can be assessed using accepted *in vitro* or *in vivo* tumor models, including but not limited to xenograft models, allograft models, MMTV models, and other known models known in the art to investigate anti-tumor activity.

The term “malignancy” refers to a non-benign tumor or a cancer. As used herein, the term “cancer” includes a malignancy characterized by deregulated or uncontrolled cell growth. Exemplary cancers include: carcinomas, sarcomas, leukemias, and lymphomas. The term “cancer” includes primary malignant tumors (*e.g.*, those whose cells have not migrated to sites in the subject's body other than the site of the original tumor) and secondary malignant tumors (*e.g.*, those arising from metastasis, the migration of tumor cells to secondary sites that are different from the site of the original tumor).

Various aspects of the invention are described in further detail in the following sections and subsections.

LRP6 and the Wnt-Signaling Pathway

The invention pertains to LRP6 antibodies and uses thereof. Inhibition of Wnt signaling by molecules directed to LRP6 lead to a loss of canonical Wnt signaling. Therefore, antagonism of LRP6 receptor function with an antibody will inhibit Wnt signaling and aid in diseases associated with canonical Wnt signaling, *e.g.*, cancer. In particular, the LRP6

antibodies can specifically increase or decrease signaling mediated by Wnt1 or Wnt3a class proteins in different disease settings.

Misregulation of the Wnt/ β -catenin signaling pathway has been linked to various human diseases such as cancer and bone disorders. Molecules that restore the balance of Wnt signaling in these diseases might have therapeutic potential. Using phage-based panning, LRP6 antibodies have been identified that either inhibit or enhance Wnt signaling. Remarkably, two classes of LRP6 antagonistic antibodies have been identified. One class of antibodies specifically inhibits Wnt proteins represented by Wnt1, while the second class specifically inhibits Wnt proteins represented by Wnt3a. Epitope mapping experiments indicate that Wnt1-specific and Wnt3a-specific LRP6 antibodies bind to the first propeller and the third propeller of LRP6 respectively, suggesting that Wnt1 and Wnt3a proteins bind to different propellers of LRP6 (See International Serial No. PCT/EP2008/064821 filed October 31, 2008, the contents of which are incorporated herein by reference in their entirety).

Additional characterization of the Propeller 3 domain of LRP6 identified residues in this domain responsible for interaction with the antibodies. Antibody binding sites within YWTD-EGF region of Propeller 3 were identified using hydrogen-deuterium exchange (HDx) mass spectrometry (MS) and correspond to a concave surface between blade 1 and 6 of Propeller 3 domain.

The Wnt signaling pathway is important in embryonic development and postnatal tissue maintenance. This is achieved by directing a specific set of genes that control temporal and spatial regulation of cell growth, movement and cell survival (reviewed in Barker and Clevers (2006) *Nature Rev.* 5:997). Proper regulation of this pathway is important for maintaining tissue homeostasis. Chronic activation of this pathway promotes uncontrolled cell growth and survival and can consequently drive the development of cell proliferative diseases, such as cancer. Alternatively, abnormal inhibition of this pathway can result in many disease states, for example loss of bone mass and other bone diseases. Wnt proteins initiate downstream signaling by interacting with a Frizzled receptor and one of two cell-surface receptors, which are members of the low-density-lipoprotein receptor (LDLR)-related proteins (LRPs): LRP5 and LRP6 (reviewed in He *et al.*, (2004) *Development* 31:1663-1677).

The role of LRP6 in canonical Wnt signaling was discovered via genetic studies. Mutant mice lacking LRP6 exhibited composite phenotypes similar to mutations in several individual Wnt genes (Pinson *et al.*, (2000) Nature 407:535-538). In *Xenopus* embryos, dominant-negative LRP6 blocked signaling by several Wnt proteins, whereas overexpression of LRP6 activated Wnt/ β -catenin signaling (Tamai *et al.*, (2000) Nature 407:530-535). Furthermore, it has been shown that expression of either LRP6 or LRP5 is necessary for cells to respond to canonical Wnt signaling (reviewed in He *et al.*, *supra*, 2004).

LRP5 and LRP6 are highly homologous and share 73% and 64% identity in their extra- and intracellular domains, respectively. They are widely co-expressed during embryogenesis and in adult tissues and share some functional redundancy.

The extracellular domains of LRP5 and LRP6 comprise three basic domains: 1) a YWTD (tyrosine, tryptophan, threonine, aspartic acid)-type β -propeller region, 2) an EGF (epidermal growth factor)-like domain, and 3) a LDLR type A (LA) domain.

The YWTD-type β -propeller region contains six YWTD repeats of 43-50 amino acid residues each and forms a six-bladed β -propeller structure. In LRP5 and LRP6, there are four YWTD-type β -propeller regions that are each followed by an EGF-like domain, which comprises about 40 amino acid residues with conserved cysteine residues, which in turn are followed by three LA domains. (Springer *et al.*, (1998) J. Mol. Biol. 283:837-862; Jeon *et al.*, (2001) Nat. Struct. Biol. 8:499-504). The β -propeller-EGF-like domains may bind extracellular ligands. The extracellular domain of LRP6 is defined by amino acid residues 19 to 1246 and contains four β -propeller domains at amino acid residues 43-324, 352-627, 654-929, and 957-1250, which correspond to β -propeller regions 1, 2, 3 and 4, respectively. Propeller domains 1-2 include amino acids 19-629, and Propeller domains 3-4 include amino acids 631-1246.

LRP6 Antibodies

The present invention provides antibodies that specifically bind to LRP6 (*e.g.*, human LRP6, cynomolgus LRP6, mouse LRP6, and rat LRP6). The invention is based on the surprising finding that Wnt proteins capable of activating β -catenin signaling can be divided into two classes and they require different propellers of LRP6 for signaling as described in International Serial No. PCT/EP2008/064821 filed October 31, 2008 the

contents of which are incorporated herein by reference in their entirety. In addition, dimeric/bivalent LRP6 antibodies (e.g., IgG) strongly sensitize cells to Wnt signaling, for example through dimerization of endogenous LRP6. These results suggest that Propeller 1 and Propeller 3 are differentially required for signaling activity of Wnt1 and Wnt 3. These findings provide new insights on Wnt-induced LRP6 activation and pave the way for the development of LRP6 antibodies to modulate Wnt signaling in different diseases. The conversion of fragments of the LRP6 antibodies (e.g., Fabs) into an IgG format results in an antibody that clusters LRP6 receptors and in the presence of a ligand protein can potentiate a Wnt signal.

In one embodiment, the antibodies potentiate a Wnt signal. In such an embodiment, the Wnt signal is activated and enhanced upon conversion of a fragment of an antibody to a full length IgG LRP6 antibody in the presence of a Wnt ligand. For example, a Wnt 1 Fab binds to the Propeller 1 region of the LRP6 receptor and blocks Wnt 1 pathway in absence of a Wnt ligand, e.g., Wnt 3. In the presence of a Wnt ligand, e.g., Wnt 3, the Wnt 1 Fab blocks signaling through the Wnt 1 pathway, but signal activation may occur through the Wnt 3 pathway, thereby producing a signal. When the Wnt 1 Fab is converted to a full length Wnt 1 IgG, the Wnt 1 IgG binds to the Propeller 1 regions of two LRP6 receptors and blocks the Wnt 1 pathway, however, in the presence of a Wnt ligand, e.g., Wnt 3; signal activation occurs through the Wnt 3 pathway and is also enhanced. While not required to provide a theory of action, one possible mechanism is that the IgG clusters together two or more LRP6 receptors by binding to the Propeller 1 regions of each LRP6 receptor, which in the presence of a Wnt 3 ligand results in a stronger signal through the Wnt 3 pathway. Dimerization of the LRP6 receptors promotes Wnt signaling, perhaps through the increases avidity of the various interactions involving LRP6.

The reverse results are obtained with a Wnt 3 Fab that binds to the Propeller 3 region of the LRP6 receptor and blocks the Wnt 3 pathway. In the presence of a Wnt 1 ligand, the Wnt 3 Fab blocks the Wnt 3 pathway, but activates the Wnt 1 pathway to generate a signal. When the Wnt 3 Fab is converted to a full length Wnt 3 IgG, the Wnt 3 IgG binds to the Propeller 3 regions of two LRP6 receptors, and in the presence of a Wnt 1 ligand, inhibits signaling through the Wnt 1 pathway. In another embodiment, the antibodies avoid potentiating a Wnt signal. In some embodiments, the present invention provides antibodies that specifically bind to both human and cynomolgus LRP6. In one

embodiment, the LRP6 antibodies are antagonistic antibodies. In another embodiment, the LRP6 antibodies are agonistic antibodies.

As different Wnt proteins require different Propellers of LRP6 for signaling and because clustering or dimerization of LRP6 potentiates Wnt signaling, therapy using the LRP6 antibodies can be regulated by using different combinations of antibodies.

In one embodiment, the LRP6 antibodies are used as monomeric antibodies or fragments thereof such as single chain antibodies, unibodies, and the like. In one embodiment, a monomeric LRP6 antibody that binds to the Propeller 1 region of LRP6 is used in combination with a monomeric LRP6 antibody that binds to the Propeller 3 region of LRP6. In another embodiment, the LRP6 antibodies are used as multimeric antibodies or fragments thereof such as bispecific, biparatopic LRP6 antibodies.

In addition to Wnt ligands LRP6 Propeller 1 antibodies are expected to inhibit the interaction with other Propeller 1 binding ligands (e.g. Sclerostin, Dkk1). Similarly, Propeller 3 antibodies are expected to inhibit the interaction with other propeller 3 binding ligands (e.g. Dkk1). Furthermore, propeller 1 and 3 binding antibodies may be expected to affect the activity of other Wnt signaling modulators e.g. R-spondins.

The present invention also provides antibodies that specifically bind to a LRP6 protein (e.g., human and/or cynomologus LRP6), the antibodies comprising a VH CDR having an amino acid sequence of any one of the VH CDRs listed in Table 1, *infra*. In particular, the invention provides antibodies that specifically bind to a LRP6 protein (e.g., human and/or cynomologus LRP6), the antibodies comprising (or alternatively, consisting of) one, two, three, four, five or more VH CDRs having an amino acid sequence of any of the VH CDRs listed in Table 1, *infra*.

The present invention provides antibodies that specifically bind a LRP6 protein (e.g., human and/or cynomologus LRP6), the antibodies comprising a VH domain having an amino acid sequence of SEQ ID NOs: 14, 34, 36, 44, 60 and 62. The present invention provides antibodies that specifically bind to a LRP6 protein (e.g., human and/or cynomologus LRP6), the antibodies comprising a VL domain having an amino acid sequence of SEQ ID NOs: 13, 33, 35, 43, 59, and 61.

The present invention provides antibodies that specifically bind a LRP6 protein (e.g., human and/or cynomologus LRP6), the antibodies comprising a VH domain having an

amino acid sequence of SEQ ID NOs: 82, 89, 106, 108, 128, 130, and 138. The present invention provides antibodies that specifically bind to a LRP6 protein (*e.g.*, human and/or cynomologus LRP6), the antibodies comprising a VL domain having an amino acid sequence of SEQ ID NOs: 81, 90, 105, 107, 127, and 129.

Other antibodies of the invention include amino acids that have been mutated, yet have at least 60%, 70%, 80%, 90%, 95% or 98% identity in the CDR regions with the CDR regions depicted in the sequences described in Table 1. In some embodiments, it includes mutant amino acid sequences wherein no more than 1, 2, 3, 4 or 5 amino acids have been mutated in the CDR regions when compared with the CDR regions depicted in the sequence described in Table 1, while still maintaining their specificity for the the original antibody's epitope .

Other antibodies of the invention include amino acids that have been mutated, yet have at least 60%, 70%, 80%, 90%, 95% or 98% identity in the framework regions with the framework regions depicted in the sequences described in Table 1. In some embodiments, it includes mutant amino acid sequences wherein no more than 1, 2, 3, 4, 5, 6, or 7 amino acids have been mutated in the framework regions when compared with the framework regions depicted in the sequence described Table 1, while still maintaining their specificity for the the original antibody's epitope.

The present invention also provides nucleic acid sequences that encode VH, VL, the full length heavy chain, and the full length light chain of the antibodies that specifically bind to a LRP6 protein (*e.g.*, human and/or cynomologus LRP6). Such nucleic acid sequences can be optimized for expression in mammalian cells (for example, Table 1 for MOR08168, MOR08545, and MOR06706 for β -propeller 1 antibodies and MOR06475, MOR08193, and MOR08473 for β -propeller 3 antibodies).

The LRP6 antibodies of the invention bind to distinct LRP6 β -propeller regions. Propeller 1 antibodies bind to the β -propeller 1 domain and block Propeller1-dependent Wnts such as Wnt1, Wnt2, Wnt6, Wnt7A, Wnt7B, Wnt9, Wnt10A, Wnt10B. Propeller 3 antibodies bind to the β -propeller 3 domain and block Propeller 3-dependent Wnts such as Wnt3a and Wnt3.

Table 1: Examples of LRP6 Antibodies of the Present Invention

SEQ ID NUMBER	Ab region	Sequence
MOR08168 Prop1		
SEQ ID NO:1 (Kabat)	HCDR1	DYVIN
SEQ ID NO:2 (Kabat)	HCDR2	GISWSGVNTHYADSVKG
SEQ ID NO:3 (Kabat)	HCDR3	LGATANNIRYKFMDV
SEQ ID NO:4 (Kabat)	LCDR1	SGDSLNRNKVY
SEQ ID NO:5 (Kabat)	LCDR2	KNNRPS
SEQ ID NO:6 (Kabat)	LCDR3	QSYDGQKSLV
SEQ ID NO:7 (Chothia)	HCDR1	GFTFSDY
SEQ ID NO:8 (Chothia)	HCDR2	SWSGVN
SEQ ID NO:9 (Chothia)	HCDR3	LGATANNIRYKFMDV
SEQ ID NO:10 (Chothia)	LCDR1	DSLNRK
SEQ ID NO:11 (Chothia)	LCDR2	KN
SEQ ID NO:12 (Chothia)	LCDR3	YDGQKSL
SEQ ID NO:13	VL	DIELTQPPSVSVAPGQATARISCSGDSLNRNKVYVYQKPGQAPVLVIYKNNRPSGIPERFSGNSGNTATLTISGTQA EEDADYYCQSYDGQKSLVFGGGTKLTVL
SEQ ID NO:14	VH	QVQLVESGGGLVQPGGSLRLSAASGFTFSDYVINWVRQAPGKLEWVSGISWSGVNTHYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVVYCARLGATANNIRYKFMDVWGQGLTVTVSS
SEQ ID NO:15	DNA VL	GATATCGAACTGACCCAGCCGCTTCAGTGAGCGTTGCACCAGGTGACACCGCGCATCTCGTGTAGCGGC GATTCTCTCGTAATAAGGTTTATTGGTACCAGCAGAAACCCGGGCAGGCGCCAGTTCCTGTGATTATAAGA ATAATCGTCCCTCAGGCATCCCGGAACGCTTACGGGATCCAAACAGCGGCAACACCGCGACCTGACCATTAG CGGCACTCAGGCGGAAGACGAAGCGGATTATTATGCCAGTCTTATGATGGTCAGAAGTCTCTTGTGTTGGC GGCGGCACGAAGTTAACCGTCCTA
SEQ ID NO:16	DNA VH	CAGGTGCAATTGGTGAAAGCGCGGGCGGCTGGTGCAACCGGGCGGCAGCCTGCGTCTGAGCTGCGCGGC CTCCGGATTACCTTTCTGATTATGTTAATAATGGGTGCGCCAAGCCCCTGGGAAGGGTCTCGAGTGGGTG AGCGGTATTCTTGGTCTGGTGTAAATACTCATTATGCTGATTCTGTTAAGGGTCTGTTTACCATTTCACGTGAT AATTCGAAAAACCCCTGTATCTGCAATGAACAGCCTGCGTGCGGAAGATACGGCCGTGATTATTGCGCGC GTCTTGGTGCTACTGCTAATAATATTCGTTATAAGTTTATGGATGTTTGGGCAAGGCACCTGTTGACGGT

		TAGCTCA
SEQ ID NO:17	Light Lambda	DIELTQPPSVSVAPGQTARISCSGDSL RNKVYVYQQKPGQAPVLVIYKNNRPSGIPERFSGNSGNTATLTISGTQA EDEADYQCQSYDGQKSLVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSP VKAGVETTP5KQSNKYAASSYLSLTP EQWKSHRSYSCQVTHEGSTVEKTVAPTECS
SEQ ID NO:18	Heavy IgG1 LALA	QVQLVESGGGLVQPGGSLRLSCAASGFTFSDYVINWVRQAPGKGLEWVSGISW5GVNTHYADSVKGRFTISRDN SKNTLYLQMNLSRAEDTAVYYCARLGATANNIRYKFMVWVGQTLTVSSASTKGPSVFLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSVHTFPAVLQSSGLYSLSSVTVPS5SLGTQTYICNVNHKPSNTKYDKRVEPKS CDKHTCPPCPAPEAAGGPSVFLFPPKPKD TLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNV F5CSVMHEALHNHYTQKLSLSLP GK
SEQ ID NO: 19	DNA Light Lambda	GATATCGAACTGACCCAGCCGCTTCAGTGAGCGTTGCACCAGGTGAGACCCGCGGTATCTCGGTAGCGGC GATTCTCTTCGTAATAAGGTTTATTGGTACCAGCAGAAAACCCGGCAGGCGCCAGTCTTGTGATTATAAGA ATAATCGTCCCTCAGGCATCCCGGAACGCTTAGCGGATCCAACAGCGGCAACCCGCGACCTGACCATTAG CGGCACTCAGGCGGAAGACGAAGCGGATTATTA TTGCCAGTCTTATGATGGTCAGAAGTCTCTGTGTTGGC GGCGGCACGAAGTTAACCGTCTAGGTACGCCAAGGCTGCCCTCGGTACTCTGTTCCGCGCTCCTCTG AGGAGTTCAAGCCAACAAGGCCA CACTGGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGG CCTGGAAGGCAGATAGCAGCCCCGTAAGGCGGGAGTGGAGACCACCACCCCTCAAACAAGCAACAAC AAGTACGCGGCAGCAGCTATCTGAGCCTGACGCTGAGCAGTGGAAAGTCCACAGAAGCTACAGCTGCCAG GTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCTACAGAATGTCA
SEQ ID NO: 20	DNA Heavy IgG1 LALA	CAGGTGCAATTGGTGAAAGCGGGCGGCTGGTGCAACCGGGCGGAGCCTGCGTCTGAGCTGCGCGGC CTCCGGATTACCTTTCTGATTATGTTAATAATTGGGTGCGCCAAGCCCTGGGAAGGGTCTCGAGTGGGTG AGCGGTATTTCTGGTCTGGTGTAAATACTATTATGCTGATTCTGTTAAGGGTCTGTTTACCATTTACAGTGT AATTCGAAAAACCCCTGTATCTGCAAATGAACAGCCTGCGTGGGAAGATACGGCCGTGATTATTGCGCGC GTCTGGTGTACTGCTAATAATATTCGTTATAAGTTATAGGATGTTTGGGGCCAAGGCACCTGTTGACGGT TAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCTGGCACCTCTCCAAGAGCACCTCTGGGGGCACA GCGGCCCTGGGCTGCTGGTCAAGGACTACTTCCCGAACCGGTGACGGTGTCTGGAAGTCAAGCGCCCTG ACCAGCGGCGTGCACACCTCCCGGCTGTCTACAGTCTCAGGACTACTCTCCAGCAGCGTGGTGACCG TGCCCTCCAGCAGCTTGGCACCCAGACTACATCTGCAACGTGAATACAAGCCAGCAAACCAAGGTGG ACAAGAGAGTTGAGCCAAATCTTGACAAAACCTCACATGCCCCAGCTGCCACAGCTGAAGCAGCGG GGGACCGTCACTCTCTCTTCCCCCAAACCAAGGACACCTCATGATCTCCCGGACCCCTGAGGTAC ATGCGTGGTGGTGGACGTGAGCCACGAAGACCTGAGGTCAAGTTCAACTGGTACGTGGACGGCTGGAGG TGATAATGCCAAGACAAGCCGCGGGAGGAGCAGTACAACAGCAGTACCGGGTGGTCAAGCTCTCACC GTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGAAGGTCTCCAACAAGCCCTCCAGCCCC ATCGAGAAAACCATCTCCAAGCCAAGGGCAGCCCCGAGAACCACAGGTGTACACCTGCCCCATCCGG GAGGAGATGACCAAGAACCAGGTGAGCCTGACCTGCTGGTCAAAGGCTTCTATCCAGCGACATCGCCGTG GAGTGGGAGAGCAATGGCAGCCGGAGAACAACACTACAAGACCAGCCTCCCGTCTGACTCCGACGGCTC CTTCTCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGCTTCTCATGCTCCGTG ATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCTCTCCCTGTCTCCGGGTAAA
MDR08545 Prop1		
SEQ ID NO:21 (Kabat)	HCDR1	VNGMH
SEQ ID NO:22 (Kabat)	HCDR2	VIDGMGHTYYADSVKG
SEQ ID NO:23 (Kabat)	HCDR3	YDYIKYGAFDP
SEQ ID NO:24 (Kabat)	LCDR1	SGDNIGSKYVH
SEQ ID NO:25	LDCR2	GDSNRPS

(Kabat)		
SEQ ID NO:26 (Kabat)	LCDR3	TRTSTPISGV
SEQ ID NO:27 (Chothia)	HCDR1	GFTFSVN
SEQ ID NO:28 (Chothia)	HCDR2	DGMGH
SEQ ID NO:29 (Chothia)	HCDR3	YDYIKYGAFDP
SEQ ID NO:30 (Chothia)	LCDR1	DNIGSKY
SEQ ID NO:31 (Chothia)	LDCR2	GDS
SEQ ID NO:32 (Chothia)	LCDR3	TSTPISG
SEQ ID NO:33	VL	DIELTQPPSVSVAPGQTARISCSGDNIGSKYVHWYQKPGQAPVLIYGDSDNRPSGIPERFSGSNSGNTATLTISGT QAEDEADYYCTRTSTPISGVFGGGTKLTVL
SEQ ID NO:34	VH	QVQLVESGGGLVQPGGSLRLSCAASGFTFSVNGMHWVRQAPGKLEWVSVIDGMGHTTYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVVYCARVDYIKYGAFDPWGQGLTVTVSS
SEQ ID NO:35	VL Germlined	SYELTQPPSVSVSPGQTASITCSGDNIGSKYVHWYQKPGQSPVLIYGDSDNRPSGIPERFSGSNSGNTATLTISGT QAMDEADYYCTRTSTPISGVFGGGTKLTVL
SEQ ID NO:36	VH Germlined	EVQLVESGGGLVQPGGSLRLSCAASGFTFSVNGMHWVRQAPGKLEWVSVIDGMGHTTYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVVYCARVDYIKYGAFDPWGQGLTVTVSS
SEQ ID NO:37	DNA VL	GATATCGAACTGACCCAGCCGCTTCAGTGAGCGTTGCACCCAGGTCAGACCCGCGGTATCTCGTGTAGCGGC GATAATATTGGTTCTAAGTATGTTTCATTGGTACCAGCAGAAACCCGGGCAGGCGCCAGTCTTGTGATTTATG GTGATTCTAATCGTCCCTCAGGCATCCCGGAACGCTTTAGCGGATCCAACAGCGGCAACACCCGCGACCCCTGAC CATTAGCGGCACTCAGGCGGAAGACGAAGCGGATTATTATGCACTCGTACTTCTACTCTATTCTCGGTGTGT TTGGCGGCGGCACGAAGTAAACCGTCTT
SEQ ID NO:38	DNA VH	CAGGTGCAATTGGTGGAAAGCGGCGCGCCCTGGTGCAACCGGGCGGCAGCCTGCGTCTGAGCTGCGCGGC CTCCGGATTTACCTTTCTGTTAATGGTATGCAATGGGTGCGCCAAGCCCTGGGAAGGGTCTCGAGTGGGTG AGCGTATTGATGGTATGGGTCACTATTATGCTGATTCTGTTAAGGGTCGTTTTACCATTTACGATGATAA TTCGAAAAACACCTGTATCTGCAATGAACAGCCTGCGTGCGGAAGATACGGCCGTGATTATTGCGCGCGT TATGATTATTAAGTATGGTCTTTGATCCTTGGGGCCAAGGCACCCCTGGTGACGGTTAGCTCA
SEQ ID NO:39	Light lambda	DIELTQPPSVSVAPGQTARISCSGDNIGSKYVHWYQKPGQAPVLIYGDSDNRPSGIPERFSGSNSGNTATLTISGT QAEDEADYYCTRTSTPISGVFGGGTKLTVLQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSS PVKAGVETTTPSKQSNKYAASSYLSLTPAQWKSRSYSCQVTHEGSTVEKTVAPTEA
SEQ ID NO:40	Heavy Fab	QVQLVESGGGLVQPGGSLRLSCAASGFTFSVNGMHWVRQAPGKLEWVSVIDGMGHTTYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVVYCARVDYIKYGAFDPWGQGLTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGLVK DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKVKPEKS
SEQ ID NO:41	DNA Light lambda	GATATCGAACTGACCCAGCCGCTTCAGTGAGCGTTGCACCCAGGTCAGACCCGCGGTATCTCGTGTAGCGGC GATAATATTGGTTCTAAGTATGTTTCATTGGTACCAGCAGAAACCCGGGCAGGCGCCAGTCTTGTGATTTATG GTGATTCTAATCGTCCCTCAGGCATCCCGGAACGCTTTAGCGGATCCAACAGCGGCAACACCCGCGACCCCTGAC CATTAGCGGCACTCAGGCGGAAGACGAAGCGGATTATTATGCACTCGTACTTCTACTCTATTCTCGGTGTGT TTGGCGGCGGCACGAAGTAAACCGTCTTGGCCAGCCGAAAGCCGACCCGAGTGACGCTGTTCCGCCGA GCAGCGAAGAAATTGCAGCGCAACAAAGCGACCCCTGGTGTGCTGATTAGCGACTTTATCCGGGAGCCGTGA CAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAGGCGGGAGTGAGACCACCACCCCTCAAACAAGC AACAAACAAGTACGCGCCAGCAGCTATCTGAGCCTGACGCTGAGCAGTGGAAAGTCCCAACAAGCTACAGC

		TGCCAGGTACGCATGAGGGGAGCACCGTGGAAAAACCGTTGCGCCGACTGAGGCC
SEQ ID NO:42	DNA Heavy Fab	CAGGTGCAATTGGTGGAAAGCGGCGGGCCTGGTGAACCGGGCGGCAGCCTGCGTCTGAGCTGCGCGGC CTCCGGATTACCTTTCTGTTAATGGTATGCATTGGGTGCGCCAAGCCCTGGGAAGGGTCTCGAGTGGGTG AGCGTTATTGATGGTATGGGTCACTTATTATGCTGATTCTGTTAAGGGTCGTTTTACCAATTCACGTGATAA TTCGAAAAACACCTGTATCTGCAAATGAACAGCCTGCGTGCAGGAAGATACGGCCGTGATTATTGCGCGCGT TATGATTATATTAAGTATGGTGCTTTTGATCCTTGGGGCCAAGGCACCTGGTGACGGTTAGCTCAGCGTCGA CCAAAGGTCCAAGCGTGTTCGCTGGCTCCGAGCAGCAAAAGCACCAGCGGGCGGCACGGTGCCTGGGT GCCTGGTTAAAGATTATTTCCGGGAACCAGTACCCTGAGCTGGAACAGCGGGCGCTGACCAGCGCGTGC ATACCTTCCGGCGGTGCTGCAAAGCAGCGGCCTGTATAGCTGAGCAGCGTTGTGACCGTCCGAGCAGCA GCTTAGGCACTCAGACCTATTTGCAACGTGAACATAAACCGAGCAACACCAAAGTGGATAAAAAAGTGG AACCGAAAAAGC
SEQ ID NO:43	VL Germlined	SYELTQPLSVSVALGQTARITCGGDNIGSKYVHWYQQKPGQAPVLIYVIGDSNRPSPGIPERFSGNSNGTATLTISRA QAGDEADYYCTRSTPISGVFGGGKTLTVL
SEQ ID NO:44	VH Germlined	EVQLLESGGGLVQPGGSLRLSCAASGFTFVSNGMHWVRQAPGKLEWVSVIDGMGHTYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARYDYIKYGAFFDPWGQGLTVTVSS
SEQ ID NO:45	DNA VL Germlined	AGCTATGAACTGACCCAGCCGCTGTCTGTGAGCGTGGCGCTGGGCCAGACCGCGGTATTACCTGCGGTGGC GATAACATTGGCAGCAAATATGTGCATTGGTATCAGCAGAAACCGGGCCAGGCGCCGGTCTGGTGATTAT GGCGATAGCAACCGTCCGAGCGGCATTCCGGAACGTTTTAGCGGCAGCAACAGCGGCAACACCGCGACCTG ACCATTCTCGCGCGCAGCGGGTATGAAGCGGATTATTATGACCCGTACCAGCACCCCGATTAGCGGC GTGTTTGGCGCGGTACGAAGTTAACGTTCTT
SEQ ID NO:46	DNA VH Germlined	GAGGTGCAATTGCTGGAAAGCGGCGGGCCTGGTGAACCGGGCGGCAGCCTGCGTCTGAGCTGCGCGGC CTCCGGATTACCTTTCTGTTAATGGTATGCATTGGGTGCGCCAAGCCCTGGGAAGGGTCTCGAGTGGGTG AGCGTTATTGATGGTATGGGTCACTTATTATGCTGATTCTGTTAAGGGTCGTTTTACCAATTCACGTGATAA TTCGAAAAACACCTGTATCTGCAAATGAACAGCCTGCGTGCAGGAAGATACGGCCGTGATTATTGCGCGCGT TATGATTATATTAAGTATGGTGCTTTTGATCCTTGGGGCCAAGGCACCTGGTGACGGTTAGCTCA
MOR06706 Prop1		
SEQ ID NO:47 (Kabat)	HCDR1	DYAIH
SEQ ID NO:48 (Kabat)	HCDR2	GISYSGSSTHYADSVKG
SEQ ID NO:49 (Kabat)	HCDR3	GSHGNIMAKRYDF
SEQ ID NO:50 (Kabat)	LCDR1	SGDNIRKYYV
SEQ ID NO:51 (Kabat)	LDCR2	EDSKRPS
SEQ ID NO:52 (Kabat)	LCDR3	STADSGINNGV
SEQ ID NO:53 (Chothia)	HCDR1	GFTFSDY
SEQ ID NO:54 (Chothia)	HCDR2	SYSGSS
SEQ ID NO:55	HCDR3	GSHGNIMAKRYDF

(Chothia)		
SEQ ID NO:56 (Chothia)	LCDR1	DNIRKKY
SEQ ID NO:57 (Chothia)	LDCR2	EDS
SEQ ID NO:58 (Chothia)	LCDR3	ADSGINNG
SEQ ID NO:59	VL	DIELTQPPSVSVAPGQTARISCSGDNIRKKYVYVYQQKPGQAPVLIYEDSKRPSGIPERFSGSNSGNTATLTISGTQ AEDEADYYCSTADSGINNGVFGGGTKLTVL
SEQ ID NO:60	VH	QVQLVESGGGLVQPGGSLRLSCAASGFTFSDYAIHWVRRQAPGKLEWVSGISYSGSSSTHYADSVKGRFTISRDNK NTLYLQMNSLRAEDTAVYVCARGSHGNIMAKRYFDVWGQGLTVTVSS
SEQ ID NO:61	VL Germlined	SYELTQPPSVSVSPGQTASITCSGDNIRKKYVYVYQQKPGQSPVLIYEDSKRPSGIPERFSGSNSGNTATLTISGTQ AMDEADYYCSTADSGINNGVFGGGTKLTVL
SEQ ID NO:62	VH Germlined	EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYAIHWVRRQAPGKLEWVSGISYSGSSSTHYADSVKGRFTISRDNK NTLYLQMNSLRAEDTAVYVCARGSHGNIMAKRYFDVWGQGLTVTVSS
SEQ ID NO:63	DNA VL	GATATCGAACTGACCCAGCCGCTTCAGTGAGCGTTGCACCAGGTCAGACCCGCGTATCTCGTGATGCGGC GATAATATTCGTAAGAAGTATGTTTATTGGTACCAGCAGAAACCCGGCAGCGCCAGTCTTGTGATTTATG AGGATTCTAAGCGTCCCTCAGGCATCCCGGAACGCTTTAGCGGATCCAACAGCGGCAACACCCGCGACCTGA CCATTAGCGGCACTCAGCGGAAGACGAAGCGGATTATTATTGCTCTACTGCTGATTCTGGTATTAATAATGG TGTGTTGGCGGCGGCACGAAGTTAACCGTCTCT
SEQ ID NO:64	DNA VH	CAGGTGCAATTGGTGGAAAGCGGCGCGCCCTGGTGCAACCGGGCGGCAGCCTGCGTCTGAGCTGCGCGGC CTCCGGATTTACCTTTTCTGATTATGCTATTCATTGGGTGCGCCAAGCCCTGGGAAGGGTCTCGAGTGGGTG AGCGGTATCTCTTATTCTGGTAGCTCTACCCATTATGCGGATAGCGTGAAGGGCCGTTTTACCATTTCACGTGA TAATTCGAAAAACACCTGTATCTGCAATGAACAGCCTGCGTGCGGAAGATACGGCCGTGATTATTGCGCG CGTGGTCTCATGGTAATATTATGGCTAAGCGTATTTTGGATTTTGGGGCCAAGGCACCCCTGGTACGGTTA GCTCA
SEQ ID NO:65	Light Lambda	DIELTQPPSVSVAPGQTARISCSGDNIRKKYVYVYQQKPGQAPVLIYEDSKRPSGIPERFSGSNSGNTATLTISGTQ AEDEADYYCSTADSGINNGVFGGGTKLTVLQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADS SPVKAGVETTTSPKQSNNKYAASSYLSLTPEQWKSRSYSCQVTHEGSTVEKTVAPTECS
SEQ ID NO:66	Heavy IgG1 LALA	QVQLVESGGGLVQPGGSLRLSCAASGFTFSDYAIHWVRRQAPGKLEWVSGISYSGSSSTHYADSVKGRFTISRDNK NTLYLQMNSLRAEDTAVYVCARGSHGNIMAKRYFDVWGQGLTVTVSSASTKGPSVFLAPSSKSTSGGTAALGCL VKDYFPEPTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKRVPEKSCDK THTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTKAKAQPREPVYTLPPSREEMTKNQVSLTCLVKGFYP SDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKLSLSLSPGK
SEQ ID NO:67	DNA hlamda	GATATCGAACTGACCCAGCCGCTTCAGTGAGCGTTGCACCAGGTCAGACCCGCGTATCTCGTGATGCGGC GATAATATTCGTAAGAAGTATGTTTATTGGTACCAGCAGAAACCCGGCAGCGCCAGTCTTGTGATTTATG AGGATTCTAAGCGTCCCTCAGGCATCCCGGAACGCTTTAGCGGATCCAACAGCGGCAACACCCGCGACCTGA CCATTAGCGGCACTCAGCGGAAGACGAAGCGGATTATTATTGCTCTACTGCTGATTCTGGTATTAATAATGG TGTGTTGGCGGCGGCACGAAGTTAACCGTCTAGGTCAGCCCAAGGCTGCCCCCTCGGTCACCTCTGTTCCCG CCCTCTCTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTATAAGTGACTTCTACCCGGGAGCCG TGACAGTGGCCTGGAAGGCAGATAGCAGCCCGTCAAGGCGGGAGTGGAGACCACACCCCTCCAACAA AGCAACAACAAGTACGCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAAGTCCCACAGAAGCTAC AGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCTACAGAATGTTCA
SEQ ID NO:68	DNA Heavy IgG1 LALA	CAGGTGCAATTGGTGGAAAGCGGCGCGCCCTGGTGCAACCGGGCGGCAGCCTGCGTCTGAGCTGCGCGGC CTCCGGATTTACCTTTTCTGATTATGCTATTCATTGGGTGCGCCAAGCCCTGGGAAGGGTCTCGAGTGGGTG AGCGGTATCTCTTATTCTGGTAGCTCTACCCATTATGCGGATAGCGTGAAGGGCCGTTTTACCATTTCACGTGA TAATTCGAAAAACACCTGTATCTGCAATGAACAGCCTGCGTGCGGAAGATACGGCCGTGATTATTGCGCG CGTGGTCTCATGGTAATATTATGGCCAAGCGTATTTTGGATTTTGGGGCCAAGGCACCCCTGGTACGGTTA GCTCAGCTCCACCAAGGGTCCATCGGTCTTCCCCTGGCACCTCTCCAAGAGCACCTCTGGGGGCACAGC

		GGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCAGAACCGGTGACGGTGTCTGTGGAACTCAGGCGCCCTGAC CAGCGGCGTGACACCTTCCCAGGCTGTCTACAGTCTCAGGACTCTACTCCCTCAGCAGCGTGGTACCCTG CCCTCCAGCAGCTTGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCAGCAACACCAAGGTGAC AAGAGAGTTGAGCCAAATCTTGTGACAAAACCTCACACATGCCACCGTCCAGCAGCTGAAGCAGCGGGG GGACCGTCAGTCTTCTCTTCCCCCAAAACCAAGGACACCTCATGATCTCCCGGACCCCTGAGGTACATG CGTGGTGGTGGAGCTGAGCCACGAAGACCTGAGGTCAAGTTCAACTGGTACGTGGACGGCCTGGAGGTGC ATAATGCCAAGACAAGCCGCGGAGGAGCAGTACAACAGCAGTACCGGGTGGTACGCTCACCGTCC TGACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCAACAAGCCCTCCAGCCCCATCG AGAAAACCATCTCCAAAGCCAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCATCCCGGGAGG AGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAGCGACATCGCCGTGGAGT GGGAGAGCAATGGGAGCCGGAGAACAACTACAAGACCAGCCTCCCGTCTGGACTCCGACGGCTCTTCT TCCTTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGC ATGAGGCTCTGCACAACCACTACACGCAGAAAGCCTCTCCCTGTCTCCGGGTAAA
MOR06475 Prop3		
SEQ ID NO:69 (Kabat)	HCDR1	NRGGGVG
SEQ ID NO:70 (Kabat)	HCDR2	WIDWDDKSYSTSLKT
SEQ ID NO:71 (Kabat)	HCDR3	MHLPLVFD
SEQ ID NO:72 (Kabat)	LCDR1	RASQFIGSRYLA
SEQ ID NO:73 (Kabat)	LDCR2	GASNRAT
SEQ ID NO:74 (Kabat)	LCDR3	QQYDYPQT
SEQ ID NO:75 (Chothia)	HCDR1	GFSLNRGG
SEQ ID NO:76 (Chothia)	HCDR2	DWDDD
SEQ ID NO:77 (Chothia)	HCDR3	MHLPLVFD
SEQ ID NO:78 (Chothia)	LCDR1	SQFIGSRY
SEQ ID NO:79 (Chothia)	LDCR2	GAS
SEQ ID NO:80 (Chothia)	LCDR3	YDYPQ
SEQ ID NO:81	VL	DIVLTQSPATLSLSPGERATLSCRASQFIGSRYLAWYQQKPGQAPRLLIYGASNRATGVPARFSGSGSGTDFLTISL EPEDFATYYCQQYDYPQTFGGQTKVEIK
SEQ ID NO:82	VH	QVQLKESGPALVKPTQTLTLCTFSGFSLNRGGVGVWIRQPPGKALEWLAWIDWDDKSYSTSLKTRLTISKDTS KNQVLTMTNMDPVDTATYTCARMHLPLVFDWSWGQGLVTVSS
SEQ ID NO:83	DNA VL	GATATCGTGCTGACCCAGAGCCCGGCGACCTGAGCCTGTCTCCGGGCGAACGTGCGACCTGAGCTGCAGA GCGAGCCAGTTTATTGTTCTCGTATCTGGCTGGTACCAGCAGAAACCAGGTCAAGCACCGCTCTATTAA TTTATGGTGTCTTAATCGTCAACTGGGGTCCCGGCGCTTTTAGCGGCTCTGGATCCGGCACGGATTTTAC CCTGACCATTAGCAGCCTGGAACCTGAAGACTTTGCGACTTATTATTGCCAGCAGTATTATGATTATCTCAGA

		TGCGCCCGGATGCATCTGCCCTGGTGTTCGATAGCTGGGGCCAGGGCACCCTGGTCACCGTCAGCTCA
SEQ ID NO:92	DNA VL Germlined	GAAATCGTGCTGACCCAGAGCCCCGCCACCCTGTCTCTGAGCCCTGGCGAGAGAGCCACCCTGAGCTGCCGG GCCAGCCAGTTTCATCGGCAGCAGATACCTGGCTTGGTATCAGCAGAAAGCCCGGCCAGGCCCCAGACTGCTG ATCTACGGCGCCAGCAACCGGGCCACCGGCATCCCTGCCAGATTTCTGGCAGCGGAGCGGCACCGACTTC ACCCTGACCATCAGCAGCCTGGAACCCGAGGACTTCGCCGTGTACTACTGCCAGCAGTACTACGACTACCCCC AGACCTTCGGCCAGGGCACCAAGGTGAAATCAAG
MOR08193 Prop3		
SEQ ID NO:93 (Kabat)	HCDR1	NRGGGVG
SEQ ID NO:94 (Kabat)	HCDR2	WIDWDDDKSYSTSLKT
SEQ ID NO:95 (Kabat)	HCDR3	MHLPLVFDS
SEQ ID NO:96 (Kabat)	LCDR1	RASQFIGSRYLE
SEQ ID NO:97 (Kabat)	LCDR2	GASNRAT
SEQ ID NO:98 (Kabat)	LCDR3	QQYWSIPIT
SEQ ID NO:99 (Chothia)	HCDR1	GFSLNRRGG
SEQ ID NO:100 (Chothia)	HCDR2	DWDDD
SEQ ID NO:101 (Chothia)	HCDR3	MHLPLVFDS
SEQ ID NO:102 (Chothia)	LCDR1	SQFIGSRY
SEQ ID NO:103 (Chothia)	LCDR2	GAS
SEQ ID NO:104 (Chothia)	LCDR3	YWSIPI
SEQ ID NO:105	VL	DIVLTQSPATLSLSPGERATLSCRASQFIGSRYLAWYQQKPGQAPRLLIYGASNRATGVPARFSGSGSDFTLTISL EPEDFAVYYCQQYWSIPITFGQGTKVEIK
SEQ ID NO:106	VH	QVQLKESGPAIVKPTQTLTLCTFSGFSLNRRGGVGVWIRQPPGKALEWLAIDWDDDKSYSTSLKTRLTISKDTS KNQVVLTMNMDPVDATYYCARMHLPLVDFSWGQGTLVTVSS
SEQ ID NO:107	VL Germlined	EIVLTQSPATLSLSPGERATLSCRASQFIGSRYLAWYQQKPGQAPRLLIYGASNRATGIPARFSGSGSDFTLTISL PEDFAVYYCQQYWSIPITFGQGTKVEIK
SEQ ID NO:108	VH Germlined	QVTLKESGPAIVKPTQTLTLCTFSGFSLNRRGGVGVWIRQPPGKALEWLAIDWDDDKSYSTSLKTRLTISKDTS KNQVVLTMNMDPVDATYYCARMHLPLVDFSWGQGTLVTVSS
SEQ ID NO:109	DNA VL	GATATCGTGCTGACCCAGAGCCCCGCCACCCTGAGCCTGTCTCCGGGCGAACGTGCGACCCTGAGCTGCAGA GCGAGCCAGTTTATTGGTCTCGTTATCTGGCTGGTACCAGCAGAAACCAGGTCAAGCACCCTGCTATTAA TTTATGGTGCTTCTAATCGTGAACCTGGGGTCCCAGGCGCTTTAGCGGCTCTGGATCCGGCACGGATTTAC CCTGACCATTAGCAGCCTGGAACCTGAAGACTTTCGGGTGATTAATGCCAGCAGTATTGGTCTATTCCTATTA

		CCTTTGGCCAGGGTACGAAAGTTGAAATTA
SEQ ID NO:110	DNA VH	CAGGTGCAATTGAAAGAAAGCGGCCCGCCCTGGTGAACCGACCCAAACCCTGACCCCTGACCTGTACCTTT CCGGATTTAGCCTGTCTAATCGTGGTGGTGGTGGTGGTGGATTCCGCCAGCCCGCTGGGAAAGCCCTCGAGT GGCTGGCTGGATCGATTGGGATGATGATAAGTCTTATAGCACCAGCCTGAAAACGCGTCTGACCATTAGCA AAGATACTTCGAAAAATCAGGTGGTGTGACTATGACCAACATGGACCCGGTGGATACGGCCACCTATTATTG CGCGGTATGCATCTCTCTTGTGTTTTGATTCTTGGGGCCAAGGCACCCTGGTACGGTTAGCTCA
SEQ ID ND:111	Light kappa	DIVLTQSPATLSLSPGERATLSCRASQFIGSRYLAWYQKPGQAPRLLIYGASNRAITGVPARFSGSGSDFTLTISL EPEDFAVYYCQYWSIPITFGQGTKEIKRTVAAPSVFIFPPSDEQLKSGTASVCLLNNFYPREAKVQWVKVDNAL QSGNSQESVTEQDSKSDSTYSLSSTLTLTKADYEKHKVYACEVTHQGLSSPVTKSFNRGEA
SEQ ID ND:112	Heavy Fab	QVQLKESG PALVKPTQLTLTCTFSGFSLNRGGVGVWIRQPPGKALEWLAWIDWDDKSYSTSLKRLTISKDTS KNQVLTMTNMDPVDATYYCARMHLPLVFDWVGQGLVTVSSASTKGPSVFLAPSSKSTSGGTAALGCLVKD YFPEPVTWVNSGALTSQVHTFPAVLQSSGLYSLSSVTVPSSSLGQTQYICNVNHKPSNTKVDKKEPKS
SEQ ID NO:113	DNA Light kappa	GATATCGTGCTGACCCAGAGCCCGGCCGACCCCTGAGCCTGTCTCCGGCCGAACTGCGACCCCTGAGCTGCAGA GCGAGCCAGTTTATTGGTTCTCGTTATCTGGCTTGGTACCAGCAGAAACCAGGTCAAGCACCCGCTCTATTAA TTTATGGTCTTCTAATCGTCAACTGGGGTCCCGCCGTTTTAGCGGCTCTGGATCCGGCACGGATTTTAC CCTGACCATTAGCAGCCTGGAACCTGAAGACTTTGCGGTGATTA TTGCCAGCAGTATTGGTCTATCTCTATTA CCTTTGGCCAGGGTACGAAAGTTGAAATTAACGTACGGTGGCTGCTCCGAGCGTGTATTTTTCCGCCGAG CGATGAACAACGAAAGCGGCACGGCAGCGTGGTGTGCTGCTGAACTTTTATCCGCGTGAAGCGAA AGTTCAGTGGAAAGTAGACAACCGCTGCAAAGCGGCAACAGCCAGGAAAGCGTGACCGAACAGGATAGCA AAGATAGCACCTATTCTCTGAGCAGCACCCCTGACCCTGAGCAAAGCGGATTATGAAAAACATAAAGGTATGC GTGCGAAGTGACCCATCAAGGTCTGAGCAGCCCGGTGACTAAATCTTTAATCGTGGCGAGGCC
SEQ ID NO:114	DNA Heavy Fab	CAGGTGCAATTGAAAGAAAGCGGCCCGCCCTGGTGAACCGACCCAAACCCTGACCCCTGACCTGTACCTTT CCGGATTTAGCCTGTCTAATCGTGGTGGTGGTGGTGGTGGATTCCGCCAGCCCGCTGGGAAAGCCCTCGAGT GGCTGGCTGGATCGATTGGGATGATGATAAGTCTTATAGCACCAGCCTGAAAACGCGTCTGACCATTAGCA AAGATACTTCGAAAAATCAGGTGGTGTGACTATGACCAACATGGACCCGGTGGATACGGCCACCTATTATTG CGCGGTATGCATCTCTCTTGTGTTTTGATTCTTGGGGCCAAGGCACCCTGGTACGGTTAGCTCAGCGTCGA CCAAAGGTCGAAGCGTGTTCGCTGGCTCCGAGCAGCAAAGCACCAGCGCCGGCACGGCTGCCCTGGGCT GCCTGTTAAAGATTATTTCCCGGAACAGTACCCTGAGCTGGAACAGCGGGCGCTGACCAGCGCGCTGC ATACCTTTCCGGCGGTGCTGCAAAGCAGCGCCCTGTATAGCCTGAGCAGCGTTGTGACCGTGCCGAGCAGCA GCTTAGGCACTCAGACCTATATTTGCAACGTGAACCATAAACCAGCAACACCAAGTGGATAAAAAAGTGG AACCGAAAAGC
MOR08473 Prop3		
SEQ ID ND:115 (Kabat)	HCDR1	SYGMS
SEQ ID NO:116 (Kabat)	HCDR2	NISNDGHYTYADSVKG
SEQ ID ND:117 (Kabat)	HCDR3	FQASYLDIMDY
SEQ ID NO:118 (Kabat)	LCDR1	SGDNIGSKYVH
SEQ ID ND:119 (Kabat)	LDCR2	NDSNRPS
SEQ ID ND:120 (Kabat)	LCDR3	QAWGDNGTRV
SEQ ID NO:121 (Chothia)	HCDR1	GFTFSY

SEQ ID NO:122 (Chothia)	HCDR2	SNDGHY
SEQ ID NO:123 (Chothia)	HCDR3	FQASYLDIMDY
SEQ ID NO:124 (Chothia)	LCDR1	DNIGSKY
SEQ ID NO:125 (Chothia)	LDCR2	NDS
SEQ ID NO:126 (Chothia)	LCDR3	WGDNGTR
SEQ ID NO:127	VL	DIELTQPPSVSVAPGQSITISCSGDNIGSKYVHWYQKPGQAPVLIYVNDNRPSPGIPERFSGSNSGNTATLTISGTQ AEDEADYYCQAWGDNGTRVFGGGTKLTVL
SEQ ID NO:128	VH	QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSSWVRQAPGKGLEWVSNISNDGHYTYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARFQASYLDIMDYWGQGLTVTVSS
SEQ ID NO:129	VL Germlined	SYELTQPPSVSVSPGQTASITCSGDNIGSKYVHWYQKPGQSPVLIYVNDNRPSPGIPERFSGSNSGNTATLTISGT QAMDEADYYCQAWGDNGTRVFGGGTKLTVL
SEQ ID NO:130	VH Germlined	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSSWVRQAPGKGLEWVSNISNDGHYTYADSVKGRFTISRDN KNTLYLQMNSLRAEDTAVYYCARFQASYLDIMDYWGQGLTVTVSS
SEQ ID NO:131	DNA VL	GATATCGAACTGACCCAGCCGCTTCAGTGAGCGTTGCACCAAGGTGAGAGCATTACCATCTCGTGTAGCGGGC ATAATATTGGTTCTAAGTATGTTCAATTGGTACCAGCAGAAACCCGGGAGGGCGCAGTTCTTGTGATTATAAT GATTCTAATCGTCCCTCAGGCATCCCGGAACGCTTTAGCGGATCCAACAGCGGCAACACCCGCGACCTGACCA TTAGCGGCACTCAGCGGAAGACGAAGCGGATTAATTGCGCAGGCTTGGGGTGATAATGGTACTCGTGTGT TTGGCGGGCGCACGAAGTTAACCGTTCTT
SEQ ID NO:132	DNA VH	CAGGTGCAATTGGTGGAAAGCGGGCGGCGCTGGTGCAACCGGGCGGCAGCCTGCGTCTGAGCTGCGCGGC CTCCGGATTACCTTTTCTTCTTATGGTATGCTTGGGTGCGCCAAGCCCTGGGAAGGGTCTCGAGTGGGTG AGCAATATTTCTAATGATGGTCATTATACTTATTATGCTGATTCTGTTAAGGGTCTGTTTACCATTTACAGTGAT AATTCGAAAAACCCCTGTATCTGCAAATGAACAGCCTGCGTGCGGAAGATACGCGCGTGTATTATTGCGCGC GTTTTCAGGCTTCTTATCTTGATATTATGGATTATTGGGGCCAAGGCACCCCTGGTGACGGTTAGCTCA
SEQ ID NO:133	Light lambda	DIELTQPPSVSVAPGQSITISCSGDNIGSKYVHWYQKPGQAPVLIYVNDNRPSPGIPERFSGSNSGNTATLTISGTQ AEDEADYYCQAWGDNGTRVFGGGTKLTVLQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADS SPVKAGVETTTPSKQSNKYAASSYLSLTPAQWVSHRYSYSCQVTHEGSTVEKTVAPTEA
SEQ ID NO:134	Heavy Fab	QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSSWVRQAPGKGLEWVSNISNDGHYTYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARFQASYLDIMDYWGQGLTVTVSSASTKGPSVFLAPSSKSTSGGTAALGLVK DYFPEPVTVSWNSGALTSVHTEFPAVLQSSGLYSLSVTVPSSSLGTQTYICNVNHKPSNTKVDKVEPKS
SEQ ID NO:135	DNA Light lambda	GATATCGAACTGACCCAGCCGCTTCAGTGAGCGTTGCACCAAGGTGAGAGCATTACCATCTCGTGTAGCGGGC ATAATATTGGTTCTAAGTATGTTCAATTGGTACCAGCAGAAACCCGGGAGGGCGCAGTTCTTGTGATTATAAT GATTCTAATCGTCCCTCAGGCATCCCGGAACGCTTTAGCGGATCCAACAGCGGCAACACCCGCGACCTGACCA TTAGCGGCACTCAGCGGAAGACGAAGCGGATTAATTGCGCAGGCTTGGGGTGATAATGGTACTCGTGTGT TTGGCGGGCGCACGAAGTTAACCGTTCTTGGCCAGCCGAAAGCCGACCGAGTGTGACGCTGTTTCGCGGA GCAGCGAAGAATTGCAGCGGAACAAGCGACCTGGTGTGCTGATTAGCGACTTTTATCCGGAGCCGTGA CAGTGGCCTGGAAGGCAGATAGCAGCCCGTCAAGGCGGGAGTGGAGACCACCAACCTCCAAACAAAGC AACAAACAAGTACGCGGCCAGCAGCTATCTGAGCCTGACGCTGAGCAGTGGAAAGTCCACAGAAGCTACAGC TGCCAGGTACGCATGAGGGGAGCACCGTGGAAAAAACCGTTGCGCCGACTGAGGCC
SEQ ID NO:136	DNA Heavy Fab	CAGGTGCAATTGGTGGAAAGCGGGCGGCGCTGGTGCAACCGGGCGGCAGCCTGCGTCTGAGCTGCGCGGC CTCCGGATTACCTTTTCTTCTTATGGTATGCTTGGGTGCGCCAAGCCCTGGGAAGGGTCTCGAGTGGGTG AGCAATATTTCTAATGATGGTCATTATACTTATTATGCTGATTCTGTTAAGGGTCTGTTTACCATTTACAGTGAT AATTCGAAAAACCCCTGTATCTGCAAATGAACAGCCTGCGTGCGGAAGATACGCGCGTGTATTATTGCGCGC GTTTTCAGGCTTCTTATCTTGATATTATGGATTATTGGGGCCAAGGCACCCCTGGTGACGGTTAGCTCAGCGTC GACCAAGGTCCAAGCGTGTTCCTGCTGCTCCGAGCAGCAAAGCACCGCGGGCGCACGGCTGCCCTGG

		GCTGCCTGGTTAAAGATTATTTCCCGGAACCAAGTACCCTGAGCTGGAACAGCGGGCGCTGACCAGCGGCG TGCATACCTTTCCGGCGGTGCTGCAAAGCAGCGGCTGTATAGCTGAGCAGCGTTGTGACCGTCCGAGCA GCAGCTTAGGCACTCAGACCTATATTTGCAACGTGAACCATAAACCCAGCAACACCAAAGTGGATAAAAAAG TGAACCGAAAAGC
SEQ ID NO:137	VL Germlined	SYELTQPLSVSVALGQATARITCGDNIKSKYVHWYQQKPGQAPVLIYNDNRPSPGIPERFSGSNSGNTATLTISRA QAGDEADYVCQAWGDNTRVFGGGLKLV
SEQ ID NO:138	VH Germlined	EVQLLESGGGLVQPGGSLRSLCAASGFTFSSYGMSSWRQAPGKLEWVSINISNDGHYTYADSVKGRFTISRDN KNTLYLQMNSLRADTAVYYCARFQASYLDIMDYWGQGLVTVSS
SEQ ID NO:139	DNA VL Germlined	AGCTATGAACTGACCCAGCCGCTGAGTGTAGCTGTGCGCTGGGTGAGACCCGCGCTATTACCTGCCGCGGT GATAACATTGGCAGCAAATATGTGCAATTGGTATCAGCAGAAACCGGGCCAGGCGCGGTGCTGGTGATTTAT AACGATAGCAACCGTCCGAGCGGCATTCCGGAACGTTTTAGCGGCAGCAACAGCGGCAATACCGCGACCTG ACCATTAGCCGTGCGCAGCGGGTGATGAAGCGGATTATTATGCCAGGCGTGGGGCGATAATGGTACGCG TGTGTTGGCGGTGGTACGAAGTAAACCGTCTT
SEQ ID NO:140	DNA VH Germlined	GAGGTGCAATTGCTGGAAGCGCGCGGCCCTGGTGCACCCGGGCGGCAGCCTCGCTGAGCTGCCGCGGC CTCCGATTTACCTTTTCTTCTATGGTATGCTTGGGTGCGCCAAGCCCTGGGAAAGGGTCTCGAGTGGGTG AGCAATATTTCTAATGATGGTCATTATACTATTATGCTGATTCTGTTAAGGGTCGTTTTACCATTTACGTGAT AATTCGAAAAACCCCTGTATCTGCAAATGAACAGCCTCGCTGCCGAAGATACGGCCGTGTATTATGCCGCGC GTTTTACGGCTTCTATCTTGATATTATGGATTATTGGGGCCAAGGCACCCCTGGTGACGGTTAGCTCA
Biparatopic construction MOR06475		
SEQ ID NO:141	DNA VL-(GGGG)3-VH scFv	Gatatacgttctgaccagagtcggcaaccctgagcctgagtcgggtgaactgcccctgagctgctgcaagccagtttattgtagccg ttatctggcatggtatcagcagaaccgggtcaggcaccgctctgctgatttatggtgcaagcaatcgtgcaaccggtgtccggcagcttttag cgtagcggtagtggcaccgattttaccctgaccattagcagcctggaaccggaagattttgcaacctattattgccagcagttatgattacc gcagacccttggtcagggcaccaggtggaattaaagtggtggtgtagcgggtggtgctcaggtggtggcgtagtcaggttcaattg aaagaaagcggtcggcactggttaaccgaccagaccctgacctgacatgaccttttagcggttttagcctgagcaatcgtggtggtggt tggtggattcgtcagctccgggtaagcactggaatggctggcatggatgattgggagatgataaaagctatagcaccagcctgaaacc cgtctgacctagtagaagataaccagcaaaatcaggtggtctgacctgacctatggatccggtgatagccaccctattattgtgacgt atgcatctccgctggttttagatagctgggtcaggttacactagttaccgttagcagc
SEQ ID NO:142	VL-(GGGG)3-VH scFv	DIVLTQSPATLSLSPGERATLSCRASQFIGSRYLAWYQQKPGQAPRLLIYGASNRAITGVPARFSGSGSDFTLTISL EPEDFATYYCQQYYDYPQTFGQGTQKVEIKGGGSGGGSGGGGSSQVQLKESGPAVLPKPTQTLTLCTFSGFSLSN RGGGVGWIRQPPGKALEWLAWIDWDDKSYSTSLKTRLTISKDTSKNQVLTMTNMDPVDATYYCARMHLPL VFDSWGQGLVTVSS
SEQ ID NO:143	DNA VL-(GGGG)4-VH scFv	Gatatacgtgctgacacagagccctgccacctgtctctgagccctggcagagagccacctgagctgccggccagccagttcatcggtccc gctacctggcctggtatcagcagaagcccggacaggtcccagactgctgactacggcgcagcaacagagctaccggctgccgagcagatt ttctggcagcggcagcggcaccgacttaccctgacctcagcagcctgggaaccgaggacttggcaacctactctccagcagttactacgac tccccagaccttggccagggcaccaggtggagatcaagggcggaggcggatccgggggtggcgaagtgaggcggaggaagcggag ggggcgggaagcagggtgcaattgaaagagtcggccctgacctggtgaaagcctaccagaccctgacctgaccttaccggtttag cctgagcaacagagggcggagtggtggtggtgcatagacagcctccggcaagggcctggaatggctggctggtgactggcagcagcaca agagctacagcaccagcctgaaaccgggtgaccttccaaggacaccagcaagaaccaggtggtgctcaccatgaccaacatggacccc gtggacaccgccacctatttggcccggatgacctgcccctggtgttcgatagctggggccagggaaaccttggtagcaggtgctcagc
SEQ ID NO:144	VL-(GGGG)4-VH scFv	DIVLTQSPATLSLSPGERATLSCRASQFIGSRYLAWYQQKPGQAPRLLIYGASNRAITGVPARFSGSGSDFTLTISL EPEDFATYYCQQYYDYPQTFGQGTQKVEIKGGGSGGGSGGGGSSQVQLKESGPAVLPKPTQTLTLCTFS GFSLSNRGGGVGWIRQPPGKALEWLAWIDWDDKSYSTSLKTRLTISKDTSKNQVLTMTNMDPVDATYYCAR MHLPLVFDSWGQGLVTVSS

SEQ ID NO:153	DNA VH-(GGGGS)3-VL scFv	Cagggtcaattggttgaagcgggtggtctggttcagcctggtgtagcctgctgagctgtgacgagcaagcggtttacccttagcgattatgtgattaattgggttcgtcaggcaccgggtaaaggtctggaatgggttagcgggtattagctggtcaggtgtaataaccattatcagatagcgtgaaaggtcgtttaccattagccgtgataatagcaaaaaaccctgtaictgcagatgaatagcctgcgtgcagaagataccgcagtttatttggca cgtctgggtgcaaccgcaataatattcgtataaaatattggaigtgtgggtcagggtaacctagttaccgttagcagtggtggtgggt agcgggtggcggatctggggcgggtggcagtgatcgaactgacccagcctccagcgttagcgttgcaaccgggtcagaccgcagtatta gctgtagcgggtagtagctcgtaataaagttattggtatcagcagaaccgggtcaggtcgggtctggttattaataaaataatcgccga gcggattccggaacgttttagcggtagcaatagcggtaataccgcaacctgaccattagcggcaccaggcagaagatgaagccgattatta ttgicagagctatgatggtcagaaagcctggtttttgggtggcaccagcttaccgtctg
SEQ ID NO:154	VH-(GGGGS)3-VL scFv	QVQLVESGGGLVQPGGSLRLSCAASGFTFSYVINWVVRQAPGKGLEWVSGISWISGVNTHYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARLGATANNIRYKFMVWVWQQGLTVTVSSGGGGSGGGSGGGGSDIELTQPPS VSVAPGQTARISCSGDSLNRKVVYVYQQKPGQAPVLIYKNNRPSGIPERFSGSNSGNTATLTISGTAQEAD EADYYC QSYDGGQKSLVFGGGTKLTVL
SEQ ID NO:155	DNA VH-(GGGGS)4-VL scFv	Cagggtcaattggttgaagcgggtggtctggttcagcctggtgtagcctgctgagctgtgacgagcaagcggtttacccttagcgattatgtgattaattgggttcgtcaggcaccgggtaaaggtctggaatgggttagcgggtattagctggtcaggtgtaataaccattatcagatagcgtgaaaggtcgtttaccattagccgtgataatagcaaaaaaccctgtaictgcagatgaatagcctgcgtgcagaagataccgcagtttatttggca cgtctgggtgcaaccgcaataatattcgtataaaatattggaigtgtgggtcagggtaacctagttaccgttagcagtggtggtgggt agcgggtggcggatctggggcgggtggcagtgatcgaactgacccagcctccagcgttagcgttgcaaccgggtcagaccgcagtatta aaaaataatcgccgagcggattccggaacgttttagcggtagcaatagcggtaataccgcaacctgaccattagcggcaccaggcagaag atgaagccgattatttgcagagctatgatggtcagaaagcctggtttttgggtggcaccagcttaccgtctg
SEQ ID NO:156	VH-(GGGGS)4-VL scFv	QVQLVESGGGLVQPGGSLRLSCAASGFTFSYVINWVVRQAPGKGLEWVSGISWISGVNTHYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARLGATANNIRYKFMVWVWQQGLTVTVSSGGGGSGGGSGGGGSDIE LTQPPSVSVAPGQTARISCSGDSLNRKVVYVYQQKPGQAPVLIYKNNRPSGIPERFSGSNSGNTATLTISGTAQEAD EADYYCQSYDGGQKSLVFGGGTKLTVL
MOR08545		
SEQ ID NO:157	DNA VL-(GGGGS)3-VH scFv	Gatatacgaactgaccagcctccgagcgttagcgttcaccgggtcagaccgcagtagctgtagcgggtgataatattggcagcaaatatg tcattggtatcagcagaaccgggtcagaccggttctggtattatggtgatagcaatcgtccgagcggattccggaacgttttagcggta gcaatagcggtaataccgcaacctgaccattagcggcaccaggcagaagatgaagcagattatttgcaccgtaccagcaccgattag cgggtttttgggtggcaccagcttaccgttcggttggtgtagcgggtggtggtcaggtggtggtcaggtttagcgttgcacaggttcaattgggt gaaagtggtggtgcttggttcagcctggtgtagcctgcgtgagctgtagcagaacgggtttacccttagcgttaatggtatgcatgggttc gccaggcaccgggtaaaggtcggaaagggttagcgttattgatggtatggccataacctattagccgtagcgttaaaggtcgtttaccatta gccgtgataatagcaaaaaaccctgatactgcagatgaatagcctgctgcagaagataccgcagtttatttgcgacgctatgattatta aataggtgctttgatccgtgggtcagggtacactagttaccgttagcagc
SEQ ID NO:158	VL-(GGGGS)3-VH scFv	DIELTQPPSVSVAPGQTARISCSGDNIGSKYVHWYQQKPGQAPVLIYVDSNRPSGIPERFSGSNSGNTATLTISGT QAEDEADYYCTRTPISGVFVGGGTKLTVLGGGGSGGGSGGGGQQVQLVESGGGLVQPGGSLRLSCAASGFTFS VNGMHVVRQAPGKGLEWVSVIDGMGHYTYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARYDYIKY GAFDPWVWQQGLTVTVSS
SEQ ID NO:159	DNA VL-(GGGGS)4-VH scFv	Gatatacgaactgaccagcctccgagcgttagcgttcaccgggtcagaccgcagtagctgtagcgggtgataatattggcagcaaatatg tcattggtatcagcagaaccgggtcagaccggttctggtattatggtgatagcaatcgtccgagcggattccggaacgttttagcggta gcaatagcggtaataccgcaacctgaccattagcggcaccaggcagaagatgaagcagattatttgcaccgtaccagcaccgattag cgggtttttgggtggcaccagcttaccgttcggttggtgtagcgggtggtggtcaggtggtggtcaggtttagcgttgcacaggttca caggttcaattgggtgaaagtggtggtggtcgtggttcagcctggtgtagcctgcgtgagctgtagcagaacgggtttacccttagcgttaatg gtatgcatgggttcggcaggcaccggtaaaggtctggaatgggttagcgttattgatggtatggccataacctattagccgtagcgttaa aggtcgtttaccattagcgtgataatagcaaaaaaccctgatactgcagatgaatagcctgctgcagaagataccgcagtttatttgcgca cgtatgattataataataggtgcctttgacctgggtcagggtacactagttaccgttagcagc
SEQ ID NO:160	VL-(GGGGS)4-VH scFv	DIELTQPPSVSVAPGQTARISCSGDNIGSKYVHWYQQKPGQAPVLIYVDSNRPSGIPERFSGSNSGNTATLTISGT QAEDEADYYCTRTPISGVFVGGGTKLTVLGGGGSGGGSGGGGQQVQLVESGGGLVQPGGSLRLSCAA SGFTFSVNGMHVVRQAPGKGLEWVSVIDGMGHYTYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAR YDYIKYGAFDPWVWQQGLTVTVSS

SEQ ID NO:161	DNA VH-(GGGGS)3-VL scFv	Caggttcaattggtgaaaagcgggtggtctgggtcagcctggtgtagcctgctgtagctgtagcagcaagcggtttacctttagcgtaaatggtatgcattgggtcgtcagccagcgggtaaaaggtctggaatgggttagcgttattgatggtagggccataacctattatgccgatagcgtaaaaggtcgtttaccattagccgtgataatagcaaaaataccctgtatctgcagatgaatagccctgctgtagaagataccgagtttatttggtcccgttatgattatataataggtgctttgacccgtgggtcagggtacactgtaacgttagcagtggtgggtggttagcgggtggcggaacctggtgggtggtcagatcgaaactgaccagcctccgagcgttagcgttgaccgggtcagaccgcaactattagctgtagcgggtgataatggcaaaaatgtgcatgggtatcagcagaaccgggtcaggctccggtctggttattatggtagtagcaatcgtcgaagcggattccggaacgttttagcgttagcaatagcggtaataccgcaaccctgaccattagcggcaccagggcagaagatgaagccgattattatgcaaccgtaaccagcaccggattagcgggttttgggtgggcaccaaactcctgctg
SEQ ID NO:162	VH-(GGGGS)3-VL scFv	QVQLVESGGGLVQPGGSLRLSCAASGFTFSVNGMHVWRQAPGKGLEWVVSVIDGMGHTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARYDYIKYAFDPWQGTLTVSSGGGGSGGGGGSSGDIETQPPSVSVA PGQTARISCSGDNIGSKYVHWYQQKPGQAPVLIYVYGDNSRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCTR TSTPISGVFGGGTKLTVL
SEQ ID NO:163	DNA VH-(GGGGS)4-VL scFv	Caggttcaattggtgaaaagcgggtggtctgggtcagcctggtgtagcctgctgtagctgtagcagcaagcggtttacctttagcgtaaatggtatgcattgggtcgtcagccagcgggtaaaaggtctggaatgggttagcgttattgatggtagggccataacctattatgccgatagcgtaaaaggtcgtttaccattagccgtgataatagcaaaaataccctgtatctgcagatgaatagccctgctgtagaagataccgagtttatttggtcccgttatgattatataataggtgctttgacccgtgggtcagggtacactgtaacgttagcagtggtgggtggttagcgggtggcggaacctggtgggtggtcaggtgggtggtgtagatcgaaactgaccagcctccgagcgttagcgttgaccgggtcagaccgcaactattagctgtagcgggtgataatggcaaaaatgtgcatgggtatcagcagaaccgggtcaggctccggtctggttattatggtagtagcaatcgtcgaagcggattccggaacgttttagcgttagcaatagcggtaataccgcaaccctgaccattagcggcaccagggcagaagatgaagccgattattatgcaaccgtaaccagcaccggattagcgggttttgggtggcacaagcttaccgttctg
SEQ ID NO:164	VH-(GGGGS)4-VL scFv	QVQLVESGGGLVQPGGSLRLSCAASGFTFSVNGMHVWRQAPGKGLEWVVSVIDGMGHTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARYDYIKYAFDPWQGTLTVSSGGGGSGGGGGSSGDIETQPP SVSVAPGQTARISCSGDNIGSKYVHWYQQKPGQAPVLIYVYGDNSRPSGIPERFSGSNSGNTATLTISGTQAEDEAD YYCTRSTPISGVFGGGTKLTVL
Biparatopic MOR08168/MOR06475		
SEQ ID NO:165	DNA Heavy MDR08168 hlgG1 LALA MDR06475 scFv	cagggtcaattggtcgagctggcggaggactggtcagcctgggtggcagcctgagatcagctgtagcagcagcgggttcacctcagcagact acgtgatcaactgggtgagcagcggcctggaaagggcctggaatgggtgtccggcatctctggctgtagcgtgaaaccccactacccgagcag cgtgaaggccgggttcaccatcagcgggacaacagcaagaacacccctgtacctgtagatgaacagcctgtagagccgaggacaaccgctgt actactgtgcaagactggggcaccgcaacaacatcgggtacaagttcatggacgtgtagggccagggcaactggtgacctgagctcag ctgaccaccaaggcccccagcgtgtccccctggccccagcagcaagagcaccagcggcggaacagcggcctggctgctgtagaggact acttccccagcccgtgacctgtcctggaaacagcggagccctgacccctggcgtgcaacacttccccggctgctgtagagcagcggctgtgac agcctgtccagcgtgtagcagtgccagcagcagcctggcaccagacctacatctgcaactgaaaccacaagcccagcaaccacaaggtg gacaagagagtgagcccaagagctgcaagaaccacacctgccccctgcccagcccagggcaagggcgggaccctcgtgttctcct gttcccccaagcccaggaacacctgatgatcagcaggaaccgagggtagctgctggtggtggagctgagccaggaaccagaggt gaagttcaactggtacgtggacggcgtggaggtgcaaacccaagaccagccagagagagcagtagcaaccagcaccctaggggtgt cctgctgacgtgctgcaaccaggactgggtgaaacggcaaggaatacaagtgaaggtctcaacaagccctgcccagccccatgaaaaga ccatcagcaaggccaaggccagccagggagccccaggtgtacaacctgccccctcccgggaggagatgaccaagaaccaggtgtccctg accctgtgtagaagggtcttaccacagacatcggctggagtgaggagcaaccggcagcccagagaacaactacaagaaccacccccca gtgctggacagcagcggcagcttctctgtagcaagctgaccgtggcaagtcagggtggcagcagggaacgtgttcagctgagcgtgac tgcagaaagcgtgcaacaactacaccagaagacctgagcctgtcccggcaagggcggctcggcggaaagcagatcgtgctgacac agagcctgccaacctgtctgagcctggcgagagagcaccctgagctgcccgggccaactggttcatcggctccccgtaacctgggtat cagcagaagcccggacaggctccagactgctgactacggcgccagcaacagagctaccggcgtgcccgcagatcttctggcagcggcagc ggaccgacttaccctgaccatcagcagcctggaaccgaggacttgcaccactactgcccagctactacactaccagaccttgc gccagggcaccaggtggagatacaaggcggaggcggatccgggggtggcggaaagtggaagggagggaagcggaggggggcggaaagccag gtagcaattgaaagagtcggccctgctggtggaagcctaccagaccagcctgacatgcaactttagcggcttccagcctgagcaacagag gcggcggagtggtggatcagacagcctccggcaaggccctggaaatggctggcctggatgactgggacagcagaagaagctacagcacc agcctgaaaaccggctgaccttccaaaggacaccagcaagaaccaggtgggtctacatgaccaactggacccccggaacccgccac ctattatgcccggatgactctgccccgtgttcgtagctggggcagggaacccctggtgacagctgtccagc

SEQ ID NO:166	Heavy MOR08168 higG1 LALA MOR06475 scFv	QVQLVESGGGLVQPGGSLRLSCAASGFTFSDYVINWVVRQAPGKGLEWVSGISWSGVNTHYADSVKGRFTISRDN SKNTLYLQMNLSRAEDTAVYYCARLGATANNIRYKFMVDVWGQGLTVTVSSASTKGPSVFLAPSSKSTSGGTAAL GCLVKDYFPEPTVSWNSGALTSVHTFPAVLQSSGLYLSVSVTVPSSSLGTQYICNVNHKPSNTKVDKRVPEKS CDKHTHTCCPPAPEAAGGSPVFLFPPKPKDLMISRTPVETCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKLSLSP GKGGSGGSDIVLTQSPATLSLSPGERATLSCRASQFIGSRYLAWYQQKPGQAPRLLIYGASNRRATGVPARFSGSGSG TDFLTISSELEDFATYYCQQYYDYPQTFGQGTKEIKGGGGSGGGGGSGGGGGSGVQLKESGPALVKPTQ TLTCTFSGFLSNRGGGVGWIRQPPGKALEWLAWIDWDDKSYSTSLKTRLTISKDTSKNQVVLTMNMDPV DTATYYCARMHLPLVFDVSWGQGLTVTVSS
SEQ ID NO:167	VL MDR08168	DIELTQPPSVSVAPGQTARISCSGDSLNRKVYVYQQKPGQAPVLIYKNNRPSGIPERFSGSNSGNTATLTISGTQA EDEADYYCQSYDGGQKSLVFGGGTKLTVL
SEQ ID NO:168	DNA VL MOR08168	GACATCGAGCTGACCCAGCCCCCTTCTGTGTCTGTGGCCCCGTCGCCAGACCCGAGAATCAGCTGCAGCGGC GACAGCCTGCGGAACAAGGTGACTGGTATCAGCAGAAGCCCCGCCAGGCTCCCGTCTGGTGTACTACAAG AACAAACCGGCCAGCGGCATCCCTGAGCGGTTACGCGGCAGCAACAGCGGCAATACCGCCACCCCTGACCATC AGCGGCACCCAGCGCCGAAGATGAGGCCGACTACTGCCCAGAGCTACGACGCCAGAAAAGCCTGGTGT CCGCGGAGGCACCAAGCTTACCCTGCTG
SEQ ID NO:169	DNA Light lambda MOR08168	Gacatcgagctgaccagccccccttctgtctgtgcccctggccagaccgccagaatcagctgcagcggcagacctcggaacaagggtg tactggtatcagcagaagcccggccaggtctccgctgctggaactacaagaacaaccggccagcggcatcctgagcggctcagcggcagc aacagcggcaataccgccacctgaccatcagcggcaaccagggcgaagaagaagccgaactactctgccaagactcagaagcagaagaag cctggtgttcggcggagggcacaagcttaccgtctggcagcccaagccgcccctgagcctgctccccccagcagcaggaaactg caggccaacaaggccaacctgctgctgactcagcgaacttaccctggcggcctgaccgtggcctggaaggccagcagcccgtgaag gccggctgggagacaaccaaccagcaagcagagcaacaacaagtacggccagcagcactcctgagcctgaccccgagcagtggaaga gccacagaagctacagctccaggtcaccacagggcagcaccgtggagaaaaccgtggccccaaccgagtcagc
SEQ ID NO:170	Light lambda MOR08168	DIELTQPPSVSVAPGQTARISCSGDSLNRKVYVYQQKPGQAPVLIYKNNRPSGIPERFSGSNSGNTATLTISGTQA EDEADYYCQSYDGGQKSLVFGGGTKLTVLQPKAAPS VTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSP VKAGVETTPSKQSNNKYAASSYLSLTPQEWKSHRSYSCQVTHEGSTVEKTVAPTECS
SEQ ID NO:171	Heavy MOR08168 higG1 LALA (w/o K) MOR06475 scFv	QVQLVESGGGLVQPGGSLRLSCAASGFTFSDYVINWVVRQAPGKGLEWVSGISWSGVNTHYADSVKGRFTISRDN SKNTLYLQMNLSRAEDTAVYYCARLGATANNIRYKFMVDVWGQGLTVTVSSASTKGPSVFLAPSSKSTSGGTAAL GCLVKDYFPEPTVSWNSGALTSVHTFPAVLQSSGLYLSVSVTVPSSSLGTQYICNVNHKPSNTKVDKRVPEKS CDKHTHTCCPPAPEAAGGSPVFLFPPKPKDLMISRTPVETCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKLSLSP GGGSGGSDIVLTQSPATLSLSPGERATLSCRASQFIGSRYLAWYQQKPGQAPRLLIYGASNRRATGVPARFSGSGSGT DFTLTISSELEDFATYYCQQYYDYPQTFGQGTKEIKGGGGSGGGGGSGGGGGSGVQLKESGPALVKPTQT TLTCTFSGFLSNRGGGVGWIRQPPGKALEWLAWIDWDDKSYSTSLKTRLTISKDTSKNQVVLTMNMDPV DTATYYCARMHLPLVFDVSWGQGLTVTVSS
SEQ ID NO:172	DNA Heavy MOR08168 higG1 LALA (w/o K) MOR06475 scFv	CAGGTGCAATTGGTCGAGTCTGGCGGAGGACTGGTGAGCCTGGTGACGCTGAGACTGAGCTGCGCCGC CAGCGGCTTACCTTCAGCGACTACGTGATCAACTGGGTGCGACAGGCCCTGGAAGGGCCTGGAATGGGT GTCCGGCATCTTGGTCTGGCTGAAACACCACTACGCCGACAGCGTGAAGGGCCGTTACCATCAGCCG GGACAACAGCAAGAACCCTGTACTCTGACAGTGAACAGCCTGAGAGCCGAGGACACCCGCTGACTACTG TGCCAGACTGGCGCCACCAGCAACAACATCCGGTACAAGTTCATGGACGTGTGGGGCAGGGCACACTGGT GACCGTCAGCTCAGTAGCACCAAGGGCCCCAGCGTGTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGG CGGCACAGCCGCCCTGGGCTGCTGGTGAAGGACTACTCCCCGAGCCCGTGACCGTGTCTGGAACAGCGG AGCCCTGACCTCCGGCTGCACACCTCCCCCGCTGCTGCAGAGCAGCGGCTGTACAGCCTGTCCAGCGTG GTGACAGTCCCAGCAGCAGCCTGGGCACCCAGACTACATCTGCAACGTGAACCACAAGCCAGCAACACC AAGGTGGACAAGAGAGTGGAGCCCAAGAGCTGCGACAAGACCACACCTGCCCCCCCTGCCAGCCCAAG GGCAGCGGGCGGACCTCCGTGTCTGTTCCCCCCAAGCCCAAGGACACCTGATGATCAGCAGGACCCCC GAGGTGACCTGCGTGGTGGTGGACGTGAGCCACGAGGACCCAGAGGTGAAGTCAACTGTCAGTGGACGG CGTGGAGGTGCACAACGCCAAGACCAAGCCAGAGAGGAGCAGTACAACAGCACCTACAGGGTGGTGTCCG TGCTGACCGTGTGCACACGACTGGCTGAACGGCAAGGAATAACAAGTGAAGGTCTCCAACAAAGGCCCTGC CAGCCCCATCGAAAAGACCATCAGCAAGGCCAAGGGCCAGCCAGGGAGCCCCAGGTGTACACCCCTGCC CCCCCGGGAGGAGATGACCAAGAACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTACCCAGCGACA TCGCCGTGGAGTGGGAGAGCAACGGCCAGCCGAGAACAACTACAAGACCACCCCCAGTGTGGACAGC GACGGCAGCTTCTCTGTACAGCAAGCTGACCGTGGACAAGTCCAGGTGGCAGCAGGGCAACGTTTCAGC

		<p>TGCAGCGTGATGCACGAAGCGCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCCCCGGCGGCGGC TCCGGCGGAAGCGATATCGTGCTGACACAGAGCCCTGCCACCCTGTCTCTGAGCCCTGGCGAGAGAGCCACC CTGAGCTGCCGGGCCAGCCAGTTCA TCGGCTCCCGCTACCTGGCCCTGGTATCAGCAGAAGCCCGGACAGGCT CCCAGACTGCTGATCTACGGCCAGCAACAGAGCTACCGGCGTGCCCGCCAGATTTCTGGCAGCGGCAGC GGCACCAGACTTACCCTGACCATCAGCAGCCTGGAACCCGAGGACTTCCACCTACTACTGCCAGCAGTACT ACGACTACCCCGAGACCTTCGGCCAGGGCACCAGGTGGAGATCAAGGGCGGAGGCGGATCCGGGGGTGG CGGAAGTGGAGGCGGAGGAAGCGGAGGGGGCGGAAGCCAGGTGCAATTGAAAGAGTCCGGCCCTGCCCTG GTGAAGCCTACCCAGACCCTGACCCTGACATGCACCTTCAGCGGCTTCAGCCTGAGCAACAGAGGCGGCGGA GTGGGCTGGATCAGACAGCCTCCCGCAAGGCCCTGGAATGGCTGGCTGGATCAGCTGGGACGACGACAA GAGCTACAGCACCAGCCTGAAAACCCGGCTGACCATCTCAAGGACACCAGCAAGAACCAGGTGGTGCTCAC CATGACCAACATGACCCCGTGACACCGCCACCTATTATTGCGCCCGGATGCATCTGCCCTGGTGTTCGAT AGCTGGGGCCAGGGAACCTGGTGACAGTGCCAGC</p>
<p>SEQ ID NO:173</p>	<p>Heavy MOR08168 hlgG1 LALA MOR06475 scFv (DP to DA)</p>	<p>QVQLVESGGGLVQPGGSLRSLCAASGFTFSQYINWVRQAPGKLEWVSGISWSGVNTHYADSVKGRFTISRDN SKNTLYLQMNLSRAEDTAVVYCARLGATANNIRYKFMVWVWQGLTVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKRVPEPKS CDKHTHTCPPCPAPEAAGGPSVFLFPPKPKDITLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSVSMHEALHNHYTQKLSLSLSP GKGGSGGSDIVLTQSPATLSLSPGERATLSCRASQFIGSRYLAWYQQKPGQAPRLLIYGASNRRATGVPARFSGSGS TDFLTITISLEPEDFATYYCQYDYDPQTFGQGTKVEIKGGGGSGGGSGGGSGGGGQVQLKESGPPALVKTQ TLTCTFSGFSLNRGGGVGWIRQPPGKALEWLAWIDWDDKSYSTSLKRLTISKDTSKNQVLTMTNMDAV DTATYYCARMHLPLVFDWVWQGLTVTVSS</p>
<p>SEQ ID NO:174</p>	<p>DNA Heavy MOR08168 hlgG1 LALA MOR06475 scFv (DP to DA)</p>	<p>CAGGTGCAATTGGTCTGAGTCTGGCGGAGGACTGGTGCAGCCTGGTGGCAGCCTGAGACTGAGCTGCCCGC CAGCGGCTTCACCTTCAGCGACTACGTGATCACTGGTGGCAGCAGCCCTGGAAAGGGCCTGGAATGGGT GTCCGGCATCTCTTGGTCTGGCGTGAACACCCACTACGCCGACAGCGTGAAGGGCCGGTTCACCATCAGCCG GGACAACAGCAAGAACACCCCTGTACCTGCAGATGAACAGCCTGAGAGCCGAGGACACCAGCCGTGTACTACTG TGCCAGACTGGGCGCCACCGCCAACATCCGGTACAAGTTCATGGACGTGTGGGGCCAGGGCACACTGGT GACCGTCAGCTCAGCTAGCACCAAGGGCCCCAGCGTGTCCCTGGCCCCAGCAGCAAGAGCACCAGCGG CGGCACAGCCGCCCTGGCTGCTGGTGAAGGACTACTTCCCGAGCCGTGACCGTGTCTGGAACAGCGG AGCCCTGACCTCCGGCGTGCACACCTTCCCGCCGTGCTGCAGAGCAGCGGCTGTACAGCCTGTCCAGCGTG GTGACAGTGCCAGCAGCAGCCTGGCCACCCAGCCTACATCTGCAACGTGAACCAAGCCAGCCAGCAACACC AAGGTGGACAAGAGAGTGGAGCCCAAGAGCTGCGACAAGACCCACCTGCCCCCAGCAGCCAGCCCGG GGCAGCGGGCGGACCCTCCGTGTTCTGTCCCCCAAGCCCAAGGACACCCCTGATGATCAGCAGCACC GAGGTGACCTGCGTGGTGGTGGAGCTGAGCCAGAGGACCCAGAGTGAAGTTCAACTGGTACGTGGACGG CGTGGAGGTGCACAACGCCAAGACCAAGCCAGAGAGGAGCAGTACAACAGCACCTACAGGTTGGTGTCCG TGCTGACCGTGTGCACCAGGACTGGCTGAACGGCAAGGAATAAAGTGCAAGGTCTCAACAAGGCCCTGC CAGCCCCATCGAAAAGACCATCAGCAAGGCCAAGGGCCAGCCAGGGAGCCCGAGGTGTACACCTGCCCC CCTCCGGGAGGAGATGACCAAGAACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCAGCGACA TCGCCGTGGAGTGGAGAGCAACGCCAGCCGAGAACAACTACAAGACACCCCGCAGTGTGGACAGC GACGGCAGCTTCTCTGTACAGCAAGCTGACCGTGGACAAGTCCAGGTGGCAGCAGGGCAACGTGTTACG TGCAGCGTGATGCACGAAGCGCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCCCCCGGAAGGGC GGCTCCGGCGGAAGCGATATCGTGCTGACACAGAGCCCTGCCACCCTGTCTCTGAGCCTGGCGAGAGAGCC ACCCCTGAGCTGCCGGGCCAGCCAGTTCA TCGGCTCCCGCTACCTGGCTGGTATCAGCAGAAGCCCGGACAG GCTCCAGACTGCTGATCTACGGCGCCAGCAACAGAGCTACCGCGTGGCCGAGATTTCTGGCAGCGGC AGCGGCACCGACTTACCCTGACCATCAGCAGCCTGGAACCCGAGGACTTCCGCCACTACTACTGCCAGCAGT ACTACGACTACCCCGAGACTTCCGGCCAGGGCACCAAGGTGGAGATCAAGGGCGGAGGCGGATCCGGGGGT GGCGGAAGTGGAGGGGAGGAAGCGGAGGGGGGGGGAAGCCAGGTGCAATTGAAAGAGTCCGGCCCTGCC CTGGTGAAGCCTACCCAGACCTGACCTGACATGCACCTTACCGGCTTCAAGCTGAGCAACAGAGCGGC GGAGTGGGCTGGATCAGACAGCCTCCGGCAAGGCCCTGGAATGGCTGGCTGGATCAGTGGGACGACGA CAAGAGCTACAGCACCAGCCTGAAAACCCGGCTGACCATCTCAAGGACACCAGCAAGAACCAGGTGGTGTCT CACCATGACCAACATGGACCGCTGGACACCGCCACCTATTATTGCGCCCGGATGCATCTGCCCTGGTGTTC GATAGCTGGGGCCAGGGAACCTGGTGACAGTGCCAGC</p>
<p>SEQ ID NO:175</p>	<p>Heavy MOR08168 hlgG1 LALA MOR06475 scFv (DP to TA)</p>	<p>QVQLVESGGGLVQPGGSLRSLCAASGFTFSQYINWVRQAPGKLEWVSGISWSGVNTHYADSVKGRFTISRDN SKNTLYLQMNLSRAEDTAVVYCARLGATANNIRYKFMVWVWQGLTVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKRVPEPKS CDKHTHTCPPCPAPEAAGGPSVFLFPPKPKDITLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSVSMHEALHNHYTQKLSLSLSP GKGGSGGSDIVLTQSPATLSLSPGERATLSCRASQFIGSRYLAWYQQKPGQAPRLLIYGASNRRATGVPARFSGSGS</p>

		TDFTLTISSLEPEDFATYYCQYYDYPQTFGQGTKEIKGGGGSGGGGSGGGGSGGGGSGVQLKESGPALVKPTQ TLTLTCTFSGFLSNRGGGVGWIRQPPGKALEWLAWIDWDDDKSYSTSLKRLTISKDTSKNQVLLTMTNMTAVD TATYYCARMHLPLVFDWSWGQGLTVVSS
SEQ ID NO:176	DNA Heavy MDR08168 hlgG1 LALA MOR06475 scFv (DP to TA)	CAGGTGCAATTGGTCGAGTCTGGCGGAGGACTGGTGACGCTGGTGCGAGCCTGAGACTGAGCTGCGCCGC CAGCGGCTTACCTTCAGCGACTACGTGATCAACTGGGTGCGACAGGCCCTGGAAAGGCCCTGGAATGGGT GTCCGGCATCTCTTGGTCTGGCGTGAACACCCACTACGCCGACAGCGTGAAGGGCCGGTTCACCATCAGCCG GGACAACAGCAAGAACACCCTGTACTGCAGATGAACAGCCTGAGAGCCGAGGACACCGCCGTGACTACTG TGCCAGACTGGGCGCCACCGCCAACAACATCCGGTACAAGTTCATGGACGTGTGGGGCCAGGGCACACTGGT GACCGTCAGCTCAGTAGCACCAAGGGCCCCAGCGTGTCCCCCTGGCCCCAGCAGCAAGAGCACCAGCGG CGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCGAGCCCGTGACCGTGTCTGGAACAGCGG AGCCCTGACCTCCGGCGTGACACCTTCCCGCCGTGCTGCAGAGCAGCGGCTGTACAGCCTGTCCAGCGTG GTGACAGTGCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCAAGCCAGCAACACC AAGGTGGACAAGAGAGTGGAGCCCAAGAGCTGCGACAAGACCACACCTGCCCCCCCTGCCAGCCCCAGA GGCAGCGGGCGGACCCTCCGTGTTCTGTTCCCCCAAGCCCAAGGACACCTGATGATCAGCAGGACCCCC GAGGTGACCTGCGTGGTGGACGTGAGCCACGAGGACCCAGAGGTGAAGTCAACTGGTACGTGGACGG CGTGGAGGTGCACAACGCCAAGACCAAGCCAGAGAGGAGCAGTACAACAGCACCTACAGGGTGTGTCCG TGCTGACCGTGTCTGACCAGGACTGGCTGAACGGCAAGGAATAACAAGTGAAGGTCTCCAACAAGGCCCTGC CAGCCCCATCGAAAGACCATCAGCAAGGCCAAGGGCCAGCCACGGGAGCCCCAGGTGTACACCTGCCCC CCTCCCGGGAGGAGATGACCAAGAACCAGGTGTCCCTGACCTGTGGAAGGCTTCTACCCAGCGACA TGCCTGTGGAGTGGAGAACCGCCAGCCCGAGAACAACTACAAGACACCCCCAGTGTGGACAGC GACGGCAGCTTCTTCTGTACAGCAAGCTGACCTGGACAAAGTCCAGGTGGCAGCAGGGCAACGTGTTACGC TGACGCTGATGCACGAAGCGCTGCACAACCTACACCCAGAAGAGCCTGAGCCTGTCCCCCGCAAGGGC GGCTCCGGCGGAAGCATATCGTGTGACACAGACCCCTGCCACCCTGTCTGTAGCCCTGGCAGAGAGCC ACCCTGAGCTGCCGGCCAGCCAGTTCATCGGCTCCCGCTACCTGGCTGGTATCAGCAGAAGCCCGGACAG GCTCCAGACTGCTGATCTACGGCGCCAGCAACAGAGCTACCGCGTGGCCGCGCAGATTTTCTGGCAGCGG AGCGGCACCGACTTACCCTGACCATCAGCAGCCTGGAACCCGAGGACTTCGCACCTACTACTGCCAGCAGT ACTACGACTACCCAGACCTTCGGCCAGGGCACCAGGTGGAGATCAAGGGCGGAGGCGGATCCGGGGGT GGCGGAAGTGGAGGCGGAGGAAAGCGGAGGGGGCGGAAGCCAGGTGCAATTGAAAGAGTCCGGCCCTGCC CTGGTGAAGCCTACCCAGACCCTGACCTGACATGCACCTTACGCGCTTACGCTGAGCAACAGAGCCGGC GGAGTGGGCTGGATCAGACAGCCTCCCGCAAGGCCCTGGAATGGCTGGCTGGATCGACTGGGACGACGA CAAGAGCTACAGCACCAGCCTGAAAACCCGGCTGACCATCTCCAAGGACACCAGCAAGAACCAGGTGGTGCT CACCATGACCAACATGACCGCCGTGGACCCGCCACTATTATTGCGCCCGGATGCATCTGCCCTGGGTGTC GATAGCTGGGGCCAGGGAACCTGGTGACAGTGTCCAGC
SEQ ID NO:177	Light MOR06475 scFv MDR08168 lambda	DIVLTQSPATLSLSPGERATLSCRASQFISGRYLAWYQKPGQAPRLLIYGASNRRATGVPARFSGSGSDTDFLTISSL EPEDFATYYCQYYDYPQTFGQGTKEIKGGGGSGGGGSGGGGSGGGGSGVQLKESGPALVKPTQTLTLTCTFS GFLSNRGGGVGWIRQPPGKALEWLAWIDWDDDKSYSTSLKRLTISKDTSKNQVLLTMTNMDPVDATYYCAR MHLPLVFDWSWGQGLTVVSSGGSGSDIETQPPSVVAPGQATARISCSGDSLRNKVYVYQKPGQAPLVVIYKN NRPSGIPERFSGNSNGNTALTIISGTAQEADEADYYCQSYDQKSLVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQA NKATLVCLISDFYPGAVTVAWKAD5SPVKAGVETTPSKQSNKYAASSYLSLTPEQWKSRSYSCQVTHEGSTVE KTVAPTECS
SEQ ID NO:178	DNA Light MOR06475 scFv MOR08168 lambda	GATATCGTGTGACACAGAGCCCTGCCACCCTGTCTCTGAGCCCTGGCGAGAGAGCCACCCTGAGCTGCGCG GCCAGCCAGTTCATCGGCTCCCGTACCTGGCCTGGTATCAGCAGAAGCCCGGACAGGCTCCAGACTGCTG ATCTACGGCGCCAGCAACAGAGCTACCGCGTGGCCGCCAGATTTTCTGGCAGCGGCAGCGGCACCAGCTTC ACCCTGACCATCAGCAGCCTGGAACCCGAGGACTTCGCCACTACTACTGCCAGCAGTACTACGACTACCCCC AGACCTTCGGCCAGGGCCACCAAGGTGGAGATCAAGGGCGGAGGCGGATCCGGGGGTGGCGGAAGTGGAG GCGGAGGAAGCGGAGGGGGCGGAAGCCAGGTGCAATTGAAAGAGTCCGGCCCTGCCCTGGTGAAGCCTAC CCAGACCCTGACCCTGACATGCACCTCAGCGGCTTACGCTGAGCAACAGAGGCGGCGGAGTGGGTGGAT CAGACAGCCTCCCGCAAGGCCCTGGAATGGCTGGCTGGATCGACTGGGACGACGACAAGAGTACAGCA CCAGCCTGAAAACCCGGCTGACCATCTCCAAGGACACCAGCAAGAACCAGGTGGTGTCTACCATGACCAACA TGGACCCCGTGGACACCGCCACTATTATTGCGCCCGGATGCATCTGCCCTGGTGTTCGATAGCTGGGGCCA GGGAACCCCTGGTACAGTGTCCAGCGCGGCTCCGGCGGAAGCGACATCGAGCTGACCCAGCCCCCTCTGT GTCTGTGGCGCCCGGCGAGACCAGCAAGATCAGCTGCAGCGGCGACAGCCTCGGGAACAAGGTGACTGGT ATCAGCAGAAGCCCGCCAGGCTCCCGTGTGGTATCTACAAGAACAACCCGGCCAGCGGCATCCCTGAGC GGTTCAGCGGCAGCAACAGCGCAATACCCGCCACTGACCATCAGCGGCACCAGGCCGAAGATGAGGCC GACTACTACTGCCAGAGCTACGACGGCCAGAAAAGCCTGGTGTTCGGCGGAGGACCAAGCTTACCCTGCTG GGCCAGCCAAAGCCGCCCTAGCGTGACCTGTCCCCCAGCAGCGAGGAACTGACGGCAACAAGGCC ACCCTGGTCTGCTGATCAGCGACTTCTACCTGGCGCGTACCCTGGCTGGAAGGCCGACAGCAGCCCC GTGAAGGCCGGCTGGAGACAACCACCCAGCAAGCAGAGCAACAACAAGTACGCCCGCAGCAGCTACT GAGCCTGACCCCCAGCAGTGAAGAGCCACAGAAGCTACAGCTGCCAGGTCAACCACGAGGGCAGCACC

		TGGAGAAAACCGTGGCCCCACCGAGTGCAGC
SEQ ID NO:179	VH MDR08168	QVQLVESGGGLVQPGGSLRLSCAASGFTFSQYVFNWVRQAPGKGLEWVSGISWGSVNTHYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVVYCARLGATANNIRYKFMVDVWGQGLTVTVSS
SEQ ID NO:180	DNA VH MDR08168	Caggtgcaattggtcagctcggcggaggactggcagcctggggcagcctgagactgagctgcccggcagcgcttcaccttcagcagcact acgtgatcaactgggtgcgacagccctggaaaggcctggaatgggtgctccggca tcttctgctgctggcgtgaa ccccactacgccgacag cgtgaaggccggttcacatcagcgggacaacaagaacaccctgtacctgcagatgaa cagcctgagagccgaggacaccgctgt actactgtccagactggcgccaccgcaacaacatccggtacaagttcatggacgtgtggggccaggccacactggtgacctcagctca
SEQ ID NO:181	Heavy MOR08168 hlgG1 LALA	QVQLVESGGGLVQPGGSLRLSCAASGFTFSQYVFNWVRQAPGKGLEWVSGISWGSVNTHYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVVYCARLGATANNIRYKFMVDVWGQGLTVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKRVKPKS CDKTHCTPCPAPEAAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTKAKGQPREPQVYVLPSSRREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSVMHEALHNHYTQKSLSLSP GK
SEQ ID NO:182	DNA Heavy MOR08168 hlgG1 LALA	CAGGTGCAATTGGTCCGAGTCTGGCGGAGGACTGGTGCAGCCTGGTGGCAGCCTGAGACTGAGCTGCCCGC CAGCGGCTTACCTTCAGCGACTACGTGATCAACTGGGTGCGACAGGCCCTGGAAAGGGCCTGGAATGGGT GTCCGGCATCTCTTGGTCTGGCGTGAACCCCACTACGCCGACAGCGTGAAGGGCCGGTTCACCATCAGCCG GGACAACAGCAAGAACACCTGTACCTGCAGATGAACAGCCTGAGAGCCGAGGACACCCTGTTACTACTG TGCCAGACTGGGCGCCACCGCAACAACATCCGGTACAAGTTCATGGACGTGTGGGGCCAGGGCACACTGGT GACCGTCAGCTCAGCTAGCACCAAGGGCCCCAGCGTGTTCCTCCCTGGCCCCCAGCAGCAAGAGCACCAGCGG CGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCGAGCCCGTACCGGTGCTGGAACAGCGG AGCCCTGACCTCCGGCGTGCACACCTTCCCGCGTGTGCAGAGCAGCGGCTGTACAGCCTGTCCAGCGTG GTGACAGTGCCAGCAGCAGCCTGGGCAACCAAGCTACATCTGCAACGTGAACCAAGCCAGCCCAACACC AAGGTGGACAAGAGAGTGGAGCCCAAGAGCTGCGACAAGACCCACACTGCCCCCCCTGCCAGCCCCAGA GGCAGCGGGCGGACCTCCGTGTTCTGTTCCCCCAAGCCCAAGGACACCCTGATGATCAGCAGGACCCCC GAGGTGACCTGCGTGGTGGTGGACGTGAGCCACGAGGACCCAGAGGTGAAGTCAACTGGTACGTGGACGG CGTGGAGGTGCACAACGCCAAGACCAAGCCAGAGAGGAGCAGTACAACAGCACCTACAGGGTGGTGTCCG TGCTGACCGTCTGCACCAGGACTGGCTGAACGGCAAGGAATACAAGTGAAGTCTCCAACAAGGCCCTGC CAGCCCCATCGAAAAGACCATCAGCAAGGCCAAGGGCCAGCCAGGGAGCCCAAGGTGTACACCTGCCCC CTCCCGGGAGGAGATGACCAAGAACAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTACCCAGCGACA TCGCCGTGGAGTGGGAGAGCAACGCCAGCCCGAGAACAATAAAGACACCCCCCAAGTGTCTGGACAGC GACGGCAGCTTCTTCTGTACAGCAAGCTGACCGTGGACAAGTCCAGGTGGCAGCAGGGCAACGTGTTACG TGCAGCGTATGCACGAGGCCCTGCACAACCACTACCCAGAGAGCCTGAGCCTGTCCCCCGGCAAG
SEQ ID NO:183	VL MOR06475	DIVLTQSPATLSLSPGERATLSCRASQFIGSRYLAWYQQKPGQAPRLLIYGASNRATGVPARFSGSGSDFTLTISSL EPEDFATYYCQQYYDYPQTFGQGTKEIK
SEQ ID NO:184	DNA VL MOR06475	Gatatcgtgctgaccagagcccggcgaacctgagcctgtctccggcgaactgagcctgagcctgagcagagcagcagcattatggttctc gttatcgtgcttggtaccagcagaaaccaggtcaagcaccgcttattaattalggctctctaa tctgtcaactggggtccggcgcttttag cggctctggatcggcagcagatlttacctgaccattagcagcctggaacctgaagactttgcaactattatgcccagcagttatgattatct cagaccttggcagggatcgaagttgaattaaa
SEQ ID NO:185	Light MOR06475 kappa	DIVLTQSPATLSLSPGERATLSCRASQFIGSRYLAWYQQKPGQAPRLLIYGASNRATGVPARFSGSGSDFTLTISSL EPEDFATYYCQQYYDYPQTFGQGTKEIKRTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAQVQWKVDNAL QSGNSQESVTEQDSKDSYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO:186	DNA Light MOR06475 kappa	GATATCGTGTGACCCAGAGCCCGGCGACCCCTGAGCCTGCTCCGGGCGAACGTGCGACCCCTGAGCTGCAGA GCGAGCCAGTTTATTGGTCTCTGTTATCTGGCTTGGTACCAGCAGAAACAGGTCAAGCACCCTGCTATTAA TTTATGGTCTTCTAATCGTGCAACTGGGTCCCGGCGCTTTTAGCGGCTCTGGATCCCGCACGGATTTTAC CCTGACCATAGCAGCCTGGAACCTGAAGACTTTGCGACTTATTAATTGCCAGCAGTATTATGATTATCTCAGA CCTTTGGCCAGGGTACGAAAAGTTGAAATTAACGTACGGTGGCCGCTCCAGCGTGTTCATCTTCCCCCAG CGACGAGCAGCTGAAGAGCGGCACCCGACCGTGGTGTGCTGTGAACAACCTTACCCCGGGAGGCCA AGGTGACGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTACCCGAGCAGGACAG CAAGGACTCCACTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCATAAGGTGTA CGCCTGCGAGGTGACCCACCAGGGCTGTCCAGCCCCGTGACCAAGAGCTTCAACAGGGGCGAGTGC

<p>SEQ ID NO:187</p>	<p>Heavy MDR06475 hlgG1LALA MDR08168 scFv (VH-3-VL)</p>	<p>QVQLKESGPALVKPTQLTLTCTFSGFSLNRRGGVGVWIRQPPGKALEWLAWIDWDDKSYSTSLKTRLTISKDTS KNQVVLMTNMDPVDATYYCARMHLPLVFDSWGQGLTVTVSSASTKGPSVFLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSVHTFAVLAQSSGLYSLSVVTVPSSSLGQTQYICNVNHNKPSNTKVDKRVEPKSCDKHT CPPCPAPEAAGGPSVFLFPPKPKDLMISRTEPVTQVVDVSHEDPEVKFNWYVDGVEVHNAKTPREEQYNSTY RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTSKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDI AVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSVSMHEALHNHYTQKLSLSLSPGKGGSG GSQVQLVESGGGLVQPGGSLRLSCAASGFTFSQYVIVWVRQAPGKGLVWVSGISVSGVNTHYADSVKGRFTISR DNSKNTLYLQMNSLRAEDTAVYYCARLGATANNIRYKFMQVWGQGLTVTVSSGGGGGGGGGGGGGGGGGGGG PPSVSVAPGQTARISCSGDSLRNKVYVYQQKPGQAPVLIYKNNRPSGIPERFSGNSNGNTATLTISGTQAEDEAD YYCQSYDGGKSLVFGGGTKLTVL</p>
<p>SEQ ID NO:188</p>	<p>DNA Heavy MOR06475 hlgG1LALA MOR08168 scFv (VH-3-VL)</p>	<p>CAGGTGCAATTGAAAGAAAGCGGCCCGCCCTGGTGAACCGACCCAAACCTGACCTGACCTGTACCTTTT CCGGATTAGCCTGTCTAATCGTGGTGGTGGTGGTGGTGGATTCCGACCCGCTGGGAAAGCCCTCGAGT GGCTGGCTTGGATCGATTGGGATGATGATAAGTCTTATAGCACCAGCCTGAAACCGCTGACCATAGCA AAGATACTCGAAAAATCAGGTGGTGTGACTATGACCAACATGGACCCGGTGGATACGGCCACCTATTATTG CGCGCTATGCATCTTCTCTTGTTTTTGATTCTTGGGGCCAAGGCACCCCTGGTACGGTTAGCTCAGCTAGCA CCAAGGGCCCCAGCGTGTCCCGTGGCCCCCAGCAGCAAGAGCACCAGCGGGCACAGCCGCCCTGGGCT GCCTGGTGAAGGACTACTTCCCGAGCCCGTACCGTGTCTTGGAAACAGCGGAGCCCTGACCTCCGGCGTGC ACACCTTCCCGCGTGTGTCAGAGCAGCGCCCTGTACAGCCTGTCCAGCGTGGTACAGTGCACAGCAGCA GCCTGGCACCAGACTACATCTGCAACGTGAACCAAGCCAGCAACCAAGGTGGACAAGAGAGTG GAGCCCAAGAGCTGCGACAAGACCCAGCCTGCCCCCTGCCAGCCCCAGAGGAGGAGGAGAGTG GTGTTCTGTTCCTCCCAAGCCCAAGACACCCCTGATGATCAGCAGGACCCCGAGGAGTACCTGCGTGGT GTGGAGTGCAGCCAGGACCCAGAGGTAAGTTCACTGTTACGTTGACGGCGTGGAGGTGCACAACGC CAAGACCAAGCCAGAGAGGAGCAGTACAACAGCACCTACAGGGTGTGTCCGTGCTGACCGTGTGCACCA GGACTGGCTGAACGGCAAGGAATACAAGTGAAGTCTCCAACAAGGCCCTGCCAGCCCCATCGAAAAGAC CATCAGCAAGGCCAAGGGCCAGCCAGGGAGCCCGAGGTGTACACCTGCCCGCTCCCGGAGGAGATGA CCAAGAACCAGGTGTCCCTGACCTGTCTGGTGAAGGCTTCTACCCAGCGACATCGCGTGGAGTGGGAGA GCAACGGCCAGCCGAGAACAACTACAAGACCCCGCCAGTGTGACAGCGACGGCAGCTTCTTCTGT ACAGCAAGCTGACCGTGGACAAGTCCAGGTGGCAGCAGGGCAACGTTCAGCTGCAGCGTATGCACGAA GCGCTGCACAACCACTACCCAGAGAGCCTGAGCCTGTCCCCGGCAAGGGCGGCTCCGGCGGAAGCCA GGTTCAATTGGTTGAAAGCGGTGGTGGTCTGGTTCAGCCTGGTGGTAGCCTGCGTCTGAGCTGTGCAGCAAG CGGTTTACCTTAGCGATTATGTGATTAATGGGTTCTGACGGCACCGGGTAAAGGTTCTGGAATGGGTTAGC GGTATTAGCTGGTCAAGGTGTAATACCAATTATGCAGATAGCGTGAAGGTCGTTTACCATAGCCGTGATA ATAGCAAAAATACCTGTATCTGCAGATGAATAGCCTGCGTGCAGAAGATACCGCAGTTTATATTGTGCAG TCTGGGTGCAACCGCAAATAATATCGCTATAAATTTATGGATGTGTGGGGTCAAGGTACACTAGTTACCGTT AGCAGTGGTGGTGGTGGTAGCGGTGGTGGCGGATCTGGTGGCGGTGGCAGTATCGAAGTACCCAGCC TCCGAGCGTTAGCGTTGCACCGGGTCAAGCCGACGTATTAGCTGATGCGGTGATAGTCTGCGTAATAAAGTT TATTGGTATCAGCAGAAACCGGGTCAAGGCTCCGGTCTGGTTATTTATAAAAATAATCGTCCGAGCGGATTTC CGGAACGTTTTAGCGGTAGCAATAGCGGTAATACCGCAACCCTGACCATAGCGGCACCCAGGCAAGATG AAGCCGATTATTATTGTCAGAGCTATGATGGTCAGAAAAGCCTGGTTTTGGTGGTGGCACCAAGCTTACCGT TCTG</p>
<p>SEQ ID NO:189</p>	<p>Heavy MDR06475 hlgG1 LALA MOR08168 scFv (VH-4-VL)</p>	<p>QVQLKESGPALVKPTQLTLTCTFSGFSLNRRGGVGVWIRQPPGKALEWLAWIDWDDKSYSTSLKTRLTISKDTS KNQVVLMTNMDPVDATYYCARMHLPLVFDSWGQGLTVTVSSASTKGPSVFLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSVHTFAVLAQSSGLYSLSVVTVPSSSLGQTQYICNVNHNKPSNTKVDKRVEPKSCDKHT CPPCPAPEAAGGPSVFLFPPKPKDLMISRTEPVTQVVDVSHEDPEVKFNWYVDGVEVHNAKTPREEQYNSTY RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTSKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDI AVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSVSMHEALHNHYTQKLSLSLSPGKGGSG GSQVQLVESGGGLVQPGGSLRLSCAASGFTFSQYVIVWVRQAPGKGLVWVSGISVSGVNTHYADSVKGRFTISR DNSKNTLYLQMNSLRAEDTAVYYCARLGATANNIRYKFMQVWGQGLTVTVSSGGGGGGGGGGGGGGGGGGGG DIELTQPPSVSVAPGQTARISCSGDSLRNKVYVYQQKPGQAPVLIYKNNRPSGIPERFSGNSNGNTATLTISGTQA EDEADYYCQSYDGGKSLVFGGGTKLTVL</p>
<p>SEQ ID NO:190</p>	<p>DNA Heavy MOR06475 hlgG1 LALA MOR08168 scFv (VH-4-VL)</p>	<p>CAGGTGCAATTGAAAGAAAGCGGCCCGCCCTGGTGAACCGACCCAAACCTGACCTGACCTGTACCTTTT CCGGATTAGCCTGTCTAATCGTGGTGGTGGTGGTGGTGGATTCCGACCCGCTGGGAAAGCCCTCGAGT GGCTGGCTTGGATCGATTGGGATGATGATAAGTCTTATAGCACCAGCCTGAAACCGCTGACCATAGCA AAGATACTCGAAAAATCAGGTGGTGTGACTATGACCAACATGGACCCGGTGGATACGGCCACCTATTATTG CGCGCTATGCATCTTCTCTTGTTTTTGATTCTTGGGGCCAAGGCACCCCTGGTACGGTTAGCTCAGCTAGCA CCAAGGGCCCCAGCGTGTCCCGTGGCCCCCAGCAGCAAGAGCACCAGCGGGCACAGCCGCCCTGGGCT GCCTGGTGAAGGACTACTTCCCGAGCCCGTACCGTGTCTTGGAAACAGCGGAGCCCTGACCTCCGGCGTGC ACACCTTCCCGCGTGTGTCAGAGCAGCGGCTGTACAGCCTGTCCAGCGTGGTACAGTGCACAGCAGCA GCCTGGGCACCAGACTACATCTGCAACGTGAACCAAGCCAGCAACCAAGGTGGACAAGAGAGTG</p>

		GAGCCCAAGAGCTGCGACAAGACCCACACCTGCCCCCCCTGCCAGCCCCAGAGGCAGCGGGCGGACCCTCC GTGTTCTGTTCCCCCAAGCCCAAGGACACCCTGATGATCAGCAGGACCCCCGAGGTGACTGCGTGGTG GTGGACGTGAGCCACGAGGCCAGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCAACAACGC CAAGACCAAGCCCAGAGAGGAGCAGTACAACAGCACCTACAGGGTGGTGTCCTGCTGACCGTGTGCACCA GGACTGGCTGAACGGCAAGGAATACAAGTGAAGGCTCCAACAAGGCCCTGCCAGCCCCATCGAAAAGAC CATCAGCAAGGCCAAGGGCCAGCCAGGGAGGCCAGGTTACACCCTGCCCCCCCTCCGGGAGGAGATGA CCAAGAACCAGGTGTCCCTGACTGTCTGGTGAAGGGCTTACCCACAGCAGATCGCCGTGGAGTGGGAGA GCAACGGCCAGCCCAGAACTACAAGACCACCCCCAGTGTGGACAGCGACGGCAGCTTCTCTCTGT ACAGCAAGCTGACCGTGGACAAGTCCAGGTGGCAGCAGGGCAACGTGTTAGCTGCAGCGTGTGACAGAA GCGCTGCACAACACTACACCAGAAGAGCTGAGCCTGTCCCCGGCAAGGGCGCTCCGGCGGAAGCCA GGTTCAATTGGTTGAAAGCGGTGGTGGTCTGGTTCAGCTGTGGTACCTGCGTCTGAGCTGTGCAGCAAG CGGTTTACCTTAGCGATTATGTGATTAATTGGTTCGTGAGCACCAGGTAAGGTCTGGAATTGGTTAGC GGTATTAGCTGGTCAAGGTGTAATACCCATTATGCAGATAGCGTGAAGGTGCTTTTACCATTAGCCGTGATA ATAGCAAAAATACCTGTATCTGCAGATGAATAGCCTGCCTGCAGAAAGATACCGCAGTTTATTATTGTGCAG TCTGGGTGCAACCCAAATAATTCCTGATATAAATTTATGGATGTGTGGGGTCAAGGTACACTAGTACCGTT AGCAGTGGTGGTGGTGGTAGCGGTGGTGGCGGATCTGGTGGCGGTGGTTCAGGTGGTGGTGGCAGTATA TCGAACTGACCCAGCCTCCGAGCGTTAGCGTTGACCCGGGTGAGCCGACCGTATTAGCTGTAGCGGTGATA GTCTGCGTAATAAAGTTATTGGTATCAGCAGAAACCGGGTCAAGCTCCGGTCTGTTATTATAAAAAATAA TCGTCCGAGCGGATTCCGGAACGTTTTCAGCGTAGCAATAGCGGTAATACCGCAACCCGACCATAGCGGC ACCCAGGCAGAAGATGAAGCCGATTATTATTGTGAGACTATGATGGTCAGAAAAGCCTGGTTTTTGGTGGT GGACCAAGCTTACCGTTCTG
SEQ ID NO:191	VL MOR08168wt	DIELTQPPSVSVAPGQTARISCSGDSLNRKVVYVYQKPGQAPVLIYKNNRPSGIPERFSGNSNGNTALTLISGTQA EDEADYYCQSYDGQKSLVFGGGTKLTVL
SEQ ID NO:192	DNA VL MDR08168 wt	GACATCGAGCTGACTCAGCCCCCTAGCGTGTGAGTGGCTCCTGGCCAGACCGCTAGAATTAGCTGTAGCGGC GATAGCTGCGTAACAAGGTCTACTGGTATCAGCAGAAGCCCCGGCCAGGCCCTGTGCTGGTATCTATAAG AACAATAGGCCTAGCGGCATCCCCGAGCGGTTAGCGGCTCTAATAGCGGCAACACCGCTACCCCTGACTATTA GCGGCACTCAGGCCGAGGACGAGGCCGACTACTACTGTGAGTCTACGACGGCCAGAAAGTCACTGGTCTTTG GCGGCGGAACCTAAGCTGACCGTGTGGGACAGCCTAAGGCTGCCCCAGCGTACCTGTCCCCCAGCA GCGAGGAGCTGACGGCCAACAAGGCCACCCCTGGTGTGCTGATCAGCGACTTACCCAGCGCGCGTGAACCG TGGCTGGAAGGCCGACAGCAGCCCCGTGAAGGCCGGCGTGGAGACCACCCACCCAGCAAGCAGAGCAAC AACAAGTACGCCGCCAGCAGCTACCTGAGCCTGACCCCGAGCAGTGAAGAGGCCACAGGCTCAGAGCTGC CAGGTGACCCAGGAGGCCAGCAGCCGTGGAAAAGACCGTGGCCCCAACCGAGTGCAGC
SEQ ID NO:193	Light lambda MDR08168 wt	DIELTQPPSVSVAPGQTARISCSGDSLNRKVVYVYQKPGQAPVLIYKNNRPSGIPERFSGNSNGNTALTLISGTQA EDEADYYCQSYDGQKSLVFGGGTKLTVLQPKAAPSVTLFPPSSEELQANKATLVLIISDFYPGAVTVAWKADSSP VKAGVETTPSKQSNKYAASSYLSLTPQWKSRSYSCQVTHEGSTVEKTVAPTECS
SEQ ID NO:194	DNA Light lambda MOR08168 wt	GACATCGAGCTGACTCAGCCCCCTAGCGTGTGAGTGGCTCCTGGCCAGACCGCTAGAATTAGCTGTAGCGGC GATAGCTGCGTAACAAGGTCTACTGGTATCAGCAGAAGCCCCGGCCAGGCCCTGTGCTGGTATCTATAAG AACAATAGGCCTAGCGGCATCCCCGAGCGGTTAGCGGCTCTAATAGCGGCAACACCGCTACCCCTGACTATTA GCGGCACTCAGGCCGAGGACGAGGCCGACTACTACTGTGAGTCTACGACGGCCAGAAAGTCACTGGTCTTTG GCGGCGGAACCTAAGCTGACCGTGTGGGACAGCCTAAGGCTGCCCCAGCGTACCTGTCCCCCAGCA GCGAGGAGCTGACGGCCAACAAGGCCACCCCTGGTGTGCTGATCAGCGACTTACCCAGCGCGCGTGAACCG TGGCTGGAAGGCCGACAGCAGCCCCGTGAAGGCCGGCGTGGAGACCACCCACCCAGCAAGCAGAGCAAC AACAAGTACGCCGCCAGCAGCTACCTGAGCCTGACCCCGAGCAGTGAAGAGGCCACAGGCTCAGAGCTGC CAGGTGACCCAGGAGGCCAGCAGCCGTGGAAAAGACCGTGGCCCCAACCGAGTGCAGC
SEQ ID NO:195	Heavy MDR08168IgG 1LALA_6475sc Fv wt	QVQLVESGGGLVQPGGSLRLSCAASGFTFSFDYVINVWRQAPGKGLEWVSGISWSGWNTHYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVVYCARLGAANNIRYKFMVWVWGQGLTVTVSSASTKGPSVFLPLAPSKSTSGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSVVTVPS5SLGTQTYICNVNHPKSNKTKVDRKVEPKS CDKTHCTPPCPAPEAAGGSPVFLFPPKPKDTLMSIRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTTPVLDSDG5FFLYSKLTVDKSRWQQGNVFSVSMHEALHNNHYTKLSLSP GKGGSGSDIVLTQSPATLSLSPGERATLSCRASQFIGSRYLAWYQQKPGQAPRLLIYGASNRATGVPARFSGSGS TDFTLTISLEPEDFATYYCQQYYDYPQTFGQGTKEIKGGGGSGGGSGGGG5QVQLKESGPAVLKPTQ TLTLCTFSGFSLNRGGGTVIRWPPGKALEWLAIDWDDDKSY5TSLKTRLTISKDTSKNQVVLMTNMDPV DTATYYCARMHLPLVFD5WGQGLTVTVSS
SEQ ID NO:196	DNA Heavy MDR08168IgG 1LALA_6475sc Fv wt	CAGGTGCAGCTGGTGAATCAGGGCGGAGGACTGGTCCAGCCTGGCGGATCACTAGACTGAGCTGTGCCGC TAGTGGCTTACCTTTAGCGACTATGTGATTAACCTGGGTCGACAGGCCCTGGCAAGGGACTGGAATGGGT GTCAGGCATTAGTTGAGCGCGGTGAACTACCTACAGCCGATAGCGTGAAGGGCCGGTTCATTATTAGCCG GGATAACTTAAGAACACCCCTGTACCTGACAGTGAATAGCCTGAGAGCCGAGGACACCCGCCCTACTACTG CGTAGACTGGGCGCTACCGCTAACCAACATCCGCTATAAGTTCATGGAGCTGTGGGGCCAGGGCACCCCTGGT CACAGTGTCTCAGCTAGCACTAAGGGCCCTCAGTGTCCCCCTGGCCCTAGCTCTAAGTCACTAGCGGTG

		GCACCGCCGCTCTGGGCTGCTGGTCAAGGACTACTTCCCCGAGCCCGTGACCGTGTCTTGAATAGCGGCG CTCTGACTAGCGGAGTGCACACCTTCCCCGCCGTGCTGCAGTCTAGCGGCTGTATAGCCTGTCTAGCGTCTGT GACCGTGCCTAGCTCTAGCCTGGGCACTCAGACCTATATCTGTAACGTGAACCACAAGCCTAGTAACACTAAG GTGGACAAGCGGGTGAACCTAAGTCTTGGCGATAAGACTCAGACCTGTCCCCCTGCCCTGCCCGAGAAGCTG CTGGCGGACCTAGCGTGTCTGTTCCACCTAAGCCTAAAGACACCCTGATGATTAGTAGGACCCCGAAGT GACCTGCGTGGTGGTGGAGCTCAGCCACGAGGACCCTGAAGTGAAGTTCATTTGGTATGTGGACGGCGTGG AAGTGCACAACGCTAAGACTAAGCCTAGAGAGGAAAGTATAAAGTCTCAACCTATAGGGTGGTGTGAGTGTGA CCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTATAAGTGTAAAGTCTCTAACAGGCCCTGCTGCC CTATCGAAAAGACTATCTTAAGGCTAAGGGCCAGCCTAGAGAACCCAGGCTCACACCCTGCCCTAGTAG AGAAGAGATGACTAAGAATCAGGTGTCCCTGACCTGTCTGGTCAAGGGCTTACCCTAGCGATATCGCCGTG GAGTGGGAGTCTAACGGCCAGCCGAGAACAATAAGACTACCCCCCTGTGTGGATAGCGACGGCTCT TTCTTCTGTACTCTAAACTGACCGTGGACAAGTCTAGGTGGCAGCAGGGCAACGTGTTGACTGTAGCGTGA TGACAGGCGCCTGCACAATCACTACTCAGAAGTCACTGAGCCTGAGTCCCGCAAGGGCGGCTCAGGCG GTAGCGATATCGTGTGACTCAGTCAACCCCTACCTGAGTCTGAGCCCTGGCGAGCGGGTCACTGAGCT GTAGAGCTAGTCAGTTTATCGGCTCAGCTACCTGCTGCTGATCAGCAGAAGCCCGGCCAGGCCCTAGACT GCTGATCTACGGCGTAGTAATAGAGTACCAGGCGTGCCTGCTAGGTTAGCGGCTCAGGATCAGGCACCGA CTTTACCTGACTATTAGTAGCTGGAACCCGAGGACTTCTGCTACTACTGTGACGAGTACTACGACTACC CTCAGACCTTCGGCCAGGGAACAAAGTTCGAGATTAAGGGCGGTGGCGGTAGCGCGGAGGGCGGATCAGG TGGTGGTGGTGTGGCGGGGAGGTAGTCAAGTCCAGCTGAAAGAGTCAAGCCCTGCCCTGGTCAAGCCTA CTCAGACCTGACCTGACCTGACTTTAGCGGCTTAGCCTGAGTAAAGAGGCGGGGAGTGGGCTGGA TTAGACAGCCTCCAGGCAAAGCCCTGAGTGGCTGGCTGATCGACTGGACGACGATAAGTCTACTCCA CTAGCCTGAAAATAGGCTGACAATCAGCAAGGACACTAGTAAAACCCAGGTGGTGTGACTATGACTAATA TGGACCCCGTGGACCCGCTACCTATTATTGCGCTAGAATGCACCTCCACTGCTGTTCGATAGCTGGGGTCA GGGAACCTGCTCACAGTCACTAGC
SEQ ID NO:197	VL MOR08168 DI	SYELTQPPSVSVAPGQTARISCSGDSLNRNKVYVYQKPGQAPVLVIVKNNRPSGIPERFSGSNSGNTATLTISGTQA EDEADYYCQSYDGGQKSLVFGGGTKLTVL
SEQ ID NO:198	DNA VL MOR08168 DI	TCTTACGAGCTGACCCAGCCCCCTCCGGTGTCTGTGGCTCTGGCCAGACCCGCAAGTCTCTTGTCTCCGGCGA CTCCCTGCGGAACAAGGTGTACTGGTATCAGCAGAAGCCCGGCCAGGCCCTGTGTGGTTCATCTACAAGAA CAACCGGCCCTCCGGCATCCCCGAGAGATTCTGTGGCTCCAACCTCCGGCAACCCGCCACCTGACAATCTCT GGCACACAGGCCGAGGACGAGGCCGACTACTACTGCCAGTCTACGACGCCAGAAATCACTGGTGTTCGGC GGAGGCACCAAGCTGACAGTGTCTGGGACAGCCTAAGGCTGCCCCAGCGTACCTGTTCACCCCGCAGCAGC GAGGAGCTGCAGGCCAACAGGCCACCCTGGTGTGCTGATCAGCGACTTCTACCCAGGCGCGTACCCGTG GCCTGGAAGGCCGACAGCAGCCCCGTGAAGGCCGGCGTGGAGACCACCACCCCAAGCAGAGCAACAA CAAGTACGCCGCCAGCAGCTACTGAGCCTGACCCCGAGCAGTGAAGAGCCACAGGCTCTACAGCTGCCA GGTGACCCACGAGGGCAGCACCGTGGAAAAGACCGTGGCCCCAACCGAGTGACG
SEQ ID NO:199	Light lambda MOR08168 DI	SYELTQPPSVSVAPGQTARISCSGDSLNRNKVYVYQKPGQAPVLVIVKNNRPSGIPERFSGSNSGNTATLTISGTQA EDEADYYCQSYDGGQKSLVFGGGTKLTVLQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSP VKAGVETTTTPSKQSNKYAASSYLSLTPEQWKSRSYSCQVTHEGSTVEKTVAPTECS
SEQ ID NO:200	DNA Light lambda MOR08168 DI	TCTTACGAGCTGACCCAGCCCCCTCCGGTGTCTGTGGCTCTGGCCAGACCCGCAAGTCTCTTGTCTCCGGCGA CTCCCTGCGGAACAAGGTGTACTGGTATCAGCAGAAGCCCGGCCAGGCCCTGTGTGGTTCATCTACAAGAA CAACCGGCCCTCCGGCATCCCCGAGAGATTCTGTGGCTCCAACCTCCGGCAACCCGCCACCTGACAATCTCT GGCACACAGGCCGAGGACGAGGCCGACTACTACTGCCAGTCTACGACGCCAGAAATCACTGGTGTTCGGC GGAGGCACCAAGCTGACAGTGTCTGGGACAGCCTAAGGCTGCCCCAGCGTACCTGTTCACCCCGCAGCAGC GAGGAGCTGCAGGCCAACAGGCCACCCTGGTGTGCTGATCAGCGACTTCTACCCAGGCGCGTACCCGTG GCCTGGAAGGCCGACAGCAGCCCCGTGAAGGCCGGCGTGGAGACCACCACCCCAAGCAGAGCAACAA CAAGTACGCCGCCAGCAGCTACTGAGCCTGACCCCGAGCAGTGAAGAGCCACAGGCTCTACAGCTGCCA GGTGACCCACGAGGGCAGCACCGTGGAAAAGACCGTGGCCCCAACCGAGTGACG
SEQ ID NO:201	Heavy MOR08168IgG 1LALA_6475sc Fv DI	QVQLVESGGGLVQPGGSLRLSAAAGFTFSDYVINWVROAPGKGLEWVSGISWVSGVNTHYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARLGATANNIRYKFMVWVGGTLVTVSSASTKGPSVFLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSVHTFPAVLQSSGLYSLSSVTVPPSSSLGTQTYICNVNHKPSNTKVDKRVPEKS CDKHTHTCPPCPAPEAAGGSPVFLFPPKPKDLMISRTPVETCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTPPVLDSDGFFLYSKLTVDKSRWQQGNVFCVSMHEALHNHYTQKSLSLSP GKGGSGGSDIVLTQSPATLSLSPGERATLSCRASQFIGSRYLAWYQQKPGQAPRLIYGASNRAATGVPARFSGSGG TDFLTLSLEPEDFATYYCQQYDYPTFGQGTKEIKGGGSGGGGSGGGGSGGGGSGVQLKESGPAALVKPTQ TLTCTFSGFSLNRGGVGVWIRQPPGKALEWLAIDWDDDKSYSTSLKTRLTISKDTSKNQVLLTMNMDPV DTATYYCARMHLPLVFDVWGGTGLTVVSS
SEQ ID NO:202	DNA Heavy MOR08168IgG 1LALA_6475sc	CAGGTGCAGCTGGTGAATCAGGCGGAGGACTGGTCCAGCCTGGCGGATCACTTAGACTGAGCTGTGCCGC TAGTGGCTTACCTTTAGCGACTATGTGATTAAGTGGTCCGACAGGCCCTGGCAAGGGACTGGAATGGGT GTCAGGCATTAGTTGAGCGGGCGTGAACACTCACTACGCCGATAGCGTGAAGGGCCGGTCACTATTAGCCG

	Fv DI	GGATAACTCTAAGAACACCCTGTACTGCGAGATGAATAGCCTGAGAGCCGAGGACACCGCCGCTACTACTG CGCTAGACTGGGGCTACCGCTAACAACTCCGCTATAAGTTTCATGGACGTGTGGGGCCAGGGACCCCTGGT CACAGTGTCTTACAGTACTAAGGGCCCTCAGTGTCCCCCTGGCCCCCTAGCTCTAAGTCTACTAGCGGTG GCACCGCCGCTCTGGGCTGCCTGGTCAAGGACTACTTCCCGAGCCCGTGACCCTGCTTGGAAATAGCGGCG CTCTGACTAGCGGAGTGCACACCTTCCCGCCGTGCTGAGTCTAGCGGCTGTATAGCCTGCTAGCGCTCGT GACCGTGCCTAGCTCTAGCCTGGGCACTCAGACCTATATCTGTAACGTGAACACAAGCCTAGTAACTAAG GTGGACAAGCGGGTGAACCTAAGTCTTGGATAAAGACTCACACCTGTCCCCCTGCCCTGCCCAAGAAGCTG CTGGCGGACTAGCGTGTTCCTGTCCCACTAAGCCTAAGACACCCCTGATGATTAGTAGGACCCCGAAAGT GACCTGCGTGGTGGTGGACGTGACCCAGAGGACCCCTGAAGTGAAGTTCAATTGGTATGTGGACGGCGTGG AAGTGACAACGCTAAGACTAAGCCTAGAGAGGAACAGTATAACTCCACCTATAGGGTGGTGTAGTGTGTA CCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTATAAGTGTAAAGTCTTAAACAAGGCCCTGCCCTGCC CTATCGAAAAGACTATCTAAGGCTAAGGGCCAGCCTAGAGAAACCCAGGTCTACCCCTGCCCTAGTAG AGAAGAGATGACTAAGAATCAGGTGTCCCTGACCTGCTGGTCAAGGGCTTCTACCTAGCGATATCGCGGTG GAGTGGGAGTCTAACGGCCAGCCGAGAACTATAAGACTACCCCTGCTGCTGGATAAGCAGCGCTCT TTCTTCTGTACTCTAACTGACCGTGGACAAGTCTAGGTGGCAGCAGGGCAACGTGTTACGCTGTAGCGTGA TGCACGAGGCCCTGCACAATCACTCACTCAGAAGTCACTGAGCCTGAGTCCCGGCAAGGGCGGCTCAGGCG GTAGCGATATCGTGTGACTCAGTACCCCGTACCCTGAGTCTGAGCCCTGGCGAGCGGGCTACACTGAGCT GTAGAGCTAGTCAAGTTATCGGCTCAGCTACTGGCTGGTATCAGCAGAAGCCCGCCAGGCCCTAGACT GCTGATCTACGGCGTAGTAATAGAGTACCAGGCTGCCCGTAGGTTTACGCGCTCAGGATCAGGCCAGCA CTTTACCCTGACTATTAGTACCTGGAACCCGAGGACTTCCCTACTACTGCTCAGCAGTACTACGACTACC CTCAGACTTCGGCCAGGGAACCTAAGGTGAGATTAAAGGGCGGTGGCGGTAGCGGGAGGCGGATCAGG TGGTGGTGGTGTAGTGGCGGGAGGTAGTCAAGTCCAGCTGAAAGAGTCAAGCCCTGCCCTGGTCAAGCCTA CTCAGACCTGACCTGACCTGACTTTTAGCGGCTTTAGCCTGAGTAATAGAGGGCGGAGTGGCTGGA TTAGACAGCCTCCAGGCAAAGCCTGGAGTGGTGGCCTGGATCGACTGGGACGACGATAAGTCTACTCCA CTAGCCTGAAAAGTGGCTGACAATCAGCAAGGACACTAGTAAAACAGGTTGGTGTGACTATGACTAATA TGGACCCCGTGGACACCGCTACTATTATTGCGCTAGAAAGCACCTCCACTGGTGTTCGATAGCTGGGGTCA GGGAACCTCTGGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGT
SEQ ID NO:203	VL MOR08168 GL	SYELTQPLSVSVALGQTARITCSGDSLNRKVVYVYQKPGQAPVLVIYKNNRPSGIPERFSGSNGNTATLTISRAQA GDEADYYCQSYDGGQKSLVFGGGTKLTVL
SEQ ID NO:204	DNA VL MOR08168 GL	AGCTACGAGCTGACTCAGCCCTGAGCGTGTGAGTGGCTCTGGGCCAGACCCTAGAATCACCTGTAGCGGC GATAGCCTGAGAAACAAGGTCTACTGGTATCAGCAGAAGCCCGCCAGGCCCTGTGCTGGTCACTATAAG AACAATAGGCTAGCGGCATCCCCGAGCGGTTTAGCGGCTCTAATAGCGGCAACACCGCTACCTGACTATTA GTAGGGCTCAGGCCGGCGCAGGCGGACTACTACTGTAGTCTACGACGGCCAGAAAGTCACTGGTCTTTG GCGGGGAACTAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGT
SEQ ID NO:205	Light lambda MOR08168 GL	SYELTQPLSVSVALGQTARITCSGDSLNRKVVYVYQKPGQAPVLVIYKNNRPSGIPERFSGSNGNTATLTISRAQA GDEADYYCQSYDGGQKSLVFGGGTKLTVLQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKA DSSPVKAGVETTPSKQSNKYAASSYLSLTPAQWKSQRSYSCQVTHEGSTVEKTVAPTECS
SEQ ID NO:206	DNA Light lambda MOR08168 GL	AGCTACGAGCTGACTCAGCCCTGAGCGTGTGAGTGGCTCTGGGCCAGACCCTAGAATCACCTGTAGCGGC GATAGCCTGAGAAACAAGGTCTACTGGTATCAGCAGAAGCCCGCCAGGCCCTGTGCTGGTCACTATAAG AACAATAGGCTAGCGGCATCCCCGAGCGGTTTAGCGGCTCTAATAGCGGCAACACCGCTACCTGACTATTA GTAGGGCTCAGGCCGGCGCAGGCGGACTACTACTGTAGTCTACGACGGCCAGAAAGTCACTGGTCTTTG GCGGGGAACTAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGT GCGAGGAGCTGAGGCCAACCAAGGCCACCCTGGTGTGCTGATCAGCGACTTCTACCCAGGCCCGTGA TGGCCTGGAAGGCCGACAGCAACCCCTGAAAGGCCGGCGTGGAGACACCACCCCAAGCAGGCAAGCAAC AACAAGTACGCCCGCAGCAGTACTCTGAGCCTGACCCCGAGCAGTGGAAAGAGCCACAGGCTCTACAGCTGC CAGGTGACCCAGGAGGCGCAGCAGTGGAAAGACCGTGGCCCCAACCGAGTGCAGC
SEQ ID NO:207	Heavy MOR08168IgG 1LALA_6475sc Fv GL	EVQLLESGGGLVQPGGSLRISCAASGFTFSDYVINVVRQAPGKLEWVSGISWVSVNTHYADSVKGRFTISRDNS KNTLYLQMNSLRAEDTAVYYCARLGATANNIRYKFMDFVWVGGTGLTVVSSASTKGPSVFLAPSSKSTSGGTAALG CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSLSLGTQYICNVNHKPSNTKVDKRVKPKSC DKHTCCPCPAPEAAGGPSVFLFPPKPKDRLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGF YPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFNFCVSMHEALHNHYTQKLSLSLSPGK GGSGGSDIVLTQSPATLSLSPGERATLSCRASQFIGSRYLAWYQQKPGQAPRLLIYGASNRATGVPARFSGSGSDT FTLTISLEPEDFATYYCQQYDYPQTFGGQTVEIKGGGGSGGGGSGGGGSGGGGSGVQLKESGPAALVKTPTL TLCTFSGFSLNRGGGVWIRQPPGKALEW/LAWIDWDDDKSYSTLSKRLTISKDTSKNQVLTMTNMDPVD ATYYCARMHLPLVFDVWVGGTGLTVVSS

<p>SEQ ID NO:208</p>	<p>DNA Heavy MOR08168IgG 1LALA_6475sc Fv GL</p>	<p>GAGGTGCAGCTGCTGGAATCAGGCGGAGGACTGGTGCAGCCTGGCGGATCACTGAGACTGAGCTGTGCCGCTAGTGGCTTACCTTTAGCGACTATGTGATTAAGTGGGTCGACAGGCCCTGGCAAGGGGACTGGAATGGGTGTGAGGCAATAGTTGGAGCGCGGTGAACACTCACTACGCCGATAGCGTGAAGGGCCGGTTCCTACTATTAGCCGGATAACTCTAAGAACACCCTGTACTGCAGATGAATAGCCTGAGAGCCGAGGACACCCCGTCTACTACTGCGCTAGACTGGGCGTACCCTAACCAATCCGCTATAAGTTCATGGACGTGTGGGGCCAGGGACCCCTGGTACACAGTGTCTCAGTAGCACTAAGGGCCCTCAGTGTCCCCCTGGCCCTAGCTCTAAGTCTACTAGCCGGTGGCACCGCCGCTCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAGCCCGTACCCTGTCTTGGAAATAGCGCGCTCTGACTAGCGGAGTGCACACCTTCCCCGCGTGTGCAGTCTAGCGGCTGTATAGCCTGTCTAGCGTGTGACCCGTGCCTAGCTTAGCCTGGGCACTCAGACCTATCTGTAACGTGAACCACAAGCCTAGTAACACTAAGGTGGACAAGCGGGTGGAACTAAGTCTTGGCGATAAGACTCACACCTGTCCCCCTGCCCTGCCCGAGAAGCTGCTGGCGGACCTAGCGTGTCTGTTCCCACTAAGCCTAAAGACACCCTGATGATTAGTAGGACCCCGAAGTGACCTGCGTGGTGGTGGACGTACGCCACGAGGACCCTGAAGTGAAGTTCATTGGTATGTGGACGGCGTGAAGTGCACAACGCTAAGACTAAGCCTAGAGAGGAACAGTATAACTCCACCTATAGGGTGGTGTGACGTCTGACCGTGTGCACCAGGACTGGCTGAACGGCAAAGAGTATAAGTGTAAAGTCTCTAACAAAGGCCCTGCTGCCCTATCGAAAAGACTATCTCTAAGGCTAAGGGCCAGCCTAGAGAACCCAGGTCTACACCTGCCCTAGTAGAGAAGAGATGACTAAGAATCAGGTGTCCCTGACCTGTCTGGTCAAGGGCTTCTACCTAGCGATATCGCCGTGGAGTGGGAGTCTAACGGCCAGCCGAGAACTATAAGACTACCCCCCTGTGCTGGATAGCGACGGCTCTTCTTCTGTACTCTAACTGACCGTGGACAAGTCTAGGTGGCAGCAGGGCAACGTGTTCACTGTAGCGTGTGACAGGCGCTGCACAATCACTACACTCAGAAGTCACTGAGCCTGAGTCCCAGGCAAGGGCGGCTCAGGCGGTAGCGATATCGTGTGACTCAGTCAACCCGCTACCCTGAGTCTGAGCCCTGGCGAGCGGGCTACACTGAGCTGTAGAGCTAGTCAAGTTATCGGCTCACGCTACCTGGCCTGGTATCAGCAGAAGCCCGCCAGGCCCCCTAGACTGCTGATCTACGGCGCTAGTAATAGAGCTACCGCGTGCCCCGCTAGGTTTAGCGGCTCAGGATCAGGACCCGACTTTACCTGACTATTAGTAGCCTGGAACCCGAGGACTTCGCTACCTACTACTGTGAGCAGGACTACTGACTACCCTCAGACCTTCGGCCAGGGAAGTAAAGTTCGAGATTAAGGGCGGTGCGGAGCGGAGCGGATCAGGTGGTGGTAGTGGCGGCGGAGGTAGTCAAGTCCAGCTGAAAGAGTCAAGGCCCTGCCCTGGTCAAGCCTACTCAGACCTGACCTGACCTTTAGCGGCTTAGCCTGAGTAATAGAGCGGCGGAGTGGGCTGGAATAGACAGCCTCCAGGCAAAGCCTGGAGTGGCTGGCTGGATCGACTGGGACGACGATAAGTCTACTCCACTAGCCTGAAAAGTGGCTGACAATCAGCAAGGACACTAGTAAAACAGGTGGTGTGACTATGACTAATAAGGACCCCGTGGACACCGCTACCTATTATTGGCGTAGAATGCACCTCCCACTGGTGTTCGATAGCTGGGTCAAGGAACTCTGGTACAGTCACTAGC</p>
----------------------	---	---

Other antibodies of the invention include those where the amino acids or nucleic acids encoding the amino acids have been mutated, yet have at least 60%, 70%, 80%, 90%, 95% or 98% identity to the sequences described in Table 1. In some embodiments, it include mutant amino acid sequences wherein no more than 1, 2, 3, 4 or 5 amino acids have been mutated in the variable regions when compared with the variable regions depicted in the sequence described in Table 1, while retaining substantially the same therapeutic activity.

Since each of these antibodies can bind to LRP6, the VH, VL, full length light chain, and full length heavy chain sequences (amino acid sequences and the nucleotide sequences encoding the amino acid sequences) can be "mixed and matched" to create other LRP6 antibodies of the invention. Such "mixed and matched" LRP6 antibodies can be tested using the binding assays known in the art (e.g., ELISAs, and other assays described in the Example section). When these chains are mixed and matched, a VH sequence from a particular VH/VL pairing should be replaced with a structurally similar VH sequence. Likewise a full length heavy chain sequence from a particular full length heavy chain / full length light chain pairing should be replaced with a structurally similar full length

heavy chain sequence. Likewise, a VL sequence from a particular VH/VL pairing should be replaced with a structurally similar VL sequence. Likewise a full length light chain sequence from a particular full length heavy chain / full length light chain pairing should be replaced with a structurally similar full length light chain sequence. Accordingly, in one aspect, the invention provides an isolated monoclonal antibody or fragment thereof having: a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 34, 36, 44,60, and 62; and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 13, 33, 35, 43, 59 and 61; a heavy chain selected from the group consisting of SEQ ID NOs: 82, 106, 108, 128, 130 and 138; and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 81, and 90, 105, 107, 127, 129, and 137; wherein the antibody specifically binds to LRP6 (*e.g.*, human and/or cynomologus LRP6).

In another aspect, the present invention provides LRP6 antibodies that bind to the β propeller 1 domain of LRP6 that comprise the heavy chain and light chain CDR1s, CDR2s and CDR3s as described in Table 1, or combinations thereof. The amino acid sequences of the VH CDR1s of the antibodies are shown in SEQ ID NOs: 1, 21, and 47. The amino acid sequences of the VH CDR2s of the antibodies and are shown in SEQ ID NOs: 2, 22, and 48. The amino acid sequences of the VH CDR3s of the antibodies are shown in SEQ ID NOs: 3, 23, and 49. The amino acid sequences of the VL CDR1s of the antibodies are shown in SEQ ID NOs: 4, 24, and 50. The amino acid sequences of the VL CDR2s of the antibodies are shown in SEQ ID NOs: 5, 25, and 51. The amino acid sequences of the VL CDR3s of the antibodies are shown in SEQ ID NOs: 6, 26, and 52. The CDR regions are delineated using the Kabat system (Kabat *et al.*, (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242; Chothia *et al.*, (1987) J. Mol. Biol. 196: 901-917; Chothia *et al.*, (1989) Nature 342: 877-883; and Al-Lazikani *et al.*, (1997) J. Mol. Biol. 273, 927-948).

In another aspect, the present invention provides LRP6 antibodies that bind to the β propeller 3 domain of LRP6 that comprise the heavy chain and light chain CDR1s, CDR2s and CDR3s as described in Table 1, or combinations thereof. The amino acid sequences of the VH CDR1s of the antibodies are shown in SEQ ID NOs: 69, 93, and 115. The amino acid sequences of the VH CDR2s of the antibodies and are shown in SEQ

ID NOs: 70, 94, and 116. The amino acid sequences of the VH CDR3s of the antibodies are shown in SEQ ID NOs: 71, 95, and 117. The amino acid sequences of the VL CDR1s of the antibodies are shown in SEQ ID NOs: 72, 96, and 118. The amino acid sequences of the VL CDR2s of the antibodies are shown in SEQ ID NOs: 73, 97, and 119. The amino acid sequences of the VL CDR3s of the antibodies are shown in SEQ ID NOs: 74, 98, and 120. The CDR regions are delineated using the Kabat system (Kabat *et al.*, (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242; Chothia *et al.*, (1987) J. Mol. Biol. 196: 901-917; Chothia *et al.*, (1989) Nature 342: 877-883; and Al-Lazikani *et al.*, (1997) J. Mol. Biol. 273, 927-948).

Given that each of these antibodies can bind to LRP6 and that antigen-binding specificity is provided primarily by the CDR1, 2 and 3 regions, the VH CDR1, 2 and 3 sequences and VL CDR1, 2 and 3 sequences can be "mixed and matched" (*i.e.*, CDRs from different antibodies can be mixed and match, although each antibody must contain a VH CDR1, 2 and 3 and a VL CDR1, 2 and 3 to create other LRP6 binding molecules of the invention. Such "mixed and matched" LRP6 antibodies can be tested using the binding assays known in the art and those described in the Examples (*e.g.*, ELISAs). When VH CDR sequences are mixed and matched, the CDR1, CDR2 and/or CDR3 sequence from a particular VH sequence should be replaced with a structurally similar CDR sequence(s). Likewise, when VL CDR sequences are mixed and matched, the CDR1, CDR2 and/or CDR3 sequence from a particular VL sequence should be replaced with a structurally similar CDR sequence(s). It will be readily apparent to the ordinarily skilled artisan that novel VH and VL sequences can be created by substituting one or more VH and/or VL CDR region sequences with structurally similar sequences from the CDR sequences shown herein for monoclonal antibodies of the present invention.

Accordingly, the present invention provides an isolated LRP6 β -propeller 1 monoclonal antibody or fragment thereof comprising a heavy chain variable region CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 21, and 47; a heavy chain variable region CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 22, and 48; a heavy chain variable region CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 23, and 49; a light chain variable region CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 24, and 50; a light chain

variable region CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 25, and 51; and a light chain variable region CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 26, and 52; wherein the antibody binds LRP6.

Accordingly, the present invention provides an isolated LRP6 β -propeller 3 monoclonal antibody or fragment thereof comprising a heavy chain variable region CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 69, 93, and 115; a heavy chain variable region CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 70, 94, and 116; a heavy chain variable region CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 71, 95, and 117; a light chain variable region CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 72, 96, and 118; a light chain variable region CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 73, 97, and 119; and a light chain variable region CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 74, 98, and 120; wherein the antibody binds LRP6.

In a specific embodiment, an antibody that binds to LRP6 comprises a heavy chain variable region CDR1 of SEQ ID NO: 1; a heavy chain variable region CDR2 of SEQ ID NO: 2; a heavy chain variable region CDR3 of SEQ ID NO: 3; a light chain variable region CDR1 of SEQ ID NO: 4; a light chain variable region CDR2 of SEQ ID NO: 5; and a light chain variable region CDR3 of SEQ ID NO: 6.

In a specific embodiment, an antibody that binds to LRP6 comprises a heavy chain variable region CDR1 of SEQ ID NO: 21; a heavy chain variable region CDR2 of SEQ ID NO: 22; a heavy chain variable region CDR3 of SEQ ID NO: 23; a light chain variable region CDR1 of SEQ ID NO: 24; a light chain variable region CDR2 of SEQ ID NO: 25; and a light chain variable region CDR3 of SEQ ID NO: 26.

In a specific embodiment, an antibody that binds to LRP6 comprises a heavy chain variable region CDR1 of SEQ ID NO: 47; a heavy chain variable region CDR2 of SEQ ID NO: 48; a heavy chain variable region CDR3 of SEQ ID NO: 49; a light chain variable region CDR1 of SEQ ID NO: 50; a light chain variable region CDR2 of SEQ ID NO: 51; and a light chain variable region CDR3 of SEQ ID NO: 52.

In a specific embodiment, an antibody that binds to LRP6 comprises a heavy chain variable region CDR1 of SEQ ID NO: 69; a heavy chain variable region CDR2 of SEQ ID NO: 70; a heavy chain variable region CDR3 of SEQ ID NO: 71; a light chain variable region CDR1 of SEQ ID NO: 72; a light chain variable region CDR2 of SEQ ID NO: 73; and a light chain variable region CDR3 of SEQ ID NO: 74.

In a specific embodiment, an antibody that binds to LRP6 comprises a heavy chain variable region CDR1 of SEQ ID NO: 93; a heavy chain variable region CDR2 of SEQ ID NO: 94; a heavy chain variable region CDR3 of SEQ ID NO: 95; a light chain variable region CDR1 of SEQ ID NO: 96; a light chain variable region CDR2 of SEQ ID NO: 97; and a light chain variable region CDR3 of SEQ ID NO: 98.

In a specific embodiment, an antibody that binds to LRP6 comprises a heavy chain variable region CDR1 of SEQ ID NO: 115; a heavy chain variable region CDR2 of SEQ ID NO: 116; a heavy chain variable region CDR3 of SEQ ID NO: 117; a light chain variable region CDR1 of SEQ ID NO: 118; a light chain variable region CDR2 of SEQ ID NO: 119; and a light chain variable region CDR3 of SEQ ID NO: 120.

In a specific embodiment, an antibody that binds to LRP6 comprises a VH of SEQ ID NO: 14 and VL of SEQ ID NO: 13. In a specific embodiment, an antibody that binds to LRP6 comprises a VH of SEQ ID NO: 34 and VL of SEQ ID NO: 33. In a specific embodiment, an antibody that binds to LRP6 comprises a VH of SEQ ID NO: 35 and VL of SEQ ID NO: 36. In a specific embodiment, an antibody that binds to LRP6 comprises a VH of SEQ ID NO: 43 and VL of SEQ ID NO: 44. In a specific embodiment, an antibody that binds to LRP6 comprises a VH of SEQ ID NO: 60 and VL of SEQ ID NO: 59. In a specific embodiment, an antibody that binds to LRP6 comprises a VH of SEQ ID NO: 62 and VL of SEQ ID NO: 61. In a specific embodiment, an antibody that binds to LRP6 comprises a VH of SEQ ID NO: 82 and VL of SEQ ID NO: 81. In a specific embodiment, an antibody that binds to LRP6 comprises a VH of SEQ ID NO: 90 and VL of SEQ ID NO: 89. In a specific embodiment, an antibody that binds to LRP6 comprises a VH of SEQ ID NO: 106 and VL of SEQ ID NO: 105. In a specific embodiment, an antibody that binds to LRP6 comprises a VH of SEQ ID NO: 108 and VL of SEQ ID NO: 107. In a specific embodiment, an antibody that binds to LRP6 comprises a VH of SEQ ID NO: 128 and VL of SEQ ID NO: 127. In a specific embodiment, an antibody that binds to LRP6 comprises a VH of SEQ ID NO: 130 and VL of SEQ ID NO: 129. In a specific

embodiment, an antibody that binds to LRP6 comprises a VH of SEQ ID NO: 138 and VL of SEQ ID NO: 137.

In one embodiment, the LRP6 antibodies are antagonist antibodies. In one embodiment, the LRP6 antibodies are agonist antibodies. In certain embodiments, an antibody that binds to LRP6 is an antibody that is described in Table 1.

As used herein, a human antibody comprises heavy or light chain variable regions or full length heavy or light chains that are "the product of" or "derived from" a particular germline sequence if the variable regions or full length chains of the antibody are obtained from a system that uses human germline immunoglobulin genes. Such systems include immunizing a transgenic mouse carrying human immunoglobulin genes with the antigen of interest or screening a human immunoglobulin gene library displayed on phage with the antigen of interest. A human antibody that is "the product of" or "derived from" a human germline immunoglobulin sequence can be identified as such by comparing the amino acid sequence of the human antibody to the amino acid sequences of human germline immunoglobulins and selecting the human germline immunoglobulin sequence that is closest in sequence (*i.e.*, greatest % identity) to the sequence of the human antibody. A human antibody that is "the product of" or "derived from" a particular human germline immunoglobulin sequence may contain amino acid differences as compared to the germline sequence, due to, for example, naturally occurring somatic mutations or intentional introduction of site-directed mutations. However, in the VH or VL framework regions, a selected human antibody typically is at least 90% identical in amino acids sequence to an amino acid sequence encoded by a human germline immunoglobulin gene and contains amino acid residues that identify the human antibody as being human when compared to the germline immunoglobulin amino acid sequences of other species (*e.g.*, murine germline sequences). In certain cases, a human antibody may be at least 60%, 70%, 80%, 90%, or at least 95%, or even at least 96%, 97%, 98%, or 99% identical in amino acid sequence to the amino acid sequence encoded by the germline immunoglobulin gene. Typically, a recombinant human antibody will display no more than 10 amino acid differences from the amino acid sequence encoded by the human germline immunoglobulin gene in the VH or VL framework regions. In certain cases, the human antibody may display no more than 5, or even no more than 4, 3, 2, or 1 amino acid difference from the amino acid sequence encoded by the germline immunoglobulin gene.

The antibodies disclosed herein can be derivatives of single chain antibodies, diabodies, domain antibodies, nanobodies, and unibodies. A "single-chain antibody" (scFv) consists of a single polypeptide chain comprising a VL domain linked to a V-domain wherein VL domain and VH domain are paired to form a monovalent molecule. Single chain antibody can be prepared according to method known in the art (see, for example, Bird *et al.*, (1988) Science 242:423-426 and Huston *et al.*, (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883). A "disbud" consists of two chains, each chain comprising a heavy chain variable region connected to a light chain variable region on the same polypeptide chain connected by a short peptide linker, wherein the two regions on the same chain do not pair with each other but with complementary domains on the other chain to form a bispecific molecule. Methods of preparing diabodies are known in the art (See, e.g., Holliger *et al.*, (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448, and Poljak *et al.*, (1994) Structure 2:1121-1123). Domain antibodies (dAbs) are small functional binding units of antibodies, corresponding to the variable regions of either the heavy or light chains of antibodies. Domain antibodies are well expressed in bacterial, yeast, and mammalian cell systems. Further details of domain antibodies and methods of production thereof are known in the art (see, for example, U.S. Pat. Nos. 6,291,158; 6,582,915; 6,593,081; 6,172,197; 6,696,245; European Patents 0368684 & 0616640; WO05/035572, WO04/101790, WO04/081026, WO04/058821, WO04/003019 and WO03/002609). Nanobodies are derived from the heavy chains of an antibody. A nanobody typically comprises a single variable domain and two constant domains (CH2 and CH3) and retains antigen-binding capacity of the original antibody. Nanobodies can be prepared by methods known in the art (See e.g., U.S. Pat. No. 6,765,087, U.S. Pat. No. 6,838,254, WO 06/079372). Unibodies consist of one light chain and one heavy chain of a IgG4 antibody. Unibodies may be made by the removal of the hinge region of IgG4 antibodies. Further details of unibodies and methods of preparing them may be found in WO2007/059782.

In addition to Wnt ligands LRP6 Propeller 1 antibodies are expected to inhibit the interaction with other Propeller 1 binding ligands (e.g. Sclerostin, Dkk1). Similarly, Propeller 3 antibodies are expected to inhibit the interaction with other propeller 3 binding ligands (e.g. Dkk1). Furthermore, propeller 1 and 3 binding antibodies may be expected to affect the activity of other Wnt signaling modulators e.g. R-spondins

Homologous antibodies

In yet another embodiment, the present invention provides an antibody or fragment thereof comprising amino acid sequences that are homologous to the sequences described in Table 1, and the antibody binds to a LRP6 protein (*e.g.*, human and/or cynomologus LRP6), and retains the desired functional properties of those antibodies described in Table 1.

For example, the invention provides an isolated monoclonal antibody (or a functional fragment thereof) comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence that is at least 80%, at least 90%, or at least 95% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 34, 36, 44, 60, and 62; the light chain variable region comprises an amino acid sequence that is at least 80%, at least 90%, at least 95%, or at least 98% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13, 33, 37, 43, 59, and 61; the antibody binds to β -propeller 1 of LRP6 (*e.g.*, human and/or cynomologus LRP6), and inhibits the signaling activity of β -propeller 1 dependent Wnt proteins, which can be measured in Wnt reporter gene assay or other measure of Wnt directed signaling (*e.g.*, LRP6 phosphorylation, β -catenin stabilization and nuclear translocation, cellular proliferation/ survival) as described herein. In a specific example, such antibodies have an EC_{50} value in a Wnt1 assay of less than 10 nM when using conditioned medium or using transfected cells.

For example, the invention provides an isolated monoclonal antibody (or a functional fragment thereof) comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence that is at least 80%, at least 90%, at least 95%, or at least 98% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 82, 89, 106, 108, 128, 130, and 138; the light chain variable region comprises an amino acid sequence that is at least 80%, at least 90%, at least 95%, or at least 98% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 81, 90, 105, 107, 127, 129, and 137; the antibody binds to β -propeller 3 of LRP6 (*e.g.*, human and/or cynomologus LRP6), and inhibits the signaling activity of β -propeller 3 dependent Wnt proteins, which can be measured in Wnt reporter gene assay or other measure of Wnt directed signaling (*e.g.*, LRP6 phosphorylation, β -catenin stabilization and nuclear translocation, cellular

proliferation/ survival) as described herein. In a specific example, such antibodies have an EC₅₀ value in a Wnt3a assay of less than 10 nM when using conditioned medium or using transfected cells.

Further for Propeller 1 antibodies, variable heavy chain parental nucleotide sequences are shown in SEQ ID NOs: 16, 38, and 64. Variable light chain parental nucleotide sequences are shown in SEQ ID NOs: 15, 37, and 63. Full length heavy chain sequences optimized for expression in a mammalian cell are shown in SEQ ID NOs: 20, 42, and 68. Full length light chain sequences optimized for expression in a mammalian cell are shown in SEQ ID NOs: 19, 41, and 67. Other antibodies of the invention include amino acids or nucleic acids that have been mutated, yet have at least 60%, 70%, 80%, 90%, 95% or 98% identity to the sequences described above. In some embodiments, it includes mutant amino acid sequences wherein no more than 1, 2, 3, 4 or 5 amino acids have been mutated by amino acid deletion, insertion or substitution in the variable regions when compared with the variable regions depicted in the sequence described above.

Further for Propeller 3 antibodies, variable heavy chain parental nucleotide sequences are shown in SEQ ID NO: 84, 110, and 132. Variable light chain parental nucleotide sequences are shown in SEQ ID NO: 83, 109, and 131. Full length heavy chain sequences optimized for expression in a mammalian cell are shown in SEQ ID NO: 88, 91, 114, 136, and 140. Full length light chain nucleotide sequences optimized for expression in a mammalian cell are shown in SEQ ID NO: 87, 92, 113, 135, and 139. Other antibodies of the invention include amino acids or nucleic acids that have been mutated, yet have at least 60%, 70%, 80%, 90%, 95% or 98% identity to the sequences described above. In some embodiments, it includes mutant amino acid sequences wherein no more than 1, 2, 3, 4 or 5 amino acids have been mutated by amino acid deletion, insertion or substitution in the variable regions when compared with the variable regions depicted in the sequence described above.

In other embodiments, the VH and/or VL amino acid sequences may be 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% identical to the sequences set forth in Table 1. In other embodiments, the VH and/or VL amino acid sequences may be identical except an amino acid substitution in no more than 1, 2, 3, 4 or 5 amino acid position. An antibody having VH and VL regions having high (*i. e.*, 80% or greater) identity to the VH and VL regions of those Propeller 1 antibodies described in Table 1 can be obtained by

mutagenesis (*e.g.*, site-directed or PCR-mediated mutagenesis) of nucleic acid molecules encoding SEQ ID NOs: 14, 34, 60, 13, 33, and 59 respectively, followed by testing of the encoded altered antibody for retained function using the functional assays described herein.

An antibody having VH and VL regions having high (*i. e.*, 80% or greater) identity to the VH and VL regions of those Propeller 3 antibodies described in Table 1 can be obtained by mutagenesis (*e.g.*, site-directed or PCR-mediated mutagenesis) of nucleic acid molecules encoding SEQ ID NOs: 82, 106, 128, 81, 105, and 127 respectively, followed by testing of the encoded altered antibody for retained function using the functional assays described herein.

In other embodiments, the variable regions of heavy chain and/or light chain nucleotide sequences may be 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% identical to the sequences set forth above

As used herein, “percent identity” between the two sequences is a function of the number of identical positions shared by the sequences (*i.e.*, % identity equals number of identical positions/total number of positions x 100), taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm, as described in the non-limiting examples below.

Additionally or alternatively, the protein sequences of the present invention can further be used as a “query sequence” to perform a search against public databases to, for example, identify related sequences. For example, such searches can be performed using the BLAST program (version 2.0) of Altschul *et al.* (1990) *J.Mol. Biol.* 215:403-10.

Antibodies with Conservative Modifications

In certain embodiments, an antibody of the invention has a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences and a light chain variable region comprising CDR1, CDR2, and CDR3 sequences, wherein one or more of these CDR sequences have specified amino acid sequences based on the antibodies described herein or conservative modifications thereof, and wherein the antibodies retain the desired functional properties of the LRP6 antibodies of the invention.

Accordingly, the invention provides an isolated Propeller 1 monoclonal antibody, or a functional fragment thereof, consisting of a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences and a light chain variable region comprising CDR1, CDR2, and CDR3 sequences, wherein: the heavy chain variable region CDR1 amino acid sequences are selected from the group consisting of SEQ ID NOs: 1, 21, and, 47, and conservative modifications thereof; the heavy chain variable region CDR2 amino acid sequences are selected from the group consisting of SEQ ID NOs: 2, 22, and 48, , and conservative modifications thereof; the heavy chain variable region CDR3 amino acid sequences are selected from the group consisting of SEQ ID NOs: 3, 23, and 49, and conservative modifications thereof; the light chain variable regions CDR1 amino acid sequences are selected from the group consisting of SEQ ID NOs: 4, 24, 50, and conservative modifications thereof; the light chain variable regions CDR2 amino acid sequences are selected from the group consisting of SEQ ID NOs: 5, 25, and 51, and conservative modifications thereof; the light chain variable regions of CDR3 amino acid sequences are selected from the group consisting of SEQ ID NOs: 6, 26, and 52, and conservative modifications thereof; the antibody or fragment thereof specifically binds to LRP6, and inhibits LRP6 activity by inhibiting a Wnt signaling pathway, which can be measured in Wnt reporter gene assay or other measure of Wnt directed signaling (e.g., LRP6 phosphorylation, β -catenin stabilization and nuclear translocation, cellular proliferation/ survival) as described herein.

Accordingly, the invention provides an isolated Propeller 3 monoclonal antibody, or a fragment thereof, consisting of a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences and a light chain variable region comprising CDR1, CDR2, and CDR3 sequences, wherein: the heavy chain variable region CDR1 amino acid sequences are selected from the group consisting of SEQ ID NOs: 69, 93, and 115, and conservative modifications thereof; the heavy chain variable region CDR2 amino acid sequences are selected from the group consisting of SEQ ID NOs: 70, 94, and 116, and conservative modifications thereof; the heavy chain variable region CDR3 amino acid sequences are selected from the group consisting of SEQ ID NOs: 71, 95, and 117, and conservative modifications thereof; the light chain variable regions CDR1 amino acid sequences are selected from the group consisting of SEQ ID NOs: 72, 96, and 118, and conservative modifications thereof; the light chain variable regions CDR2 amino acid sequences are selected from the group consisting of SEQ ID NOs: 73, 97, and 119 and conservative

modifications thereof; the light chain variable regions of CDR3 amino acid sequences are selected from the group consisting of SEQ ID NOs: 74, 98, and 120, and conservative modifications thereof; the antibody or fragment thereof specifically binds to LRP6, and inhibits activities of Propeller 3-dependent Wnt proteins, which can be measured in Wnt reporter gene assay or other measure of Wnt directed signaling (e.g., LRP6 phosphorylation, β -catenin stabilization and nuclear translocation, cellular proliferation/survival) as described herein.

Antibodies That Bind to the Same Epitope

The present invention provides antibodies that bind to the same epitope as do the LRP6 antibodies described in Table 1. Additional antibodies can therefore be identified based on their ability to cross-compete (*e.g.*, to competitively inhibit the binding of, in a statistically significant manner) with other antibodies of the invention in LRP6 binding assays. The ability of a test antibody to inhibit the binding of antibodies of the present invention to a LRP6 protein (*e.g.*, human and/or cynomolgus LRP6) demonstrates that the test antibody can compete with that antibody for binding to LRP6; such an antibody may, according to non-limiting theory, bind to the same or a related (*e.g.*, a structurally similar or spatially proximal) epitope on the LRP6 protein as the antibody with which it competes. In an embodiment, the antibody that binds to the same epitope on LRP6 as the antibodies of the present invention is a human monoclonal antibody. Such human monoclonal antibodies can be prepared and isolated as described herein.

Engineered and Modified Antibodies

An antibody of the invention further can be prepared using an antibody having one or more of the VH and/or VL sequences shown herein as starting material to engineer a modified antibody, which modified antibody may have altered properties from the starting antibody. An antibody can be engineered by modifying one or more residues within one or both variable regions (*i.e.*, VH and/or VL), for example within one or more CDR regions and/or within one or more framework regions. Additionally or alternatively, an antibody can be engineered by modifying residues within the constant region(s), for example to alter the effector function(s) of the antibody.

One type of variable region engineering that can be performed is CDR grafting. Antibodies interact with target antigens predominantly through amino acid residues that

are located in the six heavy and light chain complementarity determining regions (CDRs). For this reason, the amino acid sequences within CDRs are more diverse between individual antibodies than sequences outside of CDRs. Because CDR sequences are responsible for most antibody-antigen interactions, it is possible to express recombinant antibodies that mimic the properties of specific naturally occurring antibodies by constructing expression vectors that include CDR sequences from the specific naturally occurring antibody grafted onto framework sequences from a different antibody with different properties (see, e.g., Riechmann *et al.*, (1998) *Nature* 332:323-327; Jones *et al.*, (1986) *Nature* 321:522-525; Queen *et al.*, (1989) *Proc. Natl. Acad., U.S.A.* 86:10029-10033; U.S. Patent No. 5,225,539 to Winter, and U.S. Patent Nos. 5,530,101; 5,585,089; 5,693,762 and 6,180,370 to Queen *et al.*)

Accordingly, another embodiment of the invention pertains to an isolated Propeller 1 monoclonal antibody, or fragment thereof, comprising a heavy chain variable region comprising CDR1 sequences having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 21, and 47; CDR2 sequences having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 22, and 48; CDR3 sequences having an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 23, and 49, respectively; and a light chain variable region having CDR1 sequences having an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 24, and 50; CDR2 sequences having an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 25, and 51; and CDR3 sequences consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 26, and 52, respectively. Thus, such antibodies contain the VH and VL CDR sequences of monoclonal antibodies, yet may contain different framework sequences from these antibodies.

Accordingly, another embodiment of the invention pertains to an isolated Propeller 3 monoclonal antibody, or fragment thereof, comprising a heavy chain variable region comprising CDR1 sequences having an amino acid sequence selected from the group consisting of SEQ ID NOs: 69, 93, and 115; CDR2 sequences having an amino acid sequence selected from the group consisting of SEQ ID NOs: 70, 100, and 116; CDR3 sequences having an amino acid sequence selected from the group consisting of SEQ ID NOs: 71, 95, and 117, respectively; and a light chain variable region having CDR1 sequences having an amino acid sequence selected from the group consisting of SEQ ID

NOs: 72, 96, and 118; CDR2 sequences having an amino acid sequence selected from the group consisting of SEQ ID NOs: 73, 97, and 119; and CDR3 sequences consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 74, 98, and 120, respectively. Thus, such antibodies contain the VH and VL CDR sequences of monoclonal antibodies, yet may contain different framework sequences from these antibodies.

Such framework sequences can be obtained from public DNA databases or published references that include germline antibody gene sequences. For example, germline DNA sequences for human heavy and light chain variable region genes can be found in the "Vase" human germline sequence database (available on the Internet at www.mrc-cape.cam.ac.uk/vbase), as well as in Kabat *et al.*, (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242; Chothia *et al.*, (1987) *J. Mol. Biol.* 196:901-917; Chothia *et al.*, (1989) *Nature* 342:877-883; and Al-Lazikani *et al.*, (1997) *J. Mol. Biol.* 273:927-948; Tomlinson *et al.*, (1992) *J. Mol. Biol.* 227:776-798; and Cox *et al.*, (1994) *Eur. J Immunol.* 24:827-836; the contents of each of which are expressly incorporated herein by reference.

An example of framework sequences for use in the antibodies of the invention are those that are structurally similar to the framework sequences used by selected antibodies of the invention, *e.g.*, consensus sequences and/or framework sequences used by monoclonal antibodies of the invention. The VH CDR1, 2 and 3 sequences, and the VL CDR1, 2 and 3 sequences, can be grafted onto framework regions that have the identical sequence as that found in the germline immunoglobulin gene from which the framework sequence derive, or the CDR sequences can be grafted onto framework regions that contain one or more mutations as compared to the germline sequences. For example, it has been found that in certain instances it is beneficial to mutate residues within the framework regions to maintain or enhance the antigen binding ability of the antibody (see *e.g.*, U.S. Patent Nos. 5,530,101; 5,585,089; 5,693,762 and 6,180,370 to Queen *et al.*).

Another type of variable region modification is to mutate amino acid residues within the VH and/or VL CDR1, CDR2 and/or CDR3 regions to thereby improve one or more binding properties (*e.g.*, affinity) of the antibody of interest, known as "affinity maturation." Site-directed mutagenesis or PCR-mediated mutagenesis can be performed

to introduce the mutation(s) and the effect on antibody binding, or other functional property of interest, can be evaluated in *in vitro* or *in vivo* assays as described herein and provided in the Examples. Conservative modifications (as discussed above) can be introduced. The mutations may be amino acid substitutions, additions or deletions. Moreover, typically no more than one, two, three, four or five residues within a CDR region are altered.

Accordingly, in another embodiment, the invention provides isolated Propeller 1 monoclonal antibodies, or fragment thereof, consisting of a heavy chain variable region having: a VH CDR1 region consisting of an amino acid sequence selected from the group having SEQ ID NOs: 1, 21, and 47 or an amino acid sequence having one, two, three, four or five amino acid substitutions, deletions or additions as compared to SEQ ID NOs: 1, 21, and 47; a VH CDR2 region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 22, and 48, or an amino acid sequence having one, two, three, four or five amino acid substitutions, deletions or additions as compared to SEQ ID NOs: 2, 22, and 48; a VH CDR3 region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 23, and 49, or an amino acid sequence having one, two, three, four or five amino acid substitutions, deletions or additions as compared to SEQ ID NOs: 3, 23, and 49; a VL CDR1 region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 24, and 50, or an amino acid sequence having one, two, three, four or five amino acid substitutions, deletions or additions as compared to SEQ ID NOs: 4, 24, and 50; a VL CDR2 region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 25, and 51, or an amino acid sequence having one, two, three, four or five amino acid substitutions, deletions or additions as compared to SEQ ID NOs: 5, 25, and 51; and a VL CDR3 region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 26, and 52, or an amino acid sequence having one, two, three, four or five amino acid substitutions, deletions or additions as compared to SEQ ID NOs: 6, 26, and 52.

Accordingly, in another embodiment, the invention provides isolated Propeller 3 monoclonal antibodies, or fragment thereof, consisting of a heavy chain variable region having: a VH CDR1 region consisting of an amino acid sequence selected from the group having SEQ ID NOs: 69, 93, and 115 or an amino acid sequence having one, two, three, four or five amino acid substitutions, deletions or additions as compared to SEQ ID NOs: 69, 93, and 115; a VH CDR2 region having an amino acid sequence selected from the

group consisting of SEQ ID NOs: 70, 94, and 116, or an amino acid sequence having one, two, three, four or five amino acid substitutions, deletions or additions as compared to SEQ ID NOs: 70, 94, and 116; a VH CDR3 region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 71, 95, and 117, or an amino acid sequence having one, two, three, four or five amino acid substitutions, deletions or additions as compared to SEQ ID NOs: 71, 95, and 117; a VL CDR1 region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 72, 96, and 118, or an amino acid sequence having one, two, three, four or five amino acid substitutions, deletions or additions as compared to SEQ ID NOs: 72, 96, and 118; a VL CDR2 region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 73, 97, and 119, or an amino acid sequence having one, two, three, four or five amino acid substitutions, deletions or additions as compared to SEQ ID NOs: 73, 97, and 119; and a VL CDR3 region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 74, 98, and 120, or an amino acid sequence having one, two, three, four or five amino acid substitutions, deletions or additions as compared to SEQ ID NOs: 74, 98, and 120.

Grafting Antibody Fragments Into Alternative Frameworks or Scaffolds

A wide variety of antibody/ immunoglobulin frameworks or scaffolds can be employed so long as the resulting polypeptide includes at least one binding region which specifically binds to LRP6. Such frameworks or scaffolds include the 5 main idiotypes of human immunoglobulins, or fragments thereof, and include immunoglobulins of other animal species, preferably having humanized aspects. Novel frameworks, scaffolds and fragments continue to be discovered and developed by those skilled in the art.

In one aspect, the invention pertains to generating non-immunoglobulin based antibodies using non- immunoglobulin scaffolds onto which CDRs of the invention can be grafted. Known or future non-immunoglobulin frameworks and scaffolds may be employed, as long as they comprise a binding region specific for the target LRP6 protein (*e.g.*, human and/or cynomolgus LRP6). Known non-immunoglobulin frameworks or scaffolds include, but are not limited to, fibronectin (Compound Therapeutics, Inc., Waltham, MA), ankyrin (Molecular Partners AG, Zurich, Switzerland), domain antibodies (Domantis, Ltd., Cambridge, MA, and Ablynx nv, Zwijnaarde, Belgium), lipocalin (Pieris Proteolab AG, Freising, Germany), small modular immuno-pharmaceuticals (Trubion

Pharmaceuticals Inc., Seattle, WA), maxyodies (Avidia, Inc., Mountain View, CA), Protein A (Affibody AG, Sweden), and affilin (gamma-crystallin or ubiquitin) (Scil Proteins GmbH, Halle, Germany).

The fibronectin scaffolds are based on fibronectin type III domain (*e.g.*, the tenth module of the fibronectin type III (¹⁰ Fn3 domain)). The fibronectin type III domain has 7 or 8 beta strands which are distributed between two beta sheets, which themselves pack against each other to form the core of the protein, and further containing loops (analogous to CDRs) which connect the beta strands to each other and are solvent exposed. There are at least three such loops at each edge of the beta sheet sandwich, where the edge is the boundary of the protein perpendicular to the direction of the beta strands (see US 6,818,418). These fibronectin-based scaffolds are not an immunoglobulin, although the overall fold is closely related to that of the smallest functional antibody fragment, the variable region of the heavy chain, which comprises the entire antigen recognition unit in camel and llama IgG. Because of this structure, the non-immunoglobulin antibody mimics antigen binding properties that are similar in nature and affinity to those of antibodies. These scaffolds can be used in a loop randomization and shuffling strategy *in vitro* that is similar to the process of affinity maturation of antibodies *in vivo*. These fibronectin-based molecules can be used as scaffolds where the loop regions of the molecule can be replaced with CDRs of the invention using standard cloning techniques.

The ankyrin technology is based on using proteins with ankyrin derived repeat modules as scaffolds for bearing variable regions which can be used for binding to different targets. The ankyrin repeat module is a 33 amino acid polypeptide consisting of two anti-parallel α -helices and a β -turn. Binding of the variable regions is mostly optimized by using ribosome display.

Avimers are derived from natural A-domain containing protein such as LRP6. These domains are used by nature for protein-protein interactions and in human over 250 proteins are structurally based on A-domains. Avimers consist of a number of different "A-domain" monomers (2-10) linked via amino acid linkers. Avimers can be created that can bind to the target antigen using the methodology described in, for example, U.S. Patent Application Publication Nos. 20040175756; 20050053973; 20050048512; and 20060008844.

Affibody affinity ligands are small, simple proteins composed of a three-helix bundle based on the scaffold of one of the IgG-binding domains of Protein A. Protein A is a surface protein from the bacterium *Staphylococcus aureus*. This scaffold domain consists of 58 amino acids, 13 of which are randomized to generate affibody libraries with a large number of ligand variants (See *e.g.*, US 5,831,012). Affibody molecules mimic antibodies, they have a molecular weight of 6 kDa, compared to the molecular weight of antibodies, which is 150 kDa. In spite of its small size, the binding site of affibody molecules is similar to that of an antibody.

Anticalins are products developed by the company Pieris ProteoLab AG. They are derived from lipocalins, a widespread group of small and robust proteins that are usually involved in the physiological transport or storage of chemically sensitive or insoluble compounds. Several natural lipocalins occur in human tissues or body liquids. The protein architecture is reminiscent of immunoglobulins, with hypervariable loops on top of a rigid framework. However, in contrast with antibodies or their recombinant fragments, lipocalins are composed of a single polypeptide chain with 160 to 180 amino acid residues, being just marginally bigger than a single immunoglobulin domain. The set of four loops, which makes up the binding pocket, shows pronounced structural plasticity and tolerates a variety of side chains. The binding site can thus be reshaped in a proprietary process in order to recognize prescribed target molecules of different shape with high affinity and specificity. One protein of lipocalin family, the bilin-binding protein (BBP) of *Pieris Brassicae* has been used to develop anticalins by mutagenizing the set of four loops. One example of a patent application describing anticalins is in PCT Publication No. WO 199916873.

Affilin molecules are small non-immunoglobulin proteins which are designed for specific affinities towards proteins and small molecules. New affilin molecules can be very quickly selected from two libraries, each of which is based on a different human derived scaffold protein. Affilin molecules do not show any structural homology to immunoglobulin proteins. Currently, two affilin scaffolds are employed, one of which is gamma crystalline, a human structural eye lens protein and the other is "ubiquitin" superfamily proteins. Both human scaffolds are very small, show high temperature stability and are almost resistant to pH changes and denaturing agents. This high stability is mainly due to the expanded beta sheet structure of the proteins. Examples of gamma

crystalline derived proteins are described in WO200104144 and examples of "ubiquitin-like" proteins are described in WO2004106368.

Protein epitope mimetics (PEM) are medium-sized, cyclic, peptide-like molecules (MW 1-2kDa) mimicking beta-hairpin secondary structures of proteins, the major secondary structure involved in protein-protein interactions.

In some embodiments, the Fabs are converted to silent IgG1 format by changing the Fc region. For example, antibodies MOR08168, MOR08545, MOR06706, MOR06475, MOR08193, and MOR08473 in Table 1 can be converted to IgG1 format by adding the amino acid sequence:

CDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF
 NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA
 LPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWES
 NGQPENNYKTTTPVLDSGDFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY
 TQKLSLSPGK (SEQ ID NO: 209).

and substituting the light chain with: CS if the light chain is lambda, or C if the light chain is kappa. As used herein, a "silent IgG1" is an IgG1 Fc sequence in which the amino acid sequence has been altered to decrease Fc-mediated effector functions (for example ADCC and/or CDC). Such an antibody will typically have decreased binding to Fc receptors. In some other embodiments, the Fabs are converted to IgG2 format. For example, antibodies MOR08168, MOR08545, MOR06706, MOR06475, MOR08193, and MOR08473 in Table 1 can be converted to IgG2 format by substituting the constant sequence with the constant sequence for the heavy chain of IgG2:

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPA
 VLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCP
 APPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVH
 NAKTKPREEQFNSTFRVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISK
 KGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
 TPPMLDSGDFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKLSLSPGK
 (SEQ ID NO: 210).

Human or humanized antibodies

The present invention provides fully human antibodies that specifically bind to a LRP6 protein (*e.g.*, human and/or cynomolgus LRP6). Compared to the chimeric or humanized antibodies, the human LRP6 antibodies of the invention have further decreased antigenicity when administered to human subjects.

The human LRP6 antibodies can be generated using methods that are known in the art. For example, the humaneering technology used to converting non-human antibodies into engineered human antibodies. U.S. Patent Publication No. 20050008625 describes an *in vivo* method for replacing a nonhuman antibody variable region with a human variable region in an antibody while maintaining the same or providing better binding characteristics relative to that of the nonhuman antibody. The method relies on epitope guided replacement of variable regions of a non-human reference antibody with a fully human antibody. The resulting human antibody is generally unrelated structurally to the reference nonhuman antibody, but binds to the same epitope on the same antigen as the reference antibody. Briefly, the serial epitope-guided complementarity replacement approach is enabled by setting up a competition in cells between a "competitor" and a library of diverse hybrids of the reference antibody ("test antibodies") for binding to limiting amounts of antigen in the presence of a reporter system which responds to the binding of test antibody to antigen. The competitor can be the reference antibody or derivative thereof such as a single-chain Fv fragment. The competitor can also be a natural or artificial ligand of the antigen which binds to the same epitope as the reference antibody. The only requirements of the competitor are that it binds to the same epitope as the reference antibody, and that it competes with the reference antibody for antigen binding. The test antibodies have one antigen-binding V-region in common from the nonhuman reference antibody, and the other V-region selected at random from a diverse source such as a repertoire library of human antibodies. The common V-region from the reference antibody serves as a guide, positioning the test antibodies on the same epitope on the antigen, and in the same orientation, so that selection is biased toward the highest antigen-binding fidelity to the reference antibody.

Many types of reporter system can be used to detect desired interactions between test antibodies and antigen. For example, complementing reporter fragments may be linked to antigen and test antibody, respectively, so that reporter activation by fragment

complementation only occurs when the test antibody binds to the antigen. When the test antibody- and antigen-reporter fragment fusions are co-expressed with a competitor, reporter activation becomes dependent on the ability of the test antibody to compete with the competitor, which is proportional to the affinity of the test antibody for the antigen. Other reporter systems that can be used include the reactivator of an auto-inhibited reporter reactivation system (RAIR) as disclosed in U.S. Patent Application Ser. No. 10/208,730 (Publication No. 20030198971), or competitive activation system disclosed in U.S. Patent Application Ser. No. 10/076,845 (Publication No. 20030157579).

With the serial epitope-guided complementarity replacement system, selection is made to identify cells expresses a single test antibody along with the competitor, antigen, and reporter components. In these cells, each test antibody competes one-on-one with the competitor for binding to a limiting amount of antigen. Activity of the reporter is proportional to the amount of antigen bound to the test antibody, which in turn is proportional to the affinity of the test antibody for the antigen and the stability of the test antibody. Test antibodies are initially selected on the basis of their activity relative to that of the reference antibody when expressed as the test antibody. The result of the first round of selection is a set of "hybrid" antibodies, each of which is comprised of the same non-human V-region from the reference antibody and a human V-region from the library, and each of which binds to the same epitope on the antigen as the reference antibody. One or more of the hybrid antibodies selected in the first round will have an affinity for the antigen comparable to or higher than that of the reference antibody.

In the second V-region replacement step, the human V-regions selected in the first step are used as guide for the selection of human replacements for the remaining non-human reference antibody V-region with a diverse library of cognate human V-regions. The hybrid antibodies selected in the first round may also be used as competitors for the second round of selection. The result of the second round of selection is a set of fully human antibodies which differ structurally from the reference antibody, but which compete with the reference antibody for binding to the same antigen. Some of the selected human antibodies bind to the same epitope on the same antigen as the reference antibody. Among these selected human antibodies, one or more binds to the same epitope with an affinity which is comparable to or higher than that of the reference antibody.

Using one of the mouse or chimeric LRP6 antibodies described above as the reference antibody, this method can be readily employed to generate human antibodies that bind to human LRP6 with the same binding specificity and the same or better binding affinity. In addition, such human LRP6 antibodies can also be commercially obtained from companies which customarily produce human antibodies, *e.g.*, KaloBios, Inc. (Mountain View, CA).

Camelid antibodies

Antibody proteins obtained from members of the camel and dromedary (*Camelus bactrianus* and *Camelus dromedarius*) family including new world members such as llama species (*Lama pacos*, *Lama glama* and *Lama vicugna*) have been characterized with respect to size, structural complexity and antigenicity for human subjects. Certain IgG antibodies from this family of mammals as found in nature lack light chains, and are thus structurally distinct from the typical four chain quaternary structure having two heavy and two light chains, for antibodies from other animals. See PCT/EP93/02214 (WO 94/04678 published 3 March 1994).

A region of the camelid antibody which is the small single variable domain identified as VHH can be obtained by genetic engineering to yield a small protein having high affinity for a target, resulting in a low molecular weight antibody-derived protein known as a "camelid nanobody". See U.S. patent number 5,759,808 issued June 2, 1998; see also Stijlemans *et al.*, (2004) *J Biol Chem* 279:1256-1261; Dumoulin *et al.*, (2003) *Nature* 424:783-788; Pleschberger *et al.* (2003) *Bioconjugate Chem* 14:440-448; Cortez-Retamozo *et al.* (2002) *Int J Cancer* 89:456-62; and Lauwereys *et al.* (1998) *EMBO J* 17:3512-3520. Engineered libraries of camelid antibodies and antibody fragments are commercially available, for example, from Ablynx, Ghent, Belgium. As with other antibodies of non-human origin, an amino acid sequence of a camelid antibody can be altered recombinantly to obtain a sequence that more closely resembles a human sequence, *i.e.*, the nanobody can be "humanized". Thus the natural low antigenicity of camelid antibodies to humans can be further decreased.

The camelid nanobody has a molecular weight approximately one-tenth that of a human IgG molecule, and the protein has a physical diameter of only a few nanometers. One consequence of the small size is the ability of camelid nanobodies to bind to antigenic sites that are functionally invisible to larger antibody proteins, *i.e.*, camelid nanobodies

are useful as reagents detect antigens that are otherwise cryptic using classical immunological techniques, and as possible therapeutic agents. Thus yet another consequence of small size is that a camelid nanobody can inhibit as a result of binding to a specific site in a groove or narrow cleft of a target protein, and hence can serve in a capacity that more closely resembles the function of a classical low molecular weight drug than that of a classical antibody.

The low molecular weight and compact size further result in camelid nanobodies being extremely thermostable, stable to extreme pH and to proteolytic digestion, and poorly antigenic. Another consequence is that camelid nanobodies readily move from the circulatory system into tissues, and even cross the blood-brain barrier and can treat disorders that affect nervous tissue. Nanobodies can further facilitated drug transport across the blood brain barrier. See U.S. patent application 20040161738 published August 19, 2004. These features combined with the low antigenicity to humans indicate great therapeutic potential. Further, these molecules can be fully expressed in prokaryotic cells such as *E. coli* and are expressed as fusion proteins with bacteriophage and are functional.

Accordingly, a feature of the present invention is a camelid antibody or nanobody having high affinity for LRP6. In certain embodiments herein, the camelid antibody or nanobody is naturally produced in the camelid animal, *i.e.*, is produced by the camelid following immunization with LRP6 or a peptide fragment thereof, using techniques described herein for other antibodies. Alternatively, the LRP6 camelid nanobody is engineered, *i.e.*, produced by selection for example from a library of phage displaying appropriately mutagenized camelid nanobody proteins using panning procedures with LRP6 as a target as described in the examples herein. Engineered nanobodies can further be customized by genetic engineering to have a half life in a recipient subject of from 45 minutes to two weeks. In a specific embodiment, the camelid antibody or nanobody is obtained by grafting the CDRs sequences of the heavy or light chain of the human antibodies of the invention into nanobody or single domain antibody framework sequences, as described for example in PCT/EP93/02214.

Multivalent Antibodies

The present invention features multivalent antibodies (e.g., biparatopic, bispecific antibodies) comprising at least two receptor binding domains for two different binding

sites on one or more target(s) receptors. Clinical benefits may be provided by the binding of two or more binding specificities within one antibody (Morrison *et al.*, (1997) *Nature Biotech.* 15:159-163; Alt *et al.* (1999) *FEBS Letters* 454: 90-94; Zuo *et al.*, (2000) *Protein Engineering* 13:361-367; Lu *et al.*, (2004) *JBC* 279:2856-2865; Lu *et al.*, (2005) *JBC* 280:19665-19672; Marvin *et al.*, (2005) *Acta Pharmacologica Sinica* 26:649-658; Marvin *et al.*, (2006) *Curr Opin Drug Disc Develop* 9:184-193; Shen *et al.*, (2007) *J Immun Methods* 218:65-74; Wu *et al.*, (2007) *Nat Biotechnol.* 11:1290-1297; Dimasi *et al.*, (2009) *J. Mol Biol.* 393:672-692; and Michaelson *et al.*, (2009) *mAbs* 1:128-141.

The present invention is based on the discovery that the multivalent antibodies (e.g., a single LRP6 biparatopic or bispecific antibody) have the ability to inhibit both propeller 1 (e.g. Wnt1 and propeller 3 (e.g. Wnt3) ligand-mediated signaling. Furthermore, and unexpectedly, the multivalent antibodies (e.g., a single LRP6 biparatopic or bispecific antibody) display no significant potentiation of a Wnt signal. The multivalent antibodies bind to distinct LRP6 β -propeller regions. Propeller 1 antibodies bind to the β -propeller 1 domain and block propeller1-dependent Wnts such as Wnt1, Wnt2, Wnt6, Wnt7A, Wnt7B, Wnt9, Wnt10A, Wnt10B and inhibit a Wnt 1 signal transduction pathway. Propeller 3 antibodies bind to the β -propeller 3 domain and block propeller3-dependent Wnts such as Wnt3a and Wnt3 and inhibit a Wnt3 signal transduction pathway. LRP6 antibodies differentiate propeller 1 and propeller 3 ligands into two separate classes and bind to distinct epitopes of the LRP6 target receptor. Conversion of fragments of the LRP6 antibodies (e.g., Fabs) to full length IgG antibody results in an antibody that potentiates (enhances) a Wnt signal in the presence of another protein such as a Wnt 1 or Wnt 3 ligand.

Multivalent antibodies provide advantages over traditional antibodies for example, expanding the repertoire of targets, having new binding specificities, increased potency, and no signal potentiation. A single LRP6 multivalent antibody can bind to multiple propeller regions on a single LRP6 target receptor on the same cell, and inhibit Wnt signaling. In one embodiment, the multivalent antibody binds to any combination of a β -propeller regions selected from the group consisting of propeller 1, propeller 2, propeller 3, and propeller 4. In one embodiment, the multivalent antibody binds to propeller 1 and propeller 3 domains of LRP6. Thus, a single LRP6 multivalent antibody has increased potency of action by binding to multiple β -propeller regions and inhibiting Wnt signaling

mediated by each domain. For example, a single LRP6 multivalent antibody inhibits both propeller 1 and propeller 3 mediated Wnt signaling by binding to both propeller 1 and propeller 3 domains, respectively. The increased potency of action may be due to increased avidity or better binding of the LRP6 multivalent antibody.

In one embodiment, multivalent antibodies are produced by linking an scFv to an IgG antibody. The VH and VL domains used to make an scFv may be derived from the same or from different antibodies. The scFv comprises at least one, two, three, four, five, or six CDRs.

The Fc region of the IgG antibody and the scFv fragment may be linked together in many different orientations. In one embodiment, the scFv is linked to the C-terminus of the Fc region. In other embodiments, the scFv is linked to the N-terminus of the Fc region. In other embodiments, scFvs are linked to both the N-terminus and C-terminus of the Fc region. In another embodiment, the scFv can be linked to a light chain of an antibody. The multivalent antibodies of the invention can bind multiple binding sites of a target receptor concurrently. The receptor binding domains of multivalent antibodies of the invention may bind at least 1, 2, 3, 4, 5, 6, 7, 8 or more binding sites. Each receptor binding domain can be specific for the same binding site. The multivalent antibodies of the invention comprise one or more receptor binding domains that are specific for distinct epitopes on the same target receptor, e.g., β -propeller 1 domain or β -propeller 3 domain of LRP6. Alternatively, the multivalent antibodies of the invention comprise one or more receptor binding domains that are specific for epitopes on different target receptors, e.g., LRP6 and a receptor that is not LRP6 such as Erb, cmet, IGFR1, Smoothed, and Notch receptors.

Each receptor binding domain within the multivalent antibodies of the invention can also have different (i.e. a higher or lower) affinity for the antigen compared to the traditional antibodies.

In one embodiment, the multivalent antibodies of the invention are biparatopic antibody comprising at least one receptor binding domain for a first epitope on LRP6 target receptor and a second receptor binding domain for a second epitope on the same LRP6 target receptor.

The multivalent antibody of the invention comprises at least one CDR of an antibody, at least two CDRs of a given antibody, or at least three CDRs of a given antibody, at least four CDRs of a given antibody, at least five CDRs of a given antibody, or at least six CDRs of a given antibody. The multivalent antibody of the invention comprises at least one VH domain of an antibody, at least one VL domain of a given antibody, or at least one VH domain and one VL domain of an antibody. ScFv molecules can be constructed in a VH-linker-VL orientation or VL-linker-VH orientation.

The stability of scFv molecules of the invention or fusion proteins comprising them can be evaluated in reference to the biophysical properties (e.g., thermal stability) of a conventional control scFv molecule or a full length antibody. In one embodiment, the multivalent antibodies of the invention have a thermal stability that is greater than about 0.1, about 0.25, about 0.5, about 0.75, about 1, about 1.25, about 1.5, about 1.75, about 2, about 2.5, about about 3, about 3.5, about 4, about 4.5, about 5, about 5.5, about 6, about 6.5, about 7, about 7.5, about 8, about 8.5, about 9, about 9.5, about 10 degrees, about 11 degrees, about 12 degrees, about 13 degrees, about 14 degrees, or about 15 degrees Celsius than a control binding molecule (e.g. a conventional scFv molecule).

The scFv molecules comprise an scFv linker with an optimized length and/or amino acid composition. Preferred scFv linkers of the invention improve the thermal stability of a multivalent antibody of the invention by at least about 2°C or 3°C as compared to a conventional antibody. In one embodiment, a multivalent antibody of the invention has a 1°C improved thermal stability as compared to a conventional antibody. In another embodiment, a multivalent antibody of the invention has a 2°C improved thermal stability as compared to a conventional antibody. In another embodiment, a multivalent antibody of the invention has a 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15°C improved thermal stability as compared to a conventional antibody. Comparisons can be made, for example, between the scFv molecules of the invention and scFv molecules made using prior art methods or between scFv molecules and Fab fragments of an antibody from which the scFv VH and VL were derived. Thermal stability can be measured using methods known in the art. For example, in one embodiment, T_m can be measured. Methods for measuring T_m and other methods of determining protein stability are described in more detail below.

In one embodiment, the scFv linker consists of the amino acid sequence (Gly₄Ser)₃ or

comprises a (Gly₄Ser)₄ sequence. Other exemplary linkers comprise or consist of ((Gly₄Ser)₅ and (Gly₄Ser)₆ sequences. scFv linkers of the invention can be of varying lengths. In one embodiment, an scFv linker of the invention is from about 5 to about 50 amino acids in length. In another embodiment, an scFv linker of the invention is from about 10 to about 40 amino acids in length. In another embodiment, an scFv linker of the invention is from about 15 to about 30 amino acids in length. In another embodiment, an scFv linker of the invention is from about 15 to about 20 amino acids in length. Variation in linker length may retain or enhance activity, giving rise to superior efficacy in activity studies. scFv linkers can be introduced into polypeptide sequences using techniques known in the art. For example, PCR mutagenesis can be used. Modifications can be confirmed by DNA sequence analysis. Plasmid DNA can be used to transform host cells for stable production of the polypeptides produced.

In one embodiment, a scFv molecule of the invention comprises an scFv linker having the amino acid sequence of (Gly₄Ser)₃ or (Gly₄Ser)₄ interposed between a VH domain and a VL domain, wherein the VH and VL domains are linked by a disulfide bond.

The scFv molecules of the invention can further comprise at least one disulfide bond which links an amino acid in the VL domain with an amino acid in the VH domain. Cysteine residues are necessary to provide disulfide bonds. Disulfide bonds can be included in an scFv molecule of the invention, e.g., to connect FR4 of VL and FR2 of VH or to connect FR2 of VL and FR4 of VH. Exemplary positions for disulfide bonding include: 43, 44, 45, 46, 47, 103, 104, 105, and 106 of VH and 42, 43, 44, 45, 46, 98, 99, 100, and 101 of VL, Kabat numbering. Modifications of the genes which encode the VH and VL domains may be accomplished using techniques known in the art, for example, site-directed mutagenesis.

Mutations in scFv alter the stability of the scFv and improve the overall stability of the multivalent antibody comprising the mutated scFv compared to a multivalent antibody without the mutated in the scFv. Mutations to the scFv can be generated as shown in the Examples. Stability of the mutated scFv is compared against the unmutated scFv using measurements such as T_m, temperature denaturation and temperature aggregation as

described in the Examples. The binding capacity of the mutant scFvs can be determined using assays such as ELISA.

In one embodiment, a multivalent antibody of the invention comprises at least one mutation in an scFv such that the mutated scFv confers improved stability to the multivalent antibody. In another embodiment, a multivalent antibody of the invention comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 mutations in an scFv such that the mutated scFv confers improved stability to the multivalent antibody. In another embodiment, a multivalent antibody of the invention comprises a combination of mutations in an scFv such that the mutated scFv confers improved stability to the multivalent antibody.

Multivalent antibodies, such as biparatopic antibodies of the invention are disclosed herein. These biparatopic antibodies bind to one or more epitopes of LRP6. ScFvs are linked to an Fc region, for example at the hinge region, using linkers such as GlySer linkers. In one embodiment, the invention pertains to an antibody or antigen binding fragment that binds to the β -propeller 1 domain of LRP6 linked to an scFv that binds to the β -propeller 3 domain of LRP6 using a (GlyGlySer)₂ linker linked to the CH3 region of the Fc. In one embodiment, a full length IgG antibody that binds to the LRP6 β -propeller 1 domain is used to attach a scFv fragment of an antibody that binds to the LRP6 β -propeller 3 domain.

Multivalent antibodies, such as biparatopic antibodies of the invention can be constructed using any combination of heavy and light chain sequences shown in Table 2.

Table 2: Biparatopic Constructs of the Invention

Construct	Heavy Chain SEQ ID NO:	Light Chain SEQ ID NO:
BiPa Propeller 1 IgG/Propeller 3 scFv attached to Fc	166, 171, 173, 175, 195, 201, and 207	170, 193, 199, and 205
Alternative BiPa Propeller 1 IgG/Propeller 3 scFv attached to light chain	177	181

Reverse BiPa	187, and 189	185
Propeller 3 IgG/Propeller 1 scFv attached to Fc		

Accordingly, the invention pertains to biparatopic antibodies constructed using a Propeller 1 IgG antibody and a Propeller 3 scFv. In one embodiment, the biparatopic antibody is constructed using any heavy chains sequence selected from the group consisting of SEQ ID NOs: 166, 171, 173, 175, 195, 201, and 207; and any light chain sequence selected from the group consisting of SEQ ID NOs: 170, 193, 199, and 205. In one embodiment, the biparatopic antibody comprises heavy and light chain sequences selected from the group consisting of SEQ ID NOs: 166/170, 171/170, 173/170, 175/170, 201/199, 207/205, and 195/193.

In one embodiment, the biparatopic antibody comprises heavy chain SEQ ID NO: 166 and light chain SEQ ID NO: 170. In one embodiment, the biparatopic antibody comprises heavy chain SEQ ID NO: 171 and light chain SEQ ID NO: 170. In one embodiment, the biparatopic antibody comprises heavy chain SEQ ID NO: 173 and light chain SEQ ID NO: 170. In one embodiment, the biparatopic antibody comprises heavy chain SEQ ID NO: 175 and light chain SEQ ID NO: 170. In one embodiment, the biparatopic antibody comprises heavy chain SEQ ID NO: 201 and light chain SEQ ID NO: 199. In one embodiment, the biparatopic antibody comprises heavy chain SEQ ID NO: 207 and light chain SEQ ID NO: 205. In one embodiment, the biparatopic antibody comprises heavy chain SEQ ID NO: 195 and light chain SEQ ID NO: 193.

In another embodiment, the biparatopic antibody is an “alternative biparatopic antibody” whereby the scFv is attached to the light chain of IgG. In one embodiment, the biparatopic antibody comprises heavy chain SEQ ID NO: 177 and light chain SEQ ID NO: 181.

In another embodiment, a full length IgG antibody that binds to the LPR6 β -propeller 3 domain is used to attach a scFv fragment of an antibody that binds to the LRP6 β -propeller 1 domain, referred to as “reverse biparatopic”. In one embodiment, reverse biparatopic antibodies of the invention are constructed using a Propeller 3 IgG antibody and a Propeller 1 scFv. In one embodiment, a reverse biparatopic antibody is constructed

using any heavy chains sequence selected from the group consisting of SEQ ID NOs: 187 and 189; and a light chain sequence SEQ ID NO: 185. In one embodiment, the reverse biparatopic antibody comprises heavy SEQ ID NO: 187 and light chain SEQ ID NO: 185. In one embodiment, the reverse biparatopic antibody comprises heavy chain SEQ ID NO: 189 and light chain SEQ ID NO: 185.

The invention also pertains to biparatopic antibodies having a heavy chain variable region comprising a CDR1 sequences having an amino acid sequence selected from the group consisting of 1, 21, and 47, CDR2 sequences having an amino acid sequence selected from the group consisting of 2, 22, and 48, CDR3 sequences having an amino acid sequence selected from the group consisting of 3, 23, and 49, respectively; a light chain a light chain variable region comprising a CDR1 sequences having an amino acid sequence selected from the group consisting of 4, 24, and 50, CDR2 sequences having an amino acid sequence selected from the group consisting of 5, 25, and 51, CDR3 sequences having an amino acid sequence selected from the group consisting of 6, 26, and 52; combined with a heavy chain variable region comprising a CDR1 sequences having an amino acid sequence selected from the group consisting of 69, 93, and 115, CDR2 sequences having an amino acid sequence selected from the group consisting of 70, 94, and 116, CDR3 sequences having an amino acid sequence selected from the group consisting of 71, 95, and 117, respectively; a light chain a light chain variable region comprising a CDR1 sequences having an amino acid sequence selected from the group consisting of 72, 96, and 118, CDR2 sequences having an amino acid sequence selected from the group consisting of 73, 97, and 119, CDR3 sequences having an amino acid sequence selected from the group consisting of 74, 98 and 120; the antibody binds to LRP6 (e.g., human and/or cynomologous LRP6) and inhibits LRP6 biological activity which can be measured in a Wnt reporter gene assay or any other measure of Wnt directed signaling (e.g., LRP6 phosphorylation, β -catenin stabilization and nuclear translocation, cellular proliferation/ survival) as described herein.

Antibodies that can be employed in the multivalent antibodies of the invention are human, murine, chimeric and humanized monoclonal antibodies.

The multivalent antibodies of the present invention can be prepared by conjugating the constituent receptor binding domains, using methods known in the art. For example, each receptor binding domain of the multivalent antibody can be generated separately and then

conjugated to one another. When the receptor binding domains are proteins or peptides, a variety of coupling or cross-linking agents can be used for covalent conjugation.

Examples of cross-linking agents include protein A, carbodiimide, N-succinimidyl-S-acetyl-thioacetate (SATA), 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB), o-phenylenedimaleimide (oPDM), N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), and sulfosuccinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (sulfo-SMCC) (see *e.g.*, Karpovsky *et al.*, (1984) *J. Exp. Med.* 160:1686; Liu *et al.* (1985) *Proc. Natl. Acad. Sci. USA* 82:8648). Other methods include those described in Paulus (1985) *Behring Ins. Mitt. No. 78:118-132*; Brennan *et al.*, (1985) *Science* 229:81-83), and Glennie *et al.*, (1987) *J. Immunol.* 139: 2367-2375). Conjugating agents are SATA and sulfo-SMCC, both available from Pierce Chemical Co. (Rockford, IL).

When the receptor binding domains are antibodies, they can be conjugated by sulfhydryl bonding of the C-terminus hinge regions of the two heavy chains. In a particularly embodiment, the hinge region is modified to contain an odd number of sulfhydryl residues, for example one, prior to conjugation.

Alternatively, the receptor binding domains can be encoded in the same vector and expressed and assembled in the same host cell. This method is particularly useful where multivalent antibody is a mAb x mAb, mAb x Fab, Fab x F(ab')₂ or ligand x Fab fusion protein. Methods for preparing bispecific molecules are described for example in U.S. Patent Number 5,260,203; U.S. Patent Number 5,455,030; U.S. Patent Number 4,881,175; U.S. Patent Number 5,132,405; U.S. Patent Number 5,091,513; U.S. Patent Number 5,476,786; U.S. Patent Number 5,013,653; U.S. Patent Number 5,258,498; and U.S. Patent Number 5,482,858.

Binding of the multivalent antibodies to their targets can be confirmed by, for example, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (REA), FACS analysis, bioassay (*e.g.*, growth inhibition), or Western Blot assay. Each of these assays generally detects the presence of protein-antibody complexes of particular interest by employing a labeled reagent (*e.g.*, an antibody) specific for the complex of interest.

In another aspect, the present invention provides multivalent antibodies comprising at least two different receptor binding domains of the antibodies of the invention binding to LRP6. The receptor binding domains can be linked together via protein fusion or covalent or non covalent linkage. Tetravalent antibodies can be obtained for example by

cross-linking the antibodies of the invention with an antibody that binds to the constant regions of the antibodies of the invention, for example the Fc or hinge region.

Multivalent Antibody Orientation

The invention pertains to multivalent antibodies that have multiple receptor binding domains ("RBD"), which include for example, antibody variable regions, antibody fragments (e.g., Fabs), scFvs, single chain diabodies, or IgG antibodies. Examples of RBDs are components of a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; a F(ab)₂ fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; a Fd fragment consisting of the VH and CH1 domains; a Fv fragment consisting of the VL and VH domains of a single arm of an antibody; a dAb fragment (Ward *et al.*, (1989) Nature 341:544-546), which consists of a VH domain; and an isolated complementarity determining region (CDR). RBDs also are also components of single domain antibodies, maxibodies, unibodies, minibodies, diabodies, triabodies, tetrabodies, v-NAR and bis-scFv (see, e.g., Hollinger and Hudson, (2005) Nature Biotechnology 23: 1126-1136).

The multivalent antibodies of the invention are generated in any orientation using at least one receptor binding domain (e.g., an scFv, a single chain diabody, an antibody variable region) as long as the resulting multivalent antibodies retain functional activity (e.g., inhibiting Wnt signaling). It should be understood that any number of receptor binding domains can be added to the C-terminus and /or N-terminus of the Fc as long as the resulting multivalent antibodies retain functional activity (e.g., inhibiting Wnt signaling). In an embodiment, one, two, three, or more receptor binding domains are linked to the C-terminus of the Fc region. In other embodiments one, two, three, or more receptor binding domains are linked to the N-terminus of the Fc region. In other embodiments, one, two, three, or more receptor binding domains are linked to both the N-terminus and C-terminus of the Fc region. For example, multivalent antibodies of the invention can comprise more than one receptor binding domain of the same type linked to the C-terminus and/or N-terminus of an Fc region, e.g., scFv-scFv-Fc-IgG. Alternatively, the multivalent antibodies of the invention can comprise more than one receptor binding domain of a different type linked to the C-terminus and/or N-terminus of the Fc region, e.g., scFv-diabody-Fc-IgG. In another embodiment, one, two, three or more receptor binding domains (e.g., scFv) are linked to the C-terminus of an IgG. In another embodiment, one,

two, three or more receptor binding domains (e.g., scFv) are linked to the N-terminus of an IgG. In another embodiment, one, two, three or more receptor binding domains (e.g., scFv) are linked to the N-terminus and C-terminus of an IgG.

In other embodiments, the multivalent antibodies of the invention are generated using more than one receptor binding domain of a different type linked to the C-terminus, e.g., scFv-diabody-Fc-IgG; diabody-scFv-Fc-IgG; scFv-scFv-diabody-Fc-IgG; scFv- diabody-scFv-Fc-IgG; diabody- scFv-scFv-Fc-IgG; antibody variable region-scFv-diabody-Fc-IgG; and the like. Multivalent antibodies with any number of permutations of receptor binding domains can be generated. These multivalent antibodies can be tested for functionality using the methods and assays described within.

In other embodiments, the multivalent antibodies of the invention are generated using more than one receptor binding domain of a different type linked to the N-terminus, e.g., IgG-Fc-scFv-diabody; IgG-Fc-diabody-scFv; IgG-Fc-scFv-scFv-diabody; IgG-Fc- scFv-diabody-scFv; IgG-Fc-diabody-scFv-scFv; IgG-Fc-antibody variable region-scFv-diabody; and the like.

In yet other embodiments, multivalent antibodies of the invention are generated using a single receptor binding domain (e.g., an scFv, a single chain diabody, an antibody variable region) linked to the C-terminus and N-terminus of the Fc region. In another embodiment, multiple receptor binding domains are linked to the N-terminus of the Fc region, for example, at least 1, 2, 3, 4, 5, 6, 7, 8 or more receptor binding domains linked to the C-terminus and N-terminus of the Fc region. For example, the multivalent antibodies of the invention can comprise one or more scFvs linked to the C-terminus and N-terminus of the Fc region, e.g., scFv-Fc-scFv-scFv; -scFv-scFv-Fc-scFv-scFv, and the like. In other embodiments, the multivalent antibodies of the invention are generated using more than one receptor binding domain of a different type linked to the N-terminus, e.g., scFv-Fc-scFv-diabody; scFv-Fc-diabody-scFv; scFv-Fc-scFv-scFv-diabody; scFv-Fc- scFv- diabody-scFv; scFv-Fc-diabody-scFv-scFv; scFv-Fc-antibody variable region-scFv-diabody; and the like. Multivalent antibodies with any number of permutations of receptor binding domains can be generated. These multivalent antibodies can be tested for functionality using the methods and assays described within.

Linker Length

It is known that linker length can greatly affect how the variable regions of an scFv fold and interact. In fact, if a short linker is employed (e.g., between 5-10 amino acids; between 5-20 amino acids) intrachain folding is prevented and interchain folding is required to bring the two variable regions together to form a functional epitope binding site. For examples of linker orientation and size see, e.g., Hollinger et al. 1993 Proc Natl Acad. Sci. U.S.A. 90:6444-6448, U.S. Patent Application Publication Nos. 2005/0100543, 2005/0175606, 2007/0014794, and PCT publication Nos. WO2006/020258 and WO2007/024715, is incorporated herein by reference.

It is also understood that the receptor binding domains may be separated by linker regions of various lengths. The receptor binding domains can be separated from each other, a Ckappa/lambda, CH1, Hinge, CH2, CH3, or the entire Fc region by a linker sequence. Such linker sequence may comprise a random assortment of amino acids, or a restricted set of amino acids. Such linker sequence may be flexible or rigid.

The multivalent antibodies of the invention comprise a linker sequence of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, or more amino acid residues between one or more of its receptor binding domains, Ckappa/lambda domains, CH1 domains, Hinge region, CH2 domains, CH3 domains, or Fc regions. The linker sequence may be comprised of any naturally occurring amino acid. In some embodiments, the amino acids glycine and serine comprise the amino acids within the linker sequence. In another embodiment, the linker region orientation comprises sets of glycine repeats $(\text{Gly}_4\text{Ser})_n$, where n is a positive integer equal to or greater than 1.

In one embodiment, the linkers include, but are not limited to, $(\text{Gly}_4\text{Ser})_4$ or $(\text{Gly}_4\text{Ser})_3$. In another embodiment, the linkers Glu and Lys residues can be interspersed within the Gly-Ser linkers for better solubility. In another embodiment, the linkers include multiple repeats of (Gly_2Ser) , (GlySer) or (Gly_3Ser) . In another embodiment, the linkers include combinations and multiples of $(\text{Gly}_3\text{Ser})+(\text{Gly}_4\text{Ser})+(\text{GlySer})$. In another embodiment, Ser can be replaced with Ala e.g., (Gly_4Ala) or (Gly_3Ala) . In yet another embodiment, the linker comprises the motif $(\text{GluAlaAlaAlaLys})_n$, where n is a positive integer equal to or greater than 1.

Hinge Region

The multivalent antibodies of the invention may comprise all or at least a portion of an antibody Hinge region. The Hinge region or portion thereof may be connected directly to an receptor binding domain, a CH1, a Ckappa/lambda, a CH2, or a CH3. In one embodiment, the Hinge region, or portion thereof may be connected through a variable length linker region to a receptor binding domain, a CH1, a Ckappa/lambda, a CH2, or a CH3.

The multivalent antibodies of the invention can comprise 1, 2, 3, 4, 5, 6, or more Hinge regions or portions thereof. The Hinge regions or portions thereof can either be identical or be different. In one embodiment, the multivalent antibodies of the invention comprise a Hinge region or portion thereof from a human IgG1 molecule. In further embodiments, the Hinge region or portion thereof may be engineered to remove a naturally occurring cysteine residue, introduce a non-naturally occurring cysteine residue, or substitute a naturally occurring residue for a non-naturally occurring cysteine residue. In some embodiments, the multivalent antibodies of the invention contain at least one Hinge region or portion thereof that comprises the following amino acids sequence comprising: EPKSCDKTHTCPPCP (SEQ ID NO: 211) or EPKSC (SEQ ID NO: 212). In some embodiments, at least one Hinge region or portion thereof is engineered to substitute at least one naturally occurring cysteine residue with another amino acid residue. In some embodiments, at least one naturally occurring cysteine residue is substituted with serine.

Non-naturally occurring cysteine residues useful for site-specific conjugation can be engineered into the multivalent antibodies of the invention. Such approaches, compositions and methods are exemplified in U.S. Provisional Patent Application Ser. No. 61/022,073 filed Jan. 18, 2008, entitled "Cysteine Engineered Antibodies for Site-Specific Conjugation" and U.S. Patent Application Publication No. 20070092940, filed Sep. 22, 2005, each of which are hereby incorporated by reference in its entirety for all purposes.

Methods of Evaluating Protein Stability

To assess the stability of multivalent antibodies, the stability of the least stable domain of a multidomain protein is predicted using the methods of the invention and those described below.

Such methods allow for the determination of multiple thermal unfolding transitions where the least stable domain either unfolds first or limits the overall stability threshold of a multidomain unit that unfolds cooperatively (i.e. a multidomain protein which exhibits a single unfolding transition). The least stable domain can be identified in a number of additional ways. Mutagenesis can be performed to probe which domain limits the overall stability. Additionally, protease resistance of a multidomain protein can be performed under conditions where the least stable domain is known to be intrinsically unfolded via DSC or other spectroscopic methods (Fontana, *et al.*, (1997) *Fold. Des.*, 2: R17-26; Dimasi *et al.* (2009) *J. Mol. Biol.* 393: 672-692). Once the least stable domain is identified, the sequence encoding this domain (or a portion thereof) may be employed as a test sequence in the methods of the invention.

a) Thermal Stability

The thermal stability of the compositions of the invention may be analyzed using a number of non-limiting biophysical or biochemical techniques known in the art. In certain embodiments, thermal stability is evaluated by analytical spectroscopy.

An exemplary analytical spectroscopy method is Differential Scanning Calorimetry (DSC). DSC employs a calorimeter which is sensitive to the heat absorbances that accompany the unfolding of most proteins or protein domains (see, e.g. Sanchez-Ruiz, *et al.*, *Biochemistry*, 27: 1648-52, 1988). To determine the thermal stability of a protein, a sample of the protein is inserted into the calorimeter and the temperature is raised until the Fab or scFv unfolds. The temperature at which the protein unfolds is indicative of overall protein stability.

Another exemplary analytical spectroscopy method is Circular Dichroism (CD) spectroscopy. CD spectrometry measures the optical activity of a composition as a function of increasing temperature. Circular dichroism (CD) spectroscopy measures

differences in the absorption of left-handed polarized light versus right-handed polarized light which arise due to structural asymmetry. A disordered or unfolded structure results in a CD spectrum very different from that of an ordered or folded structure. The CD spectrum reflects the sensitivity of the proteins to the denaturing effects of increasing temperature and is therefore indicative of a protein's thermal stability (see van Mierlo and Steemsma, *J. Biotechnol.*, 79(3):281-98, 2000).

Another exemplary analytical spectroscopy method for measuring thermal stability is Fluorescence Emission Spectroscopy (see van Mierlo and Steemsma, *supra*). Yet another exemplary analytical spectroscopy method for measuring thermal stability is Nuclear Magnetic Resonance (NMR) spectroscopy (see, e.g. van Mierlo and Steemsma, *supra*).

The thermal stability of a composition of the invention can be measured biochemically. An exemplary biochemical method for assessing thermal stability is a thermal challenge assay. In a "thermal challenge assay", a composition of the invention is subjected to a range of elevated temperatures for a set period of time. For example, in one embodiment, test scFv molecules or molecules comprising scFv molecules are subject to a range of increasing temperatures, e.g., for 1-1.5 hours. The activity of the protein is then assayed by a relevant biochemical assay. For example, if the protein is a binding protein (e.g. an scFv or scFv-containing polypeptide of the invention) the binding activity of the binding protein may be determined by a functional or quantitative ELISA.

Such an assay may be done in a high-throughput format and those disclosed in the Examples using *E. coli* and high throughput screening. A library of scFv variants may be created using methods known in the art. scFv expression may be induced and scFvs may be subjected to thermal challenge. The challenged test samples may be assayed for binding and those scFvs which are stable may be scaled up and further characterized.

Thermal stability is evaluated by measuring the melting temperature (T_m) of a composition of the invention using any of the above techniques (e.g. analytical spectroscopy techniques). The melting temperature is the temperature at the midpoint of a thermal transition curve wherein 50% of molecules of a composition are in a folded state (See e.g., Dimasi *et al.* (2009) *J. Mol Biol.* 393: 672-692). In one embodiment, T_m values for a scFv are about 40°C, 41°C, 42°C, 43°C, 44°C, 45°C, 46°C, 47°C, 48°C, 49°C,

50°C, 51°C, 52°C, 53°C, 54°C, 55°C, 56°C, 57°C, 58°C, 59°C, 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C, 95°C, 96°C, 97°C, 98°C, 99°C, 100°C. In one embodiment, T_m values for an IgG is about 40°C, 41°C, 42°C, 43°C, 44°C, 45°C, 46°C, 47°C, 48°C, 49°C, 50°C, 51°C, 52°C, 53°C, 54°C, 55°C, 56°C, 57°C, 58°C, 59°C, 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C, 95°C, 96°C, 97°C, 98°C, 99°C, 100°C. In one embodiment, T_m values for an multivalent antibody is about 40°C, 41°C, 42°C, 43°C, 44°C, 45°C, 46°C, 47°C, 48°C, 49°C, 50°C, 51°C, 52°C, 53°C, 54°C, 55°C, 56°C, 57°C, 58°C, 59°C, 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C, 95°C, 96°C, 97°C, 98°C, 99°C, 100°C.

Thermal stability is also evaluated by measuring the specific heat or heat capacity (C_p) of a composition of the invention using an analytical calorimetric technique (e.g. DSC). The specific heat of a composition is the energy (e.g. in kcal/mol) required to raise by 1°C, the temperature of 1 mol of water. As large C_p is a hallmark of a denatured or inactive protein composition. The change in heat capacity (ΔC_p) of a composition is measured by determining the specific heat of a composition before and after its thermal transition. Thermal stability may also be evaluated by measuring or determining other parameters of thermodynamic stability including Gibbs free energy of unfolding (ΔG), enthalpy of unfolding (ΔH), or entropy of unfolding (ΔS).

One or more of the above biochemical assays (e.g. a thermal challenge assay) is used to determine the temperature (i.e. the T_C value) at which 50% of the composition retains its activity (e.g. binding activity).

In addition, mutations to the scFv alter the thermal stability of the scFv compared with the unmutated scFv. When the mutated scFv is incorporated into a multivalent antibody, the mutated scFv confers thermal stability to the overall multivalent antibody. In one embodiment, the scFv comprises a single mutation that confers thermal stability to the

scFv. In another embodiment, the scFv comprises multiple mutations that confer thermal stability to the scFv. In one embodiment, the multiple mutations in the scFv have an additive effect on thermal stability of the scFv.

b) % Aggregation

The stability of a composition of the invention can be determined by measuring its propensity to aggregate. Aggregation can be measured by a number of non-limiting biochemical or biophysical techniques. For example, the aggregation of a composition of the invention may be evaluated using chromatography, e.g. Size-Exclusion Chromatography (SEC). SEC separates molecules on the basis of size. A column is filled with semi-solid beads of a polymeric gel that will admit ions and small molecules into their interior but not large ones. When a protein composition is applied to the top of the column, the compact folded proteins (ie. non-aggregated proteins) are distributed through a larger volume of solvent than is available to the large protein aggregates. Consequently, the large aggregates move more rapidly through the column, and in this way the mixture can be separated or fractionated into its components. Each fraction can be separately quantified (e.g. by light scattering) as it elutes from the gel. Accordingly, the % aggregation of a composition of the invention can be determined by comparing the concentration of a fraction with the total concentration of protein applied to the gel. Stable compositions elute from the column as essentially a single fraction and appear as essentially a single peak in the elution profile or chromatogram.

c) Binding Affinity

The stability of a composition of the invention can be assessed by determining its target binding affinity. A wide variety of methods for determining binding affinity are known in the art. An exemplary method for determining binding affinity employs surface plasmon resonance. Surface plasmon resonance is an optical phenomenon that allows for the analysis of real-time biospecific interactions by detection of alterations in protein concentrations within a biosensor matrix, for example using the BIAcore system (Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, N.J.). For further descriptions, see Jonsson, U., et al. (1993) *Ann. Biol. Clin.* 51:19-26; Jonsson, U., et al. (1991) *Biotechniques* 11:620-627; Johnson, B., et al. (1995) *J. Mol. Recognit.* 8:125-131; and Johnson, B., et al. (1991) *Anal. Biochem.* 198:268-277.

Antibodies with Extended Half Life

The present invention provides for antibodies that specifically bind to LRP6 protein which have an extended half-life *in vivo*. Many factors may affect a protein's half life *in vivo*. For examples, kidney filtration, metabolism in the liver, degradation by proteolytic enzymes (proteases), and immunogenic responses (*e.g.*, protein neutralization by antibodies and uptake by macrophages and dendritic cells). A variety of strategies can be used to extend the half life of the antibodies of the present invention. For example, by chemical linkage to polyethyleneglycol (PEG), reCODE PEG, antibody scaffold, polysialic acid (PSA), hydroxyethyl starch (HES), albumin-binding ligands, and carbohydrate shields; by genetic fusion to proteins binding to serum proteins, such as albumin, IgG, FcRn, and transferrin; by coupling (genetically or chemically) to other binding moieties that bind to serum proteins, such as nanobodies, Fabs, DARPs, avimers, affibodies, and anticalins; by genetic fusion to rPEG, albumin, domain of albumin, albumin-binding proteins, and Fc; or by incorporation into nancarriers, slow release formulations, or medical devices.

To prolong the serum circulation of antibodies *in vivo*, inert polymer molecules such as high molecular weight PEG can be attached to the antibodies or a fragment thereof with or without a multifunctional linker either through site-specific conjugation of the PEG to the N- or C-terminus of the antibodies or via epsilon-amino groups present on lysine residues. To pegylate an antibody, the antibody, or fragment thereof, typically is reacted with polyethylene glycol (PEG), such as a reactive ester or aldehyde derivative of PEG, under conditions in which one or more PEG groups become attached to the antibody or antibody fragment. The pegylation can be carried out by an acylation reaction or an alkylation reaction with a reactive PEG molecule (or an analogous reactive water-soluble polymer). As used herein, the term "polyethylene glycol" is intended to encompass any of the forms of PEG that have been used to derivatize other proteins, such as mono (C1-C10) alkoxy- or aryloxy-polyethylene glycol or polyethylene glycol-maleimide. In certain embodiments, the antibody to be pegylated is an aglycosylated antibody. Linear or branched polymer derivatization that results in minimal loss of biological activity will be used. The degree of conjugation can be closely monitored by SDS-PAGE and mass spectrometry to ensure proper conjugation of PEG molecules to the antibodies. Unreacted PEG can be separated from antibody-PEG conjugates by size-exclusion or by

ion-exchange chromatography. PEG-derivatized antibodies can be tested for binding activity as well as for *in vivo* efficacy using methods well-known to those of skill in the art, for example, by immunoassays described herein. Methods for pegylating proteins are known in the art and can be applied to the antibodies of the invention. See for example, EP 0 154 316 by Nishimura *et al.* and EP 0 401 384 by Ishikawa *et al.*

Other modified pegylation technologies include reconstituting chemically orthogonal directed engineering technology (ReCODE PEG), which incorporates chemically specified side chains into biosynthetic proteins via a reconstituted system that includes tRNA synthetase and tRNA. This technology enables incorporation of more than 30 new amino acids into biosynthetic proteins in *E. coli*, yeast, and mammalian cells. The tRNA incorporates a nonnative amino acid any place an amber codon is positioned, converting the amber from a stop codon to one that signals incorporation of the chemically specified amino acid.

Recombinant pegylation technology (rPEG) can also be used for serum half-life extension. This technology involves genetically fusing a 300-600 amino acid unstructured protein tail to an existing pharmaceutical protein. Because the apparent molecular weight of such an unstructured protein chain is about 15-fold larger than its actual molecular weight, the serum half-life of the protein is greatly increased. In contrast to traditional PEGylation, which requires chemical conjugation and repurification, the manufacturing process is greatly simplified and the product is homogeneous.

Polysialylation is another technology, which uses the natural polymer polysialic acid (PSA) to prolong the active life and improve the stability of therapeutic peptides and proteins. PSA is a polymer of sialic acid (a sugar). When used for protein and therapeutic peptide drug delivery, polysialic acid provides a protective microenvironment on conjugation. This increases the active life of the therapeutic protein in the circulation and prevents it from being recognized by the immune system. The PSA polymer is naturally found in the human body. It was adopted by certain bacteria which evolved over millions of years to coat their walls with it. These naturally polysialylated bacteria were then able, by virtue of molecular mimicry, to foil the body's defence system. PSA, nature's ultimate stealth technology, can be easily produced from such bacteria in large quantities and with predetermined physical characteristics. Bacterial PSA is completely non-immunogenic, even when coupled to proteins, as it is chemically identical to PSA in the human body.

Another technology include the use of hydroxyethyl starch (“HES”) derivatives linked to antibodies. HES is a modified natural polymer derived from waxy maize starch and can be metabolized by the body’s enzymes. HES solutions are usually administered to substitute deficient blood volume and to improve the rheological properties of the blood. Hesylation of an antibody enables the prolongation of the circulation half-life by increasing the stability of the molecule, as well as by reducing renal clearance, resulting in an increased biological activity. By varying different parameters, such as the molecular weight of HES, a wide range of HES antibody conjugates can be customized.

Antibodies having an increased half-life *in vivo* can also be generated introducing one or more amino acid modifications (*i.e.*, substitutions, insertions or deletions) into an IgG constant domain, or FcRn binding fragment thereof (preferably a Fc or hinge Fc domain fragment). See, *e.g.*, International Publication No. WO 98/23289; International Publication No. WO 97/34631; and U.S. Patent No. 6,277,375.

Further, antibodies can be conjugated to albumin in order to make the antibody or antibody fragment more stable *in vivo* or have a longer half life *in vivo*. The techniques are well-known in the art, see, *e.g.*, International Publication Nos. WO 93/15199, WO 93/15200, and WO 01/77137; and European Patent No. EP 413,622.

The LRP6 antibody or a fragment thereof may also be fused to one or more human serum albumin (HSA) polypeptides, or a portion thereof. HSA, a protein of 585 amino acids in its mature form, is responsible for a significant proportion of the osmotic pressure of serum and also functions as a carrier of endogenous and exogenous ligands. The role of albumin as a carrier molecule and its inert nature are desirable properties for use as a carrier and transporter of polypeptides *in vivo*. The use of albumin as a component of an albumin fusion protein as a carrier for various proteins has been suggested in WO 93/15199, WO 93/15200, and EP 413 622. The use of N-terminal fragments of HSA for fusions to polypeptides has also been proposed (EP 399 666). Accordingly, by genetically or chemically fusing or conjugating the antibodies or fragments thereof to albumin, can stabilize or extend the shelf-life, and/or to retain the molecule’s activity for extended periods of time in solution, *in vitro* and/or *in vivo*.

Fusion of albumin to another protein may be achieved by genetic manipulation, such that the DNA coding for HSA, or a fragment thereof, is joined to the DNA coding for the protein. A suitable host is then transformed or transfected with the fused nucleotide

sequences, so arranged on a suitable plasmid as to express a fusion polypeptide. The expression may be effected in vitro from, for example, prokaryotic or eukaryotic cells, or in vivo *e.g.* from a transgenic organism. Additional methods pertaining to HSA fusions can be found, for example, in WO 2001077137 and WO 200306007, incorporated herein by reference. In a specific embodiment, the expression of the fusion protein is performed in mammalian cell lines, for example, CHO cell lines.

Antibody Conjugates

The present invention provides antibodies or fragments thereof that specifically bind to a LRP6 protein recombinantly fused or chemically conjugated (including both covalent and non-covalent conjugations) to a heterologous protein or polypeptide (or fragment thereof, preferably to a polypeptide of at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90 or at least 100 amino acids) to generate fusion proteins. In particular, the invention provides fusion proteins comprising an antibody fragment described herein (*e.g.*, a Fab fragment, Fd fragment, Fv fragment, F(ab)₂ fragment, a VH domain, a VH CDR, a VL domain or a VL CDR) and a heterologous protein, polypeptide, or peptide. Methods for fusing or conjugating proteins, polypeptides, or peptides to an antibody or an antibody fragment are known in the art. See, *e.g.*, U.S. Patent Nos. 5,336,603, 5,622,929, 5,359,046, 5,349,053, 5,447,851, and 5,112,946; European Patent Nos. EP 307,434 and EP 367,166; International Publication Nos. WO 96/04388 and WO 91/06570; Ashkenazi *et al.*, (1991) Proc. Natl. Acad. Sci. USA 88:10535-10539; Zheng *et al.*, (1995) J. Immunol. 154:5590-5600; and Vil *et al.*, (1992) Proc. Natl. Acad. Sci. USA 89:11337- 11341.

Additional fusion proteins may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling"). DNA shuffling may be employed to alter the activities of antibodies of the invention or fragments thereof (*e.g.*, antibodies or fragments thereof with higher affinities and lower dissociation rates). See, generally, U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and 5,837,458; Patten *et al.*, (1997) Curr. Opin. Biotechnol. 8:724-33; Harayama, (1998) Trends Biotechnol. 16(2):76-82; Hansson *et al.*, (1999) J. Mol. Biol. 287:265-76; and Lorenzo and Blasco, (1998) Biotechniques 24(2):308- 313 (each of these patents and publications are hereby incorporated by reference in its entirety). Antibodies or fragments thereof, or the encoded antibodies or fragments

thereof, may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. A polynucleotide encoding an antibody or fragment thereof that specifically binds to a LRP6 protein may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules.

Moreover, the antibodies or fragments thereof can be fused to marker sequences, such as a peptide to facilitate purification. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz *et al.*, (1989) Proc. Natl. Acad. Sci. USA 86:821-824, for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags useful for purification include, but are not limited to, the hemagglutinin ("HA") tag, which corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson *et al.*, (1984) Cell 37:767), and the "flag" tag.

In other embodiments, antibodies of the present invention or fragments thereof conjugated to a diagnostic or detectable agent. Such antibodies can be useful for monitoring or prognosing the onset, development, progression and/or severity of a disease or disorder as part of a clinical testing procedure, such as determining the efficacy of a particular therapy. Such diagnosis and detection can be accomplished by coupling the antibody to detectable substances including, but not limited to, various enzymes, such as, but not limited to, horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; prosthetic groups, such as, but not limited to, streptavidin/biotin and avidin/biotin; fluorescent materials, such as, but not limited to, umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; luminescent materials, such as, but not limited to, luminol; bioluminescent materials, such as but not limited to, luciferase, luciferin, and aequorin; radioactive materials, such as, but not limited to, iodine (^{131}I , ^{125}I , ^{123}I , and ^{121}I), carbon (^{14}C), sulfur (^{35}S), tritium (^3H), indium (^{115}In , ^{113}In , ^{112}In , and ^{111}In), technetium (^{99}Tc), thallium (^{201}Tl), gallium (^{68}Ga , ^{67}Ga), palladium (^{103}Pd), molybdenum (^{99}Mo), xenon (^{133}Xe), fluorine (^{18}F), ^{153}Sm , ^{177}Lu , ^{159}Gd , ^{149}Pm , ^{140}La , ^{175}Yb , ^{166}Ho , ^{90}Y , ^{47}Sc , ^{186}Re , ^{188}Re , ^{142}Pr , ^{105}Rh , ^{97}Ru , ^{68}Ge , ^{57}Co , ^{65}Zn , ^{85}Sr , ^{32}P , ^{153}Gd , ^{169}Yb , ^{51}Cr , ^{54}Mn , ^{75}Se , ^{113}Sn , and ^{117}Tm ; and positron emitting metals using various positron emission tomographies, and non-radioactive paramagnetic metal ions.

The present invention further encompasses uses of antibodies or fragments thereof conjugated to a therapeutic moiety. An antibody or fragment thereof may be conjugated to a therapeutic moiety such as a cytotoxin, *e.g.*, a cytostatic or cytotoxic agent, a therapeutic agent or a radioactive metal ion, *e.g.*, alpha-emitters. A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells.

Further, an antibody or fragment thereof may be conjugated to a therapeutic moiety or drug moiety that modifies a given biological response. Therapeutic moieties or drug moieties are not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein, peptide, or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, cholera toxin, or diphtheria toxin; a protein such as tumor necrosis factor, α -interferon, β -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, an anti-angiogenic agent; or, a biological response modifier such as, for example, a lymphokine. In one embodiment, the anti-LRP6 antibody, or a fragment thereof, conjugated to a therapeutic moiety, such as a cytotoxin, a drug (*e.g.*, an immunosuppressant) or a radiotoxin. Such conjugates are referred to herein as "immunoconjugates". Immunoconjugates that include one or more cytotoxins are referred to as "immunotoxins." A cytotoxin or cytotoxic agent includes any agent that is detrimental to (*e.g.*, kills) cells. Examples include taxon, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, t. colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1 -dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents also include, for example, antimetabolites (*e.g.*, methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), ablating agents (*e.g.*, mechlorethamine, thioepa chloraxnbucil, meiphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin, anthracyclines (*e.g.*, daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (*e.g.*, dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (*e.g.*, vincristine and vinblastine). (See *e.g.*, Seattle Genetics US20090304721).

Other examples of therapeutic cytotoxins that can be conjugated to an antibody of the invention include duocarmycins, calicheamicins, maytansines and auristatins, and derivatives thereof. An example of a calicheamicin antibody conjugate is commercially available (Mylotarg™; Wyeth-Ayerst).

Cytotoxins can be conjugated to antibodies of the invention using linker technology available in the art. Examples of linker types that have been used to conjugate a cytotoxin to an antibody include, but are not limited to, hydrazones, thioethers, esters, disulfides and peptide-containing linkers. A linker can be chosen that is, for example, susceptible to cleavage by low pH within the lysosomal compartment or susceptible to cleavage by proteases, such as proteases preferentially expressed in tumor tissue such as cathepsins (e.g., cathepsins B, C, D).

For further discussion of types of cytotoxins, linkers and methods for conjugating therapeutic agents to antibodies, see also Saito *et al.*, (2003) *Adv. Drug Deliv. Rev.* 55:199-215; Trail *et al.*, (2003) *Cancer Immunol. Immunother.* 52:328-337; Payne, (2003) *Cancer Cell* 3:207-212; Allen, (2002) *Nat. Rev. Cancer* 2:750-763; Pastan and Kreitman, (2002) *Curr. Opin. Investig. Drugs* 3:1089-1091; Senter and Springer, (2001) *Adv. Drug Deliv. Rev.* 53:247-264.

Antibodies of the present invention also can be conjugated to a radioactive isotope to generate cytotoxic radiopharmaceuticals, also referred to as radioimmunoconjugates. Examples of radioactive isotopes that can be conjugated to antibodies for use diagnostically or therapeutically include, but are not limited to, iodine¹³¹, indium¹¹¹, yttrium⁹⁰, and lutetium¹⁷⁷. Method for preparing radioimmunoconjugates are established in the art. Examples of radioimmunoconjugates are commercially available, including Zevalin™ (DEC Pharmaceuticals) and Bexxar™ (Corixa Pharmaceuticals), and similar methods can be used to prepare radioimmunoconjugates using the antibodies of the invention. In certain embodiments, the macrocyclic chelator is 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA) which can be attached to the antibody via a linker molecule. Such linker molecules are commonly known in the art and described in Denardo *et al.*, (1998) *Clin Cancer Res.* 4(10):2483-90; Peterson *et al.*, (1999) *Bioconjug. Chem.* 10(4):553-7; and Zimmerman *et al.*, (1999) *Nucl. Med. Biol.* 26(8):943-50, each incorporated by reference in their entireties.

Techniques for conjugating therapeutic moieties to antibodies are well known, see, *e.g.*, Arnon *et al.*, “Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy”, in *Monoclonal Antibodies And Cancer Therapy*, Reisfeld *et al.* (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom *et al.*, “Antibodies For Drug Delivery”, in *Controlled Drug Delivery (2nd Ed.)*, Robinson *et al.* (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, “Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review”, in *Monoclonal Antibodies 84: Biological And Clinical Applications*, Pinchera *et al.* (eds.), pp. 475-506 (1985); “Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy”, in *Monoclonal Antibodies For Cancer Detection And Therapy*, Baldwin *et al.* (eds.), pp. 303-16 (Academic Press 1985), and Thorpe *et al.*, (1982) *Immunol. Rev.* 62:119-58.

Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

Methods of Producing Antibodies of the Invention

(i) Nucleic Acids Encoding the Antibodies

The invention provides substantially purified nucleic acid molecules which encode polypeptides comprising segments or domains of the LRP6 antibody chains described above. Some of the nucleic acids of the invention comprise the nucleotide sequence encoding the Propeller 1 antibody heavy chain variable region shown in SEQ ID NO: 14, 34, and 60, and/or the nucleotide sequence encoding the light chain variable region shown in SEQ ID NOs: 13, 33, and 59. In a specific embodiment, the nucleic acid molecules are those identified in Table 1. Some of the nucleic acids of the invention comprise the nucleotide sequence encoding the Propeller 3 antibody heavy chain variable region shown in SEQ ID NOs: 82, 106, and 128, and/or the nucleotide sequence encoding the light chain variable region shown in SEQ ID NOs: 81, 105, and 127. Some other nucleic acid molecules of the invention comprise nucleotide sequences that are substantially identical (*e.g.*, at least 65, 80%, 95%, or 99%) to the nucleotide sequences of those identified in Table 1. When expressed from appropriate expression vectors, polypeptides encoded by these polynucleotides are capable of exhibiting LRP6 antigen binding capacity.

Also provided in the invention are polynucleotides which encode at least one CDR region and usually all three CDR regions from the heavy or light chain of the LRP6 antibody set forth above. Some other polynucleotides encode all or substantially all of the variable region sequence of the heavy chain and/or the light chain of the LRP6 antibody set forth above. Because of the degeneracy of the code, a variety of nucleic acid sequences will encode each of the immunoglobulin amino acid sequences.

The nucleic acid molecules of the invention can encode both a variable region and a constant region of the antibody. Some of nucleic acid sequences of the invention comprise nucleotides encoding a mature heavy chain variable region sequence that is substantially identical (*e.g.*, at least 80%, 90%, or 99%) to the mature heavy chain variable region sequence of a Propeller 1 antibody set forth in SEQ ID NOs: 14, 34, and 60. Some other nucleic acid sequences comprising nucleotide encoding a mature light chain variable region sequence that is substantially identical (*e.g.*, at least 80%, 90%, or 99%) to the mature light chain variable region sequence of a Propeller 1 antibody set forth in SEQ ID NOs: 13, 33, and 59.

The nucleic acid molecules of the invention can encode both a variable region and a constant region of the antibody. Some of nucleic acid sequences of the invention comprise nucleotides encoding a mature heavy chain variable region sequence that is substantially identical (*e.g.*, at least 80%, 90%, or 99%) to the mature heavy chain variable region sequence of a Propeller 3 antibody set forth in SEQ ID NOs: 82, 106, and 128. Some other nucleic acid sequences comprising nucleotide encoding a mature light chain variable region sequence that is substantially identical (*e.g.*, at least 80%, 90%, or 99%) to the mature light chain variable region sequence of a Propeller 3 antibody set forth in SEQ ID NOs: 81, 105, and 127.

The polynucleotide sequences can be produced by *de novo* solid-phase DNA synthesis or by PCR mutagenesis of an existing sequence (*e.g.*, sequences as described in the Examples below) encoding an LRP6 antibody or its binding fragment. Direct chemical synthesis of nucleic acids can be accomplished by methods known in the art, such as the phosphotriester method of Narang *et al.*, (1979) *Meth. Enzymol.* 68:90; the phosphodiester method of Brown *et al.*, (1979) *Meth. Enzymol.* 68:109; the diethylphosphoramidite method of Beaucage *et al.*, (1981) *Tetra. Lett.*, 22:1859; and the solid support method of U.S. Patent No. 4,458,066. Introducing mutations to a

polynucleotide sequence by PCR can be performed as described in, *e.g.*, PCR Technology: Principles and Applications for DNA Amplification, H.A. Erlich (Ed.), Freeman Press, NY, NY, 1992; PCR Protocols: A Guide to Methods and Applications, Innis *et al.* (Ed.), Academic Press, San Diego, CA, 1990; Mattila *et al.*, (1991) Nucleic Acids Res. 19:967; and Eckert *et al.*, (1991) PCR Methods and Applications 1:17.

Also provided in the invention are expression vectors and host cells for producing the LRP6 antibodies described above. Various expression vectors can be employed to express the polynucleotides encoding the LRP6 antibody chains or binding fragments. Both viral-based and nonviral expression vectors can be used to produce the antibodies in a mammalian host cell. Nonviral vectors and systems include plasmids, episomal vectors, typically with an expression cassette for expressing a protein or RNA, and human artificial chromosomes (see, *e.g.*, Harrington *et al.*, (1997) Nat Genet 15:345). For example, nonviral vectors useful for expression of the LRP6 polynucleotides and polypeptides in mammalian (*e.g.*, human) cells include pThioHis A, B & C, pcDNA3.1/His, pEBVHis A, B & C, (Invitrogen, San Diego, CA), MPSV vectors, and numerous other vectors known in the art for expressing other proteins. Useful viral vectors include vectors based on retroviruses, adenoviruses, adenoassociated viruses, herpes viruses, vectors based on SV40, papilloma virus, HBP Epstein Barr virus, vaccinia virus vectors and Semliki Forest virus (SFV). See, Brent *et al.*, (1995) *supra*; Smith, Annu. Rev. Microbiol. 49:807; and Rosenfeld *et al.*, (1992) Cell 68:143.

The choice of expression vector depends on the intended host cells in which the vector is to be expressed. Typically, the expression vectors contain a promoter and other regulatory sequences (*e.g.*, enhancers) that are operably linked to the polynucleotides encoding an LRP6 antibody chain or fragment. In some embodiments, an inducible promoter is employed to prevent expression of inserted sequences except under inducing conditions. Inducible promoters include, *e.g.*, arabinose, lacZ, metallothionein promoter or a heat shock promoter. Cultures of transformed organisms can be expanded under noninducing conditions without biasing the population for coding sequences whose expression products are better tolerated by the host cells. In addition to promoters, other regulatory elements may also be required or desired for efficient expression of an LRP6 antibody chain or fragment. These elements typically include an ATG initiation codon and adjacent ribosome binding site or other sequences. In addition, the efficiency of expression may be enhanced by the inclusion of enhancers appropriate to the cell system

in use (see, *e.g.*, Scharf *et al.*, (1994) *Results Probl. Cell Differ.* 20:125; and Bittner *et al.*, (1987) *Meth. Enzymol.*, 153:516). For example, the SV40 enhancer or CMV enhancer may be used to increase expression in mammalian host cells.

The expression vectors may also provide a secretion signal sequence position to form a fusion protein with polypeptides encoded by inserted LRP6 antibody sequences. More often, the inserted LRP6 antibody sequences are linked to a signal sequences before inclusion in the vector. Vectors to be used to receive sequences encoding LRP6 antibody light and heavy chain variable domains sometimes also encode constant regions or parts thereof. Such vectors allow expression of the variable regions as fusion proteins with the constant regions thereby leading to production of intact antibodies or fragments thereof. Typically, such constant regions are human.

The host cells for harboring and expressing the LRP6 antibody chains can be either prokaryotic or eukaryotic. *E. coli* is one prokaryotic host useful for cloning and expressing the polynucleotides of the present invention. Other microbial hosts suitable for use include bacilli, such as *Bacillus subtilis*, and other enterobacteriaceae, such as *Salmonella*, *Serratia*, and various *Pseudomonas* species. In these prokaryotic hosts, one can also make expression vectors, which typically contain expression control sequences compatible with the host cell (*e.g.*, an origin of replication). In addition, any number of a variety of well-known promoters will be present, such as the lactose promoter system, a tryptophan (*trp*) promoter system, a beta-lactamase promoter system, or a promoter system from phage lambda. The promoters typically control expression, optionally with an operator sequence, and have ribosome binding site sequences and the like, for initiating and completing transcription and translation. Other microbes, such as yeast, can also be employed to express LRP6 polypeptides of the invention. Insect cells in combination with baculovirus vectors can also be used.

In some preferred embodiments, mammalian host cells are used to express and produce the LRP6 antibodies of the present invention. For example, they can be either a hybridoma cell line expressing endogenous immunoglobulin genes (*e.g.*, the 1D6.C9 myeloma hybridoma clone as described in the Examples) or a mammalian cell line harboring an exogenous expression vector (*e.g.*, the SP2/0 myeloma cells exemplified below). These include any normal mortal or normal or abnormal immortal animal or human cell. For example, a number of suitable host cell lines capable of secreting intact

immunoglobulins have been developed including the CHO cell lines, various Cos cell lines, HeLa cells, myeloma cell lines, transformed B-cells and hybridomas. The use of mammalian tissue cell culture to express polypeptides is discussed generally in, *e.g.*, Winnacker, FROM GENES TO CLONES, VCH Publishers, N.Y., N.Y., 1987.

Expression vectors for mammalian host cells can include expression control sequences, such as an origin of replication, a promoter, and an enhancer (see, *e.g.*, Queen *et al.*, (1986) Immunol. Rev. 89:49-68), and necessary processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences. These expression vectors usually contain promoters derived from mammalian genes or from mammalian viruses. Suitable promoters may be constitutive, cell type-specific, stage-specific, and/or modulatable or regulatable. Useful promoters include, but are not limited to, the metallothionein promoter, the constitutive adenovirus major late promoter, the dexamethasone-inducible MMTV promoter, the SV40 promoter, the MRP polIII promoter, the constitutive MPSV promoter, the tetracycline-inducible CMV promoter (such as the human immediate-early CMV promoter), the constitutive CMV promoter, and promoter-enhancer combinations known in the art.

Methods for introducing expression vectors containing the polynucleotide sequences of interest vary depending on the type of cellular host. For example, calcium chloride transfection is commonly utilized for prokaryotic cells, whereas calcium phosphate treatment or electroporation may be used for other cellular hosts. (See generally Sambrook, *et al.*, *supra*). Other methods include, *e.g.*, electroporation, calcium phosphate treatment, liposome-mediated transformation, injection and microinjection, ballistic methods, virosomes, immunoliposomes, polycation:nucleic acid conjugates, naked DNA, artificial virions, fusion to the herpes virus structural protein VP22 (Elliot and O'Hare, (1997) Cell 88:223), agent-enhanced uptake of DNA, and *ex vivo* transduction. For long-term, high-yield production of recombinant proteins, stable expression will often be desired. For example, cell lines which stably express LRP6 antibody chains or binding fragments can be prepared using expression vectors of the invention which contain viral origins of replication or endogenous expression elements and a selectable marker gene. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth of cells which successfully express the introduced sequences in selective media. Resistant, stably

transfected cells can be proliferated using tissue culture techniques appropriate to the cell type.

(ii) Generation of monoclonal antibodies

Monoclonal antibodies (mAbs) can be produced by a variety of techniques, including conventional monoclonal antibody methodology *e.g.*, the standard somatic cell hybridization technique of Kohler and Milstein, (1975) *Nature* 256: 495. Many techniques for producing monoclonal antibody can be employed *e.g.*, viral or oncogenic transformation of B lymphocytes.

An animal system for preparing hybridomas is the murine system. Hybridoma production in the mouse is a well established procedure. Immunization protocols and techniques for isolation of immunized splenocytes for fusion are known in the art. Fusion partners (*e.g.*, murine myeloma cells) and fusion procedures are also known.

Chimeric or humanized antibodies of the present invention can be prepared based on the sequence of a murine monoclonal antibody prepared as described above. DNA encoding the heavy and light chain immunoglobulins can be obtained from the murine hybridoma of interest and engineered to contain non-murine (*e.g.*, human) immunoglobulin sequences using standard molecular biology techniques. For example, to create a chimeric antibody, the murine variable regions can be linked to human constant regions using methods known in the art (see *e.g.*, U.S. Patent No. 4,816,567 to Cabilly *et al.*). To create a humanized antibody, the murine CDR regions can be inserted into a human framework using methods known in the art. See *e.g.*, U.S. Patent No. 5225539 to Winter, and U.S. Patent Nos. 5530101; 5585089; 5693762 and 6180370 to Queen *et al.*

In a certain embodiment, the antibodies of the invention are human monoclonal antibodies. Such human monoclonal antibodies directed against LRP6 can be generated using transgenic or transchromosomal mice carrying parts of the human immune system rather than the mouse system. These transgenic and transchromosomal mice include mice referred to herein as HuMAb mice and KM mice, respectively, and are collectively referred to herein as "human Ig mice."

The HuMAb mouse[®] (Medarex, Inc.) contains human immunoglobulin gene miniloci that encode un-rearranged human heavy (μ and γ) and κ light chain immunoglobulin sequences, together with targeted mutations that inactivate the endogenous μ and κ chain

loci (see *e.g.*, Lonberg, *et al.*, (1994) *Nature* 368(6474): 856-859). Accordingly, the mice exhibit reduced expression of mouse IgM or κ , and in response to immunization, the introduced human heavy and light chain transgenes undergo class switching and somatic mutation to generate high affinity human IgG κ monoclonal (Lonberg *et al.*, (1994) *supra*; reviewed in Lonberg, (1994) *Handbook of Experimental Pharmacology* 113:49-101; Lonberg and Huszar, (1995) *Intern. Rev. Immunol.* 13: 65-93, and Harding and Lonberg, (1995) *Ann. N. Y. Acad. Sci.* 764:536-546). The preparation and use of HuMAb mice, and the genomic modifications carried by such mice, is further described in Taylor *et al.*, (1992) *Nucleic Acids Research* 20:6287-6295; Chen *et al.*, (1993) *International Immunology* 5: 647-656; Tuailleon *et al.*, (1993) *Proc. Natl. Acad. Sci. USA* 94:3720-3724; Choi *et al.*, (1993) *Nature Genetics* 4:117-123; Chen *et al.*, (1993) *EMBO J.* 12:821-830; Tuailleon *et al.*, (1994) *J. Immunol.* 152:2912-2920; Taylor *et al.*, (1994) *International Immunology* 579-591; and Fishwild *et al.*, (1996) *Nature Biotechnology* 14: 845-851, the contents of all of which are hereby specifically incorporated by reference in their entirety. See further, U.S. Patent Nos. 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,789,650; 5,877,397; 5,661,016; 5,814,318; 5,874,299; and 5,770,429; all to Lonberg and Kay; U.S. Patent No. 5,545,807 to Surani *et al.*; PCT Publication Nos. WO 92103918, WO 93/12227, WO 94/25585, WO 97113852, WO 98/24884 and WO 99/45962, all to Lonberg and Kay; and PCT Publication No. WO 01/14424 to Korman *et al.*

In another embodiment, human antibodies of the invention can be raised using a mouse that carries human immunoglobulin sequences on transgenes and transchromosomes such as a mouse that carries a human heavy chain transgene and a human light chain transchromosome. Such mice, referred to herein as "KM mice", are described in detail in PCT Publication WO 02/43478 to Ishida *et al.*

Still further, alternative transgenic animal systems expressing human immunoglobulin genes are available in the art and can be used to raise LRP6 antibodies of the invention. For example, an alternative transgenic system referred to as the Xenomouse (Abgenix, Inc.) can be used. Such mice are described in, *e.g.*, U.S. Patent Nos. 5,939,598; 6,075,181; 6,114,598; 6,150,584 and 6,162,963 to Kucherlapati *et al.*

Moreover, alternative transchromosomic animal systems expressing human immunoglobulin genes are available in the art and can be used to raise LRP6 antibodies of

the invention. For example, mice carrying both a human heavy chain transchromosome and a human light chain transchromosome, referred to as "TC mice" can be used; such mice are described in Tomizuka *et al.*, (2000) Proc. Natl. Acad. Sci. USA 97:722-727. Furthermore, cows carrying human heavy and light chain transchromosomes have been described in the art (Kuroiwa *et al.*, (2002) Nature Biotechnology 20:889-894) and can be used to raise LRP6 antibodies of the invention.

Human monoclonal antibodies of the invention can also be prepared using phage display methods for screening libraries of human immunoglobulin genes. Such phage display methods for isolating human antibodies are established in the art or described in the examples below. See for example: U.S. Patent Nos. 5,223,409; 5,403,484; and 5,571,698 to Ladner *et al.*; U.S. Patent Nos. 5,427,908 and 5,580,717 to Dower *et al.*; U.S. Patent Nos. 5,969,108 and 6,172,197 to McCafferty *et al.*; and U.S. Patent Nos. 5,885,793; 6,521,404; 6,544,731; 6,555,313; 6,582,915 and 6,593,081 to Griffiths *et al.*

Human monoclonal antibodies of the invention can also be prepared using SCID mice into which human immune cells have been reconstituted such that a human antibody response can be generated upon immunization. Such mice are described in, for example, U.S. Patent Nos. 5,476,996 and 5,698,767 to Wilson *et al.*

(iii) Framework or Fc engineering

Engineered antibodies of the invention include those in which modifications have been made to framework residues within VH and/or VL, *e.g.* to improve the properties of the antibody. Typically such framework modifications are made to decrease the immunogenicity of the antibody. For example, one approach is to "backmutate" one or more framework residues to the corresponding germline sequence. More specifically, an antibody that has undergone somatic mutation may contain framework residues that differ from the germline sequence from which the antibody is derived. Such residues can be identified by comparing the antibody framework sequences to the germline sequences from which the antibody is derived. To return the framework region sequences to their germline configuration, the somatic mutations can be "backmutated" to the germline sequence by, for example, site-directed mutagenesis. Such "backmutated" antibodies are also intended to be encompassed by the invention.

Another type of framework modification involves mutating one or more residues within the framework region, or even within one or more CDR regions, to remove T cell - epitopes to thereby reduce the potential immunogenicity of the antibody. This approach is also referred to as "deimmunization" and is described in further detail in U.S. Patent Publication No. 20030153043 by Carr *et al.*

In addition or alternative to modifications made within the framework or CDR regions, antibodies of the invention may be engineered to include modifications within the Fc region, typically to alter one or more functional properties of the antibody, such as serum half-life, complement fixation, Fc receptor binding, and/or antigen-dependent cellular cytotoxicity. Furthermore, an antibody of the invention may be chemically modified (*e.g.*, one or more chemical moieties can be attached to the antibody) or be modified to alter its glycosylation, again to alter one or more functional properties of the antibody. Each of these embodiments is described in further detail below. The numbering of residues in the Fc region is that of of Kabat (*Supra*).

In one embodiment, the hinge region of CH1 is modified such that the number of cysteine residues in the hinge region is altered, *e.g.*, increased or decreased. This approach is described further in U.S. Patent No. 5,677,425 by Bodmer *et al.* The number of cysteine residues in the hinge region of CH1 is altered to, for example, facilitate assembly of the light and heavy chains or to increase or decrease the stability of the antibody.

In another embodiment, the Fc hinge region of an antibody is mutated to decrease the biological half-life of the antibody. More specifically, one or more amino acid mutations are introduced into the CH2-CH3 domain interface region of the Fc-hinge fragment such that the antibody has impaired Staphylococcal protein A (SpA) binding relative to native Fc-hinge domain SpA binding. This approach is described in further detail in U.S. Patent No. 6,165,745 by Ward *et al.*

In yet other embodiments, the Fc region is altered by replacing at least one amino acid residue with a different amino acid residue to alter the effector functions of the antibody. For example, one or more amino acids can be replaced with a different amino acid residue such that the antibody has an altered affinity for an effector ligand but retains the antigen-binding ability of the parent antibody. The effector ligand to which affinity is altered can be, for example, an Fc receptor or the C1 component of complement. This approach is

described in further detail in U.S. Patent Nos. 5,624,821 and 5,648,260, both by Winter *et al.*

In another embodiment, one or more amino acids selected from amino acid residues can be replaced with a different amino acid residue such that the antibody has altered C1q binding and/or reduced or abolished complement dependent cytotoxicity (CDC). This approach is described in further detail in U.S. Patent Nos. 6,194,551 by Idusogie *et al.*

In another embodiment, one or more amino acid residues are altered to thereby alter the ability of the antibody to fix complement. This approach is described further in PCT Publication WO 94/29351 by Bodmer *et al.*

In yet another embodiment, the Fc region is modified to increase the ability of the antibody to mediate antibody dependent cellular cytotoxicity (ADCC) and/or to increase the affinity of the antibody for an Fcγ receptor by modifying one or more amino acids.

This approach is described further in PCT Publication WO 00/42072 by Presta.

Moreover, the binding sites on human IgG1 for FcγRI, FcγRII, FcγRIII and FcRn have been mapped and variants with improved binding have been described (see Shields *et al.*, (2001) J. Biol. Chem. 276:6591-6604).

In still another embodiment, the glycosylation of an antibody is modified. For example, an aglycosylated antibody can be made (*i.e.*, the antibody lacks glycosylation).

Glycosylation can be altered to, for example, increase the affinity of the antibody for "antigen". Such carbohydrate modifications can be accomplished by, for example, altering one or more sites of glycosylation within the antibody sequence. For example, one or more amino acid substitutions can be made that result in elimination of one or more variable region framework glycosylation sites to thereby eliminate glycosylation at that site. Such aglycosylation may increase the affinity of the antibody for antigen. Such an approach is described in further detail in U.S. Patent Nos. 5,714,350 and 6,350,861 by Co *et al.*

Additionally or alternatively, an antibody can be made that has an altered type of glycosylation, such as a hypofucosylated antibody having reduced amounts of fucosyl residues or an antibody having increased bisecting GlcNac structures. Such altered glycosylation patterns have been demonstrated to increase the ADCC ability of antibodies. Such carbohydrate modifications can be accomplished by, for example,

expressing the antibody in a host cell with altered glycosylation machinery. Cells with altered glycosylation machinery have been described in the art and can be used as host cells in which to express recombinant antibodies of the invention to thereby produce an antibody with altered glycosylation. For example, EP 1,176,195 by Hang *et al.* describes a cell line with a functionally disrupted FUT8 gene, which encodes a fucosyl transferase, such that antibodies expressed in such a cell line exhibit hypofucosylation. PCT Publication WO 03/035835 by Presta describes a variant CHO cell line, Lecl3 cells, with reduced ability to attach fucose to Asn(297)-linked carbohydrates, also resulting in hypofucosylation of antibodies expressed in that host cell (see also Shields *et al.*, (2002) *J. Biol. Chem.* 277:26733-26740). PCT Publication WO 99/54342 by Umana *et al.* describes cell lines engineered to express glycoprotein-modifying glycosyl transferases (*e.g.*, beta(1,4)-N acetylglucosaminyltransferase III (GnTIII)) such that antibodies expressed in the engineered cell lines exhibit increased bisecting GlcNac structures which results in increased ADCC activity of the antibodies (see also Umana *et al.*, (1999) *Nat. Biotech.* 17:176-180).

In another embodiment, the antibody is modified to increase its biological half-life. Various approaches are possible. For example, one or more of the following mutations can be introduced: T252L, T254S, T256F, as described in U.S. Patent No. 6,277,375 to Ward. Alternatively, to increase the biological half life, the antibody can be altered within the CH1 or CL region to contain a salvage receptor binding epitope taken from two loops of a CH2 domain of an Fc region of an IgG, as described in U.S. Patent Nos. 5,869,046 and 6,121,022 by Presta *et al.*

(iv) Methods of Engineering Altered Antibodies

As discussed above, the LRP6 antibodies having VH and VL sequences or full length heavy and light chain sequences shown herein can be used to create new LRP6 antibodies by modifying full length heavy chain and/or light chain sequences, VH and/or VL sequences, or the constant region(s) attached thereto. Thus, in another aspect of the invention, the structural features of a LRP6 antibodies of the invention are used to create structurally related LRP6 antibodies that retain at least one functional property of the antibodies of the invention, such as binding to human LRP6 and also inhibiting one or more functional properties of LRP6. For example, one or more CDR regions of the antibodies of the present invention, or mutations thereof, can be combined recombinantly

with known framework regions and/or other CDRs to create additional, recombinantly-engineered, LRP6 antibodies of the invention, as discussed above. Other types of modifications include those described in the previous section. The starting material for the engineering method is one or more of the VH and/or VL sequences provided herein, or one or more CDR regions thereof. To create the engineered antibody, it is not necessary to actually prepare (*i.e.*, express as a protein) an antibody having one or more of the VH and/or VL sequences provided herein, or one or more CDR regions thereof. Rather, the information contained in the sequence(s) is used as the starting material to create a "second generation" sequence(s) derived from the original sequence(s) and then the "second generation" sequence(s) is prepared and expressed as a protein.

Accordingly, in another embodiment, the invention provides a method for preparing a propeller 1 LRP6 antibody consisting of: a heavy chain variable region antibody sequence having a CDR1 sequence selected from the group consisting of SEQ ID NOs: 1, 21, and 47, a CDR2 sequence selected from the group consisting of SEQ ID NOs: 2, 22, and 48, and/or a CDR3 sequence selected from the group consisting of SEQ ID NOs: 3, 23, and 49; and a light chain variable region antibody sequence having a CDR1 sequence selected from the group consisting of SEQ ID NOs: 4, 24, and 50, a CDR2 sequence selected from the group consisting of SEQ ID NOs: 5, 25, and 51, and/or a CDR3 sequence selected from the group consisting of SEQ ID NOs: 6, 26, and 52; altering at least one amino acid residue within the heavy chain variable region antibody sequence and/or the light chain variable region antibody sequence to create at least one altered antibody sequence; and expressing the altered antibody sequence as a protein.

Accordingly, in another embodiment, the invention provides a method for preparing a propeller 3 LRP6 antibody consisting of: a heavy chain variable region antibody sequence having a CDR1 sequence selected from the group consisting of SEQ ID NOs: 69, 93, and 115, a CDR2 sequence selected from the group consisting of SEQ ID NOs: 70, 94, and 116, and/or a CDR3 sequence selected from the group consisting of SEQ ID NOs: 71, 95, and 117; and a light chain variable region antibody sequence having a CDR1 sequence selected from the group consisting of SEQ ID NOs: 91, 107, and 118, a CDR2 sequence selected from the group consisting of SEQ ID NOs: 73, 97, and 121, and/or a CDR3 sequence selected from the group consisting of SEQ ID NOs: 74, 98, and 120; altering at least one amino acid residue within the heavy chain variable region antibody

sequence and/or the light chain variable region antibody sequence to create at least one altered antibody sequence; and expressing the altered antibody sequence as a protein.

The altered antibody sequence can also be prepared by screening antibody libraries having fixed CDR3 sequences or minimal essential binding determinants as described in US20050255552 and diversity on CDR1 and CDR2 sequences. The screening can be performed according to any screening technology appropriate for screening antibodies from antibody libraries, such as phage display technology.

Standard molecular biology techniques can be used to prepare and express the altered antibody sequence. The antibody encoded by the altered antibody sequence(s) is one that retains one, some or all of the functional properties of the LRP6 antibodies described herein, which functional properties include, but are not limited to, specifically binding to human and/or cynomologus LRP6; the antibody binds to LRP6 and inhibits LRP6 biological activity by inhibiting the canonical Wnt signaling activity in a Wnt reporter gene assay.

The functional properties of the altered antibodies can be assessed using standard assays available in the art and/or described herein, such as those set forth in the Examples (*e.g.*, ELISAs).

In certain embodiments of the methods of engineering antibodies of the invention, mutations can be introduced randomly or selectively along all or part of an LRP6 antibody coding sequence and the resulting modified LRP6 antibodies can be screened for binding activity and/or other functional properties as described herein. Mutational methods have been described in the art. For example, PCT Publication WO 02/092780 by Short describes methods for creating and screening antibody mutations using saturation mutagenesis, synthetic ligation assembly, or a combination thereof. Alternatively, PCT Publication WO 03/074679 by Lazar *et al.* describes methods of using computational screening methods to optimize physiochemical properties of antibodies.

Characterization of the Antibodies of the Invention

The antibodies of the invention can be characterized by various functional assays. For example, they can be characterized by their ability to inhibit biological activity by inhibiting canonical Wnt signaling in a Wnt gene assay as described herein, their affinity to a LRP6 protein (*e.g.*, human and/or cynomologus LRP6), the epitope binning, their

resistance to proteolysis, and their ability to block the Wnt pathway. In addition, the antibodies are characterized by ability to potentiate a Wnt signal in the presence of a Wnt ligand. Various methods can be used to measure LRP6-mediated Wnt signaling. For example, the Wnt signaling pathway can be monitored by (i) measurement of abundance and localization of β -catenin; and (ii) measurement of phosphorylation of LRP6 or other downstream Wnt signaling proteins (e.g. DVL), and (iii) measurement of specific gene signatures or gene targets (e.g. c-myc, Cyclin-D, Axin2).

The ability of an antibody to bind to LRP6 can be detected by labelling the antibody of interest directly, or the antibody may be unlabelled and binding detected indirectly using various sandwich assay formats known in the art.

In some embodiments, the LRP6 antibodies of the invention block or compete with binding of a reference LRP6 antibody to a LRP6 polypeptide. These can be fully human LRP6 antibodies described above. They can also be other mouse, chimeric or humanized LRP6 antibodies which bind to the same epitope as the reference antibody. The capacity to block or compete with the reference antibody binding indicates that a LRP6 antibody under test binds to the same or similar epitope as that defined by the reference antibody, or to an epitope which is sufficiently proximal to the epitope bound by the reference LRP6 antibody. Such antibodies are especially likely to share the advantageous properties identified for the reference antibody. The capacity to block or compete with the reference antibody may be determined by, e.g., a competition binding assay. With a competition binding assay, the antibody under test is examined for ability to inhibit specific binding of the reference antibody to a common antigen, such as a LRP6 polypeptide. A test antibody competes with the reference antibody for specific binding to the antigen if an excess of the test antibody substantially inhibits binding of the reference antibody. Substantial inhibition means that the test antibody reduces specific binding of the reference antibody usually by at least 10%, 25%, 50%, 75%, or 90%.

There are a number of known competition binding assays that can be used to assess competition of a LRP6 antibody with the reference LRP6 antibody for binding to a LRP6 protein. These include, e.g., solid phase direct or indirect radioimmunoassay (RIA), solid phase direct or indirect enzyme immunoassay (EIA), sandwich competition assay (see Stahli *et al.*, (1983) *Methods in Enzymology* 9:242-253); solid phase direct biotin-avidin EIA (see Kirkland *et al.*, (1986) *J. Immunol.* 137:3614-3619); solid phase direct labeled

assay, solid phase direct labeled sandwich assay (see Harlow & Lane, *supra*); solid phase direct label RIA using I-125 label (see Morel *et al.*, (1988) *Molec. Immunol.* 25:7-15); solid phase direct biotin-avidin EIA (Cheung *et al.*, (1990) *Virology* 176:546-552); and direct labeled RIA (Moldenhauer *et al.*, (1990) *Scand. J. Immunol.* 32:77-82). Typically, such an assay involves the use of purified antigen bound to a solid surface or cells bearing either of these, an unlabelled test LRP6 antibody and a labelled reference antibody.

Competitive inhibition is measured by determining the amount of label bound to the solid surface or cells in the presence of the test antibody. Usually the test antibody is present in excess. Antibodies identified by competition assay (competing antibodies) include antibodies binding to the same epitope as the reference antibody and antibodies binding to an adjacent epitope sufficiently proximal to the epitope bound by the reference antibody for steric hindrance to occur.

To determine if the selected LRP6 monoclonal antibodies bind to unique epitopes, each antibody can be biotinylated using commercially available reagents (*e.g.*, reagents from Pierce, Rockford, IL). Competition studies using unlabeled monoclonal antibodies and biotinylated monoclonal antibodies can be performed using a LRP6 polypeptide coated-ELISA plates. Biotinylated MAb binding can be detected with a strep-avidin-alkaline phosphatase probe. To determine the isotype of a purified LRP6 antibody, isotype ELISAs can be performed. For example, wells of microtiter plates can be coated with 1 µg/ml of anti-human IgG overnight at 4°C. After blocking with 1% BSA, the plates are reacted with 1 µg/ml or less of the monoclonal LRP6 antibody or purified isotype controls, at ambient temperature for one to two hours. The wells can then be reacted with either human IgG1 or human IgM-specific alkaline phosphatase-conjugated probes. Plates are then developed and analyzed so that the isotype of the purified antibody can be determined.

To demonstrate binding of monoclonal LRP6 antibodies to live cells expressing a LRP6 polypeptide, flow cytometry can be used. Briefly, cell lines expressing LRP6 (grown under standard growth conditions) can be mixed with various concentrations of a LRP6 antibody in PBS containing 0.1% BSA and 10% fetal calf serum, and incubated at 37°C for 1 hour. After washing, the cells are reacted with Fluorescein-labeled anti-human IgG antibody under the same conditions as the primary antibody staining. The samples can be analyzed by FACScan instrument using light and side scatter properties to gate on single cells. An alternative assay using fluorescence microscopy may be used (in addition to or

instead of) the flow cytometry assay. Cells can be stained exactly as described above and examined by fluorescence microscopy. This method allows visualization of individual cells, but may have diminished sensitivity depending on the density of the antigen.

LRP6 antibodies of the invention can be further tested for reactivity with a LRP6 polypeptide or antigenic fragment by Western blotting. Briefly, purified LRP6 polypeptides or fusion proteins, or cell extracts from cells expressing LRP6 can be prepared and subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis. After electrophoresis, the separated antigens are transferred to nitrocellulose membranes, blocked with 10% fetal calf serum, and probed with the monoclonal antibodies to be tested. Human IgG binding can be detected using anti-human IgG alkaline phosphatase and developed with BCIP/NBT substrate tablets (Sigma Chem. Co., St. Louis, MO). Examples of functional assays are also described in the Example section below.

Prophylactic and Therapeutic Uses

The present invention provides methods of treating a disease or disorder associated with the LRP6 Wnt signaling pathway by administering to a subject in need thereof an effective amount of the antibodies of the invention. In a specific embodiment, the present invention provides a method of treating or preventing cancers (e.g., breast cancer, lung cancer, multiple myeloma, ovarian cancer, liver cancer, bladder cancer, gastric cancer, prostate cancer, acute myeloid leukemia, chronic myeloid leukemia, osteosarcoma, squamous cell carcinoma, and melanoma) by administering to a subject in need thereof an effective amount of the antibodies of the invention. In some embodiments, the present invention provides methods of treating or preventing cancers associated with a Wnt signaling pathway by administering to a subject in need thereof an effective amount of the antibodies of the invention.

In one embodiment, the present invention provides methods of treating cancers associated with a Wnt signaling pathway that include, but are not limited to breast cancer, lung cancer, multiple myeloma, ovarian cancer, bladder cancer, liver cancer, gastric cancer, prostate cancer, acute myeloid leukemia, chronic myeloid leukemia, osteosarcoma, squamous cell carcinoma, and melanoma.

LRP6 antibodies can also be used to treat or prevent other disorders associated with aberrant or defective Wnt signaling, including but are not limited to osteoporosis,

osteoarthritis, polycystic kidney disease, diabetes, schizophrenia, vascular disease, cardiac disease, non-oncogenic proliferative diseases, fibrosis, and neurodegenerative diseases such as Alzheimer's disease. The Wnt signaling pathway plays a critical role in tissue repair and regeneration. Agents that sensitize cells to Wnt signaling can be used to promote tissue regeneration for many conditions such as bone diseases, mucositis, acute and chronic kidney injury, and others.

Suitable agents for combination treatment with LRP6 antibodies include standard of care agents known in the art that are able to modulate the activities of canonical Wnt signaling pathway (e.g., PI3 kinase agents).

Diagnostic Uses

In one aspect, the invention encompasses diagnostic assays for determining LRP6 protein and/or nucleic acid expression as well as LRP6 protein function, in the context of a biological sample (e.g., blood, serum, cells, tissue) or from individual afflicted with cancer, or is at risk of developing cancer.

Diagnostic assays, such as competitive assays rely on the ability of a labelled analogue (the "tracer") to compete with the test sample analyte for a limited number of binding sites on a common binding partner. The binding partner generally is insolubilized before or after the competition and then the tracer and analyte bound to the binding partner are separated from the unbound tracer and analyte. This separation is accomplished by decanting (where the binding partner was preinsolubilized) or by centrifuging (where the binding partner was precipitated after the competitive reaction). The amount of test sample analyte is inversely proportional to the amount of bound tracer as measured by the amount of marker substance. Dose-response curves with known amounts of analyte are prepared and compared with the test results in order to quantitatively determine the amount of analyte present in the test sample. These assays are called ELISA systems when enzymes are used as the detectable markers. In an assay of this form, competitive binding between antibodies and LRP6 antibodies results in the bound LRP6 protein, preferably the LRP6 epitopes of the invention, being a measure of antibodies in the serum sample, most particularly, inhibiting antibodies in the serum sample.

A significant advantage of the assay is that measurement is made of inhibiting antibodies directly (*i.e.*, those which interfere with binding of LRP6 protein, specifically, epitopes).

Such an assay, particularly in the form of an ELISA test has considerable applications in the clinical environment and in routine blood screening.

The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with dysregulation of complement pathway activity. For example, mutations in a LRP6 gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with LRP6 protein, nucleic acid expression or activity.

Another aspect of the invention provides methods for determining LRP6 nucleic acid expression or LRP6 protein activity in an individual to thereby select appropriate therapeutic or prophylactic agents for that individual (referred to herein as "pharmacogenomics"). Pharmacogenomics allows for the selection of agents (*e.g.*, drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (*e.g.*, the genotype of the individual examined to determine the ability of the individual to respond to a particular agent.)

Yet another aspect of the invention pertains to monitoring the influence of agents (*e.g.*, drugs) on the expression or activity of LRP6 protein in clinical trials.

Pharmaceutical Compositions

To prepare pharmaceutical or sterile compositions including a LRP6 antibodies (intact or binding fragments), the LRP6 antibodies (intact or binding fragments) is mixed with a pharmaceutically acceptable carrier or excipient. The compositions can additionally contain one or more other therapeutic agents that are suitable for treating or preventing cancer (breast cancer, lung cancer, multiple myeloma, ovarian cancer, liver cancer, bladder cancer, gastric cancer, prostate cancer, acute myeloid leukemia, chronic myeloid leukemia, osteosarcoma, squamous cell carcinoma, and melanoma).

Formulations of therapeutic and diagnostic agents can be prepared by mixing with physiologically acceptable carriers, excipients, or stabilizers in the form of, *e.g.*, lyophilized powders, slurries, aqueous solutions, lotions, or suspensions (see, *e.g.*, Hardman, *et al.* (2001) Goodman and Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, N.Y.; Gennaro (2000) Remington: The Science and Practice of Pharmacy, Lippincott, Williams, and Wilkins, New York, N.Y.; Avis, *et*

al. (eds.) (1993) *Pharmaceutical Dosage Forms: Parenteral Medications*, Marcel Dekker, NY; Lieberman, *et al.* (eds.) (1990) *Pharmaceutical Dosage Forms: Tablets*, Marcel Dekker, NY; Lieberman, *et al.* (eds.) (1990) *Pharmaceutical Dosage Forms: Disperse Systems*, Marcel Dekker, NY; Weiner and Kotkoskie (2000) *Excipient Toxicity and Safety*, Marcel Dekker, Inc., New York, N.Y.).

Selecting an administration regimen for a therapeutic depends on several factors, including the serum or tissue turnover rate of the entity, the level of symptoms, the immunogenicity of the entity, and the accessibility of the target cells in the biological matrix. In certain embodiments, an administration regimen maximizes the amount of therapeutic delivered to the patient consistent with an acceptable level of side effects. Accordingly, the amount of biologic delivered depends in part on the particular entity and the severity of the condition being treated. Guidance in selecting appropriate doses of antibodies, cytokines, and small molecules are available (see, e.g., Wawrzynczak (1996) *Antibody Therapy*, Bios Scientific Pub. Ltd, Oxfordshire, UK; Kresina (ed.) (1991) *Monoclonal Antibodies, Cytokines and Arthritis*, Marcel Dekker, New York, N.Y.; Bach (ed.) (1993) *Monoclonal Antibodies and Peptide Therapy in Autoimmune Diseases*, Marcel Dekker, New York, N.Y.; Baert, *et al.* (2003) *New Engl. J. Med.* 348:601-608; Milgrom, *et al.* (1999) *New Engl. J. Med.* 341:1966-1973; Slamon, *et al.* (2001) *New Engl. J. Med.* 344:783-792; Beniaminovitz, *et al.* (2000) *New Engl. J. Med.* 342:613-619; Ghosh, *et al.* (2003) *New Engl. J. Med.* 348:24-32; Lipsky, *et al.* (2000) *New Engl. J. Med.* 343:1594-1602).

Determination of the appropriate dose is made by the clinician, e.g., using parameters or factors known or suspected in the art to affect treatment or predicted to affect treatment. Generally, the dose begins with an amount somewhat less than the optimum dose and it is increased by small increments thereafter until the desired or optimum effect is achieved relative to any negative side effects. Important diagnostic measures include those of symptoms of, e.g., the inflammation or level of inflammatory cytokines produced.

Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. The selected

dosage level will depend upon a variety of pharmacokinetic factors including the activity of the particular compositions of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors known in the medical arts.

Compositions comprising antibodies or fragments thereof of the invention can be provided by continuous infusion, or by doses at intervals of, e.g., one day, one week, or 1-7 times per week. Doses may be provided intravenously, subcutaneously, topically, orally, nasally, rectally, intramuscular, intracerebrally, or by inhalation. A specific dose protocol is one involving the maximal dose or dose frequency that avoids significant undesirable side effects. A total weekly dose may be at least 0.05 µg/kg body weight, at least 0.2 µg/kg, at least 0.5 µg/kg, at least 1 µg/kg, at least 10 µg/kg, at least 100 µg/kg, at least 0.2 mg/kg, at least 1.0 mg/kg, at least 2.0 mg/kg, at least 10 mg/kg, at least 25 mg/kg, or at least 50 mg/kg (see, e.g., Yang, *et al.* (2003) *New Engl. J. Med.* 349:427-434; Herold, *et al.* (2002) *New Engl. J. Med.* 346:1692-1698; Liu, *et al.* (1999) *J. Neurol. Neurosurg. Psych.* 67:451-456; Portielji, *et al.* (2003) *Cancer Immunol. Immunother.* 52:133-144). The desired dose of antibodies or fragments thereof is about the same as for an antibody or polypeptide, on a moles/kg body weight basis. The desired plasma concentration of the antibodies or fragments thereof is about, on a moles/kg body weight basis. The dose may be at least 15 µg, at least 20 µg, at least 25 µg, at least 30 µg, at least 35 µg, at least 40 µg, at least 45 µg, at least 50 µg, at least 55 µg, at least 60 µg, at least 65 µg, at least 70 µg, at least 75 µg, at least 80 µg, at least 85 µg, at least 90 µg, at least 95 µg, or at least 100 µg. The doses administered to a subject may number at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12, or more.

For antibodies or fragments thereof of the invention, the dosage administered to a patient may be 0.0001 mg/kg to 100 mg/kg of the patient's body weight. The dosage may be between 0.0001 mg/kg and 20 mg/kg, 0.0001 mg/kg and 10 mg/kg, 0.0001 mg/kg and 5 mg/kg, 0.0001 and 2 mg/kg, 0.0001 and 1 mg/kg, 0.0001 mg/kg and 0.75 mg/kg, 0.0001 mg/kg and 0.5 mg/kg, 0.0001 mg/kg to 0.25 mg/kg, 0.0001 to 0.15 mg/kg, 0.0001 to 0.10

mg/kg, 0.001 to 0.5 mg/kg, 0.01 to 0.25 mg/kg or 0.01 to 0.10 mg/kg of the patient's body weight.

The dosage of the antibodies or fragments thereof of the invention may be calculated using the patient's weight in kilograms (kg) multiplied by the dose to be administered in mg/kg. The dosage of the antibodies or fragments thereof of the invention may be 150 µg/kg or less, 125 µg/kg or less, 100 µg/kg or less, 95 µg/kg or less, 90 µg/kg or less, 85 µg/kg or less, 80 µg/kg or less, 75 µg/kg or less, 70 µg/kg or less, 65 µg/kg or less, 60 µg/kg or less, 55 µg/kg or less, 50 µg/kg or less, 45 µg/kg or less, 40 µg/kg or less, 35 µg/kg or less, 30 µg/kg or less, 25 µg/kg or less, 20 µg/kg or less, 15 µg/kg or less, 10 µg/kg or less, 5 µg/kg or less, 2.5 µg/kg or less, 2 µg/kg or less, 1.5 µg/kg or less, 1 µg/kg or less, 0.5 µg/kg or less, or 0.5 µg/kg or less of a patient's body weight.

Unit dose of the antibodies or fragments thereof of the invention may be 0.1 mg to 20 mg, 0.1 mg to 15 mg, 0.1 mg to 12 mg, 0.1 mg to 10 mg, 0.1 mg to 8 mg, 0.1 mg to 7 mg, 0.1 mg to 5 mg, 0.1 to 2.5 mg, 0.25 mg to 20 mg, 0.25 to 15 mg, 0.25 to 12 mg, 0.25 to 10 mg, 0.25 to 8 mg, 0.25 mg to 7 m g, 0.25 mg to 5 mg, 0.5 mg to 2.5 mg, 1 mg to 20 mg, 1 mg to 15 mg, 1 mg to 12 mg, 1 mg to 10 mg, 1 mg to 8 mg, 1 mg to 7 mg, 1 mg to 5 mg, or 1 mg to 2.5 mg.

The dosage of the antibodies or fragments thereof of the invention may achieve a serum titer of at least 0.1 µg/ml, at least 0.5 µg/ml, at least 1 µg/ml, at least 2 µg/ml, at least 5 µg/ml, at least 6 µg/ml, at least 10 µg/ml, at least 15 µg/ml, at least 20 µg/ml, at least 25 µg/ml, at least 50 µg/ml, at least 100 µg/ml, at least 125 µg/ml, at least 150 µg/ml, at least 175 µg/ml, at least 200 µg/ml, at least 225 µg/ml, at least 250 µg/ml, at least 275 µg/ml, at least 300 µg/ml, at least 325 µg/ml, at least 350 µg/ml, at least 375 µg/ml, or at least 400 µg/ml in a subject. Alternatively, the dosage of the antibodies or fragments thereof of the invention may achieve a serum titer of at least 0.1 µg/ml, at least 0.5 µg/ml, at least 1 µg/ml, at least, 2 µg/ml, at least 5 µg/ml, at least 6 µg/ml, at least 10 µg/ml, at least 15 µg/ml, at least 20 .mu.g/ml, at least 25 µg/ml, at least 50 µg/ml, at least 100 µg/ml, at least 125 µg/ml, at least 150 µg/ml, at least 175 µg/ml, at least 200 µg/ml, at least 225 µg/ml, at least 250 µg/ml, at least 275 µg/ml, at least 300 µg/ml, at least 325 µg/ml, at least 350 µg/ml, at least 375 µg/ml, or at least 400 µg/ml in the subject.

Doses of antibodies or fragments thereof of the invention may be repeated and the administrations may be separated by at least 1 day, 2 days, 3 days, 5 days, 10 days, 15 days, 30 days, 45 days, 2 months, 75 days, 3 months, or at least 6 months.

An effective amount for a particular patient may vary depending on factors such as the condition being treated, the overall health of the patient, the method route and dose of administration and the severity of side effects (see, e.g., Maynard, *et al.* (1996) A Handbook of SOPs for Good Clinical Practice, Interpharm Press, Boca Raton, Fla.; Dent (2001) Good Laboratory and Good Clinical Practice, Urch Publ., London, UK).

The route of administration may be by, e.g., cutaneous application, injection or infusion by intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial, intracerebrospinal, intralesional, or by sustained release systems or an implant (see, e.g., Sidman *et al.* (1983) Biopolymers 22:547-556; Langer, *et al.* (1981) J. Biomed. Mater. Res. 15:167-277; Langer (1982) Chem. Tech. 12:98-105; Epstein, *et al.* (1985) Proc. Natl. Acad. Sci. USA 82:3688-3692; Hwang, *et al.* (1980) Proc. Natl. Acad. Sci. USA 77:4030-4034; U.S. Pat. Nos. 6,350,466 and 6,316,024). Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lidocaine to ease pain at the site of the injection. In addition, pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent. See, e.g., U.S. Pat. Nos. 6,019,968, 5,985,320, 5,985,309, 5,934,272, 5,874,064, 5,855,913, 5,290,540, and 4,880,078; and PCT Publication Nos. WO 92/19244, WO 97/32572, WO 97/44013, WO 98/31346, and WO 99/66903, each of which is incorporated herein by reference their entirety.

A composition of the present invention may also be administered via one or more routes of administration using one or more of a variety of methods known in the art. As will be appreciated by the skilled artisan, the route and/or mode of administration will vary depending upon the desired results. Selected routes of administration for antibodies or fragments thereof of the invention include intravenous, intramuscular, intradermal, intraperitoneal, subcutaneous, spinal or other parenteral routes of administration, for example by injection or infusion. Parenteral administration may represent modes of administration other than enteral and topical administration, usually by injection, and

includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion. Alternatively, a composition of the invention can be administered via a non-parenteral route, such as a topical, epidermal or mucosal route of administration, for example, intranasally, orally, vaginally, rectally, sublingually or topically. In one embodiment, the antibodies or fragments thereof of the invention is administered by infusion. In another embodiment, the multispecific epitope binding protein of the invention is administered subcutaneously.

If the antibodies or fragments thereof of the invention are administered in a controlled release or sustained release system, a pump may be used to achieve controlled or sustained release (see Langer, *supra*; Sefton, 1987, *CRC Crit. Ref Biomed. Eng.* 14:20; Buchwald *et al.*, 1980, *Surgery* 88:507; Saudek *et al.*, 1989, *N. Engl. J. Med.* 321:574). Polymeric materials can be used to achieve controlled or sustained release of the therapies of the invention (see e.g., *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Pres., Boca Raton, Fla. (1974); *Controlled Drug Bioavailability, Drug Product Design and Performance*, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, 1983, *J., Macromol. Sci. Rev. Macromol. Chem.* 23:61; see also Levy *et al.*, 1985, *Science* 228:190; During *et al.*, 1989, *Ann. Neurol.* 25:351; Howard *et al.*, 1989, *J. Neurosurg.* 71:105); U.S. Pat. No. 5,679,377; U.S. Pat. No. 5,916,597; U.S. Pat. No. 5,912,015; U.S. Pat. No. 5,989,463; U.S. Pat. No. 5,128,326; PCT Publication No. WO 99/15154; and PCT Publication No. WO 99/20253. Examples of polymers used in sustained release formulations include, but are not limited to, poly(2-hydroxy ethyl methacrylate), poly(methyl methacrylate), poly(acrylic acid), poly(ethylene-co-vinyl acetate), poly(methacrylic acid), polyglycolides (PLG), polyanhydrides, poly(N-vinyl pyrrolidone), poly(vinyl alcohol), polyacrylamide, poly(ethylene glycol), polylactides (PLA), poly(lactide-co-glycolides) (PLGA), and polyorthoesters. In one embodiment, the polymer used in a sustained release formulation is inert, free of leachable impurities, stable on storage, sterile, and biodegradable. A controlled or sustained release system can be placed in proximity of the prophylactic or therapeutic target, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in *Medical Applications of Controlled Release*, *supra*, vol. 2, pp. 115-138 (1984)).

Controlled release systems are discussed in the review by Langer (1990, *Science* 249:1527-1533). Any technique known to one of skill in the art can be used to produce sustained release formulations comprising one or more antibodies or fragments thereof of the invention. See, e.g., U.S. Pat. No. 4,526,938, PCT publication WO 91/05548, PCT publication WO 96/20698, Ning *et al.*, 1996, "Intratumoral Radioimmunotherapy of a Human Colon Cancer Xenograft Using a Sustained-Release Gel," *Radiotherapy & Oncology* 39:179-189, Song *et al.*, 1995, "Antibody Mediated Lung Targeting of Long-Circulating Emulsions," *PDA Journal of Pharmaceutical Science & Technology* 50:372-397, Cleek *et al.*, 1997, "Biodegradable Polymeric Carriers for a bFGF Antibody for Cardiovascular Application," *Pro. Int'l. Symp. Control. Rel. Bioact. Mater.* 24:853-854, and Lam *et al.*, 1997, "Microencapsulation of Recombinant Humanized Monoclonal Antibody for Local Delivery," *Proc. Int'l. Symp. Control Rel. Bioact. Mater.* 24:759-760, each of which is incorporated herein by reference in their entirety.

If the antibodies or fragments thereof of the invention are administered topically, they can be formulated in the form of an ointment, cream, transdermal patch, lotion, gel, shampoo, spray, aerosol, solution, emulsion, or other form well-known to one of skill in the art. See, e.g., Remington's *Pharmaceutical Sciences and Introduction to Pharmaceutical Dosage Forms*, 19th ed., Mack Pub. Co., Easton, Pa. (1995). For non-sprayable topical dosage forms, viscous to semi-solid or solid forms comprising a carrier or one or more excipients compatible with topical application and having a dynamic viscosity, in some instances, greater than water are typically employed. Suitable formulations include, without limitation, solutions, suspensions, emulsions, creams, ointments, powders, liniments, salves, and the like, which are, if desired, sterilized or mixed with auxiliary agents (e.g., preservatives, stabilizers, wetting agents, buffers, or salts) for influencing various properties, such as, for example, osmotic pressure. Other suitable topical dosage forms include sprayable aerosol preparations wherein the active ingredient, in some instances, in combination with a solid or liquid inert carrier, is packaged in a mixture with a pressurized volatile (e.g., a gaseous propellant, such as freon) or in a squeeze bottle. Moisturizers or humectants can also be added to pharmaceutical compositions and dosage forms if desired. Examples of such additional ingredients are well-known in the art.

If the compositions comprising antibodies or fragments thereof are administered intranasally, it can be formulated in an aerosol form, spray, mist or in the form of drops.

Methods for co-administration or treatment with a second therapeutic agent, e.g., a cytokine, steroid, chemotherapeutic agent, antibiotic, or radiation, are known in the art (see, e.g., Hardman, et al. (eds.) (2001) Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10^{sup}.th ed., McGraw-Hill, New York, N.Y.; Poole and Peterson (eds.) (2001) Pharmacotherapeutics for Advanced Practice: A Practical Approach, Lippincott, Williams & Wilkins, Phila., Pa.; Chabner and Longo (eds.) (2001) Cancer Chemotherapy and Biotherapy, Lippincott, Williams & Wilkins, Phila., Pa.). An effective amount of therapeutic may decrease the symptoms by at least 10%; by at least 20%; at least about 30%; at least 40%, or at least 50%.

Additional therapies (e.g., prophylactic or therapeutic agents), which can be administered in combination with the antibodies or fragments thereof of the invention may be administered less than 5 minutes apart, less than 30 minutes apart, 1 hour apart, at about 1 hour apart, at about 1 to about 2 hours apart, at about 2 hours to about 3 hours apart, at about 3 hours to about 4 hours apart, at about 4 hours to about 5 hours apart, at about 5 hours to about 6 hours apart, at about 6 hours to about 7 hours apart, at about 7 hours to about 8 hours apart, at about 8 hours to about 9 hours apart, at about 9 hours to about 10 hours apart, at about 10 hours to about 11 hours apart, at about 11 hours to about 12 hours apart, at about 12 hours to 18 hours apart, 18 hours to 24 hours apart, 24 hours to 36 hours apart, 36 hours to 48 hours apart, 48 hours to 52 hours apart, 52 hours to 60 hours apart, 60 hours to 72 hours apart, 72 hours to 84 hours apart, 84 hours to 96 hours apart, or 96 hours to 120 hours apart from the antibodies or fragments thereof of the invention. The two or more therapies may be administered within one same patient visit.

The antibodies or fragments thereof of the invention and the other therapies may be cyclically administered. Cycling therapy involves the administration of a first therapy (e.g., a first prophylactic or therapeutic agent) for a period of time, followed by the administration of a second therapy (e.g., a second prophylactic or therapeutic agent) for a period of time, optionally, followed by the administration of a third therapy (e.g., prophylactic or therapeutic agent) for a period of time and so forth, and repeating this sequential administration, i.e., the cycle in order to reduce the development of resistance to one of the therapies, to avoid or reduce the side effects of one of the therapies, and/or to improve the efficacy of the therapies.

In certain embodiments, the antibodies or fragments thereof of the invention can be formulated to ensure proper distribution in vivo. For example, the blood-brain barrier (BBB) excludes many highly hydrophilic compounds. To ensure that the therapeutic compounds of the invention cross the BBB (if desired), they can be formulated, for example, in liposomes. For methods of manufacturing liposomes, see, e.g., U.S. Pat. Nos. 4,522,811; 5,374,548; and 5,399,331. The liposomes may comprise one or more moieties which are selectively transported into specific cells or organs, thus enhance targeted drug delivery (see, e.g., V. V. Ranade (1989) *J. Clin. Pharmacol.* 29:685). Exemplary targeting moieties include folate or biotin (see, e.g., U.S. Pat. No. 5,416,016 to Low et al); mannosides (Umezawa et al., (1988) *Biochem. Biophys. Res. Commun.* 153:1038); antibodies (P. G. Bloeman et al. (1995) *FEBS Lett.* 357:140; M. Owais *et al.* (1995) *Antimicrob. Agents Chemother.* 39:180); surfactant protein A receptor (Briscoe *et al.* (1995) *Am. J. Physiol.* 1233:134); p 120 (Schreier *et al.* (1994) *J. Biol. Chem.* 269:9090); see also K. Keinanen; M. L. Laukkanen (1994) *FEBS Lett.* 346:123; J. J. Killion; I. J. Fidler (1994) *Immunomethods* 4:273.

The invention provides protocols for the administration of pharmaceutical composition comprising antibodies or fragments thereof of the invention alone or in combination with other therapies to a subject in need thereof. The therapies (e.g., prophylactic or therapeutic agents) of the combination therapies of the present invention can be administered concomitantly or sequentially to a subject. The therapy (e.g., prophylactic or therapeutic agents) of the combination therapies of the present invention can also be cyclically administered. Cycling therapy involves the administration of a first therapy (e.g., a first prophylactic or therapeutic agent) for a period of time, followed by the administration of a second therapy (e.g., a second prophylactic or therapeutic agent) for a period of time and repeating this sequential administration, i.e., the cycle, in order to reduce the development of resistance to one of the therapies (e.g., agents) to avoid or reduce the side effects of one of the therapies (e.g., agents), and/or to improve, the efficacy of the therapies.

The therapies (e.g., prophylactic or therapeutic agents) of the combination therapies of the invention can be administered to a subject concurrently. The term "concurrently" is not limited to the administration of therapies (e.g., prophylactic or therapeutic agents) at exactly the same time, but rather it is meant that a pharmaceutical composition

comprising antibodies or fragments thereof of the invention are administered to a subject in a sequence and within a time interval such that the antibodies of the invention can act together with the other therapy(ies) to provide an increased benefit than if they were administered otherwise. For example, each therapy may be administered to a subject at the same time or sequentially in any order at different points in time; however, if not administered at the same time, they should be administered sufficiently close in time so as to provide the desired therapeutic or prophylactic effect. Each therapy can be administered to a subject separately, in any appropriate form and by any suitable route. In various embodiments, the therapies (e.g., prophylactic or therapeutic agents) are administered to a subject less than 15 minutes, less than 30 minutes, less than 1 hour apart, at about 1 hour apart, at about 1 hour to about 2 hours apart, at about 2 hours to about 3 hours apart, at about 3 hours to about 4 hours apart, at about 4 hours to about 5 hours apart, at about 5 hours to about 6 hours apart, at about 6 hours to about 7 hours apart, at about 7 hours to about 8 hours apart, at about 8 hours to about 9 hours apart, at about 9 hours to about 10 hours apart, at about 10 hours to about 11 hours apart, at about 11 hours to about 12 hours apart, 24 hours apart, 48 hours apart, 72 hours apart, or 1 week apart. In other embodiments, two or more therapies (e.g., prophylactic or therapeutic agents) are administered to a within the same patient visit.

The prophylactic or therapeutic agents of the combination therapies can be administered to a subject in the same pharmaceutical composition. Alternatively, the prophylactic or therapeutic agents of the combination therapies can be administered concurrently to a subject in separate pharmaceutical compositions. The prophylactic or therapeutic agents may be administered to a subject by the same or different routes of administration.

The invention having been fully described, it is further illustrated by the following examples and claims, which are illustrative and are not meant to be further limiting.

Examples

Methods and Materials

1: Pannings, antibody identification and characterization

(a) Panning

(i) HuCAL GOLD® Pannings

For the selection of antibodies recognizing human LRP6 several panning strategies were applied. Therapeutic antibodies against human LRP6 protein were generated by selection of clones having high binding affinities, using as the source of antibody variant proteins a commercially available phage display library, the MorphoSys HuCAL GOLD® library.

The phagemid library is based on the HuCAL® concept (Knappik *et al.*, (2000) J Mol Biol 296:57-86) and employs the CysDisplay™ technology for displaying the Fab on the phage surface (WO01/05950 to Lohning).

In detail, the HuCAL GOLD® library used in the current project is described in (Rothe *et al.*, (2007) J Mol Biol) Either phagemids produced with helper phage VCSM13 or produced with Hyperphage (Rondot *et al.*, (2001) Nat Biotechnol 19:75-78) were used for selection of anti-LRP6 antibodies.

(ii) Whole Cell Panning Against LRP6

For whole cell pannings, the cell line HEK293-hLRP6 Δ C-eGFP was used expressing the amino terminal fragment (amino acid 1-1482) of LRP6 fused to eGFP. Specific HuCAL GOLD® antibody phagemids were eluted after incubation to the LRP6 expressing cell line followed by post-adsorption to HEK293-LRP5/6-shRNA cells. The resulting HuCAL phage-containing supernatant was titered on *E. coli* TG1 cells and rescued after infection of *E. coli* TG1 cells using helper phage. The polyclonal amplified phage output was titered again and used in consecutive selection steps.

(iii) Fc Capture Panning Against LRP6

For Fc capture pannings, blocked phage were incubated with the Fc-captured LRP6-Fc and unspecific phage were washed away using different concentrations of PBST, and PBS at different times.

The remaining phage were eluted, and used immediately for infection of *E. coli* TG1 bacteria. Amplification, phage production and output titer determination were conducted as described above in whole cell panning against LRP6.

(iv) Differential Whole Cell Panning Against LRP6

Differential whole cell pannings with antibody selection on HEK293-hLRP6 Δ C-eGFP cells and selection on recombinant human LRP6-Fc were performed as described above for whole cell pannings and for Fc capture pannings.

During the selection process, unspecific phage were removed using different concentrations of PBS and PBST for different time periods.

Phage infection of *E. coli* TG1, amplification, phage production and output titer determination were conducted as described above in whole cell panning against LRP6.

(v) Semi-Solution Panning Against LRP6

For semi-solution pannings, recombinant human LRP6-Fc and BSA were covalently linked to tosylactivated M-280-Dynabeads.

Pre-cleared phage were incubated with LRP6-coated beads on a rotator. Beads were then collected using a magnetic separator and washed with PBST and PBS. Bead-bound phage were eluted and immediately used for infection of *E. coli* TG1 bacteria. Phage infection, amplification, phage production and output titer determination were conducted as described above in whole cell panning against LRP6.

(b) Subcloning and Microexpression of Selected Fab Fragments

To facilitate rapid expression of soluble Fab, the Fab encoding inserts of the selected HuCAL GOLD[®] phage were subcloned into an expression vector pMORPH[®]X9_FH or pMORPH[®]X9_FS. After transformation of TG1-F single clone expression and preparation of periplasmic extracts containing HuCAL[®]-Fab fragments were performed as described previously (Rauchenberger *et al.*, (2003)).

2: Screening

(i) FACS Screening on HEK293-hLRP6 Δ C-eGFP cells

Clones selected by the panning strategies whole cell panning, differential whole cell panning, and semi-solution panning were screened by flow cytometry on HEK293-hLRP6 Δ C-eGFP cells and HEK293-LRP5/6-shRNA cells for counterscreening. Primary hits of Fc capture panning strategy as described above were also tested by flow cytometry.

Cells were harvested at 70 to 80 % confluency, resuspended in FACS buffer, and stained with bacterial cell lysates in 96 well U-bottom microtiter plates. Antibody binding was revealed with fluochrome-conjugated detection antibodies. Stained cells were washed twice and mean fluorescence intensity was measured and analyzed using a FACSArray instrument (BectonDickinson).

(ii) Fc-capture Screening on Recombinant Human LRP6-Fc

Clones selected in the Fc-capture panning were screened in an Fc-capture-ELISA setup.

Maxisorp (Nunc, Rochester, NY, USA) 384 well plates were coated with goat anti-human IgG, Fc fragment specific antibody. After washing with PBST and blocking the wells, recombinant human LRP6-Fc was added. After washing the coated plates, cell lysates were added and bound Fab fragments were detected using AP-conjugated goat IgG anti-human IgG F(ab')₂ with the substrate AttoPhos. Fluorescence was read at 535 nm using a Tecan Plate Reader.

3: Expression and Purification of HuCAL[®]-Fab Antibodies in *E. coli*

Expression of Fab fragments encoded by pMORPH[®]X9_Fab_FH or pMORPH[®]X11_Fab_FH in TG-1 cells was induced by addition of IPTG. Cells were disrupted using lysozyme and Fab fragments isolated by Ni-NTA chromatography (Bio-Rad, Germany). Protein concentrations were determined by UV-spectrophotometry. Purity of Fab fragments was analyzed in denatured, reduced state using SDS-PAGE and in native state by HP-SEC.

4: Affinity Determination

(i) Surface Plasmon Resonance Measurements

For determination of K_D values, surface plasmon resonance technology was applied. Anti-human-Fc-capture CM5 chip (Biacore, Sweden) was used for capturing LRP6-Fc-Fusion followed by ligand (Fab) injection at different concentrations.

(ii) Solution Equilibrium Titration (SET) Method for K_D Determination Using Sector Imager 6000 (MSD)

For K_D determination by solution equilibrium titration (SET), monomer fractions of antibody protein were used (at least 90% monomer content, analyzed by analytical SEC; Superdex75 (Amersham Pharmacia) for Fab, or Tosoh G3000SWXL (Tosoh Bioscience) for IgG, respectively).

Affinity determination in solution was basically performed as described in the literature (Friguet *et al.*, (1985) J Immunol Methods 77:305-319). In order to improve the sensitivity and accuracy of the SET method, it was transferred from classical ELISA to ECL based technology (Haenel *et al.*, (2005) Anal Biochem. 339:182-184).

The data was evaluated with XLfit (IDBS) software applying customized fitting models. For K_D determination of Fab molecules the fit model was used (according to Haenel *et al supra*), modified according to Abraham *et al.* (1996) Journal of Molecular Recognition 9:456-461.

$$y = B_{\max} - \left(\frac{B_{\max}}{2[Fab]_t} \left([Fab]_t + x + K_D - \sqrt{([Fab]_t + x + K_D)^2 - 4x[Fab]_t} \right) \right)$$

[Fab]_t: applied total Fab concentration

x: applied total soluble antigen concentration (binding sites)

B_{max}: maximal signal of Fab without antigen

K_D: affinity

5: Screening After Affinity Maturation

EC₅₀ Determination on HEK293T/17 cells

EC₅₀ values were determined on parental HEK293T/17 cells in FACS measurements. A typical antibody titration curve contained ten to twelve different antibody dilutions, and titrations started at concentrations of approx. 150 to 200 µg / mL (final concentration). Cells were harvested using Accutase, resuspended in FACS buffer, distributed to the wells of a 96-well plate, and stained with antibody dilutions. EC₅₀ values were determined with the program GraphPad Prism using non-linear regression analysis.

6: Conversion to IgG

In order to express full length IgG, variable domain fragments of heavy (VH) and light chains (VL) were subcloned from Fab expression vectors into appropriate pMORPH[®]_hIg vectors for human IgG2, human IgG4, human IgG4_Pro, and human IgG1fLALA.

7: Transient Expression and Purification of Human IgG

Eukaryotic HKB11 cells were transfected with equal amounts of IgG heavy and light chain expression vector (pMORPH2) or expression vector DNA encoding for heavy and light chains of IgGs (pMORPH4). After sterile filtration, the solution was subjected to standard protein A affinity chromatography (MabSelect SURE, GE Healthcare). Protein concentrations were determined by UV-spectrophotometry. Purity of IgG was analyzed under denaturing, reducing and non-reducing conditions in SDS-PAGE or by using Agilent BioAnalyzer and in native state by HP-SEC.

8: Wnt Reporter Gene Assay

The ability of anti-LRP6 antibodies to inhibit Wnt signaling was tested in a Wnt1 and Wnt3a responsive luciferase reporter gene assay. Cells were either stimulated with Wnt3a conditioned medium or by co-transfection of Wnt 1, Wnt3a, or other Wnt expression plasmids.

(i) Wnt3a Reporter Gene Assay with Conditioned Medium

10⁴ HEK293-STF cells/well were seeded into a 96 well tissue culture plate, and cells were incubated overnight at 37 °C/5 % CO₂ in 100 µL medium.

The following day, various anti-LRP6 antibody dilutions and DKK1 dilutions (positive control) were prepared either in pure or in diluted in Wnt3a-conditioned medium. 60 μL /well of the supernatant was removed from the 96 well tissue culture plate and replaced by 60 μL /well of the conditioned medium/antibody dilutions.

After Incubation for 16 to 24 h at 37 °C/5 % CO₂, 100 μL BrightGlo Luciferase reagent (Promega) were added and plates were incubated for 10 min. For luminescence readout (Tecan Plate Reader), the cell lysates were transferred into a 96 well microtiter plate (Costar, Cat # 3917).

A similar assay can also be performed using co-culture of Wnt3 or Wnt3a over-expressing cells (e.g. CHO-K1, TM3, L or HEK293 cells)

(ii) Wnt1/Wnt3a Reporter Gene Assay with Transiently Transfected Cells

3x10⁴ HEK293T/17 cells/well were seeded into a 96 well tissue culture plate (Costar), and cells were incubated at 37 °C/5 % CO₂ in 100 μL medium as described in Table 3. After 12 to 16 h, cells were transfected with empty vector Wnt expression plasmid 1 ng/well; pTA-Luc-10xSTF (Firefly luciferase construct) 50 ng/well; or pRL-SV40 (Renilla luciferase construct) 0.5 ng/well.

A transfection premix (10 μL /well) was prepared containing the plasmids listed above and 0.2 μL FuGene6/well (Roche). The transfection premix was incubated 15 min at RT and then distributed into the wells. The plate was rocked at 400 rpm for 2 min at RT and then incubated for 4 h at 37 °C/5 % CO₂. In the meantime, antibodies were diluted in medium and added to the transfected cells (75 μL /well).

After 18 to 24 h, 75 μL /well DualGlo Luciferase reagent (Promega) were added and the plate was rocked for 10 min for cell lysis before readout of the Firefly luciferase activity. After luminescence readout, 75 μL /well DualGlo Stop&Glow reagent (Promega) were added and luminescence was measured again to determine Renilla luciferase activity.

For analysis, the ratio between Firefly luciferase activity and Renilla luciferase activity was calculated. For IC₅₀-determination of the anti-LRP6 antibodies, the relative luciferase values were analyzed using GraphPad Prism.

A similar assay can also be performed using co-culture of Wnt1 or other Wnt1 class ligand over-expressing cells (e.g. CHO-K1, TM3, L or HEK293 cells).

9: FACS Cross-Reactivity Studies

Cross-species reactivity to murine and cynomologus LRP6 was determined on cells by FACS analysis. FACS staining was performed essentially as described above. Human U266 cells (no expression of LRP6) were used as a negative control.

Cross-reactivity to murine LRP6 was tested on murine NIH-3T3 cells. Cross-reactivity to cynomologus LRP6 was tested on the cynomologus cell line Cynom-K1 and on transiently transfected HEK293T/17 cells:

For testing cynomologus cross-reactivity on the human cell line HEK293T/17, the cells were transiently transfected using Lipofectamine (Invitrogen) according to the manufacturer's instructions. Cells were either transfected with a mixture of the human LRP6 expression plasmid pCMV6_XL4_LRP6 and the chaperone-encoding plasmid pcDNA3.1-flag_MESD or with a mixture of pcDNA3.1-nV5-DEST_cynoLRP6 and pcDNA3.1-flag_MESD (overexpression of cynomologus LRP6). 50 µg of LRP6 expression plasmid and 20 µg of MESD expression plasmid were used per T175 flask. After 24 h, cells were detached and stained with the goat anti human LRP6 control antibody (R&D Systems) and with anti-LRP6 HuCAL antibodies. Mock-transfected HEK293T/17 cells were used for negative control stainings (low endogenous LRP6 expression).

10: Binder Optimization

Generation of Affinity Maturation Libraries

To increase affinity and biological activity of selected antibody fragments, L-CDR3 and HCDR2 regions were optimized in parallel by cassette mutagenesis using trinucleotide directed mutagenesis, while the framework regions were kept constant.

The different affinity maturation libraries were generated by standard cloning procedures and transformation of the diversified clones into electro-competent *E. coli* TOP10F cells (Invitrogen). Sequencing of randomly picked clones showed a diversity of 100%. No parental binders were found among the picked clones. Finally phage of all libraries were prepared separately.

11: MMTV-Wnt1 xenografts

Tumours from MMTV-Wnt1 transgenic mice were passaged as tumour pieces in the mammary fat pad of FVB mice for 5 passages prior to implantation into the mammary fat pad of nude mice. Eleven days post-implant, when tumours reached a mean volume of approximately 110 mm³, mice were randomized into 3 groups with 8 mice per group and dosed every three days (DeAlmeida *et al.* (2007); *Cancer Res.* 67:5371-9).

12: Inhibition in Biochemical Assays

HEK293 cells were grown in D-MEM supplemented with 10% fetal bovine serum at 37 °C with 5% CO₂. Cells were seeded into a 96 well tissue culture plate (Costar) at 3x10⁴/well and transfected with 0.1ng/well Wnt expression plasmid, 50 ng/well STF reporter, and 0.5 ng/ml phRL-SV40 (Promega) mixed with 0.2 µL/well FuGene6 (Roche). Four hours after transfection, antibodies were diluted in PBS and added to the transfected cells. After 18 h incubation, Firefly luciferase and Renilla luciferase activities were measured using DualGlo Luciferase reagent (Promega). Renilla luciferase was used to normalize transfection efficiency

All IgG formats tested have potent and complete inhibition of Wnt1 (2, 6, 7A, 7B, 9, 10A, 10B) generated canonical signal. All give rise to a bell shaped potentiation curve in the presence of a Wnt3/3A generated signal.

13: FACS-based competition assay

For FACS-based competition assay, anti-LRP6 Fabs and the negative control Fab MOR03207 were biotinylated using the ECL protein biotinylation module (GE Healthcare) according to the manufacturer's instructions. The biotinylated Fabs were used for FACS staining on HEK293-hLRP6ΔC-eGFP cells at a constant Fab concentration (20 nM final concentration) and were competed with a 100-fold molar excess of unlabelled Fab. Cells were incubated with the Fab dilutions for 1 hour at 4 °C on a plate shaker. After washing the cells 1x with FACS buffer, they were incubated with PE-conjugated Streptavidin (Dianova) for 1 hour at 4°C on a plate shaker in the dark. Cells were washed twice with FACS buffer and fluorescence was measured using FACS Array (BD). Similarly, unbiotinylated anti-LRP6 Fabs were competed with a 100-fold molar excess of

the LRP6 protein SOST and binding of the Fabs to the cells was monitored by PE-conjugated anti human IgG antibody (Dianova).

14: Immunoblotting assay

Total cell lysates were prepared in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM EDTA). Lysates were normalized for protein concentration, resolved by SDS-PAGE, transferred onto nitrocellulose membranes and probed with the indicated antibodies. pT1479 LRP6 antibody requires generation of membrane extracts to achieve satisfactory results. To generate membrane extracts, cells were lysed in hypotonic buffer (10mM Tris-HCl pH7.5, 10mM KCl) by performing four freeze-thaw cycles, and insoluble membrane fraction was solubilized using RIPA buffer. Protease inhibitor cocktail (Sigma) and 1x phosphatase inhibitor cocktail (Upstate) were added into the lysis buffers. Commercial antibodies used in the western blot assay include rabbit anti-LRP6, rabbit anti-pT1479 LRP6, and rabbit anti-pS1490 LRP6 antibodies (Cell Signaling Technology).

Example 1: Specific binding of anti-LRP6 antibodies to endogenous LRP6 by FACS

Detection of endogenous cell surface expression of LRP6 was examined on a number of tumor cells using the anti-LRP6 antibodies and FACS analysis. As shown in Fig. 1A, PA1 cells express both LRP5 and LRP6 mRNA, while U266 and Daudi cells do not express LRP6 mRNA. PA1 cells, but not U266 and Daudi cells, show significant staining with a Propeller 1 anti-LRP6 IgG. More importantly, U266 cells are not stained by anti-LRP6 antibody, although they express LRP6, demonstrating the specificity of anti-LRP6 antibody. Furthermore, anti-LRP6 antibody staining of PA1 cells is significantly reduced upon depletion of endogenous LRP6 using LRP6 shRNA, further demonstrating the specificity of the LRP6 antibody.

In additional studies, knockdown of LRP6 by shRNA in PA1 cells further confirms specificity of Prop1 and Prop3 antibodies for LRP6 (See Fig. 1B). Knockdown was achieved by infecting cells with lentivirus encoding short hairpin RNA directed to LRP6, and selecting a stable pool of infected cells. The shRNA infection method used for the study is described in Wiederschain *et al.* in 2009 Cell Cycle 8: 498-504. Epub 2009 Feb 25.

Example 2: Differential inhibition of Wnt1 and Wnt3a reporter gene assays by Propeller 1 and Propeller 3 anti-LRP6 Fabs

Different anti-LRP6 Fabs were tested in *in vitro* Wnt reporter assays. Wnt1 or Wnt3A ligands were transiently expressed in HEK293T/17 STF cells (gene reporter assay) and treated with varying concentrations of anti-LRP6 Fab fragments. STF assays were conducted using the protocols described by Huang *et al.* (2009), Nature; 461:614-20. Epub 2009 Sep 16. As seen in Fig. 2A, Propeller 1 anti-LRP6 Fabs (MOR08168, MOR08545, MOR06706) specifically reduced Wnt1-dependent signaling without much effect on Wnt3A-dependent signaling. Conversely as shown in Fig. 2B, Propeller 3 anti-LRP6 Fabs (MOR06475, MOR08193, MOR08473) specifically reduced Wnt3A-dependent signaling without significant effects on Wnt1-dependent Wnt1-dependent signaling. The results demonstrate that Wnt1 and Wnt3A activities are blocked separately by different LRP6 Fab fragment (epitopes).

Example 3: Binding of anti-LRP6 antibodies to LRP6 of different species.

To show cross-reactivity, cells expressing endogenous LRP6 of human (HEK293T/17) and mouse origin (NIH 3T3), or transiently transfected HEK293/T17 cells expressing cynomolgus LRP6, were treated and subjected to flow cytometry as described above. Fig. 3 summarizes the results of the findings of the results and show that all anti-LRP6 antibodies bind to human, mouse, and cynomologus LRP6.

Example 4: Classification of Wnts based on their sensitivity to Propeller 1 and Propeller 3 anti-LRP6 antibodies.

To evaluate Wnts based on their sensitivity Propeller 1 and Propeller 3 anti-LRP6 antibodies, various Wnt ligands were transiently expressed into HEK293T/17 STF cells (gene reporter assay) and treated with Propeller 1 or Propeller 3 anti-LRP6 antibodies. STF assays were conducted using the protocols described by Huang *et al.* (2009), Nature; 461:614-20. Epub 2009 Sep 16. The results are shown in Fig. 4 which depicts the activity inhibition of particular Wnts based on antibody binding/blocking to specific propeller regions of LRP6. Fig. 4 shows that signaling induced by Wnt1, Wnt2, Wnt6, Wnt7A, Wnt7B, Wnt9, Wnt10A, Wnt10B can be specifically inhibited by Propeller 1 anti-LRP6 Fabs, while signaling induced by Wnt3 and Wnt3A can be specifically inhibited by Propeller 3 anti-LRP6 Fabs.

Example 5: Conversion of LRP6 antibodies from Fab fragments to IgG potentiates Wnt signaling induced by the other class of Wnt.

In a rather unexpected observation, conversion of LRP6 antibodies from Fab fragments to IgG potentiates WNT signaling. Propeller 1 anti-LRP6 IgG inhibits Wnt1-dependent and potentiates Wnt3A-dependent signaling in a 293T/17 STF reporter assay. Similarly, Propeller 3 anti-LRP6 IgG inhibits Wnt3A-dependent and potentiates Wnt1-dependent signaling as shown in Fig. 5. This finding suggests that the Wnt signaling pathway may be modified or “fine tuned” using Propeller 1 and Propeller 3 antibodies. Similar effects were observed in STF reporter assays in other cellular backgrounds (e.g. MDA-MB231, MDA-MB435, PA-1, TM3 and 3t3 cells – data not shown)

Example 6: Propeller1 or Propeller 3 anti-LRP6 Fabs specifically inhibits Wnt1 or Wnt3A-induced LRP6 phosphorylation.

HEK293T/17 cells were transiently transfected with Wnt1 or Wnt3A expression plasmids and treated with Propeller 1 or Propeller 3 anti-LRP6 Fabs. As seen in Fig. 6, Propeller 1 anti-LRP6 Fabs specifically inhibits Wnt1-induced phosphorylation of LRP6, for example, T1479 and S1490 sites and Propeller 3 antibodies do not. In contrast, Propeller 3 anti-LRP6 specifically inhibits Wnt3A-induced phosphorylation of LRP6 and Propeller 1 antibodies do not. These results support that antibodies bind to distinct propeller domains of LRP6 and block specific Wnt ligands.

Example 7: Inhibition of expression of Wnt target gene in a MMTV-Wnt1 tumor xenograft model using a Propeller 1 anti-LRP6 IgG.

The LRP6 antibodies were further characterized *in vivo* in an art recognized genetically engineered mouse model known as MMTV-Wnt1. Experiments were conducted to determine if the anti-LRP6 antibodies in the IgG format could inhibit Wnt signaling and tumor growth *in vivo*. Mammary tumors derived from MMTV-Wnt1 transgenic mice are Wnt1 dependent; turning off Wnt1 expression using a tetracyclin-regulated system (Gunther *et al.* (2003), *supra*) or blocking Wnt activity using Fz8CRDFc (DeAlmeida *et al.* (2007) *Cancer Research* 67:5371-5379) inhibits tumor growth *in vivo*. To measure the effect of anti-LRP6 antibodies on Wnt signaling in MMTV-Wnt1 tumors, mice implanted with MMTV-Wnt1 tumors were dosed *i.v.* with a single dose of 5 mg/kg Wnt1 class-specific antagonistic anti-LRP6 antibody. Serum concentrations of the antibody as well

as the mRNA expression of β -catenin target gene Axin2 were analyzed over a period of two weeks. The terminal β -phase half-life of the LRP6 antibody was about 108 hours. Corresponding to the antibody injection, a significant decrease of Axin2 mRNA expression was observed in tumors, and Axin2 expression gradually recovered one week after the antibody injection when the antibody level in serum decreased. These results suggest that Wnt1 class-specific anti-LRP6 antibody suppresses Wnt signaling in MMTV-Wnt1 xenografts and this suppression is correlated with the concentration of LRP6 antibody in serum. To test the effect of anti-LRP6 antibodies on tumor growth, mice were dosed with Propeller 1 -, Propeller 3-specific anti-LRP6 antibodies, or isotype matched control antibodies. Mice were dosed i.v. with an initial dose of 20 mg/kg, followed every third day with 10 mg/kg. In this experiment Propeller 1, but not Propeller 3-specific anti-LRP6 antibody caused tumor regression. Together, these results demonstrate that Propeller 1-specific anti-LRP6 antibody induces regression of MMTV-Wnt1 xenografts, MMTV-Wnt1 tumor xenografts in nude mice were treated with MOR08168, a Propeller 1 anti-LRP6 IgG at different timepoints ranging from 1 hour to 14 days. Fig. 7 shows an inverse correlation with PK serum concentration of the antibody and mRNA expression of Wnt target gene Axin2. Axin2 gene expression levels in tumors are inhibited with MOR08168 treatment, and return as antibody is cleared from the serum.

In addition to Axin2, the effect of MOR08168 on the expression of additional genes was evaluated. Affymetrix Mouse430 2.0 Arrays were used to profile a time course experiment of MMTV-Wnt1 allograft Tumors plus or minus a single dose of MOR08168 (5 mg/kg). There were six time points in all (0, 1, 3, 8, 24, 336 hours) and there were three replicates per time point. Based on data demonstrating maximal inhibition of Axin upon treatment with antibody, 8 h was chosen as best representative time point to determine differentially expressed genes putatively responding to Wnt pathway inhibition. The R / Bioconductor framework was utilized and Limma package was employed to determine differentially expressed genes between the 0 hour time point and the 8 hour time point. An adjusted P-value of .05 was used as the threshold to determine the set of differentially expressed genes. Based on this cutoff there are 1270 probe sets called differentially expressed mapped to 972 gene(s). Fig. 8A is a table that shows genes that were upregulated >2-fold with an adjusted P-value of <0.01 and Fig. 8B is a table that shows genes that were downregulated >2-fold with an adjusted P-value of <0.01.

Example 8: Anti-tumor activities of Propeller 1 and Propeller 3 anti-LRP6 antibodies in MMTV-Wnt1 allograft model.

Anti-tumor activity of LRP6 Propeller 1 and 3 antibodies was evaluated in the MMTV-Wnt1 allograft model. MMTV-Wnt1 tumor fragments were implanted subcutaneously (s.c.) into female nude mice. 11 days after implantation, mice carrying MMTV-Wnt1 tumors (n=8, average 121 mm³; range: 100-147 mm³) were treated with vehicle IgG (10 mg/kg, intravenously (i.v.), every third day (q3d), LRP6-Propeller 1 Ab MOR08168 (10 mg/kg, i.v., q3d), or LRP6-Propeller 3 Ab MOR06475 (10 mg/kg, i.v., q3d), and tumors calipered every third day. LRP6-Propeller 1 MOR08168 Ab dose-dependently induced tumor regressions (-55%, p<0.05) (See Fig. 9).

Example 9: Anti-tumor activities of Propeller 1 and Propeller 3 anti-LRP6 antibodies in MMTV-Wnt3 allograft model.

Anti-tumor activity of LRP6 Propeller 1 and 3 antibodies was evaluated in the MMTV-Wnt3 allograft model. MMTV-Wnt3 tumor fragments were implanted subcutaneously (s.c.) into female nude mice. 15 days after implantation, mice carrying MMTV-Wnt3 tumors (n=6, average 209 mm³; range: 113-337 mm³) were treated with vehicle IgG (10mg/kg, intravenously (i.v.), twice a week (2qw), MOR08168 LRP6-Propeller 1 Ab (3 mg/kg, i.v., qw), or MOR06475 LRP6-Propeller 3 Ab (10 mg/kg, i.v., 2qw) and tumors calipered twice per week. MOR06475 LRP6-Propeller 3 Ab demonstrated antitumor activity (T/C=34%, p<0.05) (See Fig. 10).

Example 10: Evaluation of ability of Propeller 1 and 3 anti-LRP6 antibodies to inhibit Wnt3A in vivo

The ability of LRP6-Propeller 1 and 3 antibodies to inhibit Wnt3 class Wnt signaling *in vivo* was tested in a co-implant system consisting of PA1-STF reporter cells co-implanted with Wnt3A secreting L cells. Female nude mice were implanted subcutaneously with 10x10e6 PA1-STF cells and 0.5x10e6 L-Wnt3A cells and randomized in groups of 5. 24 hours later, mice received a single intravenous dose of vehicle, MOR08168 LRP6-Propeller 1 Ab (10 mg/kg), or MOR06475 LRP6-Propeller 3 Ab (10 mg/kg) and were imaged by Xenogen 6 hours, 24 hours, 48 hours, 72 hours and 168 hours later. MOR06475 was able to inhibit Wnt3a induced signaling for at least 72 hours, whereas Mor08168 increased Wnt3A induced signaling (Fig. 11).

Example 11: Epitope mapping of LRP6 PD3/4 and its antibody complex by HDx MS

To identify antibody binding sites within YWTD-EGF region of Propeller 3, hydrogen-deuterium exchange (HDx) mass spectrometry (MS) was employed. LRP6 Propeller domains 3-4 (PD3/4) has 12 cysteines and 4 N-linked glycosylation sites. All 4 N-linked glycosylation sites are positioned in Propeller 3 domain (631-932). By HDx MS, close to 100% coverage (amount of protein it was possible to get structural information for) was mapped on the Propeller 4 domain, and about 70% coverage on Propeller 3 domain.

Regions immediately surrounding the 4 glycosylated sites remain undetected (Fig. 12A).

In the presence of Fab 06745, 2 weakly solvent protected peptides were found in Propeller 3 (Phe⁶³⁶-Leu⁶⁴⁷, Tyr⁸⁴⁴-Glu⁸⁵⁶; Fig. 11A). This suggests that the residues or a fraction of the residues responsible for the epitope are either on the protected peptides or spatially nearby. Based on the crystal structure of LRP6 PD34, the solvent protected regions correspond to the concave surface between blade 1 and 6 of Prop 3.

Mutations that disrupt the interaction of ScFv06475 with LRP6 PD34

To confirm that the rim of blade 1 and 6 is responsible for antibody mediated inhibition of Wnt3a signaling, a series of LRP6 surface mutations were constructed (R638A, W767A, Y706A/E708A, W850A/S851A, R852/R853A, and D874A/Y875A) that also approximately covered the region implicated by HDx in binding. To ensure that the mutant proteins are properly folded, differential static light scattering (DSL) thermal-melt assay was performed. Temperature denaturation experiment showed that the aggregation temperature, T_{agg} , (the temperature at which 50% of the protein is denatured) of wild-type and mutant proteins was similar. Thus, the mutations had no effect on the folding or stability of the protein.

The binding capacity of mutant LRP6 to scFv MOR06475 was determined by ELISA. Mutation of residues (R638, W850/S851, and R852/R853) that are located on peptides that showed solvent protection in HDx MS experiments also showed dramatic decrease in antibody binding (See Fig. 12B). Mutation of residues (Y706/E708) that are located on peptides showing no solvent protection in HDx also showed no change in antibody binding capability (Fig. 11B). Thus the binding assay data are in good agreement with the binding interface as mapped by HDx MS suggesting the residues R638, W850, S851, R852, and R853 participate directly in the epitope.

Collectively, these results show that different Wnt proteins require different Propeller regions of LRP6 for signaling. The Wnt 1 class of Wnt proteins (Wnt1, 1, 2, 6, 7A, 7B, 9,10A, 10B) requires Propeller 1 of LRP6 for Wnt1 signaling, and they can be inhibited by Propeller 1 specific anti-LRP6 antibodies. The Wnt 3A class of Wnt proteins (Wnt3 and Wnt3a) requires Propeller 3 of LRP6 for Wnt3 signaling, and they can be inhibited by Propeller 3 specific anti-LRP6 antibodies (Fig. 13). Another unexpected finding was the Wnt-potentiating activity of the antibodies in the bivalent IgG format in the presence of Wnt ligands. All antibodies tested in IgG format enhanced either Wnt1 or Wnt3A signaling in the STF Luc reporter gene assay. Interestingly, most Fabs that inhibited Wnt1 and were inactive in the Wnt3A assay, still inhibited Wnt1 as an IgG, but potentiated Wnt3A signaling and vice versa. Most Fabs that inhibited Wnt3A potentiated Wnt1 activity as an IgG. The effect was independent of the IgG format, as several formats were tested (IgG1LALA, IgG2, IgG4, IgG4_Pro). These data shows that different Wnt proteins bind to different Propellers of LRP6 for signaling. Dimerization of LRP6 using bivalent LRP6 antibodies is not sufficient to stimulate Wnt signaling by itself, but can potentiate Wnt signaling initiated by the other class of Wnt proteins. These findings demonstrate that different canonical Wnt ligands use distinct binding sites on LRP6 and that all bivalent antibodies enhance Wnt activity in IgG format in the presence of the non-blocked Wnt Fab (single chain antibodies, unibodies). Monovalent structures of any kind as a final format circumvent the Wnt potentiation. Alternatively, the construction of a bi-specific IgG or IgG-like molecule carrying both the Wnt1- and Wnt3A inhibitory activity circumvent potentiation. Thus, LRP6 antibody constructs can be designed to control and “fine-tune” the Wnt pathway

Example 12: Generating a Biparatopic LRP6 Antibody

This example describes the production and characterization of biparatopic anti-LRP6 IgG-scFv antibodies. Various anti-LRP6 scFv's containing different domain orientations (e.g. VH-VL or VL-VH) and different linker lengths (e.g. (Gly₄Ser)₃ or (Gly₄Ser)₄) were initially expressed, purified and characterized. Based on results of the scFv study, different biparatopic anti-LRP6 IgG-scFv's were prepared and further evaluated. The scFv may be placed at various positions within the IgG including the C-terminus of CH3 or CL and the N-terminus of VH or VL. Furthermore, various linkers may be used to connect the scFv to the IgG including Gly₄Ser and (GlyGlySer)₂.

(a) Materials and Methods**(i) Generation of anti-LRP6 scFv**

Genes coding for all scFv-variants were synthesized by Gencart. DNA-fragments coding for scFv in both orientations (VH-VL and VL-VH, separated by two different linkers: (Gly₄Ser)₃ and (Gly₄Ser)₄, with N-terminal signal sequence and C-terminal 6xHis-tag) were directly cloned from Gencart vectors via NdeI/XbaI into vector pFAB15-FkpA, resulting constructs were called pFab15-MOR06475-VH-(Gly₄Ser)₃-VL, pFab15-MOR06475-VH-(Gly₄Ser)₄-VL, pFab15-MOR06475-VL-(Gly₄Ser)₃-VH, pFab15-MOR06475-VL-(Gly₄Ser)₄-VH, pFab15-MOR08168-VH-(Gly₄Ser)₃-VL, pFab15-MOR08168-VH-(Gly₄Ser)₄-VL, pFab15-MOR08168-VL-(Gly₄Ser)₃-VH, pFab15-MOR08168-VL-(Gly₄Ser)₄-VH, pFab15-MOR08545-VH-(Gly₄Ser)₃-VL, pFab15-MOR08545-VH-(Gly₄Ser)₄-VL, pFab15-MOR08545-VL-(Gly₄Ser)₃-VH and pFab15-MOR08545-VL-(Gly₄Ser)₄-VH.

(ii) Generation of biparatopic anti-LRP6 IgG-scFv**anti-LRP6 MOR08168 hIgG1LALA 6475scFv**

Vector pRS5a MOR08168 hIgG1LALA containing codon-optimized VH-sequence (synthesized by Gencart) was used as source for generation of biparatopic construct. Initially, AfeI-site was introduced by QuickChange Site-Directed Mutagenesis (Stratagene) at 3'-end of sequence coding for hIgG1LALA (primer no. 1: 5'-agcgtgatgcacgaagcgcctgcacaaccactac-3' (SEQ ID NO: 213) and primer no. 2: 5'-gtagtgggtgtgcagcgccttcgtgcatcagcgtg-3' (SEQ ID NO: 214)). Gene coding for MOR06475scFv (VL-VH-orientation, separated by (Gly₄Ser)₄-linker) was synthesized by Gencart. 5'-primer containing AfeI-site and sequence coding for (GlyGlySer)₂-linker as well as 3'-primer containing AscI-site were used for amplification of entire MOR06475-scFv-gene (primer no. 3:

5'-tgatgcacgaagcgcctgcacaaccactacaccagaagagcctgagcctgtccccggcaag

ggcggctccggcggaagcgatc-3' (SEQ ID NO: 215) and primer no. 4: 5'-

gagcggcccccggcgccc tcacagctggacactgtcaccaggg-3' (SEQ ID NO: 216)). PCR-product

was then cloned via AfeI/AscI into vector pRS5a MOR08168 hIgG1LALA resulting in

the final construct pRS5a MOR08168 hIgG1LALA-6475sc-fv. Gene coding for codon-

optimized VL of MOR08168 was synthesized by Gencart. 5'-primer containing AgeI-site

and 3'-primer containing HindIII-site were used for amplification of entire MOR08168-VL-genes (primer no. 5: (5'-gcttccggacaccaccggt gacatcgagctgaccagcc-3' SEQ ID NO: 217) and primer no. 6: 5'-cagcacggtaagctt ggtgcctccgccgaacaccag-3' (SEQ ID NO: 218)). PCR-product was then cloned via AgeI/HindIII into vector pRS5a-hlambda resulting in the final construct pRS5a MOR08168 hlambda.

anti-LRP6 MOR08168 hIgG1LALA 6475scFv without Lys (K)

Vector pRS5a MOR08168 hIgG1LALA-6475scFv (SEQ ID NO:165) was used as template DNA for removal of C-terminal Lysin at CH3. Quick Change XL Site-Directed Mutagenesis Kit (Stratagene) was used in combination with following primers:

5'-ctgtcccccgccggcgctccggc-3' (SEQ ID NO: 219)

5'-gccggagccgccgggggacag-3' (SEQ ID NO: 220)

Site-Directed Mutagenesis was done according to Stratagene protocol; resulting new construct was called pRS5a hIgG1LALA MOR08168opt 6475 scFv K.

Vector pRS5a MOR08168 hlambda (generation described for anti-LRP6_MOR08168 hIgG1LALA_6475scFv) containing codon-optimized VL-sequence (synthesized by Genart) was used w/o any modifications for expression of LC.

anti-LRP6 MOR08168 hIgG1LALA 6475scFv AspPro to AspAla (DP to DA)

Vector pRS5a MOR08168 hIgG1LALA-6475scFv (SEQ ID NO:165) was used as template DNA for substitution of DP to DA in VH of scFv. Quick Change XL Site-Directed Mutagenesis Kit (Stratagene) was used in combination with following primers:

5'-ccatgaccaacatggacgccgtggacaccgccacc-3' (SEQ ID NO: 221)

5'-ggtggcgggtgccacggcgtccatgttgatcatgg-3' (SEQ ID NO: 222)

Site-Directed Mutagenesis was done according to Stratagene protocol; resulting new construct was called pRS5a hIgG1LALA MOR08168opt 6475 scFv DP to DA.

Vector pRS5a MOR08168 hlambda (generation described for anti-LRP6_MOR08168 hIgG1LALA_6475scFv) containing codon-optimized VL-sequence (synthesized by Genart) was used w/o any modifications for expression of LC.

anti-LRP6 MOR08168 hIgG1LALA 6475scFv AspPro to ThrAla (DP to TA)

Vector pRS5a MOR08168 hIgG1LALA-6475scFv (SEQ ID NO:165) was used as template DNA for substitution of DP to TA in VH of scFv. Quick Change XL Site-Directed Mutagenesis Kit (Stratagene) was used in combination with following primers:

5'-caccatgaccaacatgaccgccgtggacaccgccacc-3' (SEQ ID NO: 223)

5'-ggtggcgggtgccacggcggatcatgttgatggtg-3' (SEQ ID NO: 224)

Site-Directed Mutagenesis was done according to Stratagene protocol; resulting new construct was called pRS5a hlgG1LALA MOR08168opt 6475 scFv DP to TA.

Vector pRS5a MOR08168 hlambda (generation described for anti-LRP6_MOR08168 hlgG1LALA_6475scFv) containing codon-optimized VL-sequence (synthesized by Genart) was used w/o any modifications for expression of LC.

anti-LRP6_MOR08168hlgG1 LALA 6475scFv at ValLeu (VL)

Vector pRS5a MOR08168 hlgG1LALA containing codon-optimized VH-sequence (synthesized by Genart) was used w/o any modifications for expression of HC.

Gene coding for codon-optimized MOR06475scFv and MOR08168-VL was synthesized by DNA2.0 and was cloned via AgeI/HindIII into vector pRS5a hlambda MOR08168.

Resulting vector was called pRS5a hlambda MOR08168 6475scFv at VL.

anti-LRP6_MOR06475hlgG1 LALA 8168scfv (VH-3-VL), where 3 represents a (Gly₄Ser)₃ amino acid linker between the VH and VL chains.

MOR06475-VH was amplified from vector pM2 hlgG1LALA MOR06475 with following primers:

5'-gttctggtcgcgatcctggaaggggtgactgccaggtgcaattgaaagaaagcg-3' (SEQ ID NO: 225)

5'-cttggaggagctgagctaac-3' (SEQ ID NO: 226)

PCR-product was cloned via NruI/BlnI into vector pRS5a hlgG1LALA MOR08168 6475scFv, resulting vector was called pRS5a hlgG1LALA MOR06475 6475scFv.

MOR08168scFv was amplified from vector pRS5a MOR08168 scFv (VH-3-VL) with following primers:

5'-gcacgaagcgtgcacaaccactacaccagaagagcctgagcctgtccccggcaagggcggctccggcggaagc caggtcaattggtgaaagc-3' (SEQ ID NO: 227)

5'-gggcctctagagcggccgccggcgcgcctcatcacagaacggtaagcttggtgcc-3' (SEQ ID NO: 228)

PCR-product was cloned via AfeI/XbaI into vector pRS5a hlgG1LALA MOR06475 6475scFv, resulting final vector was called pRS5a hlgG1LALA MOR06475 8168scFv (VH-3-VL).

MOR06475-VL was amplified from vector pM2 hkappa MOR06475 with following primers:

5'-gacaccaccggtgatatcgtgctgaccagagc-3' (SEQ ID NO: 229)

5'-gcagccaccgtacgtttaattcaac-3' (SEQ ID NO: 210)

PCR-product was cloned into vector pRS5a hkappa MOR06654 via AgeI/BsiWI, resulting vector was called pRS5a hkappa MOR06475.

anti-LRP6 MOR06475hIgG1 LALA 8168scfv (VH-4-VL), where 4 represents a (Gly₄Ser)₄ amino acid linker between the VH and VL chains.

MOR06475-VH was amplified from vector pM2 hIgG1LALA MOR06475 with following primers:

5'-gttcctggtcgcgatcctggaaggggtgcaactgccaggtgcaattgaaagaaagcg-3' (SEQ ID NO: 211)

5'-cttggtggaggctgagctaac-3' (SEQ ID NO: 212)

PCR-product was cloned via NruI/BlpI into vector pRS5a hIgG1LALA MOR08168 6475scFv, resulting vector was called pRS5a hIgG1LALA MOR06475 6475scFv.

MOR08168scFv was amplified from vector pRS5a MOR08168 scFv (VH-4-VL) with following primers:

5'-gcacgaagcgtgcacaaccactacaccagaagagcctgagcctgtccccggcaagggcggctccggcgggaagc caggttcaattggtttaaagc-3' (SEQ ID NO: 213)

5'-gggccctctagagcggccgcccggcgcctcatcacagaacggtaagcttggtgcc-3' (SEQ ID NO: 214)

MOR06475-VL was amplified from vector pM2 hkappa MOR06475 with following primers:

5'-gacaccaccggtgatategtgctgaccagagc-3' (SEQ ID NO: 215)

5'-gcagccaccgtacgtttaattcaac-3' (SEQ ID NO: 216)

PCR-product was cloned into vector pRS5a hkappa MOR06654 via AgeI/BsiWI, resulting vector was called pRS5a hkappa MOR06475.

(iii) Expression of anti-LRP6-scFv

Electrocompetent *E. coli* strain W3110 was transformed with plasmid-DNA. Pre-cultures (150 ml LB-medium containing 12.5 µg Tetracycline/ml and 0.4% Glucose, in 500 ml flask) were inoculated with a single colony and incubated over night at 37°C/230 rpm. Expression cultures (6x 500 ml SB-medium containing 12.5 µg Tetracycline/ml, in 2 l flask) were inoculated with pre-cultures to O.D600 of 0.1 and incubated at 25°C/230 rpm to O.D600 of ca. 0.6. Then IPTG (Roche) was added to an end concentration of 0.4 mM and cultures were incubated over night at 25°C/230 rpm. Cells were harvested by centrifugation (20 min at 4600 rpm, 4°C) and cell pellets were frozen at -20°C.

(iv) Purification of anti-LRP6-scFv

Pellets from 3 l expressions were suspended in 50 ml Lysis-Buffer (20 mM NaH₂PO₄, 20 mM Imidazole, 500 mM NaCl, pH 7.4; 1 tablet Complete without EDTA per 50 ml buffer, Roche # 11836170001, 10 mM MgSO₄ and Benzonase). Cell suspensions were treated by French Press (2x at 1000bar) and centrifuged for 30 min at 16000xg, 4°C. 1ml HisTrap HP column (GE Helthcare) was equilibrated with 10 ml Lysis-Buffer. Supernatants were filtrated through Stericup Filter (Millipore) and loaded into equilibrated column (1 ml/min). Column was washed with Lysis-Buffer (20 ml) and bound protein was eluted with 3 ml Elution-Buffer (as Lysis-Buffer but 250 mM Imidazole). Eluate was directly loaded on Superdex75-column (HiLoad 16/60, GE-Healthcare), equilibrated with 130 ml PBS (1 ml/min). Run was done with PBS at 1 ml/min, eluate was collected in 1.5 ml fractions and analyzed on 10% Bis-Tris-Gel (NuPage, Invitrogen). Adequate fractions were pooled, filtrated through 0.2 µm filter and stored at 4°C. All purified proteins were analyzed by LC-MS (with oxidized and reduced samples) and by SEC-MALS (aggregation analysis).

(v) Transient expression of biparatopic anti-LRP6 IgG-scFv

3.2 L HEK293-6E cells were cultivated in M11V3 Media : Lot# D07668B in a BioWave20 at Rocks 10 rpm, Angle 7°, Aeration 25 L/h, O₂ 25%, CO₂ 6% to a density of 2E6 viable cells/mL. The cells were transiently transfected with 1.8 L DNA:PEI-MIX (plasmid: pRS5a MOR08168 hIgG1 LALA-6475sc-Fv 5 mg + pRS5a MOR08168 hlambda 5 mg + 20 mg PEI). 6 hours after transfection 5 L Feeding media (Novartis) with Yeastolate: Lot# 09-021 was added to the culture. The cells were then further cultivated at Rocks 24 rpm, Angle: 7°, Aeration 25 L/h, O₂ 25%, CO₂ 0-6%. Seven days after transfection, cells were removed by crossflow filtration using Fresenius filters 0.2 µm. Afterwards the cell free material was concentrated to 1.75 L with crossflow filtration using 10 kDa cut off filter from Fresenius. After the concentration the concentrate was sterile filtered through a stericup filter (0.22 µm). The sterile supernatant was stored at 4°C. All described biparatopic anti-LRP6-scFv variants were expressed in a similar manner.

(vi) Purification of biparatopic anti-LRP6 IgG-scFv

The purification of the biparatopic IgG was performed on a ÄKTA 100 explorer Air chromatography system at 6°C in a cooling cabinet, using a freshly sanitised (0.2 M

NaOH/ 30% isopropanol) XK16/20 column with 25 ml of self-packed MabSelect SuRe resin (all GE Healthcare). All flow rates were 3.5 ml/min, except for loading, at a pressure limit of 5 bar. The column was equilibrated with 3 CV of PBS (made from 10x, Gibco), then the concentrated and sterile filtrated fermentation supernatant (1.35 L) was loaded at 2.0 ml/min o/n. The column was washed with 8 CV of PBS. Then the IgG was eluted with a pH gradient, starting at 50 mM citrate, 70 mM NaCl, pH 4.5, going linearly down in 12 CV to 50 mM citrate, 70 mM NaCl, pH 2.5, followed by a 2 CV constant step of the same pH 2.5 buffer. The biparatopic IgG eluted during the gradient in a single symmetric peak around pH 3.8, and was collected into 4 ml fractions. The fractions were pooled into three pools, left slope, main peak and right slope. The pools were immediately titrated to pH 7.0, slowly and under stirring, using 2 M Tris, pH 9.0. The pools were sterile filtered (Millipore Steriflip, 0.22 μ m), OD 280 nm was measured in a Lambda 35 Spectrometer (Perkin Elmer), and the protein concentration was calculated based on the sequence data. The pools were separately tested for aggregation (SEC-MALS) and purity (SDS-PAGE and MS), and based on the results, only the central pool (35 ml at 2.55 mg/ml protein) was further used. All described biaparatomic anti-LRP6-scFv variants were purified in a similar manner.

(vii) Cross-reactivity analysis by protein microarrays

The microarrays were custom-made high-density protein chips manufactured by Protagen AG (UNIchip® AV-VAR-EP) and contained 384 pre-defined and purified human proteins printed in quadruplicates on a nitrocellulose coated glass slide. The proteins are classified as extracellular or secretory proteins based on gene ontology and expressed as an N-terminal His-tag fusion protein using *Escherichia coli*, and purified using immobilized metal ion affinity chromatography (IMAC). The hybridization of the antibody was done using the TECAN Hybridization Station HS400Pro, programmed with a protocol developed by Protagen AG. The primary antibodies were tested at a final concentration of 5 μ g/ml. The secondary labeled antibody, a Cy5-conjugated AffiniPure Goat anti-hsIgG F(ab')₂ fragment specific (Jackson ImmunoResearch, code no. 109-175-097), was used at a final concentration of 7.5 μ g/ml. Microarray image acquisition was done using a GenePix Professional 4200A fluorescence microarray scanner (Axon Instruments, CA) equipped with a red laser (635 nm). Image analysis was performed using the GenePix Pro v6.0 software. Data analysis was done using Protagen UNIchip® Data Analysis Tool v1.8. To determine unspecific cross-reactivity derived from binding

of the secondary antibody directly to the printed antigens, the secondary antibody was also incubated on the UNChip® without the use of the primary antibody. For the determination of the level of cross reactivity normalized to the corresponding antigen, the fluorescent signal intensity value at saturated concentration (20 fmol/spot) was set as 100%. All signal intensities for a given protein, which were more than 4 % of the antigen signal, were considered as positive hits, providing they were not also found in the respective control with only the secondary labeled antibody.

(viii) Conformational stability measured by Differential Scanning Calorimetry (DSC)

DSC was measured using a capillary cell microcalorimeter VP-DSC from Microcal, equipped with a deep-well plate auto-sampler. Data were analyzed with the software Origin 7.5. The samples (400 µl), were added to 2 ml deep-well plates from Nunc™. The samples in PBS pH 7.0 were analyzed at 1 mg/ml. The reference sample contained 400 µl of the same buffer as the analyte, usually PBS. Heat change associated with thermal denaturation was measured between 20 °C and 100 °C, with a heating rate of 3.3 °C min⁻¹. The apparent melting temperature (T_m), corresponded to the thermal transition midpoint, where 50% of the analyte is unfolded.

(ix) Serum stability studies

Purified proteins were solved in 35 µl rat serum or mouse serum (Gene Tex) resulting in an end concentration of 0.3 mg/ml. Samples were incubated at 37°C in a plate incubator. 4 µl of each sample were taken at different time-points, 10 µl sample buffer (4x, NuPage, Invitrogen) and 26 µl water were added and samples were frozen at -20°C. 12 µl of each sample were loaded into 12% Bis-Tris-Gel (NuPage, Invitrogen), electrophoresis was done at 200V for 35min. Protein transfer was done to PVDF-membrane (Invitrogen) in Borate buffer (50 mM Borate, 50 mM Tris) at 30V for 1 h. Membranes were briefly washed in TBST (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% Tween80) and then incubated for 2 h at RT/shaker in TBST containing 5% milk powder. Membranes were briefly washed in TBST and then incubated for 1 h at RT/shaker in TBST containing POD-conjugated Goat-anti-human IgG, Fab fragment specific (Dianova), diluted 1:10.000 or anti-His POD (Roche) diluted 1:500. Membranes were washed three times for 5min at RT/shaker in TBST. Signal detection was done using BM Blue POD Substrate (Roche) or ECL/ECL Plus (GE-Healthcare).

(b) Results**(i) Expression, purification and characterisation of anti-LRP6-scFvs**

All scFv's were successfully expressed in *E. coli* W3110 and purified by affinity chromatography followed by size exclusion chromatography. Expected size (MOR06475 (Gly₄Ser)₃/(Gly₄Ser)₄: 26.74 and 27.06 kDa respectively, MOR08168 (Gly₄Ser)₃/(Gly₄Ser)₄: 26.5 and 26.85 kDa respectively, MOR08545 (Gly₄Ser)₃/(Gly₄Ser)₄: 25.99 and 26.31 kDa respectively was confirmed for all purified samples by LC-MS analysis done with reduced and oxidized samples and by SDS PAGE. Purities > 95% were obtained. Fig. 14 shows the results of SDS-PAGE analysis in which 1.5 µg of each purified protein were loaded into 10% Bis-Tris gel (NuPage, Invitrogen) M: Marker See Blue Plus2 (Invitrogen); (1): MOR06475-VH-(Gly₄Ser)₄-VL; (2) MOR06475-VL-(Gly₄Ser)₄-VH; (3) MOR08168-VH-(Gly₄Ser)₄-VL; (4) MOR08168-VL-(Gly₄Ser)₄-VH; (5) MOR08545-VH-(Gly₄Ser)₄-VL; (6) MOR08545-VL-(Gly₄Ser)₄-VH (7) MOR06475-VH-(Gly₄Ser)₃-VL; (8) MOR06475-VL-(Gly₄Ser)₃-VH (9) MOR08168-VH-(Gly₄Ser)₃-VL; (10) MOR08168-VL-(Gly₄Ser)₃-VH; (11) MOR08545-VH-(Gly₄Ser)₃-VL; (12) MOR08545-VL-(Gly₄Ser)₃-VH.

Thermal Stability was compared for all ScFv's by DSC. The melting temperature (T_m) was significantly higher for the MOR06475 variants. The highest T_m (64.7°C) was observed for MOR06475-VL-(Gly₄Ser)₄-VH therefore this molecule is believed to be potentially more stable than the other constructs produced.

Activity of MOR06475, MOR08168 and MOR08545 scFv and Fab constructs, as well as several biparatopic formats was assessed in the HEK293 STF assay (Fig. 17 and 18). Collectively, the data show that Propeller 1 IgG (MOR08168) inhibits Propeller 1 ligands such as Wnt1, while potentiating Propeller 3 ligands such as Wnt3 in the STF assay. Propeller 3 scFv6475 inhibits Propeller 3 ligands such as Wnt3, while having no activity on Propeller 1 ligands such as Wnt1. Furthermore, MOR08168/6475 biparatopic antibodies have activity against both Propeller 1 and Propeller 3 ligands, and no potentiating activity at any concentrations applied in the HEK293 Wnt STF assay.

(ii) Expression, purification and characterisation of biparatopic anti-LRP6 Ig-scFv

A schematic representation of biparatopic anti-LRP6 Ig-scFv format produced in this study is presented in Fig. 15. Fig. 15A represents a scFv scFv attached to the C-terminus

of an IgG; 15B scFv scFv attached to the N-terminus of an Fc; 15C represents an scFv scFv attached to the C-terminus of an Fc; and 15D represents an scFv scFv attached to the N- and C- terminus of an Fc.

The biparatopic antibody in the current experiment is the biparatopic full-IgG with scFv fused to the C-terminus of hIgG1 LALA CH3. In this particular study the scFv was separated by a (GlyGlySer)₂-linker from the full-IgG. The scFv consists of VL-VH orientation with a (Gly₄Ser)₄ linker.

Biparatopic anti-LRP6 IgG-scFv's were transiently expressed in HEK293-6E cells and purified by affinity chromatography with gradient elution from pH 4.5 to 2.5. The expected size of 197.4kDa was determined by LC-MS analysis and SDS-PAGE with a purity greater than 97% . Aggregation, determined by SEC MALS, was less than 5%. Fig. 16 is an SDS-Page analysis of purified biparatopic anti-LRP IgG-scFv. Samples were loaded into 12% Bis-Tris gel (NuPage, Invitrogen). Marker: Invitrogen Mark12; (1): Non-reduced; (2): Reduced

Biparatopic anti-LRP6 IgG scFv and parental anti-LRP6 IgG bound to human FcRn at pH 6.0 with a K_d of 0.021 and 0.023μM respectively, as determined by Biacore. Both formats demonstrated low level binding to human FcRn at pH 7.4, so this BpAb is expected to behave as a standard IgG *in vivo* (PK characteristics similar to IgG1) (See Fig. 19).

Biparatopic anti-LRP6 IgG scFv was stable in both mouse and rat serum at 37°C, tested up to 336 hours (data not shown) and showed no binding >4% when evaluated on a custom Protagen Unichip containing 384 purified extracellular or secreted proteins (data not shown).

(c) Discussion

Various anti-LRP6 scFv's were initially characterised to enable optimisation of the final biparatopic antibody. ScFv's in both orientations and with two different linker lengths were expressed in *E. coli*. Anti-LRP6 MOR06475, 8168 and 8545 were expressed as VH-VL and VL-VH scFv's with a (Gly₄Ser)₃ and (Gly₄Ser)₄ linker. All MOR06475 and MOR08168 variants were successfully expressed and purified with a low level (<5%) of

aggregates. Correctly processed protein with expected sizes were obtained. Thermal stability data showed that the most stable scFv format was MOR06475-VL- (Gly₄Ser)₄ - VH with a T_m of 64.7°C. All tested MOR08168 scFv formats showed significantly reduced thermal stability with a T_m of 50-52°C.

Biparatopic anti-LRP6 IgG's with scFv at CH3 and VL as well as modified variants (without C-terminal Lys (K) at CH3, with substitutions AspPro (DP) to AspAla (DA) and AspPro (DP) to ThrAla (TA) in VH of scFv) were successfully expressed and purified with a low level (<5%) of aggregates from cell culture. The expected sizes of approximately 197-198 kDa were determined. Constructs anti-LRP6 MOR08168 hIgG1LALA 6475scFv and anti-LRP6 MOR08168hIgG1 LALA 6475scFv at VL as well as mutated constructs (deletion of C-terminal Lys (K) at CH3 and substitutions AspPro (DP) to AspAla (DA) and AspAla (DP) to ThrAla (TA)) consisted of a scFv with VL-VH orientation and were separated by a (Gly₄Ser)₄ linker. A (GlyGlySer)₂ linker was used to attach the scFv to the CH3 domain of hIgG1 LALA and to VL of hlambda respectively. As previously discussed, however, the scFv may also consist of VH-VL separated by alternative linkers, furthermore the scFv may also be attached using alternative linkers to other positions within the IgG including the C-terminus of CL and the N-terminus of VH. Constructs with MOR08168scFv consisted of a scFv with VH-VL orientation and were separated by a (Gly₄Ser)₃ and (Gly₄Ser)₄ linker. A (GlyGlySer)₂ linker was used to attach the scFv to the CH3 domain of hIgG1 LALA.

The biparatopic anti-LRP6 MOR08168 hIgG1LALA 6475scFv was stable in serum (tested up to 336 hours). The biparatopic bound as expected to human FcRn at pH6.0, low level binding was seen at pH7.4. The parental antibody bound with similar kinetics.

Example 13: In vivo evaluation of biparatopic antibody anti-LRP6

MOR08168hIgG1LALA 6475 scfv

The ability of biparatopic antibody anti-LRP6 MOR08168hIgG1LALA 6475 scfv to inhibit Wnt3 class Wnt signaling *in vivo* was tested in a co-implant system consisting of PA1-STF reporter cells co-implanted with Wnt3A secreting L cells. Female nude mice were implanted subcutaneously with 10x10⁶ PA1-STF cells and 0.5x10⁶ L-Wnt3A cells and randomized in groups of 5. 24 hours later, mice received a single intravenous dose of vehicle, MOR08168 LRP6-Propeller 1 Ab (10 mg/kg), MOR06475 LRP6-Propeller 3 Ab (10 mg/kg), or the biparatopic antibody anti-LRP6

MOR08168hIgG1LALA 6475 scfv (1 mg/kg, 3 mg/kg, or 10 mg/kg) and were imaged by Xenogen 6 hours, 24 hours, 48 hours, 72 hours and 168 hours later. The biparatopic antibody anti-LRP6 MOR08168hIgG1LALA 6475 scfv showed a dose-related inhibition of Wnt3A induced signaling, with 1 mg/kg showing maximum inhibition at 24 hours, returning to baseline at 48 hours, and 3 mg/kg and 10 mg/kg showing sustained inhibition for at least 72 hours. The MOR06475 LRP6-Propeller 3 Ab dosed at 10 mg/kg was able to inhibit Wnt3a induced signaling for at least 72 hours, whereas MOR08168 LRP6-Propeller 1 Ab dosed at 10 mg/kg increased Wnt3a induced signaling (Fig. 20).

To measure the effect of the biparatopic antibody anti-LRP6 MOR08168hIgG1LALA 6475 scfv, relative to the MOR08168 LRP6-Propeller 1 Ab, on Wnt signaling in MMTV-Wnt1 tumors, mice implanted with MMTV-Wnt1 tumors were dosed i.v. with a single dose of 5 mg/kg of the biparatopic antibody anti-LRP6 MOR08168hIgG1LALA 6475 scfv or a single dose of 5 mg/kg of the MOR08168 LRP6-Propeller 1 antibody. Serum concentrations of the biparatopic antibody, and propeller 1 antibody, as well as the mRNA expression of β -catenin target gene Axin2, were analyzed over a period of two weeks. The terminal β -phase half-life of the biparatopic antibody was around 48 hours, whereas that of the LRP6 antibody was about 72 hours. A significant decrease of Axin2 mRNA expression was observed in tumors obtained from mice dosed with either the biparatopic antibody, or the propeller 1 antibody, and Axin2 expression gradually recovered with no significant differences observed between the biparatopic antibody anti-LRP6 MOR08168hIgG1LALA 6475 scfv and the MOR08168 LRP6-Propeller 1 antibody (Fig. 21).

Anti-tumor activity of the biparatopic antibody anti-LRP6 MOR08168hIgG1LALA 6475 scfv was evaluated in the MMTV-Wnt1 allograft model. MMTV-Wnt1 tumor fragments were implanted subcutaneously (s.c.) into female nude mice. 7 days after implantation, mice carrying MMTV-Wnt1 tumors (n=8, average 137 mm³; range: 81-272 mm³) were treated with vehicle IgG, MOR08168 LRP6-Propeller 1 Ab (3 mg/kg, i.v., qw), or biparatopic antibody anti-LRP6 MOR08168hIgG1LALA 6475 scfv (3 mg/kg, i.v., 2qw), and tumors calipered twice a week. Both MOR08168 LRP6-Propeller 1 Ab and biparatopic antibody anti-LRP6 MOR08168hIgG1LALA 6475 scfv antibody induced tumor regressions (-93%, p<0.05 and -91%, p<0.05 respectively) (See Fig. 22). The dose dependency of the biparatopic antibody anti-LRP6 MOR08168hIgG1LALA 6475 scfv was evaluated and is depicted in Fig. 23.

Inhibition of Wnt signaling in colorectal cancer cells by β -catenin siRNA or dominant-negative TCF-4 causes rapid cell cycle arrest and induces an intestinal differentiation program (van der Wetering *et al.* (2002), *Cell*, 111, 241-250; van der Wetering *et al.* (2003), *EMBO Reports*, 4, 609-615). To determine if inhibition of Wnt signaling by antagonistic LRP6 antibodies has similar consequences in murine MMTV-Wnt1 mammary tumors, secretory differentiation was examined by Oil Red O staining for lipid, a major component of milk. MMTV-Wnt1 tumor bearing mice were treated with either a single dose of PBS (control) or 5 mg/kg anti-LRP6 MOR08168hIgG1LALA 6475 scfv 24 h, 72 h or 5 days after treatment, sections of frozen murine tumor allografts were cut at 5 μ m thickness. Slides were air-dried for 30-60 minutes at room temperature and then fixed in ice-cold 10% formalin for 5-10 minutes. Slides were immediately rinsed three times in dH₂O. Oil Red O staining was performed using an Oil Red O staining kit (Poly Scientific R&D, Cat # k043). Slides were scanned with ScanScope CS/GL scanner (Aperio Technologies), and tissue sections analyzed with ImageScope v10.2.1.2315 software (Aperio Technologies), using the IHC color deconvolution algorithm with a positive-pixel count. Representative images of Oil Red O staining are shown in Fig 24A and quantification in Fig 24B. The graph represents mean \pm SEM values. n=4 in the 72 hour group, n=3 in 24 hour group, n=2 in the 5 Day group, and n=1 for PBS (control) and demonstrate an increase in Oil Red O staining during the time course of the experiment. Together, these results suggest that inhibition of Wnt signaling in mammary tumor cells may lead to cell cycle arrest and induction of a secretory differentiation program.

Anti-tumor activity of the biparatopic antibody anti-LRP6 MOR08168hIgG1LALA 6475 scfv was further evaluated in the MDA-MB-231 breast xenograft model. 5×10^6 MDA-MB-231 cells in 50% matrigel were implanted subcutaneously (s.c.) into female nude mice. 31 days after implantation, mice carrying MDA-MB-231 tumors (n=7, average 165 mm³; range 99-238 mm³) were treated with vehicle, or biparatopic antibody anti-LRP6 MOR08168hIgG1LALA 6475 scfv (3mg/kg, i.v., qw), and tumors calipered twice a week. The biparatopic antibody anti-LRP6 MOR08168hIgG1LALA 6475 scfv antibody dosed at 3 mg/kg weekly, significantly delayed tumor growth (T/C=23%, p<0.05) (See Fig. 25).

Example 14: In vivo evaluation of additional biparatopic antibodies in the MMTV-Wnt1 model

As described in Example 10, additional anti-LRP6 reverse biparatopic antibodies were generated consisting of the propeller 3 antibody MOR06475 and the propeller 1 MOR08168 scfv domains. The ability of these biparatopic antibodies (MOR06475hIgG1 LALA_8168scfv_(VH-3-VL) and MOR06475hIgG1 LALA_8168scfv_(VH-4-VL) to inhibit Wnt1 signaling *in vivo*, relative to MOR08168hIgG1LALA 6475 scfv, was determined in the MMTV-Wnt1 model. Mice implanted with MMTV-Wnt1 tumors were dosed i.v. with a single dose of 5 mg/kg of each of the antibodies described above. Serum concentrations of each antibody (MOR08168hIgG1LALA 6475 scfv, MOR06475hIgG1 LALA_8168scfv_(VH-3-VL), and MOR06475hIgG1 LALA_8168scfv_(VH-4-VL), as well as the mRNA expression of β -catenin target gene Axin2, were analyzed over a period of 5 days (timepoints evaluated were 0, 2, 7, 24, 72 and 120 h). Both of the reverse biparatopic antibodies showed a significant decrease in axin2 mRNA expression to the same maximal extent as MOR08168hIgG1LALA 6475 scfv. However, the duration of the decrease of axin2 mRNA expression was shorter than that observed with MOR08168hIgG1LALA 6475 scfv, with the signal returning to baseline at the 24 h timepoint for both of the reverse biparatopic molecules. This was consistent with decreased exposure of these molecules, with serum levels dropping to below 5 μ g/ml at 24 h compared with 120 h for MOR08168hIgG1LALA 6475 scfv.

Example 15: Binding affinity of a biparatopic antibody to recombinant LRP6 PD1/2 And PD 3/4

Binding affinities of anti-LRP6 MOR08168hIgG1LALA 6475 scfv, MOR08168, and MOR6475 to Propeller Domains 1-2 of LRP6 (PD1/2, amino acid residues 19 to 629 of Accession No. NP002327) and Propeller Domains 3-4 of LRP6 (PD3/4, amino acids 631-1246 of Accession No. NP002327) were evaluated via surface plasmon resonance (SPR) using a Biacore T-100 (GE Healthcare). For the affinity determinations, anti-human IgG Fcy specific antibody (#109-005-098, Jackson Immunology) was diluted in 10 mM sodium acetate (pH 5.0) buffer, and then immobilized onto CM4 chip (GE Healthcare, BR-1005-34) for all 4-flow cells to a density of \sim 2000 RU using standard amine coupling chemistry. The carboxymethyl dextran surface was activated with a 7 min injection of a 1:1 ratio of 0.4 M EDC (1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride) and 0.1 M NHS (*N*-hydroxysuccinimide). Excess reactive esters were then blocked with

1M ethanolamine. anti-LRP6 MOR08168hIgG1LALA 6475 scfv was prepared at 10 $\mu\text{g/ml}$ in HBS-EP buffer (GE Healthcare), and captured onto a separate flow cell of the CM4 chip to a density of ~ 70 RU at flow rate 10 $\mu\text{l/min}$. PD1/2 and PD3/4 were prepared as two fold concentration series starting at 50 nM, and injected at 30 $\mu\text{l/min}$ for 1 min. This allowed a 40 min dissociation phase over the anti-LRP6 MOR08168hIgG1LALA 6475 scfv-captured surface and the control surface without captured ligands. The surfaces were then regenerated two times with 10 mM glycine (pH 2.2). For the dual binding analysis of anti-LRP6 MOR08168hIgG1LALA 6475 scfv to PD1/2 and PD3/4, anti-LRP6 MOR08168hIgG1LALA 6475 scfv was captured onto the CM4 chip immobilized with anti-human IgG Fc γ specific antibody. PD3/4 at a saturating concentration of 100 nM was then flowed over the surface at a flow rate of 30 $\mu\text{l/min}$ for 30 min. A saturating concentration of 100 nM PD1/2 was injected immediately after the PD3/4. The dissociation constant (K_D), association (k_{on}), and dissociation (k_{off}) rates were calculated from the baseline subtracted corrected binding curves using the BIAevaluation software (GE Healthcare).

Anti-LRP6 MOR08168hIgG1LALA 6475 scfv (biparatopic antibody) binding to PD1/2 and PD3/4 was compared with that of MOR08168 (propeller 1 antibody) and MOR6475(propeller 3 antibody). Fig. 26A shows affinities of the molecules for corresponding LRP6 receptor domains, PD1/2 and PD3/4. The determined K_D of anti-LRP6 MOR08168hIgG1LALA 6475 scfv for PD1/2 and PD3/4 was similar to that of MOR08168 to PD1/2 and MOR6475 to PD3/4, respectively. Fig. 26B shows the association and dissociation phases of anti-LRP6 MOR08168hIgG1LALA 6475 scfv binding to each of the proteins. The off-rate for binding of anti-LRP6 MOR08168hIgG1LALA 6475 scfv to PD1/2 is slower than that to PD3/4. Further studies demonstrated in which PD1/2 and PD3/4 were injected sequentially indicated that, as expected, anti-LRP6 MOR08168hIgG1LALA 6475 scfv was capable of binding to both propeller domain constructs (Fig. 26C).

Example 16: scFv Mutations to Improve Thermostability of scFv08168 and scFv06475

This Example describes mutations made in the scFvs of propeller 1 and propeller 3 antibodies and the effect of individual and a combination of mutations to the stability of the scFv as determined by thermal stability. Improvements in the stability of the scFv can be translated to the overall stability of an antibody construct comprising the mutated scFv.

Material and methods

Constructs

For IgG based biparatopic molecules, scFv06475 was fused to the C-terminal of MOR08168 IgG1 via a GlyGlySer linker to make biparatopic antibody designated “901” in Fig. 27 (MOR08168IgG1LALA 6475 scfv), or scFv08168 was fused to the C-terminal of MOR06475 IgG1 via a GGS linker to make biparatopic antibody designated “902” in Fig. 27. . For detailed information, please refer to other parts of this patent application.

Rational design of the focused library for scFv06475 and scFv08168

Two approaches were used for selection of point mutations to stabilize scFv06475 and scFv08168: sequence consensus analysis and structure based mutation design using homology modeling in Molecular Operating Environment (MOE).

For sequence consensus analysis, the amino acid sequences of the VH and VL domains of scFv06475, and of the VH and VL domains of scFv08168 were BLASTed against the non-redundant protein sequence database of NCBI. After each BLAST run, the query sequence and the top 250 homologous sequences were aligned by the clustalW program. An in-house computer program was used to count the most common amino acid at every residue position among the aligned sequences. At each position where the amino acid in the query sequence differed from the most common amino acid in the aligned sequence pool, a mutation was designed to mutate the residue from its wild type amino acid to the most common amino acid.

A homology model of scFv06475 and a homology model of scFv08168 were built in MOE. The sequences were first read into the “sequence editor” module of MOE. Existing X-ray structures with homologous sequences were searched in the “antibody modeler” module of MOE. The X-ray structure 3L5X and 1W72 were identified by MOE as the suitable templates to build the homology models for scFv06475 and scFv08168, respectively. Homology models were then built by MOE, using the CHARMM27 force field to minimize the energy.

Models produced by MOE were then subject to five stages of energy minimization and MD simulation in NAMD. The whole models were energy minimized for 5000 steps in the first to the third stage, and with restraints of 30 kcal/mol/Å² applied on different sets of atoms. In the first stage, the restraints were applied to all atoms but the side chain

atoms in CDRs. In the second stage, the restraints were applied to all atoms but the residues in CDRs. In the third stage, the restraints were applied only to backbone atoms. The models were then simulated in vacuum for 100 ps at 50K in the fourth stage, with restraints of 30 kcal/mol/Å² applied on the backbone atoms. In the last and the fifth stage, the models were energy minimized for 5000 steps with restraints of 30 kcal/mol/Å² applied on the backbone atoms. The models after these five stages of minimization and MD simulation were taken as the homology models for structure based mutation design.

Mutant models were built upon the wild type homology models. The “mutate” command of the “psfgen” module of VMD was used to mutate residues to the designed amino acids (William Humphrey *et al.* (1996) *J. Molecular Graphics*, 14: 33-38). The mutated models were then energy minimized and simulated in six stages. 5000 steps of energy minimization were performed in the first to the fourth stage. Restraints of 30 kcal/mol/Å² were applied on all atoms but the side chain of the mutated residue in the first stage. Restraints of the same strength were applied on all atoms but the mutated residue in the second stage. The restraints on the side chain atoms of the residues within 5 Å to the mutated residue were removed in the third stage. The restraints on the backbone atoms of the residues within 5 Å to the mutated residue were released as well in the fourth stage. With the same restraints as those in the fourth stage applied, the mutated models were simulated in vacuum for 100 ps at 50K. The last snapshots of the simulation trajectories were then energy minimized for 5000 steps again, with the same restraints as those in the fourth stage. These minimized models were taken as the homology models of the mutants.

Plate based-library construction, expression and purification in E. coli system

High throughput mutagenesis was performed using QuikChange XL site-directed mutagenesis kit (Stratagene). Primers were designed according to primer design software Mutaprimer and were ordered from IDT in a 96 well format with normalized concentrations. Mutant strand synthesis reaction volume was scaled down from 50 to 25 µl. The reactions were carried out in the 96 well PCR plate. After the cycling, 0.5 µl DpnI enzyme was added to each amplification reaction and incubated at 37°C for 2 h to digest the parental dsDNA. Transformation was done by adding 2 µl of DpnI digested mutagenesis reaction into 20 µl Acella chemical competent cells in 96 well PCR plate.

Three individual colonies were picked from each transformation plate for expression and purification. Expression was done in two 96-well deep-well plates using autoinduction

media. Aliquots of bacterial culture were saved as glycerol stocks and sent for sequencing analysis. Bacterial pellet combined from the two plates for each individual colony was lysed and purified with MagneHis protein purification system from Promega. KingFisher instrument was set up for high-throughput purification. 1 M NaCl was added into the lysis and wash buffer to improve protein purity. Protein was eluted with 100 μ l of 300 mM imidazole in PBS. Protein quantity was briefly checked with Coomassie plus (Thermo) in order to determine the optimal amount of protein for Differential Scanning Fluorimetry (DSF).

Screening of thermostable mutations by DSF and Differential Scanning Calorimetry (DSC)

Depending on the protein amount purified for each sample, usually 10 to 20 μ l of elution was used for DSF analysis. Specifically, samples of 10-20 μ l were mixed with Sypro Orange (Invitrogen) of a final dilution at 1:1000, in a total volume of 25 μ l in PBS. The samples were run by BioRad CFX1000 (25°C for 2 min, then increment 0.5°C for 30 second, 25 to 95°C). Hits were defined as T_m over 2C above wild type scFv. scFv binding activity was determined by one-point ELISA.

Protein production in mammalian cells

Mutations were introduced into mammalian construct pRS5a that has scFv06475 or scFv08168 with His tag. The constructs were transiently expressed in 50 ml of 293T suspension cells. Briefly, PEI was mixed with DNA 50 μ g at 1:3 for optimal transfection efficiency. Cells at 1.4 e6 per ml were use for transfection. Transfected cells were collected after six days of incubation in CO₂ chamber 80 rpm shaking in filter paper flask of 250 ml. Supernatant was concentrated to around 1 ml for optimal protein recovery. Protein is purified manually by MagneHis kit according to the instructions from the manufacturer. Purified protein was dialyzed in PBS overnight with changing of buffers. Protein samples either before or after dialysis were used for DSF analysis.

Affinity measurement for scFvs

Binding EC₅₀ of scFvs against LRP6 protein was measured by ELISA. Maxisorp plate was coated with LRP6-Fc (R&D Sysytems, catalog No: 1505-LR) at 3 μ g/ml at 4°C overnight. The plate was blocked with 50 μ l of 2% BSA for one hour, and washed five times with the wash solution. The samples were diluted with 1% BSA accordingly. The

plate was incubated at RT for 1 h, and washed for 3 times. Detection was done by adding 50 μ l pentaHis-HRP (Qiagen Mat. No. 1014992) at 1:2000 dilution in 1% BSA, incubated at RT for 1 h, and washed 3 times. 50 μ l of substrate reagent A plus B (R&D systems) was added, then incubated for 5-20 min depending on the color. The reaction was stopped by adding 25 μ l of the stop solution, followed by plate reading at 450 nm.

Kinetics experiments were performed using BioRad's Proteon XPR36 biosensor. All experiments were performed at room temperature using PBST (phosphate buffered saline with 0.05% Tween-20) as the running buffer. All of the six vertical channels on a GLM chip were activated for 5 min at a flow rate of 30 μ l/min using freshly prepared mixture of EDC (400 mM) and sNHS (100 mM). Anti-His mouse IgG1 (R&D systems, catalog No: MAB050) was diluted to 20 μ g/ml in 10 mM sodium acetate, PH 5.0 and coupled to the chip for 5 min along separate vertical channels at a flow rate of 30 μ l/min. 1 M ethanolamine was then injected for 5 min at 30 μ l/min to deactivate the un-reacted sNHS groups. 2 μ g/ml MOR08168 scFv wild type or 2 μ g/ml MOR08168 D1 mutant was then immobilized on different vertical channels for 15 sec at 100 μ l/min followed by two 1 min injection of the running buffer at 30 μ l/min in the horizontal direction. The sixth vertical channel was used as the channel reference and no ligand was immobilized on this channel. A dilution series of a 360 KD homodimer antigen LRP6-Fc (R&D systems, catalog No: 1505-LR) was prepared at final concentrations of 300, 100, 33, 11, and 3.7 nM and injected at 30 μ l/min along each horizontal channel. Association was monitored for 5 min and dissociation was monitored for 20 min. Buffer was injected in the sixth channel to serve as a row reference for real time baseline drifting correction. Chip surface was regenerated by applying 0.85% phosphoric acid at 100 μ l/min for 18 s in the horizontal direction followed by the same running condition in the vertical direction. Kinetics analysis on the Proteon was performed in Proteon Manager v.2.1.1. Each interaction spot data was subtracted by a channel reference followed by a row reference to correct the real time baseline drifting. The processed data were fit globally to a bivalent analyte model.

Results

The plate-based mutagenesis, expression and purification in E. coli allowed more efficient screening from focused libraries

In order to achieve high yield to facilitate downstream analysis, the effect of the leader sequence on expression was tested. It was shown that the leader with pelB yielded the highest amount of purified protein among the seven leaders tested, as shown in Fig. 28A. Several bacterial strains including BL21 (DE3), XL-1 Blue and W3110 were tested for expression with IPTG induction. The expression level of scFv06475 in BL21 (DE3) was higher than in XL-1 blue and slightly higher than in W3110, as shown in Fig. 28B. In order to facilitate mutagenesis cloning, transformation and expression, Acella (a derivative of BL21) was used for all the subsequent experiments as cloning and expression can be done in the same strain with high efficiency. The protein was purified from cell lysate by KingFisher using MagneHis kit. Estimated yield for scFv08168 was around 10 µg per sample of combined wells from deep well culturing plate, of which 2 µg was used for DSF thermostability analysis. The plate based HTP screening has shorted the time significantly to around one week from primers to hits with improved thermostability.

scFv thermostability improvement by single point mutation from focused libraries

A hit for improved thermostability was defined as improvement of T_m at least 1°C above wild type consistently. There were 9 hits from a total of 51 sequence confirmed variants for scFv06475 and 15 hits from a total of 83 sequence confirmed variants for scFv08168. Selected hits were shown in Fig. 28 for scFv06475 and Fig. 29 for scFv08168.

Two approaches were used for selection of point mutations to stabilize scFv06475 and scFv08168: sequence consensus analysis and structure based mutation design. Among the top 250 sequences homologous to the VH domain of scFv06475, VH: 34 position was commonly occupied by either Met (45%) or Val (48%) (all numbering system in the text is from Kabat system). Yet this position was a Gly residue in the wild type sequence of scFv06475. Two mutants, VH:G34M and VH:G34V, were designed to mutate the wild type amino acid to the more popular amino acids at this position. As listed in Fig. 28, the VH:G34V mutant consistently showed higher stability than the wild type scFv06475 when expressed and purified by two different protocols. The VH:G34M mutant did not

express well in bacterial, likely due to wrong sequence caused by errors in the PCR procedure.

Based on the same sequence consensus analysis, mutations of VH:I34M, VH:G50S, VH:W52aG and VH:H58Y were designed to mutate residues in scFv08168 to the consensus amino acids in its top 250 homologous sequences. As shown in Fig. 30, these mutations improved the T_m of scFv08168 by 7.5°C, 3.0°C, 7.0°C, and 3.5°C, respectively.

In the structure based approach, a homology model of scFv06475 and a homology model of scFv08168 were first built with MOE then energy minimized with NAMD. These models were then visually inspected for potential mutations to enhance local interaction. Mutations on various residues of scFv06475 and scFv08168 were designed, based on five biophysical understandings of protein stability.

The first approach was to increase the size of side chains in the protein core to improve packing. A few hydrophobic residues with side chains facing the protein core were mutated to larger side chains so as to improve the packing around these residues. After screening, three mutations designed by this approach were found to improve the stability of scFv08168. As listed in Fig. 30, the VH:I34F, VL:V47L and VL:G64V mutations improved the melting temperature of the scFv08168 by 4.0°C, 2.5°C, and 2.0°C, respectively.

The second approach was to mutate hydrophobic residues to aromatic residues to form pi-pi stacking interaction. In the wild type scFv06475 homology model, as shown in Fig. 33a, the side chain of the VH:I37 residue was in close vicinity to two aromatic residues of VH:W103 and VL:F98. The closest distance between any non-hydrogen side chain atom of VH:I37 and any non-hydrogen side chain atom of VH:W103 was 3.82Å. The counterpart distance between VH:I37 and VL:F98 was 3.77Å. As shown in Fig. 33b, two perpendicular pi-pi stacking interaction were formed when an Phe residue was introduced to this local region through the VH:I37F mutation: one between VH:F37 and VH:W103, and the other between VH:F37 and VL:F98. Newly formed pi-pi stacking interaction must be stronger than the original hydrophobic interaction in this localized region, as the melting temperature of scFv6475 was improved by this mutation from 61 to 64.5°C (Fig. 28). The VH:M95F mutation also improved the stability of scFv06475 by forming pi-pi stacking interaction with VH:W50 and VH:F100 (Fig. 29). The T_m was improved from 61 to 64.5°C.

The third approach was to mutate non-charged residues to charged residues so as to form salt bridge. The VH:K43 residue of scFv6475 did not form a salt bridge with neighboring residues in the homology model. Since the VH:V85 side chain faced directly to VH:K43 in the homology model of scFv06475 (Fig. 33e), it was mutated to negative charged to form a salt bridge with VH:K43. As shown in Figure 33f, the distance between the mutated VH:E85 side chain non-hydrogen atoms and the VH:K43 side chain non-hydrogen atoms could be as short as 2.61Å, suggesting that a salt bridge could be established between the two residues. Improved stability of scFv6475 upon the VH:V85E mutation listed in Fig. 29 indeed supported the design rationale at this position.

The fourth approach was to mutate hydrophobic residues to polar residues to establish hydrogen bonds. As illustrated in Fig. 33c, the hydrophobic VH:V33 residue was close to a polar residue VH:N100a in the homology model of scFv08168. When a polar residue was inserted to this region through the VH:V33N mutation, an extra hydrogen bond could be formed between VH:N33 and VH:N100a. Homology modeling suggested that the distance between the ND2 atom of VH:N33 and one of the OD atoms of VH:N100a could be as short as 2.80Å, which was within the range of a hydrogen bond, as shown in Fig. 33d. As shown in Fig. 29, this VH:V33N mutation improved the stability of scFv08168 by 2.0°C. Likewise, the stability enhancement of the VL:D93N mutation on scFv06475 (see Fig. 29) could be attributed to the improved hydrogen bond geometry with VL:Q27 and VL:Q90.

Based on the surprising observation in the homology model of scFv08168 that two polar residues of VL:T78 and VH:S49 were both surrounded by purely hydrophobic side chains, the fifth approach was utilized to mutate the two polar residues in the otherwise hydrophobic environment to non-polar residues. Two polar residues of VL:T78 and VH:S49 were both surrounded by purely hydrophobic side chains. As listed in Fig. 29, the VL:T78V and VH:S49A mutations increased the melting temperature of scFv08168 by 2.5°C and 5.5°C, respectively.

One point ELISA was carried out to evaluate binding activity. Certain hits were eliminated due to reduced or loss of binding activity towards LRP6. For example, the mutation VH:W052aG of scFv08168 improved T_m by 7°C but showed much reduced binding activity as compared to wild type scFv08168. Therefore it was not selected for further analysis.

The presence of 300 mM imidazole in the elution buffer sometimes caused an overall shift of T_m by DSF, as observed in scFv06475. But the effect did not affect the ranking of T_m . There was also difference in protein produced in *E. coli* vs. in mammalian cells for scFv06475, as shown in Fig. 28. On the contrary, the presence of imidazole has minimal effect on T_m of scFv8168, as shown in Fig. 30 and Fig. 31. In addition, the T_m value remained unchanged for protein produced from *E. coli* or from mammalian for scFv08168, as shown in Fig. 31. Whether there was shift in T_m or not, the T_m ranking remained the same.

To confirm the effect of thermostability in proteins produced in mammalian cells, these mutations were introduced into construct for mammalian expression vector and expressed in 293T suspension cells. They were purified by MagneHis beads. T_m was checked and hits were confirmed for improved thermostability in proteins expressed in mammalian cells as shown in Fig. 31 for scFv08168. The single point mutation with highest thermostability improvement for scFv08168 is VH: I34M with an improvement of 7.5°C.

Combination of mutations to further improve thermostability

To further improve thermostability single mutations that improved the thermostability of the scFv combined to make double mutations in scFv08168. As shown in Fig. 31, the additive effects were observed for most of the double mutants including D1, which showed a improvement of 12.5°C by combination of two mutations of VH: I34M and VH: S49A, whereas the single mutation led to 7.5 and 5.5°C increase in T_m , respectively.

Thermostable mutants characterized for binding and functional activity

Affinity analysis ELISA EC_{50} was carried out for both scFv08168 and scFv06475 wild type and variants. As shown in Fig. 32, for scFv08168, the hits showed mostly comparable EC_{50} as wild type scFv08168, with a few mutants appeared to be a little more active than wild type, including the double mutant D1. This was confirmed with Proteon affinity measurement and STF cell based assay activity (performed as described earlier in this application (Materials and Methods, section 8), as shown in Fig. 32. Affinity ranking by Octet of scFv08168 variants showed that they were comparable to wild type (data not shown), In Proteon kinetics analysis, K_D of D1 was 2.55 nM, whereas K_D of wild type was 3.82 nM (Fig.32).

For scFv06475, there were two mutations affecting the activity as detected by ELISA and Proteon kinetics analysis. Specifically, in ELISA, VH: G34V and VH: I37F showed EC₅₀ to be 27 nM and 4.3 nM respectively as compared to wild type of 0.76 nM. In Proteon analysis, VH: G34V and VH: I39F showed significant drop in off rate (data not shown).

Improved thermostability of biparatopic molecules

For IgG based fusion molecules 902 and mutant version 902T, the first T_m peak shifted from 47°C to 62°C. This peak corresponded to scFv08168 unfolding. The second peak shifted from 72 °C to 76°C. This peak corresponded to Fab06475, as shown in Fig. 34.

Discussion

Rational design based on sequence analysis and homology modeling has yielded thermostable mutations for scFvs. In the current examples, the hit rate was around 18% for both scFv08168 and scFv06475. The most significant improvement was 7.5°C increase in T_m over wild type by a single point mutation VH: I34M in scFv08168. On the sequence perspective, this position was highly conserved to Met. Structurally, a larger hydrophobic side chain at this position could improve the packing around this residue. Another point mutation VH: S49A in scFv08168 variant raised T_m by 5°C. This mutation was picked by homology modeling. Though this position is more conserved to Ser than to Ala, structurally Ala may fit better due to the lack of polar side chain around this residue.

For structure based mutation design using homology modeling, a combination of mechanisms was utilized. In scFv06475 and scFv08168, positive hits were discovered by each of the five biophysical considerations: packing improvement, more Pi-Pi stacking, more hydrogen bonds, more salt bridges and removal of buried polar groups. It was by this combination of mechanisms that a total of 10 stabilizing mutations have been identified, as listed in Fig. 29 and 30.

Combination of mutations identified to improve thermal stability (“beneficial mutations”) further improve thermostability if they were located in different areas. This was demonstrated in the case of scFv08168. When beneficial mutation VH: I34M and VH: S49A were combined, T_m was further increased to 62.5°C vs wild type at 49 °C. This was 13.5°C increase over wild type, where the individual mutation VH I34M and VH: S49A

each raised T_m by 7.5°C and 5°C respectively. This was a clear indication for additive effect.

I34M was very close to CDR1-H of scFv08168, however the mutation did not affect the binding affinity as evidenced by a number of assays. CDR plays a role in overall scFv or full antibody stability. Significant improvement may be achieved through engineering of residues close to the CDR region using the methods disclosed, as long as the mutation does not affect binding affinity and specificity.

Most of stabilizing mutations have been located on VH. Out of the 15 stabilizing mutations listed in Fig. 29 and 30, 11 were mutations on the VH domain whereas only 4 were on the VL domain.

When incorporated into IgG or other formats (e.g. serum albumin fusions), the stabilized VH and VL led to a dramatic improvement in thermostability of the molecules. For IgG fusion, the lower T_m of 47°C corresponded to the T_m of scFv08168, whereas the higher peak at 72.5°C correspond to the T_m of CH2 and Fab06475. The incorporation of two mutations VH: I34M and VH: S49A has improved the T_m of scFv08168 from 47°C to 62°C, whereas the incorporation of VH: M95F in 6475 further improved the T_m of Fab from 72.5°C to 76°C. The improvement was not only shown on scFv itself, but also on the Fab due to the improved stability of VH and VL. This may provide a more general strategy for improving overall antibody stability.

Rational design coupled with HTP screening in *E. coli* system has offered very quick turnaround time and high hit rate. T_m measured with materials from *E. coli* correlated with that from mammalian, or ranking remained the same. This greatly simplified screening process to implemented as HTP in *E. coli*. Plate based mutagenesis, transformation, expression and purification has shorted the time to less than one week. Using the methods disclosed herein, a number of mutations can be made in scFvs or other antigen binding fragments and screened for thermal stability. These mutated scFvs or antigen binding fragments can then be used as components of larger antibody constructs such as biparatopic antibodies, to confer such stability to the larger antibody construct.

Claims:

1. An isolated bivalent antibody or a bivalent fragment thereof to a low density lipoprotein-related protein 6 (LRP6) that potentiates a Wnt signal by clustering one or more LRP6 receptors in the presence of an unblocked LRP6 binding protein.
2. The isolated bivalent antibody or a bivalent fragment thereof of claim 1, wherein the antibody clusters one or more LRP6 receptors by binding to a Propeller region selected from the group consisting of Propeller 1 and Propeller 3.
3. The isolated bivalent antibody or fragment thereof of claim 2, wherein the LRP6 binding protein is a Wnt binding protein selected from the group consisting of Wnt 1, Wnt 3, and Wnt 3a.
4. An isolated monovalent antibody or monovalent fragment thereof to a low density lipoprotein-related protein 6 (LRP6) that avoids potentiation of a Wnt signal by clustering one or more LRP6 receptors in the presence of an unblocked LRP6 binding protein.
5. An isolated antibody or fragment thereof to a low density lipoprotein-related protein 6 (LRP6) protein, having a dissociation (K_D) of at least $1 \times 10^7 M^{-1}$, $10^8 M^{-1}$, $10^9 M^{-1}$, $10^{10} M^{-1}$, $10^{11} M^{-1}$, $10^{12} M^{-1}$, $10^{13} M^{-1}$, wherein the antibody or fragment thereof is monovalent or bivalent.
6. The isolated antibody or fragment thereof of claim 5, wherein the antibody or fragment thereof inhibits a canonical Wnt pathway as measured by *in vitro* binding to human LRP6 in a Solution Equilibrium Titration assay with a K_D of 0.001 nM-1 μ M, and wherein the antibody or fragment thereof is monovalent or bivalent.
7. An isolated antibody or fragment thereof to a low density lipoprotein-related protein 6 (LRP6) protein that inhibits a phosphorylation of LRP6 as assessed by a Wnt ligand induced phosphorylation assay, wherein the antibody or fragment thereof is monovalent or bivalent.
8. An isolated antibody or fragment thereof to a low density lipoprotein-related protein 6 (LRP6) protein that inhibits a canonical Wnt pathway as measured by *in vitro* binding to human LRP6 in a Solution Equilibrium Titration (SET) assay with a EC_{50} of less than or equal to 300 μ M, wherein the antibody or fragment thereof is monovalent or bivalent.

9. An antibody or fragment thereof to LRP6 protein, that cross competes with an antibody described in Table 1, wherein the antibody or fragment thereof is monovalent or bivalent.
10. An antibody or fragment thereof, that binds to the same epitope as an antibody described in Table 1, wherein the antibody or fragment thereof is monovalent or bivalent .
11. The antibody of claims 1, 4, 9, or 10, wherein said antibody is a monoclonal antibody.
12. The antibody of claim 11, wherein said antibody is a human or humanized antibody.
13. The antibody of claim 11, wherein said antibody is a chimeric antibody.
14. The antibody of claim 11, wherein said antibody comprises a human heavy chain constant region and a human light chain constant region.
15. The antibody of claim 11, wherein said antibody is a single chain antibody.
16. The antibody of claim 11, wherein said antibody is a Fab fragment.
17. The antibody of claim 11, wherein said antibody is a scFv.
18. The antibody of claim 11 binds to both human LRP6 and cynomologus LRP6.
19. The antibody of claim 11 is an IgG isotype.
20. The antibody of claim 11, wherein said antibody comprises a framework in which amino acids have been substituted into the antibody framework from the respective human VH or VL germline sequences.
21. An isolated antibody or fragment thereof to LRP6 comprising 1, 2, 3, 4, 5, or 6 CDRs of any of the antibodies in Table 1, wherein the antibody or fragment thereof is monovalent or bivalent.
22. An isolated antibody or fragment thereof to LRP6 comprising a heavy chain CDR3 selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 25, SEQ and SEQ ID NO: 43, wherein the antibody or fragment thereof is monovalent or bivalent.
23. An isolated antibody or fragment thereof to LRP6 which antibody comprises a VH selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 44, SEQ ID NO: 60, and SEQ ID NO: 62 and a VL selected from the group

consisting of SEQ ID NO: 13, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 43, SEQ ID NO: 59, and SEQ ID NO: 61, wherein the antibody or fragment thereof is monovalent or bivalent.

24. An isolated antibody or fragment thereof to LRP6 which antibody comprises a VH comprising SEQ ID NO: 14 and a VL comprising SEQ ID NO: 13, wherein the antibody or fragment thereof is monovalent or bivalent.

25. An isolated antibody or fragment thereof to LRP6 which antibody comprises a VH comprising SEQ ID NO: 34 and a VL comprising SEQ ID NO: 33, wherein the antibody or fragment thereof is monovalent or bivalent.

26. An isolated antibody or fragment thereof to LRP6 which antibody comprises a VH comprising SEQ ID NO: 36 and a VL comprising SEQ ID NO: 35, wherein the antibody or fragment thereof is monovalent or bivalent.

27. An isolated antibody or fragment thereof to LRP6 which antibody comprises a VH comprising SEQ ID NO: 44 and a VL comprising SEQ ID NO: 43, wherein the antibody or fragment thereof is monovalent or bivalent.

28. An isolated antibody or fragment thereof to LRP6 which antibody comprises a VH comprising SEQ ID NO: 36 and a VL comprising SEQ ID NO: 35, wherein the antibody or fragment thereof is monovalent or bivalent.

29. An isolated antibody or fragment thereof to LRP6 which antibody comprises a VH comprising SEQ ID NO: 60 and a VL comprising SEQ ID NO: 59, wherein the antibody or fragment thereof is monovalent or bivalent.

30. An isolated antibody or fragment thereof to LRP6 which antibody comprises a VH comprising SEQ ID NO: 61 and a VL comprising SEQ ID NO: 62, wherein the antibody or fragment thereof is monovalent or bivalent.

31. An isolated antibody or fragment thereof, comprising at least one heavy chain CDR sequence that is identical to SEQ ID NO: 1, 2, 3, 21, 22, 23, 47, 48, and 49, wherein the antibody binds to human LRP6 protein.

32. An isolated monovalent monoclonal antibody, or fragment thereof, comprising at least one light chain CDR sequence that is identical to SEQ ID NO: 4, 5, 6, 24, 25, 26 50,

51 and 52, wherein the antibody binds to human LRP6 protein, wherein the antibody or fragment thereof is monovalent or bivalent.

33. An isolated antibody or fragment thereof, comprising at least one heavy chain CDR sequence having at least 95% sequence identity to SEQ ID NO: 1, 2, 3, 21, 22, 23, 47, 48, and 49, 47, 48, and 49, wherein the antibody binds to human LRP6 protein, wherein the antibody or fragment thereof is monovalent or bivalent.

34. An isolated antibody or fragment thereof, comprising at least one light chain CDR sequence having at least 95% sequence identity to SEQ ID NO: 4, 5, 6, 24, 25, 26 50, 51 and 52, wherein the antibody binds to human LRP6 protein, wherein the antibody or fragment thereof is monovalent or bivalent.

35. An isolated antibody or fragment thereof, comprising a heavy chain variable region CDR1 of SEQ ID NO: 1; a heavy chain variable region CDR2 of SEQ ID NO: 2; a heavy chain variable region CDR3 of SEQ ID NO: 3; a light chain variable region CDR1 of SEQ ID NO: 4; a light chain variable region CDR2 of SEQ ID NO: 5; and a light chain variable region CDR3 of SEQ ID NO: 6, wherein the antibody or fragment thereof is monovalent or bivalent.

36. An isolated antibody or fragment thereof, comprising a heavy chain variable region CDR1 of SEQ ID NO: 21; a heavy chain variable region CDR2 of SEQ ID NO: 22; a heavy chain variable region CDR3 of SEQ ID NO: 23; a light chain variable region CDR1 of SEQ ID NO: 24; a light chain variable region CDR2 of SEQ ID NO: 25; and a light chain variable region CDR3 of SEQ ID NO: 26, wherein the antibody or fragment thereof is monovalent or bivalent.

37. An isolated antibody or fragment thereof, comprising a heavy chain variable region CDR1 of SEQ ID NO: 47; a heavy chain variable region CDR2 of SEQ ID NO: 48; a heavy chain variable region CDR3 of SEQ ID NO: 49; a light chain variable region CDR1 of SEQ ID NO: 50; a light chain variable region CDR2 of SEQ ID NO: 51; and a light chain variable region CDR3 of SEQ ID NO: 52, wherein the antibody or fragment thereof is monovalent or bivalent.

38. A fragment of an antibody of anyone of the previous claim that binds to LRP6 selected from the group consisting of; Fab, F(ab₂)', F(ab)₂', ScFV, VHH, VH, VL, dAbs, wherein the fragment is monovalent or bivalent.

39. A pharmaceutical composition comprising an antibody or fragment thereof selected from claims 1-38 and a pharmaceutically acceptable carrier, wherein the antibody or fragment thereof is monovalent or bivalent.
40. A nucleic acid comprising a nucleotide sequence encoding a polypeptide comprising a heavy chain variable region identity to SEQ ID NO: 14, 34, 36, 44, 60, and 62.
41. A nucleic acid comprising a nucleotide sequence encoding a polypeptide comprising a light chain variable region identity to SEQ ID NO: 13, 33, 35, 43, 59 and 61.
42. A nucleic acid comprising a nucleotide sequence encoding a polypeptide comprising a heavy chain variable region having at least 98% sequence identity to SEQ ID NO: 14, 34, 36, 44, 60, and 62.
43. A nucleic acid comprising a nucleotide sequence encoding a polypeptide comprising a light chain variable region having at least 98% sequence identity to SEQ ID NO: 13, 33, 35, 43, 59 and 61.
44. A vector comprising the nucleic acid of claims 40-43.
45. An isolated antibody or fragment thereof to LRP6 comprising a CDR3 selected from the group consisting of SEQ ID NO: 69, SEQ ID NO: 93, and SEQ ID NO: 115, wherein the antibody or fragment thereof is monovalent or bivalent.
46. An isolated antibody or fragment thereof to LRP6 comprising a heavy chain CDR1 selected from the group consisting of SEQ ID NO: 69, SEQ ID NO: 93, and SEQ ID NO: 115; a CDR2 selected from the group consisting of SEQ ID NO: 70, SEQ ID NO: 94, and SEQ ID NO: 116; and a CDR3 selected from the group consisting of SEQ ID NO: 71, SEQ ID NO: 95, and SEQ ID NO: 117, wherein the antibody or fragment thereof is monovalent or bivalent.
47. An isolated antibody or fragment thereof to LRP6 comprising a light chain CDR1 selected from the group consisting of SEQ ID NO: 72, SEQ ID NO: 96, and SEQ ID NO: 118; a CDR2 selected from the group consisting of SEQ ID NO: 73, SEQ ID NO: 97, and SEQ ID NO: 119; and a CDR3 selected from the group consisting of SEQ ID NO: 74, SEQ ID NO: 98, and SEQ ID NO: 120, wherein the antibody or fragment thereof is monovalent or bivalent.

48. An isolated antibody or fragment thereof to LRP6 which antibody comprises a VH selected from the group consisting of SEQ ID NO: 82, SEQ ID NO: 89, SEQ ID NO: 106, SEQ ID NO: 108, SEQ ID NO: 128, SEQ ID NO: 130, and SEQ ID NO: 138; and a VL selected from the group consisting of SEQ ID NO: 81, SEQ ID NO: 90, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 127, SEQ ID NO: 129, and SEQ ID NO: 137, wherein the antibody or fragment thereof is monovalent or bivalent.
49. An isolated antibody or fragment thereof to LRP6 which antibody comprises a VH comprising SEQ ID NO: 82 and a VL comprising SEQ ID NO: 81, wherein the antibody or fragment thereof is monovalent or bivalent.
50. An isolated antibody or fragment thereof to LRP6 which antibody comprises a VH comprising SEQ ID NO: 90 and a VL comprising SEQ ID NO: 89, wherein the antibody or fragment thereof is monovalent or bivalent.
51. An isolated antibody or fragment thereof to LRP6 which antibody comprises a VH comprising SEQ ID NO: 106 and a VL comprising SEQ ID NO: 105, wherein the antibody or fragment thereof is monovalent or bivalent.
52. An isolated antibody or fragment thereof to LRP6 which antibody comprises a VH comprising SEQ ID NO: 108 and a VL comprising SEQ ID NO: 107, wherein the antibody or fragment thereof is monovalent or bivalent.
53. An isolated antibody or fragment thereof to LRP6 which antibody comprises a VH comprising SEQ ID NO: 128 and a VL comprising SEQ ID NO: 127, wherein the antibody or fragment thereof is monovalent or bivalent.
54. An isolated antibody or fragment thereof to LRP6 which antibody comprises a VH comprising SEQ ID NO: 128 and a VL comprising SEQ ID NO: 127, wherein the antibody or fragment thereof is monovalent or bivalent.
55. An isolated antibody or fragment thereof to LRP6 which antibody comprises a VH comprising SEQ ID NO: 130 and a VL comprising SEQ ID NO: 129, wherein the antibody or fragment thereof is monovalent or bivalent.
56. An isolated antibody or fragment thereof to LRP6 which antibody comprises a VH comprising SEQ ID NO: 138 and a VL comprising SEQ ID NO: 137, wherein the antibody or fragment thereof is monovalent or bivalent.

57. An isolated antibody or fragment thereof, comprising at least one heavy chain CDR sequence that is identical to SEQ ID NO: 69, 70, 71, 93, 94, 95, 115, 116, and 117, wherein said antibody binds to human LRP6 protein, wherein the antibody or fragment thereof is monovalent or bivalent.

58. An isolated antibody or fragment thereof, comprising at least one light chain CDR sequence that is identical to SEQ ID NO: 72, 73, 74, 96, 97, 98, 118, 119, and 120, wherein said antibody binds to human LRP6 protein, wherein the antibody or fragment thereof is monovalent or bivalent.

59. An isolated antibody or fragment thereof, comprising at least one heavy chain CDR sequence having at least 95% sequence identity to SEQ ID NO: 70, 71, 93, 94, 95, 115, 116, and 117, wherein said antibody binds to human LRP6 protein, wherein the antibody or fragment thereof is monovalent or bivalent.

60. An isolated antibody or fragment thereof, comprising at least one light chain CDR sequence having at least 95% sequence identity to SEQ ID NO: 72, 73, 74, 96, 97, 98, 118, 119, and 120, wherein said antibody binds to human LRP6 protein, wherein the antibody or fragment thereof is monovalent or bivalent.

61. An isolated antibody or fragment thereof, comprising a heavy chain variable region CDR1 of SEQ ID NO: 69; a heavy chain variable region CDR2 of SEQ ID NO: 70; a heavy chain variable region CDR3 of SEQ ID NO: 71; a light chain variable region CDR1 of SEQ ID NO: 72; a light chain variable region CDR2 of SEQ ID NO: 73; and a light chain variable region CDR3 of SEQ ID NO: 74, wherein the antibody or fragment thereof is monovalent or bivalent.

62. An isolated antibody or fragment thereof, comprising a heavy chain variable region CDR1 of SEQ ID NO: 93; a heavy chain variable region CDR2 of SEQ ID NO: 94; a heavy chain variable region CDR3 of SEQ ID NO: 95; a light chain variable region CDR1 of SEQ ID NO: 96; a light chain variable region CDR2 of SEQ ID NO: 97; and a light chain variable region CDR3 of SEQ ID NO: 98, wherein the antibody or fragment thereof is monovalent or bivalent.

63. An isolated antibody or fragment thereof, comprising a heavy chain variable region CDR1 of SEQ ID NO: 115; a heavy chain variable region CDR2 of SEQ ID NO: 116; a heavy chain variable region CDR3 of SEQ ID NO: 117; a light chain variable region

CDR1 of SEQ ID NO: 118; a light chain variable region CDR2 of SEQ ID NO: 119; and a light chain variable region CDR3 of SEQ ID NO: 120, wherein the antibody or fragment thereof is monovalent or bivalent.

64. A combination of a monoclonal antibody or fragment thereof selected from the group consisting of any one of the antibodies in claims 35-37 with any one of the antibodies in claims 65-63, wherein the antibody or fragment thereof is monovalent.

65. A combination of a monoclonal antibody or fragment thereof selected from the group consisting of any one of the antibodies in claims 35-37 with any one of the antibodies in claims 65-63, wherein the antibody or fragment thereof is bivalent.

66. A fragment of the antibody of any previous claim that binds with LRP6 selected from the group consisting of; Fab, F(ab₂)', F(ab)₂', ScFV, VHH, VH, VL, dAbs, wherein the fragment is monovalent or bivalent.

67. A pharmaceutical composition comprising antibody selected from claims 45-63 and a pharmaceutically acceptable carrier, wherein the antibody is monovalent or bivalent.

68. A nucleic acid comprising a nucleotide sequence encoding a polypeptide comprising a heavy chain variable region selected from the group consisting of SEQ ID NO: 82, 89, 106, 108, 128, 130, and 138.

69. A nucleic acid comprising a nucleotide sequence encoding a polypeptide comprising a light chain variable region selected from the group consisting of SEQ ID NO: 81, 90, 105, 107, 127, 129, and 137.

70. A nucleic acid comprising a nucleotide sequence encoding a polypeptide comprising a heavy chain variable region having at least 98% sequence identity to SEQ ID NO: 82, 89, 106, 108, 128, 130, and 138.

71. A nucleic acid comprising a nucleotide sequence encoding a polypeptide comprising a light chain variable region having at least 98% sequence identity to SEQ ID NO: 81, 90, 105, 107, 127, 129, and 137.

72. A vector comprising the nucleic acid of claims 68-71.

73. A method of treating a cancer comprising selecting a subject having an LRP6 expressing cancer, administering to said subject an effective amount of a composition

comprising an antibody or fragment thereof selected from claims 1-38 and 45-65, wherein the antibody or fragment thereof is monovalent or bivalent.

74. The method of claim 73, wherein the subject is a human.

75. A method of treating a cancer mediated by a canonical Wnt signaling pathway comprising selecting a subject having an LRP6 expressing cancer, administering to the subject an effective amount of a composition comprising an antibody or fragment thereof selected from claims 1-39 and 45-66, wherein said antibody or fragment thereof is monovalent or bivalent, and wherein said cancer is selected from the group consisting of breast cancer, lung cancer, multiple myeloma, ovarian cancer, liver cancer, bladder cancer, gastric cancer, prostate cancer, acute myeloid leukemia, chronic myeloid leukemia, osteosarcoma, squamous cell carcinoma, and melanoma.

76. The method of claim 75, wherein said cancer is breast cancer.

77. A method of treating a cancer comprising selecting a subject having an LRP6 expressing cancer, administering to said subject an effective amount of a composition comprising an antibody or fragment thereof that binds to a propeller 1 region of LRP6 in combination with an antibody or fragment thereof that binds to a propeller 3 region of LRP6, wherein the antibody or fragment thereof is monovalent or bivalent.

78. A method of treating a cancer comprising selecting a subject having an LRP6 expressing cancer, administering to said subject an effective amount of a composition comprising an antibody or fragment thereof that binds to LRP6 and inhibits Wnt1 signalling by LRP6 in combination with an antibody or fragment thereof that binds to LRP6 and inhibits Wnt3 signalling by LRP6, wherein the antibodies or fragments thereof are monovalent or bivalent.

79. Use of an antibody or fragment thereof of any one of the previous claims in the manufacture of a medicament for the treatment of a cancer mediated by a canonical Wnt signaling pathway selected from the group consisting of breast cancer, lung cancer, multiple myeloma, ovarian cancer, liver cancer, bladder cancer, gastric cancer, prostate cancer, acute myeloid leukemia, chronic myeloid leukemia, osteosarcoma, squamous cell carcinoma, and melanoma, wherein the antibody or fragment thereof is monovalent or bivalent.

80. An antibody having VH of SEQ ID NO: 14 and VL of SEQ ID NO: 13 for use in treating a cancer mediated by a canonical Wnt signaling pathway, wherein the antibody is monovalent or bivalent.
81. An antibody having VH of SEQ ID NO: 34 and VL of SEQ ID NO: 36 for use in treating a cancer mediated by a canonical Wnt signaling pathway, wherein the antibody is monovalent or bivalent.
82. An antibody having VH of SEQ ID NO: 36 and VL of SEQ ID NO: 35 for use in treating a cancer mediated by a canonical Wnt signaling pathway, wherein the antibody is monovalent or bivalent.
83. An antibody having VH of SEQ ID NO: 44 and VL of SEQ ID NO: 43 for use in treating a cancer mediated by a canonical Wnt signaling pathway, wherein the antibody is monovalent or bivalent.
84. An antibody having VH of SEQ ID NO: 60 and VL of SEQ ID NO: 59 for use in treating a cancer mediated by a canonical Wnt signaling pathway, wherein the antibody is monovalent or bivalent.
85. An antibody having VH of SEQ ID NO: 62 and VL of SEQ ID NO: 61 for use in treating a cancer mediated by a canonical Wnt signaling pathway, wherein the antibody is monovalent or bivalent.
86. An antibody having VH of SEQ ID NO: 82 and VL of SEQ ID NO: 81 for use in treating a cancer mediated by a canonical Wnt signaling pathway, wherein the antibody is monovalent or bivalent.
87. An antibody having VH of SEQ ID NO: 90 and VL of SEQ ID NO: 89 for use in treating a cancer mediated by a canonical Wnt signaling pathway, wherein the antibody is monovalent or bivalent.
88. An antibody having VH of SEQ ID NO: 106 and VL of SEQ ID NO: 105 for use in treating a cancer mediated by a canonical Wnt signaling pathway, wherein the antibody is monovalent or bivalent.

89. An antibody having VH of SEQ ID NO: 108 and VL of SEQ ID NO: 107 for use in treating a cancer mediated by a canonical Wnt signaling pathway, wherein the antibody is monovalent or bivalent.

90. An antibody having VH of SEQ ID NO: 128 and VL of SEQ ID NO: 127 for use in treating a cancer mediated by a canonical Wnt signaling pathway, wherein the antibody is monovalent or bivalent.

91. An antibody having VH of SEQ ID NO: 130 and VL of SEQ ID NO: 129 for use in treating a cancer mediated by a canonical Wnt signaling pathway, wherein the antibody is monovalent or bivalent.

92. An antibody having VH of SEQ ID NO: 138 and VL of SEQ ID NO: 137 for use in treating a cancer mediated by a canonical Wnt signaling pathway, wherein the antibody is monovalent or bivalent.

93. An antibody having VH of SEQ ID NO: 14 and VL of SEQ ID NO: 13 for use as a drug, wherein the antibody is monovalent or bivalent.

94. An antibody having VH of SEQ ID NO: 34 and VL of SEQ ID NO: 33 for use as a drug, wherein the antibody is monovalent or bivalent.

95. An antibody having VH of SEQ ID NO: 36 and VL of SEQ ID NO: 35 for use as a drug, wherein the antibody is monovalent or bivalent.

96. An antibody having VH of SEQ ID NO: 44 and VL of SEQ ID NO: 43 for use as a drug, wherein the antibody is monovalent or bivalent.

97. An antibody having VH of SEQ ID NO: 60 and VL of SEQ ID NO: 59 for use as a drug, wherein the antibody is monovalent or bivalent.

98. An antibody having VH of SEQ ID NO: 62 and VL of SEQ ID NO: 61 for use as a drug, wherein the antibody is monovalent or bivalent.

99. An antibody having VH of SEQ ID NO: 82 and VL of SEQ ID NO: 81 for use as a drug, wherein the antibody is monovalent or bivalent.

100. An antibody having VH of SEQ ID NO: 90 and VL of SEQ ID NO: 89 for use as a drug, wherein the antibody is monovalent or bivalent.

101. An antibody having VH of SEQ ID NO: 106 and VL of SEQ ID NO: 105 for use as a drug, wherein the antibody is monovalent or bivalent.
102. An antibody having VH of SEQ ID NO: 108 and VL of SEQ ID NO: 107 for use as a drug, wherein the antibody is monovalent or bivalent.
103. An antibody having VH of SEQ ID NO: 128 and VL of SEQ ID NO: 127 for use as a drug, wherein the antibody is monovalent or bivalent.
104. An antibody having VH of SEQ ID NO: 130 and VL of SEQ ID NO: 129 for use as a drug, wherein the antibody is monovalent or bivalent.
105. An antibody having VH of SEQ ID NO: 138 and VL of SEQ ID NO: 137 for use as a drug, wherein the antibody is monovalent or bivalent.
106. An antibody or fragment thereof of claims 1-38 and 45-66, for use as a medicament.
107. An antibody or fragment thereof of claims 1-38 and 45-66, for use as a medicament for treatment of an LRP6 expressing cancer.
108. An antibody or fragment thereof of claims 1-38 and 45-66, for use as a medicament for treatment of an LRP6 expressing cancer, wherein the cancer is selected from the group consisting of breast cancer, lung cancer, multiple myeloma, ovarian cancer, liver cancer, bladder cancer, gastric cancer, prostate cancer, acute myeloid leukemia, chronic myeloid leukemia, osteosarcoma, squamous cell carcinoma, and melanoma.

Fig. 1A






Fig. 1A continued

Daudi

LRP5 - LRP6 -



mRNA Expression
relative to PA1 cell line




Fig. 1B





Fig. 1B continued




Fig. 2A




Fig. 2B




Fig. 3

	Prop 1			Prop3		
	MOR08168	MOR08545	MOR06706	MOR06475	MOR08193	MOR08473
human LRP6	0.28	0.09	0.14	0.31	0.36	0.74
mouse LRP6	0.12	0.06	n/a	0.96	0.08	0.46
cynomolgus LRP6	0.88	0.30	0.46	0.22	0.20	0.52

EC₅₀ values expressed in nM.

Fig. 4




Fig. 5




Fig. 6





Fig. 7



Time points: 1, 4, 8 and 24 hours, 3, 7 and 14 days

Fig. 8A

Probe ID	Gene Symbol	Gene Title	Entrez Gene ID	log(2)fold change	adj.P.Val
				0 h vs. 8 h	0 h vs. 8 h
1435154_at	AU018091	expressed sequence AU018091	245128	2.51	0.008168
1418743_a_at	LOC100047138 /// Tesc	similar to Tescalcin /// tescalcin	100047138 /// 57816	2.42	0.000707
1418744_s_at	LOC100047138 /// Tesc	similar to Tescalcin /// tescalcin	100047138 /// 57816	2.41	0.001168
1447891_at	---	---	---	2.35	0.00122
1417956_at	Cidea	cell death-inducing DNA fragmentation factor, alpha subunit-like effector A	12683	2.32	0.006174
1436279_at	---	---	---	2.25	0.000742
1451139_at	Slc39a4	solute carrier family 39 (zinc transporter), member 4	72027	2.04	0.000336
1417130_s_at	Angptl4	angiopoietin-like 4	57875	1.94	0.000722
1434918_at	Sox6	SRY-box containing gene 6	20679	1.79	0.002107
1451612_at	Mt1	metallothionein 1	17748	1.74	0.004696
1441915_s_at	Z310076L09Rik	RIKEN cDNA Z310076L09 gene	66968	1.71	0.0025
1423860_at	Ptgds	prostaglandin D2 synthase (brain)	19215	1.66	0.001237
1428283_at	Cyp2s1	cytochrome P450, family 2, subfamily s, polypeptide 1	74134	1.64	0.004778
1439036_a_at	Atp1b1	ATPase, Na ⁺ /K ⁺ transporting, beta 1 polypeptide	11931	1.63	0.00705
1451410_a_at	Crip3	cysteine-rich protein 3	114570	1.62	0.000223
1459898_at	Sbsn	suprabasin	282619	1.60	0.002259
1433888_at	Atp2b2	ATPase, Ca ⁺⁺ transporting, plasma membrane 2	11941	1.58	0.009975
1450435_at	L1cam	L1 cell adhesion molecule	16728	1.57	0.001168

Fig. 8A continued

Probe ID	Gene Symbol	Gene Title	Entrez Gene ID	log(2)fold change		adj. P. Val
				0 h vs. 8 h	0 h vs. 8 h	
145506_at	Slc25a34	solute carrier family 25, member 34	384071	1.55	7.26E-05	
1422820_at	Lipe	lipase, hormone sensitive	16890	1.52	0.003431	
1447655_x_at	Sox6	SRY-box containing gene 6	20679	1.51	0.003772	
1451204_at	Scara5	scavenger receptor class A, member 5 (putative)	71145	1.51	0.001792	
1451828_a_at	Acs14	acyl-CoA synthetase long-chain family member 4	50790	1.48	6.46E-05	
1451331_at	Ppp1r1b	protein phosphatase 1, regulatory (inhibitor) subunit 1B	19049	1.44	0.002536	
1418453_a_at	Atp1b1	ATPase, Na+/K+ transporting, beta 1 polypeptide	11931	1.43	0.004956	
1419706_a_at	Akap12	A kinase (PRKA) anchor protein (gravin) 12	83397	1.42	0.000118	
1418911_s_at	Acs14	acyl-CoA synthetase long-chain family member 4	50790	1.40	0.003297	
1439630_x_at	Sbsn	suprabasin	282619	1.38	0.00074	
1438261_at	Cited4	Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 4, mRNA (cDNA clone IMAGE:3670674)	56222	1.36	0.006783	
1429952_at	Mospd4	motile sperm domain containing 4	72076	1.36	0.005578	
1435595_at	1810011010Rik	RIKEN cDNA 1810011010 gene	69068	1.34	0.000592	
1429352_at	Mocos	molybdenum cofactor sulfuryase	68591	1.32	0.009036	
1459897_a_at	Ibsn	suprabasin	282619	1.32	0.001447	
1447845_s_at	Vnn1	vanin 1	22361	1.31	0.004465	
1421841_at	Fgfr3	fibroblast growth factor receptor 3	14184	1.29	7.26E-05	
1424937_at	2310076L09Rik	RIKEN cDNA 2310076L09 gene	66968	1.29	0.000118	
1449403_at	Pde9a	phosphodiesterase 9A	18585	1.27	0.009729	
1424218_a_at	Creb3l4	cAMP responsive element binding protein 3-like 4	78284	1.21	0.002044	

Fig. 8A continued

Probe ID	Gene Symbol	Gene Title	Entrez Gene ID	log(2)fold change 0 h vs. 8 h	adj. P. Val 0 h vs. 8 h
1424763_at	Rsph9	radial spoke head 9 homolog (Chlamydomonas)	75564	1.21	0.006783
1420521_at	Papln	papilin, proteoglycan-like sulfated glycoprotein	170721	1.21	0.004502
1434442_at	Stbd1	starch binding domain 1	52331	1.19	0.004723
1438033_at	Tef	thyrotroph embryonic factor	21685	1.17	0.001335
1442335_at	---	---	---	1.16	0.006174
1448227_at	Grb7	growth factor receptor bound protein 7	14786	1.14	0.001261
1416596_at	Slc44a4	solute carrier family 44, member 4	70129	1.14	0.008898
1439620_at	Car13	carbonic anhydrase 13	71934	1.13	0.00323
1418780_at	Cyp39a1	cytochrome P450, family 39, subfamily a, polypeptide 1	56050	1.12	0.006174
1460409_at	Cpt1a	carnitine palmitoyltransferase 1a, liver	12894	1.10	0.003297
1449146_at	Notch4	Notch gene homolog 4 (Drosophila)	18132	1.10	0.008351
1443841_x_at	Uap1l1	UDP-N-acetylglucosamine pyrophosphorylase 1-like 1	227620	1.08	0.00764
1417273_at	Pdk4	pyruvate dehydrogenase kinase, isoenzyme 4	27273	1.08	0.006174
1430278_a_at	Dqx1	DEAQ RNA-dependent ATPase	93838	1.07	0.0025
1426065_a_at	Trib3	tribbles homolog 3 (Drosophila)	228775	1.04	0.002859
1438038_at	4930402H24Rik	RIKEN cDNA 4930402H24 gene	228602	1.03	0.00599
1427537_at	Eppk1	epiplakin 1	223650	1.02	0.00114
1416457_at	Ddah2	dimethylarginine dimethylaminohydrolase 2	51793	1.01	0.005738

Fig. 8B

Probe ID	Gene Symbol	Gene Title	Entrez Gene	log(2)fold change 0 h vs. 8 h	adj.P.Val 0 h vs. 8 h
1449451_at	Serpincb11	serine (or cysteine) peptidase inhibitor, clade B (ovalbumin), member 11	66957	-3.95	7.37E-07
1451129_at	Calb2	calbindin 2	12308	-3.14	0.006783
1436845_at	Axin2	axin2	12006	-2.92	4.53E-07
1416468_at	Aldh1a1	aldehyde dehydrogenase family 1, subfamily A1	11668	-2.83	0.000506
1427508_at	Arsi	arylsulfatase i	545260	-2.55	0.000592
1418601_at	Aldh1a7	aldehyde dehydrogenase family 1, subfamily A7	26358	-2.55	0.005578
1432592_at	Pappa	pregnancy-associated plasma protein A	18491	-2.55	6.46E-05
1425985_s_at	Masp1	mannan-binding lectin serine peptidase 1	17174	-2.48	0.001787
1434802_s_at	Ntf3	neurotrophin 3	18205	-2.43	0.000914
1425978_at	Myocd	myocardin	214384	-2.39	0.00374
1436221_at	Ildr2	immunoglobulin-like domain containing receptor 2	100039795	-2.36	0.00296
1418678_at	Has2	hyaluronan synthase 2	15117	-2.31	0.000996
1436894_at	Ildr2	immunoglobulin-like domain containing receptor 2	100039795	-2.3	0.0025
1427633_a_at	Pappa	pregnancy-associated plasma protein A	18491	-2.21	0.002187
1436293_x_at	Ildr2	immunoglobulin-like domain containing receptor 2	100039795	-2.17	0.002799
1433959_at	Zmat4	zinc finger, matrin type 4	320158	-2.14	0.00638
1427600_at	---	---	---	-2.12	6.46E-05
1432591_at	Pappa	pregnancy-associated plasma protein A	18491	-2.07	0.001159

Fig. 8B continued

Probe ID	Gene Symbol	Gene Title	Entrez Gene	log(2)fold change 0 h vs. 8 h	adj. P. Val 0 h vs. 8 h
1448397_at	Gjb6	gap junction protein, beta 6	14623	-2.06	0.002796
1449926_at	Cd70	CD70 antigen	21948	-2.05	0.006174
1441807_s_at	---	---	---	-2.02	0.004956
1438602_s_at	Masp1	mannan-binding lectin serine peptidase 1	17174	-2.01	0.00255
1425212_a_at	Tnfrsf19	tumor necrosis factor receptor superfamily, member 19	29820	-1.94	6.46E-05
1428223_at	Mfsd2	major facilitator superfamily domain containing 2	76574	-1.93	0.006536
1420006_at	Bmp15	Bone morphogenetic protein 15 (Bmp15), mRNA	12155	-1.91	0.000707
1429506_at	Nkd1	naked cuticle 1 homolog (Drosophila)	93960	-1.91	0.001459
1433894_at	Jazf1	JAZF zinc finger 1	231986	-1.9	0.000592
1422699_at	Alox12	arachidonate 12-lipoxygenase	11684	-1.89	0.001168
1460449_at	Anks1b	ankyrin repeat and sterile alpha motif domain containing 1B	77531	-1.87	0.000592
1417275_at	Mal	myelin and lymphocyte protein, T-cell differentiation protein	17153	-1.87	0.002349
1449169_at	Has2	hyaluronan synthase 2	15117	-1.8	0.000707
1420005_s_at	Bmp15	bone morphogenetic protein 15	12155	-1.78	0.002107
1449033_at	Tnfrsf11b	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	18383	-1.76	0.00402
1433990_at	Lhfp13	lipoma HMGIC fusion partner-like 3	269629	-1.73	0.001503
1431229_at	lpw	imprinted gene in the Prader-Willi syndrome region	16353	-1.71	0.0022
1429592_at	Lhfp13	lipoma HMGIC fusion partner-like 3	269629	-1.7	0.004465

Fig. 8B continued

Probe ID	Gene Symbol	Gene Title	Entrez Gene	log(2)fold change 0h vs. 8 h	adj. P. Val 0h vs. 8 h
1457617_at	---	---	---	-1.64	0.008658
1434265_s_at	Ank2	ankyrin 2, brain	109676	-1.64	0.006936
1449634_a_at	Anks1b	ankyrin repeat and sterile alpha motif domain containing 1B	77531	-1.6	0.005666
1455436_at	Diras2	DIRAS family, GTP-binding RAS-like 2	68203	-1.56	0.00813
1457429_s_at	Gm106	gene model 106, (NCBI)	226866	-1.56	0.000118
1425425_a_at	Wif1	Wnt inhibitory factor 1	24117	-1.55	0.000336
1415921_a_at	Tnfrsf19	tumor necrosis factor receptor superfamily, member 19	29820	-1.53	8.15E-05
1457948_at	Gas7	Growth arrest-specific 7-cb protein (Gas7-cb)	14457	-1.53	0.006196
1439954_at	6430514M23Rik	RIKEN cDNA 6430514M23 gene	399595	-1.52	0.006504
1417709_at	Cyp46a1	cytochrome P450, family 46, subfamily a, polypeptide 1	13116	-1.52	0.004364
1445247_at	C530044C16Rik	RIKEN cDNA C530044C16 gene	319981	-1.52	0.000604
1428665_at	Pfn4	profilin family, member 4	382562	-1.51	0.006174
1448147_at	Tnfrsf19	tumor necrosis factor receptor superfamily, member 19	29820	-1.47	2.14E-08
1456335_at	Gm106	gene model 106, (NCBI)	226866	-1.47	0.001787
1440546_at	9630002D21Rik	RIKEN cDNA 9630002D21 gene	319560	-1.44	0.003664
1450506_a_at	Aen	apoptosis enhancing nuclease	68048	-1.43	0.005422
1453041_at	Ano9	anoctamin 9	71345	-1.41	0.000592
1453700_s_at	4933403O03Rik /// EG245263	RIKEN cDNA 4933403O03 gene /// predicted gene, EG245263	245263 /// 74399	-1.41	0.004956

Fig. 8B continued

Probe ID	Gene Symbol	Gene Title	Entrez Gene	log(2)fold change 0 h vs. 8 h	adj. P. Val 0 h vs. 8 h
1449478_at	Mmp7	matrix metalloproteinase 7	17393	-1.39	0.009569
1452938_at	Anks1b	ankyrin repeat and sterile alpha motif domain containing 1B	77531	-1.37	0.006568
1444541_at	---	---	---	-1.37	0.000828
1450728_at	Fjx1	four jointed box 1 (Drosophila)	14221	-1.36	0.00323
1452728_at	Kirrel3	kin of IRRE like 3 (Drosophila)	67703	-1.36	0.005549
1430118_at	2700046A07Rik	RIKEN cDNA 2700046A07 gene	78449	-1.31	0.008169
1441272_at	Matr3	Matrin 3, mRNA (cDNA clone MGC:28206 IMAGE:3989914)	17184	-1.29	0.002269
1419539_at	Irx4	Iroquois related homeobox 4 (Drosophila)	50916	-1.26	0.005098
1442456_at	Spata5	spermatogenesis associated 5	57815	-1.26	0.006174
1456672_at	---	---	---	-1.24	0.006783
1439026_at	Trpm3	transient receptor potential cation channel, subfamily M, member 3	226025	-1.23	0.006174
1440446_at	---	---	---	-1.21	0.001125
1426139_a_at	Ccrl1	chemokine (C-C motif) receptor-like 1	252837	-1.2	0.009707
1435941_at	Rhbd13	rhomoid, veinlet-like 3 (Drosophila)	246104	-1.18	0.004465
1453645_at	2700046A07Rik	RIKEN cDNA 2700046A07 gene	78449	-1.18	0.000692
1444905_at	D1Ertd705e	DNA segment, Chr 1, ERATO Doi 705, expressed	51940	-1.17	0.003297
1422733_at	Fjx1	four jointed box 1 (Drosophila)	14221	-1.14	0.007138
1423957_at	Aen	apoptosis enhancing nuclease	68048	-1.07	0.000391

Fig. 8B continued

Probe ID	Gene Symbol	Gene Title	Entrez Gene	log(2)fold change 0 h vs. 8 h	adj.P.Val 0 h vs. 8 h
1433084_at	4930402C16Rik	RIKEN cDNA 4930402C16 gene	73812	-1.07	0.006802
1421498_a_at	2010204K13Rik	RIKEN cDNA 2010204K13 gene	68355	-1.07	0.007469
1426981_at	Pcsk6	proprotein convertase subtilisin/kexin type 6	18553	-1.06	0.000506
1446846_at	---	---	---	-1.05	0.004364
1429861_at	Pcdh9	protocadherin 9	211712	-1.04	0.006174
1447958_at	---	---	---	-1.02	0.000592
1435608_at	LOC631806 /// Znrf3	similar to Goliath homolog precursor (Ring finger protein 130) (R-goliath) /// zinc and ring finger 3	407821 /// 631806	-1.02	0.000118
1456266_at	---	---	---	-1.02	0.002282
1421341_at	Axin2	axin2	12006	-1.02	0.001447
1418495_at	Zc3h8	zinc finger CCCH type containing 8	57432	-1.01	0.000233

Fig. 9A




Fig. 9B




Fig. 10




Fig. 11




Fig. 12A



■ Solvent protection
■ No DXMS detection

Fig. 12B




Fig. 13




Fig. 14




Fig. 15




Fig. 16




Fig. 17
Wnt1-STF




Fig. 17 continued

Wnt3-STF




Fig. 18

	HEK STF IC50 ($\mu\text{g/ml}$)	
	WNT1	WNT3a
MOR06475-sc-fv-VI-Vh	n/a	0.07
MOR06475-sc-fv-Vh-VI	n/a	0.06
MOR06475-sc-fv-VI-Vh-(GGGGS)3	n/a	0.08
MOR06475-sc-fv-Vh-VI-(GGGGS)3	n/a	0.08
MOR06475-Fab	n/a	0.11
MOR08168-sc-fv-VI-Vh	0.05	n/a
MOR08168-sc-fv-Vh-VI	0.06	n/a
MOR08168-sc-fv-VI-Vh-(GGGGS)3	0.07	n/a
MOR08168-sc-fv-Vh-VI-(GGGGS)3	0.1	n/a
MOR08168-Fab	0.15	n/a
MOR08545-sc-fv-VI-Vh	0.53	n/a
MOR08545-sc-fv-Vh-VI	0.06	n/a
MOR08545-sc-fv-VI-Vh-(GGGGS)3	n/a	n/a
MOR08545-sc-fv-Vh-VI-(GGGGS)3	0.05	n/a
MOR08545-Fab	0.05	n/a
anti-LRP6 MOR08168 hlgG1 LALA 6475scfv_at VL	0.013	0.0071
anti-LRP6 MOR06475_hlgG1 LALA_8168scfvatCH3_(VH-3-VL)	0.013	0.0082
anti-LRP6 MOR06475_hlgG1 LALA_8168scfvatCH3_(VH-4-VL)	0.016	0.0094
anti-LRP6 MOR08168_hlgG1 LALA 6475scfvatCH3_opt DPtoDA	0.02	0.0076
anti-LRP6 MOR08168_hlgG1 LALA 6475scfvatCH3_opt DPtoTA	0.026	0.0098
anti-LRP6 MOR08168_hlgG1 LALA_6475scfvatCH3_opt_w/o-K	0.015	0.0064
MOR06475 IgG	n/a	0.0039
MOR08168 IgG	0.025	n/a
MOR08168hlgG1LALA 6475 scfv	0.016	0.011

Fig. 19

Antibody	K _d [μM]: binding of Ab's to FcRn			
	huFcRn, pH6.0	huFcRn, pH7.4	cynoFcRn, pH6.0	cynoFcRn, pH7.4
MOR08168	0.023	LLB	0.28	LLB
MOR08168/6475 8pAB	0.021	LLB	0.12	LLB

LLB: low level binding

Fig. 20




Fig. 21




Fig. 22





Fig. 23




Fig. 24A




Fig. 24B




Fig. 25





Fig. 26A


Summary of KD measurement of MOR08168 IgG LALA 6475scFv, MOR08168 and MOR06475 binding to PD1/2 and PD3/4

Binding to PD1/2	Ka (1/Ms)	Kd (1/3s)	KD (M)	N
MOR08168 IgG LALA 6475scFV	1.27E+05	6.10E-05	8.68E-10	3
MOR08168	8.72E+04	9.05E-05	1.08E-09	4
Binding to PD3/4	Ka (1/Ms)	Kd (1/3s)	KD (M)	N
MOR08168 IgG LALA 6475scFV	2.11E+05	3.14E-04	1.93E-09	3
MOR06475	2.01E+05	2.17E-04	1.13E-09	4

Fig. 26B

Binding to PD1/2

MOR08168 IgG LALA 6475scFv



MOR08168





Fig. 26B continued

Binding to PD3/4

MOR08168 IgG LALA 6475scFv



MOR06475




Fig. 26C




Fig. 27





Fig. 28

b. Effect of Bacterial strains and constructs



a. Effect of leader sequences




Fig. 29

T _m of single point mutations in scFv06475			
Construct ID	mutation*	T _m on protein from E.coli	T _m on protein from mammalian
scFv06475 WT		59	61
6475-S2	VH:G34V	61	64
6475-S3	VH:I37F	61	64.5
6475-S6	VH:V85E	60	62.5
6475-S8	VH:M95F	61.5	64.5
6475-S9	VL:D93N	59.5	60.5

*Both kabat and Chothia numbering system have been used. The numbering is the same for all mutations but VH:G34V in scFv6475. This would be VH:G32V in Chothia numbering system. The numbering system in the text is Kabat system.

Fig. 30

T _m of single point mutations in scFv08168		
Construct ID	mutation	T _m on protein from E.coli ^a
WT	WT	48.50
B02	VH:V033N	50.50
B03-S1	VH:I034M	56.00
B04	VH:I034F	52.50
C05	VH:S049A	54.00
C07	VH:G050S	51.50
C08	VH:W052aG	55.50
C10	VH:H058Y	52.00
F11	VL:V047L	51.00
G02	VL:G064V	50.50
G07	VL:T078V	51.00

^aProteins were expressed from Acella strain. Samples were analyzed by DSF without removal of imidazole.

Fig. 31

Tm of single vs double mutations in scFv08168

Construct ID	Mutation	T _m on protein from E. coli ^a	T _m on protein from mammalian ^b	T _m on protein from mammalian
scFv08168 WT	WT	48.50	49	49
scFv08168 B02	VH:V33N	50.50		
scFv08168 B03-S1	VH:I34M	56.00	57	56.5
scFv08168 B04	VH:I34F	52.50		
scFv08168 C05	VH:S49A	54.00		
scFv08168 C07	VH:G50S	51.50		
scFv08168 C10	VH:H58Y	52.00		
scFv08168 F11	VL:V47L	51.00		
scFv08168 G02	VL:G64V	50.50		
scFv08168 G07	VL:T78V	51.00		

^aProteins were expressed from Acella strain. Samples were analyzed by DSF without removal of imidazole
^bProtein expressed from 293T suspension cells. Samples were analyzed by DSF without removal of imidazole.

Fig. 31 continued

T _m of single vs double mutations in scFv08168			
Construct ID	Mutation	T _m on protein from <i>E. coli</i> ^a	T _m on protein from mammalian ^b
scFv08168 D1	VH S49A, I34M	61	61.5
scFv08168 D2	VH S49A, I34F	57.5	58
scFv08168 D4	VH I34M, G50S	59.5	59.5
scFv08168 D5	VH I34M, H58Y	59	59
scFv08168 D6	VH I34M, V48I	57	56
scFv08168 D7	VH I34M, VL S22T	57	57
scFv08168 D8	VH I34M, VL V47L	57.5	56
scFv08168 D9	VH I34M, VL G64V	57.5	58.5

^aProteins were expressed from *Acetia* strain. Samples were analyzed by DSF without removal of imidazole

^bProtein expressed from 293T suspension cells. Samples were analyzed by DSF without removal of imidazole.

Fig. 32

Activity of scFv06475, scFv08168 and the variants in different assays					
Construct ID	Mutations	EC50 by ELISA nM	Affinity by Proteon nM	IC50 by STF assay for Wnt1 inhibition (nM)	IC50 by STF assay for Wnt3a inhibition (nM)
scFv06475 WT		0.76	-	-	1.48
scFv06475-S2	VH:G34V	27.4	-	-	-
scFv06475-S3	VH:I37F	4.3	-	-	-
scFv06475-S6	VH:V85E	0.73	-	-	1.33
scFv06475-S8	VH:M95F	1.0	-	-	0.96
scFv06475-S9	VL:D93N	0.88	-	-	-
scFv08168 WT		2.04	3.82	7.41	-
scFv08168 B03-S1	VH:I34M	0.98	-	5.19	-
scFv08168-D1	VH S49A, I34M	1.61	2.55	2.44	-
scFv08168-D2	VH S49A, I34F	1.68	-	2.59	-
scFv08168-D4	VH I34M, G50S	1.47	-	5.56	-
scFv08168-D5	VH I34M, H58Y	1.22	-	-	-
scFv08168-D6	VH I34M, V48I	1.24	-	0.74	-
scFv08168-D7	VH I34M, VL S22T	1.15	-	4.81	-
scFv08168-D8	VH I34M, VL V47L	0.91	-	-	-
scFv08168-D9	VH I34M, VL G64V	1.26	-	11.11	-

Fig. 33

Selected examples of stabilizing mutations




Fig. 34

Thermostability measurement of HSA fusion and IgG based biparatopic molecules		
	T_m by DSF (ProteoSTAT)	T_m by DSC
MOR6475 IgG1-scFv8168 (902wt)	47,72.5	ND
MOR6475 IgG1-scFv8168 (902 mutant)	62,76	ND

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2011/057202

A. CLASSIFICATION OF SUBJECT MATTER
 INV. C07K16/28 A61K39/395 A61P35/00 C07K16/46
 ADD. C12N15/113

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 C07K A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
 EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2009/056634 A2 (NOVARTIS AG [CH]; CONG FENG [US]; RANGWALA SHAMINA M [US]; ETTENBERG S) 7 May 2009 (2009-05-07) whole document, especially Examples 1, 3 and 4 ----- -/--	1-26,28, 31-36, 38-50, 57-61, 64-82, 86,87, 93-95, 99,100, 106-108

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search 28 September 2011	Date of mailing of the international search report 06/10/2011
--	--

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Luyten, Kattie
--	--

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2011/057202

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	M. E. BINNERTS ET AL: "The First Propeller Domain of LRP6 Regulates Sensitivity to DKK1", MOLECULAR BIOLOGY OF THE CELL, vol. 20, no. 15, 1 August 2009 (2009-08-01), pages 3552-3560, XP55003126, ISSN: 1059-1524, DOI: 10.1091/mbc.E08-12-1252 whole document, especially the Abstract and Figure 2A	1-26,28, 31-36, 38-50, 57-61, 64-82, 86,87, 93-95, 99,100, 106-108
X	----- WO 2009/064944 A2 (NUVELO INC [US]; ABO ARIE [US]; BINNERTS MINKE [US]) 22 May 2009 (2009-05-22) examples 1-4	1-26,28, 31-36, 38-50, 57-61, 64-82, 86,87, 93-95, 99,100, 106-108
X,P	----- S. A. ETTENBERG ET AL: "Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 35, 31 August 2010 (2010-08-31), pages 15473-15478, XP55002447, ISSN: 0027-8424, DOI: 10.1073/pnas.1007428107 the whole document	1-26,28, 31-36, 38-50, 57-61, 64-82, 86,87, 93-95, 99,100, 106-108
X,P	----- YAN GONG ET AL: "Wnt Isoform-Specific Interactions with Coreceptor Specify Inhibition or Potentiation of Signaling by LRP6 Antibodies", PLOS ONE, vol. 5, no. 9, 13 September 2010 (2010-09-13), page E12682, XP55003122, the whole document	1-26,28, 31-36, 38-50, 57-61, 64-82, 86,87, 93-95, 99,100, 106-108

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2011/057202

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
24-26, 28, 35, 36, 46, 49, 50, 61, 80-82, 86, 87, 93-95, 99
100(completely); 1-23, 31-34, 38-45, 47, 48, 57-60, 64-79
106-108(partially)
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 24, 35, 80, 93(completely); 1-3, 5, 6, 9-15, 18-23, 31, 33, 34, 38-44, 64-66, 73-79, 106-108(partially)

An isolated bivalent antibody or a bivalent fragment thereof to LRP6 that potentiates a Wnt signal by clustering one or more LRP6 receptors in the presence of an unblocked LRP6 binding protein, wherein said antibody is anti-LRP6 antibody MOR08168, having the VH sequence of SEQ ID NO: 14 and the VL sequence of SEQ ID NO: 13, corresponding products, methods and uses thereof.

2. claims: 25, 26, 28, 36, 81, 82, 94(completely); 1-3, 5, 6, 9-15, 18-23, 31, 33, 34, 38-44, 64-66, 73-79, 95, 106-108(partially)

An isolated bivalent antibody or a bivalent fragment thereof to LRP6 that potentiates a Wnt signal by clustering one or more LRP6 receptors in the presence of an unblocked LRP6 binding protein, wherein said antibody is anti-LRP6 antibody MOR08545, having the VH sequence of SEQ ID NO: 34 and the VL sequence of SEQ ID NO: 33, corresponding products, methods and uses thereof.

3. claims: 1-108(partially)

An isolated bivalent antibody or a bivalent fragment thereof to LRP6 that potentiates a Wnt signal by clustering one or more LRP6 receptors in the presence of an unblocked LRP6 binding protein, wherein said antibody is anti-LRP6 antibody MOR06706, having the VH sequence of SEQ ID NO: 60 and the VL sequence of SEQ ID NO: 59, corresponding products, methods and uses thereof.

4. claims: 46, 49, 50, 61, 86, 87, 99, 100(completely); 1-3, 5, 6, 9-15, 18-21, 38, 39, 45, 47, 48, 57-60, 65-79, 106-108(partially)

An isolated bivalent antibody or a bivalent fragment thereof to LRP6 that potentiates a Wnt signal by clustering one or more LRP6 receptors in the presence of an unblocked LRP6 binding protein, wherein said antibody is anti-LRP6 antibody MOR06475, having the VH sequence of SEQ ID NO: 82 and the VL sequence of SEQ ID NO: 81, corresponding products, methods and uses thereof.

5. claims: 1-108(partially)

An isolated bivalent antibody or a bivalent fragment thereof

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

to LRP6 that potentiates a Wnt signal by clustering one or more LRP6 receptors in the presence of an unblocked LRP6 binding protein, wherein said antibody is anti-LRP6 antibody MOR08193, having the VH sequence of SEQ ID NO: 106 and the VL sequence of SEQ ID NO: 105, corresponding products, methods and uses thereof.

6. claims: 1-108(partially)

An isolated bivalent antibody or a bivalent fragment thereof to LRP6 that potentiates a Wnt signal by clustering one or more LRP6 receptors in the presence of an unblocked LRP6 binding protein, wherein said antibody is anti-LRP6 antibody MOR08473, having the VH sequence of SEQ ID NO: 128 and the VL sequence of SEQ ID NO: 127, corresponding products, methods and uses thereof.

7. claims: 24, 35, 80, 93(completely); 1-3, 5, 6, 9-15, 18-23, 31, 33, 34, 38-44, 64-66, 73-79, 106-108(partially)

An isolated monovalent antibody or a monovalent fragment thereof to LRP6 that avoids potentiation of a Wnt signal by clustering one or more LRP6 receptors in the presence of an unblocked LRP6 binding protein, wherein said antibody is anti-LRP6 antibody MOR08168, having the VH sequence of SEQ ID NO: 14 and the VL sequence of SEQ ID NO: 13, corresponding products, methods and uses thereof.

8. claims: 25, 26, 28, 36, 81, 82, 94(completely); 1-3, 5, 6, 9-15, 18-23, 31, 33, 34, 38-44, 64-66, 73-79, 95, 106-108(partially)

An isolated monovalent antibody or a monovalent fragment thereof to LRP6 that avoids potentiation of a Wnt signal by clustering one or more LRP6 receptors in the presence of an unblocked LRP6 binding protein, wherein said antibody is anti-LRP6 antibody MOR08545, having the VH sequence of SEQ ID NO: 34 and the VL sequence of SEQ ID NO: 33, corresponding products, methods and uses thereof.

9. claims: 1-108(partially)

An isolated monovalent antibody or a monovalent fragment thereof to LRP6 that avoids potentiation of a Wnt signal by clustering one or more LRP6 receptors in the presence of an unblocked LRP6 binding protein, wherein said antibody is anti-LRP6 antibody MOR06706, having the VH sequence of SEQ ID NO: 60 and the VL sequence of SEQ ID NO: 59, corresponding products, methods and uses thereof.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

10. claims: 46, 49, 50, 61, 86, 87, 99, 100(completely); 1-3, 5, 6, 9-15, 18-21, 38, 39, 45, 47, 48, 57-60, 65-79, 106-108(partially)

An isolated monovalent antibody or a monovalent fragment thereof to LRP6 that avoids potentiation of a Wnt signal by clustering one or more LRP6 receptors in the presence of an unblocked LRP6 binding protein, wherein said antibody is anti-LRP6 antibody MOR06475, having the VH sequence of SEQ ID NO: 82 and the VL sequence of SEQ ID NO: 81, corresponding products, methods and uses thereof.

11. claims: 1-108(partially)

An isolated monovalent antibody or a monovalent fragment thereof to LRP6 that avoids potentiation of a Wnt signal by clustering one or more LRP6 receptors in the presence of an unblocked LRP6 binding protein, wherein said antibody is anti-LRP6 antibody MOR08193, having the VH sequence of SEQ ID NO: 106 and the VL sequence of SEQ ID NO: 105, corresponding products, methods and uses thereof.

12. claims: 1-108(partially)

An isolated monovalent antibody or a monovalent fragment thereof to LRP6 that avoids potentiation of a Wnt signal by clustering one or more LRP6 receptors in the presence of an unblocked LRP6 binding protein, wherein said antibody is anti-LRP6 antibody MOR08473, having the VH sequence of SEQ ID NO: 128 and the VL sequence of SEQ ID NO: 127, corresponding products, methods and uses thereof.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2011/057202

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2009056634	A2	07-05-2009	
		AU 2008320823 A1	07-05-2009
		CA 2700433 A1	07-05-2009
		CN 101951954 A	19-01-2011
		EA 201000718 A1	30-06-2011
		EP 2209491 A2	28-07-2010
		JP 2011503025 A	27-01-2011
		KR 20100091170 A	18-08-2010
		US 2010254980 A1	07-10-2010

WO 2009064944	A2	22-05-2009	
		CA 2705923 A1	22-05-2009
		EP 2220247 A2	25-08-2010
